

Sequence 22, Appl
Sequence 20, Appl
Sequence 8, Appl
Sequence 22, Appl
Sequence 20, Appl
Sequence 9, Appl
Sequence 10, Appl

Sequence 22, Appl
Sequence 20, Appl
Sequence 8, Appl
Sequence 22, Appl
Sequence 20, Appl
Sequence 9, Appl
Sequence 10, Appl

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:51:52 ; Search time 11 Seconds
(without alignments)
3.823 Million cell updates/sec

Title: US-10-664-775-4

Perfect score: 2279
Sequence: 1 gatcactctctagtgaag.....ttgtattctaggtctgtat 2279

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues

Total number of hits satisfying chosen parameters: 40

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : rni:db*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Query Score	Match	Length	DB ID	Description
C 1	20.6	0.9	1440	1	US-07-882-202A-3
C 2	20.6	0.9	1440	1	US-08-021-615A-3
C 3	20.6	0.9	1440	1	US-08-321-777-3
C 4	20.6	0.9	1440	1	US-09-009-217-13
C 5	20.6	0.9	1440	1	US-09-009-656-13
C 6	20.6	0.9	1440	1	PCT-US93-04493-3
C 7	16.6	0.7	1440	1	US-07-882-202A-3
C 8	16.6	0.7	1440	1	US-08-021-615A-3
C 9	16.6	0.7	1440	1	US-08-321-777-3
C 10	16.6	0.7	1440	1	US-09-009-217-13
C 11	16.6	0.7	1440	1	US-09-009-656-13
C 12	16.6	0.7	1440	1	PCT-US93-04493-3
C 13	14.0	0.6	38	1	US-09-558-027-4
C 14	12.8	0.6	141	1	US-08-849-248-6
C 15	12.6	0.6	141	1	US-08-849-248-6
C 16	12.0	0.5	38	1	US-09-558-027-4
C 17	11.2	0.5	27	1	US-08-293-778-16
C 18	11.0	0.5	27	1	US-08-293-778-16
C 19	10.6	0.5	42	1	US-08-955-636-9
C 20	10.6	0.5	45	1	US-08-756-506-13
C 21	10.4	0.5	45	1	US-08-756-506-13
C 22	10.0	0.4	35	1	US-07-998-972A-7
C 23	10.0	0.4	35	1	US-08-463-953-7
C 24	10.0	0.4	35	1	US-08-463-953-7
C 25	10.0	0.4	35	1	PCT-US92-11357-7
C 26	9.8	0.4	27	1	US-08-293-778-16
C 27	9.4	0.4	27	1	US-08-293-778-16
C 28	9.4	0.4	35	1	US-07-998-972A-7
C 29	9.4	0.4	35	1	US-08-463-953-7
C 30	9.4	0.4	35	1	PCT-US92-11357-7
C 31	9.4	0.4	35	1	PCT-US92-11357-7
C 32	9.4	0.4	36	1	US-08-955-636-9
C 33	9.4	0.4	36	1	US-08-955-636-10

ALIGNMENTS

RESULT 1

US-07-882-202A-3/c
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note="Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-07-882-202A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24;

QY 440 TTCAATGCTTTTATCTGCGAGACTTGTGTTTGTGTTTGAATATGATTCATTTGG 498
DB 659 TTCTGCGCATTTCTTTTCTTAGAATAGGTATTTTCCACATGGATTCACATGTTGG 601

RESULT 2
US-08-021-615A-3/c
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTTGAATATGATTCATTTGG 498
DB 659 TTTCGTCGATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACACTGTGG 601

RESULT 3
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-321-777-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTTGAATATGATTCATTTGG 498
DB 659 TTTCGTCGATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACACTGTGG 601

RESULT 4
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas

COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,217
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/042,427
FILING DATE: 27-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,205
FILING DATE: 27-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/035,920
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hibler, David W.
REGISTRATION NUMBER: 41,071
REFERENCE/DOCKET NUMBER: UTSD:537
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-656-13
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATATGATTCATTTGG 498
Db 659 TTGCTGCAATTTCTTTTCTAGATAGTATTTTCCACATGATATCAACTGTGG 601
RESULT 6
PCT-US93-04493-3/c
Sequence 3, Application PC/TUS9304493
GENERAL INFORMATION:
APPLICANT: Morrissey, James H.
APPLICANT: Comp, Philip C.
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
TITLE OF INVENTION: FVII Activator for Blood Coagulation
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Richards, Medlock & Andrews
STREET: 1201 Elm Street, Suite 4500
CITY: Dallas
STATE: Texas
COUNTRY: US
ZIP: 75270-2197
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/04493
FILING DATE: 19930512
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/882202
FILING DATE: 13-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/021615
FILING DATE: 19-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: Trujillo, Doreen Y.
REGISTRATION NUMBER: 35,719
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 214-939-4500
TELEFAX: 214-939-4600
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs

COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,217
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/042,427
FILING DATE: 27-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,205
FILING DATE: 27-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/035,920
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hibler, David W.
REGISTRATION NUMBER: 41,071
REFERENCE/DOCKET NUMBER: UTSD:536
TELECOMMUNICATION INFORMATION:
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-217-13
Query Match 0.9%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.99;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATATGATTCATTTGG 498
Db 659 TTGCTGCAATTTCTTTTCTAGATAGTATTTTCCACATGATATCAACTGTGG 601
RESULT 5
US-09-009-656-13/c
Sequence 13, Application US/09009656
Patent No. 6132730
GENERAL INFORMATION:
APPLICANT: Thorpe, Philip E.
APPLICANT: King, Steven W.
APPLICANT: Gao, Boning
TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
TITLE OF INVENTION: TREATMENT
NUMBER OF SEQUENCES: 27
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P.O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,656
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:

Qy 1761 TCCTTTGGTTTTCATAGTCTCTCGCTTCCTGGATG 1799
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGCTGCCTGGCTG 96

US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FvIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: CMRF B34290C
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHEICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:

NAME/KEY: CDS
; LOCATION: 36-1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-321-777-3
Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 1761 TCCTTTGGTTTTCATAGTCTCTCGCTTCCTGGATG 1799
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGCTGCCTGGCTG 96

RESULT 10
US-09-009-217-13
; Sequence 13, Application US/09009217

; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA: US 60/042,427
; APPLICATION NUMBER:
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
Qy 1761 TCCTTTGGTTTTCATAGTCTCTCGCTTCCTGGATG 1799
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGCTGCCTGGCTG 96

RESULT 11
US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433

CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/009,656
FILING DATE: Concurrently Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/042,427
FILING DATE: 27-MAR-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/036,205
FILING DATE: 27-JAN-1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/035,920
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Hibler, David W.
REGISTRATION NUMBER: 41,071
REFERENCE/DOCKET NUMBER: UTSD:537
TELEPHONE: 512/418-3000
TELEFAX: 512/474-7577
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-009-656-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 1761 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1799
Db 58 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 96

RESULT 12
PCT-US93-04493-3
Sequence 3, Application PC/TUS9304493
GENERAL INFORMATION:
APPLICANT: Morrissey, James H.
APPLICANT: Comp, Philip C.
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
TITLE OF INVENTION: FVII Activator for Blood Coagulation
NUMBER OF SEQUENCES: 4
CORRESPONDENCE ADDRESS:
ADDRESSEE: Richards, Medlock & Andrews
STREET: 1201 Elm Street, Suite 4500
CITY: Dallas
STATE: Texas
COUNTRY: US
ZIP: 75270-2197
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/04493
FILING DATE: 19930512
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/882202

FILING DATE: 13-MAY-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/021615
FILING DATE: 19-FEB-1993
ATTORNEY/AGENT INFORMATION:
NAME: Trujillo, Doreen Y.
REGISTRATION NUMBER: 35,719
REFERENCE/DOCKET NUMBER: OMRP B34290CIPC/PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 214-939-4500
TELEFAX: 214-939-4600
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 1440 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
TISSUE TYPE: Blood
FEATURE:
NAME/KEY: CDS
LOCATION: 36..1433
OTHER INFORMATION: /product= "Tissue Factor"
OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
OTHER INFORMATION: /citation= {[1]}
PCT-US93-04493-3

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
QY 1761 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1799
Db 58 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 96

RESULT 13
US-09-558-027-4
Sequence 4, Application US/09558027
Patent No. 6329176
GENERAL INFORMATION:
APPLICANT: Woldike, Helle
APPLICANT: Wiberg, Finn
APPLICANT: Nielsen, Lars
TITLE OF INVENTION: Method for the Production of FVII
FILE REFERENCE: 5565.204-US
CURRENT APPLICATION NUMBER: US/09/558,027
CURRENT FILING DATE: 2000-04-25
PRIOR APPLICATION NUMBER: 60/108,065
PRIOR FILING DATE: 1998-11-12
NUMBER OF SEQ ID NOS: 4
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 4
LENGTH: 38
TYPE: DNA
ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match 0.6%; Score 14; DB 1; Length 38;
Best Local Similarity 77.3%; Pred. No. 8;
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
QY 3 TCACCTCTCTAGTGAAGGTGG 24
Db 8 TCACCTAGTCTAGGGAATGGGG 29
RESULT 14
US-08-849-248-6/c

; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyl, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match 0.6%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 65;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 147 TCGCTGCGAATCTCTGGGCT 170
DB 25 TCAGCTGGTCATCCTTGCTCT 2

RESULT 15:

; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyl, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
; US-08-849-248-6

Query Match 0.6%; Score 12.6; DB 1; Length 141;
Best Local Similarity 55.8%; Pred. No. 73;
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1394 TTCTAAGTGCATGTCTGGCTGACATCTGTAGTCTCTTGA 1436
DB 97 TGCACGAGGGGTACTCTCTGTCGACACGGGGTCTCTCA 139

RESULT 16

; US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
; US-09-558-027-4

Query Match 0.5%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 45;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 893 AGGGCCATTTCCTTAGAATA 912
DB 31 AGCCCATTCCTTAGACTA 12

RESULT 17

; US-08-293-778-17/c
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-17

Query Match 0.5%; Score 11.2; DB 1; Length 27;
Best Local Similarity 81.2%; Pred. No. 63;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1788 GCTTCTCGATGTTT 1803
Db 23 GCGTCTCGAAGATT 8

RESULT 18
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149

```

```

; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2087 TCTTCAAGGAC 2097
Db 11 TCTTCAAGGAC 21

RESULT 19
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGCTAGGGGAC 262
Db 2 CACTCCGCTCCAGGCTCTGGGAC 26

RESULT 20
US-08-756-506-13/c
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.

```

;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
;; TITLE OF INVENTION: ANIMALS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: ZymoGenetics, Inc.
;; STREET: 1201 Eastlake Avenue East
;; CITY: Seattle
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 98102
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent in Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/756,506
;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6672
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13

Query Match 0.5%; Score 10.6; DB 1; Length 45;
Best Local Similarity 57.6%; Pred. No. 1.5e+02;
Matches 19; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 241 TTCTGGCGCAGGTAGGCGACTACCGCATTC 273
DB 35 TGCTGCAACGGCGCAAGCGCGCAACTCCTTC 3

RESULT 21
US-08-756-506-13
; Sequence 13, Application US/08/756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian R.
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Frankard, Donna E.
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; TITLE OF INVENTION: ANIMALS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506

;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6672
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13

Query Match 0.5%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 1.7e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 642 GTTGGAGAGAAATGGGTATTGCAAGTAGC 669
DB 10 GTTGGCGCGCTTGGCGCGTTCAGCACC 37

RESULT 22
US-07-998-972A-7/c
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```

; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-07-998-972A-7

Query Match      0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGGCCTGAC 1419
Db 21 GGAGTTGGCTGCCGGAC 4

RESULT 23
US-08-463-953-7/c
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-462-261-7

Query Match      0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGGCCTGAC 1419
Db 21 GGAGTTGGCTGCCGGAC 4

RESULT 25
PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

```

ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/11357
FILING DATE: 19921230
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGCCTGAC 1419
Db 21 GCAGTTGGCTCCCGGAC 4

RESULT 26
US-08-293-778-16/c
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agiris, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.4%; Score 9.8; DB 1; Length 27;
Best Local Similarity 66.7%; Pred. No. 1.9e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 553 GTCTCTAAATATCTTAGTTC 573
Db 21 GTCTTGAAGATCTCCCGGC 1

RESULT 27
US-08-293-778-17
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/898,248
;; FILING DATE: 12-JUN-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Agis, Cheryl H.
;; REGISTRATION NUMBER: 34,086
;; REFERENCE/DOCKET NUMBER: 3129,224-US
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 212-867-0123
;; TELEFAX: 212-867-0298
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 27 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: cDNA
;; US-08-293-778-17

Query Match 0.4%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.6e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2087 TCTTCAGGAC 2097
Db 11 TCTTCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTGGATG 1799
Db 21 CTTCTGGAGG 31

RESULT 30
US-08-462-261-7

;; IMMEDIATE SOURCE:
;; CLONE: ZC1324
;; US-07-998-972A-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTGGATG 1799
Db 21 CTTCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08463,953
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.9e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTGGATG 1799
Db 21 CTTCTGGAGG 31

RESULT 30
US-08-462-261-7


```

; Sequence 7, Application US/08462261
; Patent No. 5537692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

; Query Match 0.4%; Score 9.4; DB 1; Length 35;
; Best Local Similarity 90.9%; Pred. No. 2.9e+02;
; Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTGTGGATG 1799
Db 21 CTTCTGTGGAGG 31

; RESULT 32
; US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

; Query Match 0.4%; Score 9.4; DB 1; Length 36;
; Best Local Similarity 68.4%; Pred. No. 2.9e+02;
; Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 259 GCACACCCGACCTCTCT 277
Db 13 GCGGTGCGCGACGCTCTCT 31

; RESULT 33

```

US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsesuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.4%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.9e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 259 GCCTACGCGATTCCTCT 277
Db 24 GCGTGGCGAGCTCTCT 6

RESULT 34

US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; FILING DATE: 25-JUN-1987
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; FILING DATE: 25-JUN-1987
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129-224-US
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

REFERENCE/DOCKET NUMBER: 3129-224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match 0.4%; Score 9.2; DB 1; Length 26;
Best Local Similarity 78.6%; Pred. No. 2.9e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1920 GTCTCTGAGGTTC 1933
Db 25 GTCTCGACCTTC 12

RESULT 35

US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; FILING DATE: 25-JUN-1987
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; FILING DATE: 25-JUN-1987
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129-224-US
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

```

APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agtis, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129,224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 26 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match 0.4%; Score 8.6; DB 1; Length 26;
Best Local Similarity 73.3%; Pred. No. 4.2e+02;
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 16 GAAGGTCGGGGTCT 30
Db 12 GGAGGTCGGAGACT 26

RESULT 38
US-08-293-778-20/c
Sequence 20, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaissen, Else M.
APPLICANT: Bjørn, Søren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESS: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 52nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989

```

```

, PRIOR APPLICATION DATA:
, APPLICATION NUMBER: PCT/DK88/00103
, FILING DATE: 24-JUN-1988
, PRIOR APPLICATION DATA:
, APPLICATION NUMBER: US 07/898,248
, FILING DATE: 12-JUN-1992
, ATTORNEY/AGENT INFORMATION:
, NAME: Agis, Cheryl H.
, REGISTRATION NUMBER: 34,086
, REFERENCE/DOCKET NUMBER: 3129-224-US
, TELECOMMUNICATION INFORMATION:
, TELEPHONE: 212-867-0123
, TELEFAX: 212-867-0298
, INFORMATION FOR SEQ ID NO: 20:
, SEQUENCE CHARACTERISTICS:
, LENGTH: 27 base pairs
, TYPE: nucleic acid
, STRANDEDNESS: single
, TOPOLOGY: linear
, MOLECULE TYPE: cDNA
, US-08-293-778-20

```

```
Query Match      0.4%; Score 8.6; DB 1; Length 27;
Best Local Similarity 60.9%; Pred. No. 4.2e+02;
Matches 14; Conservative 0; Mismatches 9; Indels
```

```

RESULT 39
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; -OTHER INFORMATION: Protein C mutagenic oligonuc-
US-08-955-636-9

```

Query Match 0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred. No. 4.5e+02;
Matches 12: Conservative 0; Mismatches 6; Indels

```

RESULT 40
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35

```

```

; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match          0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred NO. 4.5e+02;
Matches 12; Conservative 0; Mismatches 6; Indels

QY      158 TACTCTCTGGGGCTGCTGC 175
          ||| ||| ||| |||
Db       2 TCTTAGAGGAGTGGGCGC 19

Search completed: August 9, 2004, 16:52:04
Job time : 12 secs

```

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:54:36 ; Search time 31 Seconds

(without alignments)
3.697 Million cell updates/sec

Title: us-10-664-775-4

Perfect score: 2279
Sequence: 1 gatcactctctagtagaaag.....ttgtaattcttagtgctgat 2279

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpsdb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	0.9	1332	1	US-10-411-037-7
C 2	20.6	0.9	1332	1	US-10-411-026-7
C 3	20.6	0.9	1332	1	US-10-410-962-7
C 4	20.6	0.9	1332	1	US-10-411-049-7
C 5	20.6	0.9	1332	1	US-10-410-930-7
C 6	20.6	0.9	1332	1	US-10-410-997-7
C 7	20.6	0.9	1332	1	US-10-411-012-7
C 8	20.6	0.9	1332	1	US-10-287-994-7
C 9	20.6	0.9	1332	1	US-10-410-913-7
C 10	20.6	0.9	1440	1	US-10-375-741-13
C 11	20.6	0.9	2040	1	US-10-617-619-12
C 12	20.6	0.9	2106	1	US-10-617-619-9
C 13	19.4	0.9	1361	1	US-10-382-248-35
C 14	17.2	0.8	1361	1	US-10-382-248-35
C 15	17	0.7	483	1	US-09-918-995-8429
C 16	17	0.7	1332	1	US-10-411-037-7
C 17	17	0.7	1332	1	US-10-411-026-7
C 18	17	0.7	1332	1	US-10-410-962-7
C 19	17	0.7	1332	1	US-10-411-049-7
C 20	17	0.7	1332	1	US-10-410-930-7
C 21	17	0.7	1332	1	US-10-410-997-7
C 22	17	0.7	1332	1	US-10-411-012-7
C 23	17	0.7	1332	1	US-10-287-994-7
C 24	17	0.7	1332	1	US-10-410-913-7
C 25	17	0.7	2040	1	US-10-617-619-12
C 26	16.6	0.7	1338	1	US-09-782-587B-2
C 27	16.6	0.7	1357	1	US-09-782-587B-2
C 28	16.6	0.7	1440	1	US-10-375-741-13
C 29	16.6	0.7	2106	1	US-10-617-619-9
C 30	16.4	0.7	483	1	US-09-918-995-8429
C 31	14.8	0.6	555	1	US-10-029-386-9623
C 32	14.6	0.6	222	1	US-10-029-386-9623
C 33	14.6	0.6	555	1	US-10-029-386-9623

C 107 9.2 0.4 34 1 US-09-951-121A-3 Sequence 3, Appli
C 108 9.2 0.4 34 1 US-10-295-682-2 Sequence 2, Appli
C 109 9.2 0.4 34 1 US-10-295-682-3 Sequence 3, Appli
C 110 9.2 0.4 36 1 US-10-281-727-2 Sequence 2, Appli
C 111 9.2 0.4 36 1 US-10-281-727-3 Sequence 3, Appli
C 112 9 0.4 33 1 US-09-951-121A-14 Sequence 14, Appli
C 113 9 0.4 33 1 US-09-951-121A-15 Sequence 15, Appli
C 114 9 0.4 33 1 US-10-295-682-14 Sequence 14, Appli
C 115 9 0.4 33 1 US-10-295-682-15 Sequence 15, Appli
C 116 8.8 0.4 42 1 US-09-803-810-8 Sequence 8, Appli
C 117 8.8 0.4 42 1 US-10-298-330-8 Sequence 8, Appli
C 118 8.2 0.4 31 1 US-10-017-122-4 Sequence 4, Appli
C 119 7.8 0.3 34 1 US-09-951-121A-2 Sequence 2, Appli
C 120 7.8 0.3 34 1 US-09-951-121A-3 Sequence 3, Appli
C 121 7.8 0.3 34 1 US-10-295-682-2 Sequence 2, Appli
C 122 7.8 0.3 34 1 US-10-295-682-3 Sequence 3, Appli

ALIGNMENTS

RESULT 1
US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3; Mismatches 0; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
US-10-411-037-7

Qy 440 TTCATTGCTTTTATCTGTCGAGACTTGGCTTTGTTTGAATATGATTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 500

RESULT 2
US-10-411-026-7/c
; Sequence 7, Application US/10411026

; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3; Mismatches 0; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
US-10-411-026-7

Qy 440 TTCATTGCTTTTATCTGTCGAGACTTGGCTTTGTTTGAATATGATTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGG 500

RESULT 3
US-10-410-962-7/c
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-962-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3; Mismatches 0; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
US-10-411-037-7

; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-962-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGATATTCACGTGG 500

RESULT 4
US-10-411-049-7/c
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-049-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGATATTCACGTGG 500

RESULT 5
US-10-410-930-7/c
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn

; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGATATTCACGTGG 500

RESULT 6
US-10-410-997-7/c
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-997-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
|||
DB 558 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 500
|||

RESULT 7

US-10-411-012-7/c
Sequence 7, Application US/10411012
Publication No. US20040132640A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: GLYCOPGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
FILE REFERENCE: 040853-01-5051
CURRENT APPLICATION NUMBER: US/10/411,012
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-411-012-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
|||
DB 558 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 500
|||

RESULT 8

US-10-287-994-7/c
Sequence 7, Application US/1028994
Publication No. US20040137557A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert

APPLICANT: Bowe, Caryn
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
FILE REFERENCE: 040853-01-5052-00
CURRENT APPLICATION NUMBER: US/10/287,994
CURRENT FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 62
SOFTWARE: PatentIn version 3.1
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-287-994-7

Query Match 0.9%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.3;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
|||
DB 558 TTGCTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 500
|||

RESULT 9

US-10-410-913-7/c
Sequence 7, Application US/10410913
Publication No. US20040142856A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bowe, Caryn
TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
FILE REFERENCE: 040853-01-5081
CURRENT APPLICATION NUMBER: US/10/410,913
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332


```

; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match          0.9%; Score 20.6; DB 1; Length 2040;
Best Local Similarity 59.3%; Pred.No. 3.2; 24; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 0;

QY 440 TTCATTCCTTTTATCTGTCGAGACTTCGTTTGTTCGAAATATGTATTCATTTTGG 498
DB 558 TTGCTGCATTTCTTTTTTCTAGAATAGGTATTTTCCACATGGATATTCACCTGTGG 500

RESULT 12
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455-200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.9%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred.No. 3.3; 24; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 0;

QY 440 TTCATTCCTTTTATCTGTCGAGACTTCGTTTGTTCGAAATATGTATTCATTTTGG 498
DB 624 TTGCTGCATTTCTTTTTTCTAGAATAGGTATTTTCCACATGGATATTCACCTGTGG 566

RESULT 13
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/386,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqlist version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA

```

```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match          0.8%; Score 19.4; DB 1; Length 1361;
Best Local Similarity 55.1%; Pred. No. 6.2;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2160 CTCAGGCGCTATTGTAATAGGGTTTACGAGGACATATGTCCTCGTTGTTATGTCG 2219
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1312 CTGCTGGCTAGGGAATGGGCTCGAGGAGGACTCTCGGGGCTGCTGAGCGCATG 1253

Qy 2220 TGTGTTTGC 2228
      ||| ||| |||
Db 1252 AGCTTTTGC 1244

RESULT 14
US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; PRIOR FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Curasequid version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match          0.8%; Score 17.2; DB 1; Length 1361;
Best Local Similarity 51.3%; Pred. No. 26;
Matches 40; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

Qy 6 CTCCTCTAGTGAAGGTGGGGTCTGAGGCTCAATGGTTGTGATGGTAGAGTATCT 65
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 441 CTCCTCGCTTCGAGGGCCGGAAGTGTGAGACGCTTGAATATCCATGCGAAAAATACCT 500

Qy 66 CATACAGAGGATAGCACT 83
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 501 ATTCTAGAAAAAGAAAT 518

RESULT 15
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
```

```
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match          0.7%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 13;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGCATAGTGTCTCTGGCTTCCTCGATGTTTTATGCCT 1809
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 122 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCGCTGCGCTGCGCTTCGCT 170

RESULT 16
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGCATAGTGTCTCTGGCTTCCTCGATGTTTTATGCCT 1809
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 23 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCGCTGCGCTGCGCTTCGCT 71

RESULT 17
US-10-411-026-7
; Sequence 7, Application US/10411026
```

Publication No. US2004006391A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: Defrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi

TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5053

CURRENT APPLICATION NUMBER: US/10/411,026

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-411-026-7

Query Match

Best Local Similarity 0.7%; Score 17; DB 1; Length 1332;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTGGTTTGCATAGTCTCTGGCTTCCTGATGTTTATGCCT 1809

Db 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTGCTTCTGCT 71

RESULT 18

US-10-410-962-7

Sequence 7, Application US/10410962

Publication No. US20040077836A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND

TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF

FILE REFERENCE: 040853-01-5054

CURRENT APPLICATION NUMBER: US/10/410,962

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-962-7

Query Match

Best Local Similarity 0.7%; Score 17; DB 1; Length 1332;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTGGTTTGCATAGTCTCTGGCTTCCTGATGTTTATGCCT 1809

Db 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTGCTTCTGCT 71

RESULT 19

US-10-411-049-7

Sequence 7, Application US/10411049

Publication No. US20040082026A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

TITLE OF INVENTION: ALPHA

FILE REFERENCE: 040853-01-5055

CURRENT APPLICATION NUMBER: US/10/411,049

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-411-049-7

Query Match

Best Local Similarity 0.7%; Score 17; DB 1; Length 1332;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTGGTTTGCATAGTCTCTGGCTTCCTGATGTTTATGCCT 1809

Db 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTGCTTCTGCT 71

RESULT 20

US-10-410-930-7

Sequence 7, Application US/10410930

Publication No. US20040115168A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

```
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: BETA
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTGCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTTCTCGT 71

RESULT 21
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: FSH
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTGCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTTCTCGT 71

RESULT 22
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTGCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTTCTCGT 71

RESULT 23
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
```

```
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTGCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTTCTCGT 71

RESULT 22
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTGCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGCTGCTGCTTCTCGT 71

RESULT 23
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
```

APPLICANT: Bayer, Robert
APPLICANT: Bove, Caryn
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
FILE REFERENCE: 040853-01-5052-00
CURRENT APPLICATION NUMBER: US/10/287,994
CURRENT FILING DATE: 2002-11-05
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 62
SOFTWARE: PatentIn version 3.1
SEQ ID NO 7
LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-287-994-7

Query Match 0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809
|||||
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 24
US-10-410-913-7
Sequence 7, Application US/10410913
Publication No. US20040142856A1
GENERAL INFORMATION:
APPLICANT: Neose Technologies, Inc.
APPLICANT: DeFrees, Shawn
APPLICANT: Zopf, David
APPLICANT: Bayer, Robert
APPLICANT: Hakes, David
APPLICANT: Chen, Xi
APPLICANT: Bove, Caryn
TITLE OF INVENTION: METHODS
FILE REFERENCE: 040853-01-5081
CURRENT APPLICATION NUMBER: US/10/410,913
CURRENT FILING DATE: 2003-04-09
PRIOR APPLICATION NUMBER: US 60/328,523
PRIOR FILING DATE: 2001-10-10
PRIOR APPLICATION NUMBER: US 60/344,692
PRIOR FILING DATE: 2001-10-19
PRIOR APPLICATION NUMBER: US 60/387,292
PRIOR FILING DATE: 2002-06-07
PRIOR APPLICATION NUMBER: US 60/391,777
PRIOR FILING DATE: 2002-06-25
PRIOR APPLICATION NUMBER: US 60/396,594
PRIOR FILING DATE: 2002-07-17
PRIOR APPLICATION NUMBER: US 60/404,249
PRIOR FILING DATE: 2002-08-16
PRIOR APPLICATION NUMBER: US 60/407,527
PRIOR FILING DATE: 2002-08-28
NUMBER OF SEQ ID NOS: 75
SOFTWARE: PatentIn version 3.2
SEQ ID NO 7

LENGTH: 1332
TYPE: DNA
ORGANISM: Homo sapiens
US-10-410-913-7

Query Match 0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809
|||||
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 25
US-10-617-619-12
Sequence 12, Application US/10617619
Publication No. US20040110929A1
GENERAL INFORMATION:
APPLICANT: Bjorn, Soren E.
APPLICANT: Nicolaissen, Else M
APPLICANT: Jorgensen, Anker S
TITLE OF INVENTION: TF Binding Compound
FILE REFERENCE: 6455.200-US
CURRENT APPLICATION NUMBER: US/10/617,619
CURRENT FILING DATE: 2003-07-11
PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
PRIOR FILING DATE: 2002-07-12
PRIOR APPLICATION NUMBER: US 60/404,568
PRIOR FILING DATE: 2002-08-19
NUMBER OF SEQ ID NOS: 13
SOFTWARE: PatentIn version 3.2
SEQ ID NO 12
LENGTH: 2040
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match 0.7%; Score 17; DB 1; Length 2040;
Best Local Similarity 59.2%; Pred. No. 24;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809
|||||
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 26
US-09-782-587B-2/c
Sequence 2, Application US/09782587B
Publication No. US20030096338A1
GENERAL INFORMATION:
APPLICANT: PEDERSEN, ANDERS H.
APPLICANT: ANDERSON, KIM V.
APPLICANT: BORNAES, CLAUD
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
FILE REFERENCE: 31-001100US
CURRENT APPLICATION NUMBER: US/09/782,587B
CURRENT FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: PA 2000 00218
PRIOR FILING DATE: 2000-02-11
PRIOR APPLICATION NUMBER: 60/184,036
PRIOR FILING DATE: 2000-02-22
PRIOR APPLICATION NUMBER: 60/241,916
PRIOR FILING DATE: 2000-10-18
NUMBER OF SEQ ID NOS: 19
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 2
LENGTH: 1338
TYPE: DNA
ORGANISM: Homo sapiens

```
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match      0.7%; Score 16.6; DB 1; Length 1338;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1228 GGCTCGAATTATTATTATTCATATTTCTTGAATGTG 1266
Db 567 GCCTGGGGTTGCTAGCGTTCGCTTTCTAGAAATGGG 529

RESULT 27
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNHARS, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match      0.7%; Score 16.6; DB 1; Length 1357;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1228 GGCTCGAATTATTATTATTCATATTTCTTGAATGTG 1266
Db 580 GCCTGGGGTTGCTAGCGTTCGCTTTCTAGAAATGGG 542

RESULT 28
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US2003032753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boming
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; FILE REFERENCE: 4001,001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
```

```
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 31;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTTCATAGTGTCTCTGGCTTCCTGGATG 1799
Db 58 TCCTCTGCCTTCTCTGGGCTTCAGGGCTGCCTGGCTG 96

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolson, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TP Binding Compound
; FILE REFERENCE: 6455,200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.7%; Score 16.6; DB 1; Length 2106;
Best Local Similarity 64.1%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTTCATAGTGTCTCTGGCTTCCTGGATG 1799
Db 23 TCCTCTGCCTTCTCTGGGCTTCAGGGCTGCCTGGCTG 61

RESULT 30
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; TITLE OF INVENTION: FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
```

```
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1)-(483)
/ OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match      0.7%; Score 16.4; DB 1; Length 483;
Best Local Similarity 55.2%; Pred. No. 30;
Matches 32; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 686 AGGTCATATGATTTTATGCTAGCTGTGCTGTTTATGAACCTGGGTGACATGG 743
Db 415 AGGACTGGAGTGGTCTTTCGAGGAGCCCCCATCTTGGCAGGACTTGGAGGCACATG 358

RESULT 31
US-10-029-386-9623
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: J02933.1, EVALUATION 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATION 5.00e-76
US-10-029-386-9623

Query Match      0.6%; Score 14.8; DB 1; Length 555;
Best Local Similarity 56.0%; Pred. No. 75;
Matches 28; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 254 TAGGGCATTAGGATTCCTCTCTCTCCAAACACTTCTATTCTTGA 303
Db 12 TGGGGAGTCTCCACCTTCCGTAAGTCTGCGAGGAGTCTGCGTCAATCA 61

RESULT 32
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
```

```
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ FEATURE:
/ OTHER INFORMATION: MAP TO CHR13.3
/ OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
/ OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
/ OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
/ OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
/ OTHER INFORMATION: NT HIT: g114783796, EVALUATION 1.00e-122
/ OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATION 3.00e-26
/ OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATION 3.00e-37
US-10-029-386-23323

Query Match      0.6%; Score 14.6; DB 1; Length 222;
Best Local Similarity 54.7%; Pred. No. 69;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 1905 CTGTCAGTGAGGCTGCTCTGAGGTTCTGTGGTTCTTAATTTTTCATT 1957
Db 152 CTGCCGGAACGAGCGTCTCTGAGGAGCGTCTGCGCTTCTGCGCTTCTCAT 100

RESULT 33
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
/ ORGANISM: Homo sapiens
/ FEATURE:
/ OTHER INFORMATION: MAP TO CHR13.3
/ OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
/ OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
/ OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
/ OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
/ OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUATION 7.00e-63
/ OTHER INFORMATION: NT HIT: J02933.1, EVALUATION 0.00e+00
/ OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUATION 5.00e-76
US-10-029-386-9623

Query Match      0.6%; Score 14.6; DB 1; Length 555;
Best Local Similarity 54.7%; Pred. No. 79;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 1905 CTGTCAGTGAGGCTGCTCTGAGGTTCTGTGGTTCTTAATTTTTCATT 1957
Db 188 CTGCCGGAACGAGCGTCTCTGAGGAGCGTCTGCGCTTCTGCGCTTCTCAT 136

RESULT 34
US-10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
```


Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
| | | | | | | | | | | | | | | | | | | | | |
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGATCCTT 24
| | | | | | | | | | | | | | | | | | | | | |

RESULT 38

US-10-272-665-107/c
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGATCCTT 4
| | | | | | | | | | | | | | | | | | | | | |

RESULT 39

US-10-273-321-107/c
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGATCCTT 4
| | | | | | | | | | | | | | | | | | | | | |

RESULT 40

US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
| | | | | | | | | | | | | | | | | | | | | |
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGATCCTT 4
| | | | | | | | | | | | | | | | | | | | | |

RESULT 41

US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

```
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCCTCTATTCCTT 1765
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 42
US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106-
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCCTCTATTCCTT 1765
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 43
US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCCTCTATTCCTT 1765
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 44
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCCTCTATTCCTT 1765
Db 38 TGTGGCCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 45
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
```

```
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCTTCTCCCTTCTCTCTATTCCTT 1765
Db      |||||
38 TGTGGCCCTCCACTGTCCTCCCTTGGAGGATCCTT 4

RESULT 46
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match      0.6%; Score 14.2; DB 1; Length 1338;
Best Local Similarity 70.4%; Pred. No. 38;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTCTGGCAATCTTCTGGGGCTGCTG 174
Db      |||||
22 CTCTGTGCTGCTCTCTCTGGGGCTGCAG 48

RESULT 47
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
```

```
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match      0.6%; Score 14.2; DB 1; Length 1357;
Best Local Similarity 70.4%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTCTGGCAATCTTCTGGGGCTGCTG 174
Db      |||||
35 CTCTGTGCTGCTCTCTCTGGGGCTGCAG 61

RESULT 48
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AROMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annotmax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: G114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match      0.5%; Score 12; DB 1; Length 222;
Best Local Similarity 58.3%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 763 AAGATTGCAATGCTCTTGGTGGATTTCCTTGTG 798
Db      |||||
112 ACGAAGCCAGCGTCTCTCTAGAGACGTGCTGCTG 147

RESULT 49
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
```

```

; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-349-858-8

Query Match          0.5%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.6%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1925 TGAGGTTCCCTGTTGGGTTCTTAA 1947
Db 29 TGGGCTTCCTCCCTGGGTACGAA 7

RESULT 50
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1999 TTCACCTTTCAGGTCCTG 2016
Db 26 TCCACCTTCCTGCTCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1999 TTCACCTTTCAGGTCCTG 2016
Db 26 TCCACCTTCCTGCTCTG 9

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTTCTTGAAGCTCTGCTGGC 155
Db 10 TAAACGCTTCTCTGGAGGCTGGGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; OTHER INFORMATION:

```

APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
APPLICANT: Pingel, Hans K
APPLICANT: Klausen, Niels K
TITLE OF INVENTION: Factor VII Glycoforms
FILE REFERENCE: 6207.510-US
CURRENT FILING DATE: 2002-10-02
PRIORITY APPLICATION NUMBER: US/09/969,357
PRIORITY FILING DATE: 2002-10-02
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2000 01456
PRIORITY FILING DATE: 2000-10-02
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00262
PRIORITY FILING DATE: 2001-02-16
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00430
PRIORITY FILING DATE: 2001-03-14
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00751
PRIORITY FILING DATE: 2001-05-14
PRIORITY APPLICATION NUMBER: US 60/238,944
PRIORITY FILING DATE: 2000-10-10
PRIORITY APPLICATION NUMBER: US 60/271,581
PRIORITY FILING DATE: 2001-02-26
PRIORITY APPLICATION NUMBER: US 60/276,322
PRIORITY FILING DATE: 2001-03-16
NUMBER OF SEQ ID NOS: 2
SOFTWARE: Patent in version 3.2
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTTCTGAAGCCTCTGCTGGC 155
DB 10 TAAACGGCTTCTCGAGAGCTGCGGCC 38

RESULT 54
US-10-254-394-2
Sequence 2, Application US/10254394
Publication No. US20030096366A1
GENERAL INFORMATION:
APPLICANT: Knudsen, Ida Molgaard
TITLE OF INVENTION: Method for Production of Recombinant
PROTEINS IN EUKARYOTE CELLS
FILE REFERENCE: 6480.500-US
CURRENT FILING DATE: US/10/254,394
PRIORITY APPLICATION NUMBER: PCT/DK01/00632
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PCT/DK01/00634
PRIORITY FILING DATE: 2001-10-02
PRIORITY APPLICATION NUMBER: PA 2002 00460
PRIORITY FILING DATE: 2002-03-26
PRIORITY APPLICATION NUMBER: 60/374,855
PRIORITY FILING DATE: 2002-10-04
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTTCTGAAGCCTCTGCTGGC 155
DB 10 TAAACGGCTTCTCGAGAGCTGCGGCC 38

RESULT 55
US-10-272-665-22
Sequence 22, Application US/10272665
Publication No. US20030180748A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMERASE CHAIN REACTION (PCR) PRODUCTS
FILE REFERENCE: 24736-2033E
CURRENT FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: US/10/272,665
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:
OTHER INFORMATION: Probe
US-10-272-665-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;
Best Local Similarity 56.8%; Pred. No. 3.1e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCTATTGTAATAGGCTTTTAGCAGGACATAT 2198
DB 23 CAAGGACTCTGCAAGGGGAGCAGTGGAGCCCAT 59

RESULT 56
US-10-273-321-22
Sequence 22, Application US/10273321
Publication No. US20030180749A1
GENERAL INFORMATION:
APPLICANT: Braun et al.
TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYMERASE CHAIN REACTION (PCR) PRODUCTS
FILE REFERENCE: 24736-2033B
CURRENT FILING DATE: 2002-10-15
PRIORITY APPLICATION NUMBER: US/10/273,321
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/687,483
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/217,658
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 60/159,176
PRIORITY FILING DATE: 1999-10-13
PRIORITY APPLICATION NUMBER: 60/217,251
PRIORITY FILING DATE: 2000-07-10
PRIORITY APPLICATION NUMBER: 09/663,968
PRIORITY FILING DATE: 2000-09-19
NUMBER OF SEQ ID NOS: 118
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 60
TYPE: DNA
ORGANISM: Homo Sapien
FEATURE:
OTHER INFORMATION: Primer

TITLE OF INVENTION: METHODS FOR GENERATING
 TITLE OF INVENTION: GENETIC MARKERS
 FILE REFERENCE: 24736-2033D
 CURRENT APPLICATION NUMBER: US/10/273,228
 CURRENT FILING DATE: 2002-10-15
 PRIOR APPLICATION NUMBER: 09/687,483
 PRIOR FILING DATE: 2000-07-10

```

; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321

```



```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 3 TGCAGGAGTCTTGGCGCCATCCG 26

RESULT 69
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 31 TGCAGGAGTCTTGGCGCCATCCG 8

RESULT 70
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 3 TGCAGGAGTCTTGGCGCCATCCG 26

RESULT 71
US-09-951-121A-8/c
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTGTAA 2018
      ||||| ||||| ||||| |||||
Db 33 CACGTTGAGGACCTGGA 17

RESULT 72
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
```

```
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20

RESULT 73
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20

RESULT 74
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20

RESULT 75
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCCTGAA 2018
DB 33 CACGTTGAGGACCTGGA 17

RESULT 76
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20
```

```
RESULT 77
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 78
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 79
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; OTHER INFORMATION:
US-10-272-665-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 1085 TGTGATTCTTGTATCTTGCACCTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACCGTCCCGGTAGTGGGTG 2

RESULT 80
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; OTHER INFORMATION:
US-10-273-321-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 1085 TGTGATTCTTGTATCTTGCACCTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACCGTCCCGGTAGTGGGTG 2

RESULT 81
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
```

GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTTATCTTCACCTGTGAGAGTGTGTGTG 1125
DB 42 TGAGATGCCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 82
US-10-273-228-23/c
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTTATCTTCACCTGTGAGAGTGTGTGTG 1125
DB 42 TGACGATGCCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 83

US-10-281-727-2/c
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match 0.5%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1911 GTGAGGCTTCTCTCTGAGGTTCTCTGTTG 1938
DB 35 GGGAGTCTCCACGTCGCGTTCCTGCTG 8

RESULT 84
US-10-281-727-3
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match 0.5%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 4.8e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1911 GTGAGGCTTCTCTCTGAGGTTCTCTGTTG 1938
DB 2 GGGAGTCTCCACGTCGCGTTCCTGCTG 29

RESULT 85
US-10-281-727-6
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1

```
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      16 GAAAGTGGGGTCT 30
Db      16 GGAAGTGGGAGACT 30

RESULT 86
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      16 GAAAGTGGGGTCT 30
Db      17 GGAAGTGGGAGACT 3

RESULT 87
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2135 CCTGTGCTTCAGCT 2149
Db      9 CCTGTGCTCCAGGT 23

RESULT 88
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2135 CCTGTGCTTCAGCT 2149
Db      28 CCTGTGCTCCAGGT 14

RESULT 89
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
```

```
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2135 CCTGTGCTTCAGCT 2149
Db 9 CCTGGTGCTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/255,032
; PRIOR FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: PA 2000 01361
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; PRIOR FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2135 CCTGTGCTTCAGCT 2149
Db 28 CCTGGTGCTCCAGGT 14

RESULT 91
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2135 CCTGTGCTTCAGCT 2149
Db 28 CCTGGTGCTCCAGGT 14

RESULT 93
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; OTHER INFORMATION: Synthetic
```

SOFTWARE: PatentIn version 3.2
SEQ ID NO 20
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match 0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATCTCTCGGGCTG 171
Db 34 GCAGCTCCTCCAGGAAGCGTTTAGCGCG 4

RESULT 94
US-09-969-357-2/c
Sequence 2, Application US/09969357
Publication No. US20020137673A1
GENERAL INFORMATION:
APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
APPLICANT: Pingel, Hans K
APPLICANT: Klausen, Niels K
TITLE OF INVENTION: Factor VII Glycoforms
FILE REFERENCE: 6207.510-US
CURRENT APPLICATION NUMBER: US/09/969,357
CURRENT FILING DATE: 2002-10-02
PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
PRIOR FILING DATE: 2000-10-02
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
PRIOR FILING DATE: 2001-02-16
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
PRIOR FILING DATE: 2001-03-14
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
PRIOR FILING DATE: 2001-05-14
PRIOR APPLICATION NUMBER: US 60/238,944
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/271,581
PRIOR FILING DATE: 2001-02-26
PRIOR APPLICATION NUMBER: US 60/276,322
PRIOR FILING DATE: 2001-03-16
NUMBER OF SEQ ID NOS: 2
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial
FEATURE:
OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATCTCTCGGGCTG 171
Db 34 GCAGCTCCTCCAGGAAGCGTTTAGCGCG 4

RESULT 95
US-10-254-394-2/c
Sequence 2, Application US/10254394
Publication No. US2003009366A1
GENERAL INFORMATION:
APPLICANT: Knudsen, Ida Molgaard
TITLE OF INVENTION: Method for Production of Recombinant
TITLE OF INVENTION: Proteins in Eukaryote Cells
FILE REFERENCE: 6480.500-US
CURRENT APPLICATION NUMBER: US/10/254,394

CURRENT FILING DATE: 2002-09-25
PRIOR APPLICATION NUMBER: PCT/DK01/00632
PRIOR FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: PCT/DK01/00634
PRIOR FILING DATE: 2001-10-02
PRIOR APPLICATION NUMBER: PA 2002 00460
PRIOR FILING DATE: 2002-03-26
PRIOR APPLICATION NUMBER: 60/374,855
PRIOR FILING DATE: 2002-10-04
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 38
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.4%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 5.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATCTCTCGGGCTG 171
Db 34 GCAGCTCCTCCAGGAAGCGTTTAGCGCG 4

RESULT 96
US-10-109-498-5/c
Sequence 5, Application US/10109498
Publication No. US20030044908A1
GENERAL INFORMATION:
APPLICANT: Persson, Egon
TITLE OF INVENTION: Coagulation Factor VII Derivatives
FILE REFERENCE: 6286.200-US
CURRENT APPLICATION NUMBER: US/10/109,498
CURRENT FILING DATE: 2002-03-22
PRIOR APPLICATION NUMBER: 60/281,261
PRIOR FILING DATE: 2001-04-03
PRIOR APPLICATION NUMBER: PA 2001 00477
PRIOR FILING DATE: 2001-03-22
NUMBER OF SEQ ID NOS: 20
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 5
LENGTH: 35
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 679 GTGTGTGAGGTCAATATGTGATTTAGTGATG 712
Db 34 GTCAGTAGGACACGGGACAGTCACGGCGGAGC 1

RESULT 97
US-10-109-498-6
Sequence 6, Application US/10109498
Publication No. US20030044908A1
GENERAL INFORMATION:
APPLICANT: Persson, Egon
TITLE OF INVENTION: Coagulation Factor VII Derivatives
FILE REFERENCE: 6286.200-US
CURRENT APPLICATION NUMBER: US/10/109,498
CURRENT FILING DATE: 2002-03-22
PRIOR APPLICATION NUMBER: 60/281,261
PRIOR FILING DATE: 2001-04-03

; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 6.2e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 679 GTGTGAGCTCATATGTCATTTAGCTGTAGC 712
DB 2 GTGAGTGGAGCACCGGACAGTGCAGGCGGAGC 35

RESULT 98

US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:

; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match 0.4%; Score 9.8; DB 1; Length 54;
Best Local Similarity 84.6%; Pred. No. 7.3e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 117 AGACATTCATAA 129
DB 1 AGAGTCTTCGTA 13

RESULT 99

US-10-272-665-23
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
DB 4 CCCACTACCGGGCACGTGGT 24

RESULT 100

US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGAGGT 689
DB 4 CCCACTACCGGGCACGTGGT 24

RESULT 101

US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23
Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 669 CCCACTATCTGTGTGTGAGGT 689
DB 4 CCCACTACGGGGCAGGTGGT 24
RESULT 102
US-10-273-228-23
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
Query Match 0.4%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 7.1e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 669 CCCACTATCTGTGTGTGAGGT 689
DB 4 CCCACTACGGGGCAGGTGGT 24
RESULT 103
US-10-109-498-5
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22

; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5
Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 1599 TGCACGTGGGGAGTTTCT 1617
DB 9 TGCACGTGCCCGTGTCT 27
RESULT 104
US-10-109-498-6/c
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6
Query Match 0.4%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 8.8e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 1599 TGCACGTGGGGAGTTTCT 1617
DB 27 TGCACGTGCCCGTGTCT 9
RESULT 105
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA

; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match 0.4%; Score 9.2; DB 1; Length 31;
Best Local Similarity 56.7%; Pred. No. 9.6e+02;
Matches 17; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1620 TCCGGTCCAACTATTGGTGTGTTTGTATG 1649
Db 2 TCCTGTCCGTCCCATGAGGGGTACTCTCTG 31

RESULT 106

US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 107

US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR FILING DATE: 2000-09-29
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.8%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 108

US-10-295-682-2
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 109

US-10-295-682-3/c
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295.682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.4%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 9.7e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAAGTGTGTGTGTGTGTGTG 1133
Db 32 GAATTGTGGGGCGCGGTGTG 11

```

US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 193 TCCTAGGTCAGGTTTACCCTGCT 217
Db 4 TACTCGGATGCGCGCAAGGACTCCT 28

RESULT 113
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 193 TCCTAGGTCAGGTTTACCCTGCT 217
Db 30 TACTCGGATGCGCGCAAGGACTCCT 6

RESULT 114
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon

```

```

US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match      0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 968 TGGATCGACGAGTA 981
Db 2 TGCCTGCACGAGGA 15

RESULT 111
US-10-281-727-3/c
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match      0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 968 TGGATCGACGAGTA 981
Db 35 TGCCTGCACGAGGA 22

RESULT 112

```


US-10-017-122-4

Query Match 0.4%; Score 8.2; DB 1; Length 31;
Best Local Similarity 61.9%; Pred. No. 1.4e+03;
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1384 CAGAAAGTTTCTTAAGTCA 1404
|||||
Db 31 CAGAGAGTACCCCTCATGGCA 11

RESULT 119

US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756
|||||
Db 31 TTGTGGGCACA 21

RESULT 120

US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756
|||||
Db 4 TTGTGGGCACA 14

RESULT 121

US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756
|||||
Db 31 TTGTGGGCACA 21

RESULT 122

US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756
|||||
Db 4 TTGTGGGCACA 14

Mon Aug 9 17:47:28 2004

10664775-4.rnpb

Page 34

Search completed: August 9, 2004, 16:55:08
Job time : 32 secs

TITLE
JOURNAL
COMMENT

The WashU-HHMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. 609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTITTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTCGACACA."

Query Match 0.7%; Score 16.3; DB 1; Length 609;
Best Local Similarity 63.5%; Pred. No. 4.3;
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

Qy 166 GGCTGCTGCTTTTCTCCCTGCTGATTCCTAGGTAGGGTTAC-CACCTGCTCTCTC 224
|||||
Db 209 GGCTGCTTGAAGATCCCGGCGCTCTCAAGAGAGACATGTTCTCTCATGCTCTCTC 150
|||||

Qy 225 TCC 227
149 TCC 147

RESULT 6
AI099321
LOCUS
DEFINITION
ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1482509.5, similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN)); mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 609)
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Willson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)

REFERENCE
AUTHORS
JOURNAL
COMMENT

TITLE
JOURNAL
COMMENT

The WashU-HHMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. 609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTITTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTCGACACA."

Query Match 0.7%; Score 16.3; DB 1; Length 609;
Best Local Similarity 63.5%; Pred. No. 4.3;
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

Qy 166 GGCTGCTGCTTTTCTCCCTGCTGATTCCTAGGTAGGGTTAC-CACCTGCTCTCTC 224
|||||
Db 209 GGCTGCTTGAAGATCCCGGCGCTCTCAAGAGAGACATGTTCTCTCATGCTCTCTC 150
|||||

Qy 225 TCC 227
149 TCC 147

RESULT 6
AI099321
LOCUS
DEFINITION
ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1482509.5, similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN)); mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
1 (bases 1 to 609)
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Willson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)

REFERENCE
AUTHORS
JOURNAL
COMMENT

TITLE
JOURNAL
COMMENT

The WashU-HHMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. 609
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTITTTTTTTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTCGACACA."

Query Match 0.6%; Score 14.4; DB 1; Length 609;
Best Local Similarity 65.8%; Pred. No. 7.4;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 519 CAAGAAGGTACAGTCTTTGTGTTTGGTGAA 550
|||||
Db 360 CAAGATGAACAGTTGATCTGTGCAAAATGAA 391
|||||

RESULT 7
AI116939
LOCUS
DEFINITION
ue29g08.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1481822.5, similar to gb:M13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN)); mRNA sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 645)
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Willson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HHMI Mouse EST Project
Washington University School of MedicineP
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930178

Seq primer: custom primer used
High quality sequence stop: 483.

FEATURES

```

source
1..645
  /organism="Mus musculus"
  /mol_type="mRNA"
  /strain="C57BL"
  /db_xref="taxon:10090"
  /clone="IMAGE:1481822"
  /sex="female"
  /dev_stage="adult"
  /lab_host="DH10B"
  /clone_lib="Sugano mouse liver mlia"
  /notes="Organ: liver; Vector: pME18S-FL3; Site_1: DraIII
(CACTGTGTG); Site_2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [GTGTGGCCACTGTG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTGTCTCTAAAGCTGG and 3' end
primer CGACCTGCAGCTCGAGCACA."

```

Query Match 0.8%; Score 13.8; DB 1; Length 645;

Best Local Similarity 56.4%; Pred. No. 7.7; Mismatches 32; Indels 2; Gaps 1;

```

Matches 44; Conservative 0;
QY 2129 TCCTTGCCTTGTCTTCAGCTATGTTCATCTCAGGCG--CTATTGTAAATAGGGTTTAA 2186
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 50 TCCTCTGCTTTCGTCTCAGCTCCAGGAGCTCTAGGAGCTGCAGTTCATTAACCCAGGA 109

```

```

QY 2187 GCAGGGACATATTGTCTCT 2204
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 110 GGAAGCACATGGTGTCTCT 127

```

RESULT 8

AU099140/c

LOCUS

DEFINITION AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVII2463, mRNA sequence.

ACCESSION AU099140

VERSION AU099140.1 GI:13550269

KEYWORDS EST.

SOURCE Homo sapiens (human)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 300)

Authors: Suzuki, Y., Tsunoda, T., Taira, H., Mizushima-Sugano, J., Sese, J.,
Okubo, K., Suyama, A. and Sugano, S.

Title: In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by

Oligo-capping method

Unpublished (2001)

Contact: Yutaka Suzuki

Department of Virology

Institute of Medical Science, University of Tokyo

4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan

Email: ysuzuki@ims.u-tokyo.ac.jp

Suzuki, Y., Yoshitomo-Nakagawa, K., Maruyama, K., Suyama, A. and

Sugano, S. Construction and characterization of a full

length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),

149-156 (1997).

Location/Qualifiers

source

1..300

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/clone="HEP20983"

/clone_lib="Sugano Homo sapiens cDNA library"

Query Match

Best Local Similarity 61.1%; Score 13.6; DB 1; Length 300;

Matches 22; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 756 AGACATTAAAGAAATTCGAATGTCCTCTTGTGGATTT 791

||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

Db 277 AGAATCCAGACAGCTTCGTCCTCTCGCGTCCTT 242

Search completed: August 9, 2004, 16:55:39

Job time : 4 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:38:01 ; Search time 629 Seconds
(without alignments)
3.846 Million cell updates/sec

Title: us-10-664-775-3

Perfect score: 2003

Sequence: 1 agcttcacagagacttca.....tcaaggacatttatgaatt 2003

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Listing first 250 summaries

Database : rgedb:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	44.7	2.2	289	1	AR162089
C 2	44.7	2.2	289	1	AR166614
C 3	43	2.1	2422	1	AR030786
C 4	43	2.1	2422	1	AR045090
C 5	43	2.1	2422	1	AR052946
C 6	43	2.1	2422	1	AR122899
C 7	43	2.1	2422	1	AR127821
C 8	43	2.1	2462	1	AR095304
C 9	43	2.1	2462	1	AR103988
C 10	43	2.1	2462	1	AX335083
C 11	43	2.1	2462	1	AX409604
C 12	43	2.1	2462	1	HUMFV11
C 13	43	2.1	2483	1	E01076
C 14	43	2.1	2483	1	I07990
C 15	41.6	2.1	2177	1	E01075
C 16	41.6	2.1	2438	1	I07991
C 17	37.4	1.9	1573	1	BC040125
C 18	32.4	1.6	300	1	BD211952
C 19	28	1.4	1403	1	BC009726
C 20	27.2	1.4	1792	1	BC034377
C 21	25.2	1.3	1843	1	AR390759
C 22	25.2	1.3	1843	1	AX411026
C 23	25.2	1.3	1843	1	HSRPTC
C 24	24.4	1.2	251	1	AY083553
C 25	24	1.2	1439	1	MUSCP
C 26	24	1.2	1580	1	AF318182
C 27	24	1.2	1603	1	BC013896
C 28	23.8	1.2	364	1	AR425705
C 29	23.8	1.2	364	1	BD121258
C 30	23.8	1.2	394	1	AX399180
C 31	23.8	1.2	868	1	BD124660
C 32	23.8	1.2	868	1	BD124660
C 33	23.6	1.2	1671	1	AY040345

C 34	23	1.1	364	1	AR425705
C 35	23	1.1	364	1	BD121258
C 36	23	1.1	1329	1	AF465274
C 37	23	1.1	1507	1	AX774765
C 38	23	1.1	1507	1	HUMFACX
C 39	22	1.1	193	1	HUMKALR4
C 40	22	1.1	385	1	AX892787
C 41	22	1.1	385	1	BD028320
C 42	22	1.1	409	1	AX839163
C 43	21.8	1.1	274	1	AF306920
C 44	21.6	1.1	860	1	AF011898
C 45	21.6	1.1	861	1	AF011352
C 46	21.6	1.1	1869	1	BC061149
C 47	21.4	1.1	1129	1	AX464088
C 48	21.4	1.1	1129	1	AX359106
C 49	21.4	1.1	6098	1	AX565990
C 50	21.2	1.1	1541	1	BC046125
C 51	21	1.0	267	1	BD060364
C 52	21	1.0	289	1	AR162089
C 53	21	1.0	289	1	AR166614
C 54	21	1.0	1732	1	AF515269
C 55	20.8	1.0	484	1	RATCFX
C 56	20.6	1.0	1206	1	E63001
C 57	20.6	1.0	1206	1	E63002
C 58	20.6	1.0	1221	1	E62997
C 59	20.6	1.0	1221	1	E62998
C 60	20.6	1.0	1221	1	E62999
C 61	20.6	1.0	1221	1	E63000
C 62	20.6	1.0	1440	1	AR112953
C 63	20.6	1.0	1440	1	AR112969
C 64	20.6	1.0	1440	1	I19358
C 65	20.6	1.0	1440	1	I19360
C 66	20.6	1.0	1440	1	BD194674
C 67	20.6	1.0	6098	1	AX565990
C 68	20.4	1.0	223	1	AX908508
C 69	20.4	1.0	223	1	BD044041
C 70	20.4	1.0	280	1	AF306917
C 71	20.4	1.0	280	1	AF306913
C 72	20.4	1.0	280	1	AF306914
C 73	20.4	1.0	280	1	AF306915
C 74	20.4	1.0	280	1	AF306919
C 75	20.4	1.0	2072	1	AF272774
C 76	20.2	1.0	183	1	AY155152
C 77	20.2	1.0	214	1	AB083386
C 78	20.2	1.0	214	1	AB084901
C 79	20.2	1.0	227	1	AY022473
C 80	20.2	1.0	227	1	AY023221
C 81	20.2	1.0	272	1	HUMPROS01
C 82	20.2	1.0	352	1	HUMPS02
C 83	20.2	1.0	885	1	AR108139
C 84	20.2	1.0	1543	1	AX401899
C 85	20.2	1.0	1543	1	RNPROC
C 86	20	1.0	855	1	AF011899
C 87	20	1.0	1130	1	AR234337
C 88	20	1.0	1142	1	AR219285
C 89	20	1.0	1166	1	AR212173
C 90	20	1.0	1169	1	AR219284
C 91	20	1.0	1722	1	AF515269
C 92	19.8	1.0	254	1	AX587861
C 93	19.8	1.0	268	1	HSLKB1P07
C 94	19.8	1.0	384	1	BD095271
C 95	19.8	1.0	394	1	AX814618
C 96	19.8	1.0	556	1	BV036036
C 97	19.8	1.0	813	1	PIGRIFA
C 98	19.8	1.0	1850	1	MMU44795
C 99	19.8	1.0	2078	1	AF272773
C 100	19.6	1.0	474	1	HAMCFX
C 101	19.6	1.0	596	1	AX193364
C 102	19.6	1.0	609	1	AX763043
C 103	19.6	1.0	873	1	HUMCFIX
C 104	19.6	1.0	882	1	AX675583
C 105	19.6	1.0	1142	1	BD219285
C 106	19.6	1.0	1161	1	AX675581

ACCESSION:AR425705
ACCESSION:BD121258
ACCESSION:AF465274
ACCESSION:AX774765
ACCESSION:M57285
ACCESSION:M33108
ACCESSION:AX892787
ACCESSION:BD028320
ACCESSION:AX839163
ACCESSION:AF306920
ACCESSION:AF011898
ACCESSION:AF011352
ACCESSION:BC061149
ACCESSION:AX464088
ACCESSION:AV359106
ACCESSION:AX565990
ACCESSION:BD060364
ACCESSION:AR162089
ACCESSION:AR166614
ACCESSION:AF515269
ACCESSION:D21215
ACCESSION:E63001
ACCESSION:E63002
ACCESSION:E62997
ACCESSION:E62998
ACCESSION:E62999
ACCESSION:E63000
ACCESSION:AR112953
ACCESSION:AR112969
ACCESSION:I19358
ACCESSION:I19360
ACCESSION:BD194674
ACCESSION:AX565990
ACCESSION:AX908508
ACCESSION:BD044041
ACCESSION:AF306917
ACCESSION:AF306913
ACCESSION:AF306914
ACCESSION:AF306915
ACCESSION:AF306919
ACCESSION:AF272774
ACCESSION:AY155152
ACCESSION:AB083386
ACCESSION:AB084901
ACCESSION:AY022473
ACCESSION:AY023221
ACCESSION:M36551
ACCESSION:M57841
ACCESSION:AR108139
ACCESSION:AX401899
ACCESSION:AX64336
ACCESSION:AF011899
ACCESSION:AR234337
ACCESSION:AR219285
ACCESSION:AR212173
ACCESSION:AR219284
ACCESSION:AF515269
ACCESSION:AX587861
ACCESSION:AF055326
ACCESSION:BD095271
ACCESSION:AX814618
ACCESSION:BV036036
ACCESSION:M26235
ACCESSION:U44795
ACCESSION:AF272773
ACCESSION:D21216
ACCESSION:AX193364
ACCESSION:AX763043
ACCESSION:M35672
ACCESSION:AX675583
ACCESSION:AR219285
ACCESSION:AX675581

C 107	19.6	1.0	1169	1	AR219284	ACCESSION:AR219284	C 180	18.6	0.9	1467	1	AX082959	ACCESSION:AX082959
C 108	19.4	1.0	177	1	AR109618	ACCESSION:AR109618	C 181	18.6	0.9	1467	1	BD070392	ACCESSION:BD070392
C 109	19.4	1.0	177	1	AR150638	ACCESSION:AR150638	C 182	18.6	0.9	1467	1	BD070435	ACCESSION:BD070435
C 110	19.4	1.0	177	1	E16187	ACCESSION:E16187	C 183	18.6	0.9	1514	1	AF191307	ACCESSION:AF191307
C 111	19.4	1.0	177	1	E27213	ACCESSION:E27213	C 184	18.4	0.9	193	1	HUMKALR4	ACCESSION:HUMKALR4
C 112	19.4	1.0	177	1	E28271	ACCESSION:E28271	C 185	18.4	0.9	249	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 113	19.4	1.0	177	1	AR300928	ACCESSION:AR300928	C 186	18.4	0.9	249	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 114	19.4	1.0	204	1	AR109885	ACCESSION:AR109885	C 187	18.4	0.9	249	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 115	19.4	1.0	204	1	AR150703	ACCESSION:AR150703	C 188	18.4	0.9	249	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 116	19.4	1.0	249	1	AX596104	ACCESSION:AX596104	C 189	18.4	0.9	249	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 117	19.4	1.0	290	1	AX839191	ACCESSION:AX839191	C 190	18.4	0.9	256	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 118	19.4	1.0	352	1	HUMS602	ACCESSION:HUMS602	C 191	18.4	0.9	264	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 119	19.4	1.0	394	1	AX839180	ACCESSION:AX839180	C 192	18.4	0.9	279	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 120	19.4	1.0	471	1	DOGA2	ACCESSION:DOGA2	C 193	18.4	0.9	279	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 121	19.4	1.0	823	1	SHPTXIA	ACCESSION:SHPTXIA	C 194	18.4	0.9	279	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 122	19.4	1.0	829	1	BC061135	ACCESSION:BC061135	C 195	18.4	0.9	279	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 123	19.4	1.0	1126	1	AR095306	ACCESSION:AR095306	C 196	18.4	0.9	283	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 124	19.4	1.0	1126	1	AR103990	ACCESSION:AR103990	C 197	18.4	0.9	285	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 125	19.4	1.0	1126	1	HUMFX	ACCESSION:HUMFX	C 198	18.4	0.9	285	1	HUMDEBIA	ACCESSION:HUMDEBIA
C 126	19.4	1.0	1404	1	A93124	ACCESSION:A93124	C 199	18.4	0.9	804	1	AF312826	ACCESSION:AF312826
C 127	19.4	1.0	1414	1	HUMCFX	ACCESSION:HUMCFX	C 200	18.4	0.9	823	1	SHPTXIA	ACCESSION:SHPTXIA
C 128	19.4	1.0	1551	1	AX147505	ACCESSION:AX147505	C 201	18.4	0.9	832	1	AF011900	ACCESSION:AF011900
C 129	19.4	1.0	1850	1	MMU44795	ACCESSION:MMU44795	C 202	18.4	0.9	1293	1	AF465275	ACCESSION:AF465275
C 130	19.4	1.0	1869	1	BC061149	ACCESSION:BC061149	C 203	18.4	0.9	1505	1	AX523898	ACCESSION:AX523898
C 131	19.2	1.0	281	1	MUSACROS02	ACCESSION:MUSACROS02	C 204	18.2	0.9	171	1	S78934	ACCESSION:S78934
C 132	19.2	1.0	471	1	GOTR3	ACCESSION:GOTR3	C 205	18.2	0.9	240	1	AX318568	ACCESSION:AX318568
C 133	19.2	1.0	596	1	BOV094002	ACCESSION:BOV094002	C 206	18.2	0.9	251	1	AY083553	ACCESSION:AY083553
C 134	19.2	1.0	826	1	RABTHRO	ACCESSION:RABTHRO	C 207	18.2	0.9	265	1	HSTCRB9	ACCESSION:HSTCRB9
C 135	19.2	1.0	1302	1	AF465270	ACCESSION:AF465270	C 208	18.2	0.9	836	1	AF011901	ACCESSION:AF011901
C 136	19.2	1.0	1373	1	BOVPBC	ACCESSION:BOVPBC	C 209	18.2	0.9	987	1	AF542056	ACCESSION:AF542056
C 137	19.2	1.0	1619	1	OCU77477	ACCESSION:OCU77477	C 210	18.2	0.9	1558	1	AX523898	ACCESSION:AX523898
C 138	19.2	1.0	244	1	HSCRYB2S3	ACCESSION:HSCRYB2S3	C 211	18.2	0.9	199	1	S68634	ACCESSION:S68634
C 139	18.8	0.9	340	1	AR263850	ACCESSION:AR263850	C 212	18.2	0.9	276	1	AY267909S2	ACCESSION:AY267909S2
C 140	18.8	0.9	340	1	AR263851	ACCESSION:AR263851	C 213	18.2	0.9	276	1	HSAS07648	ACCESSION:HSAS07648
C 141	18.8	0.9	352	1	DMU58868	ACCESSION:DMU58868	C 214	18.2	0.9	276	1	HSJAAGN2	ACCESSION:HSJAAGN2
C 142	18.8	0.9	586	1	AX193364	ACCESSION:AX193364	C 215	18.2	0.9	290	1	AR249144	ACCESSION:AR249144
C 143	18.8	0.9	882	1	AX675583	ACCESSION:AX675583	C 216	18.2	0.9	299	1	AX312474	ACCESSION:AX312474
C 144	18.8	0.9	1161	1	AX675581	ACCESSION:AX675581	C 217	18.2	0.9	302	1	ATA271156	ACCESSION:ATA271156
C 145	18.8	0.9	1505	1	AX523898	ACCESSION:AX523898	C 218	18.2	0.9	383	1	AF266240	ACCESSION:AF266240
C 146	18.8	0.9	1671	1	AY040345	ACCESSION:AY040345	C 219	18.2	0.9	815	1	AX921761	ACCESSION:AX921761
C 147	18.6	0.9	168	1	AR077689	ACCESSION:AR077689	C 220	18.2	0.9	873	1	HUMCFIX	ACCESSION:HUMCFIX
C 148	18.6	0.9	168	1	AR081819	ACCESSION:AR081819	C 221	18.2	0.9	1329	1	AF465274	ACCESSION:AF465274
C 149	18.6	0.9	168	1	AR098999	ACCESSION:AR098999	C 222	18.2	0.9	1389	1	E02492	ACCESSION:E02492
C 150	18.6	0.9	168	1	AR116830	ACCESSION:AR116830	C 223	17.8	0.9	177	1	AX381010	ACCESSION:AX381010
C 151	18.6	0.9	168	1	AR127061	ACCESSION:AR127061	C 224	17.8	0.9	239	1	AR152169	ACCESSION:AR152169
C 152	18.6	0.9	168	1	AR141647	ACCESSION:AR141647	C 225	17.8	0.9	315	1	AX400017	ACCESSION:AX400017
C 153	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 226	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 154	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 227	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 155	18.6	0.9	174	1	HUMPRBS01	ACCESSION:HUMPRBS01	C 228	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 156	18.6	0.9	189	1	AY135778S1	ACCESSION:AY135778S1	C 229	17.8	0.9	927	1	AX375719	ACCESSION:AX375719
C 157	18.6	0.9	189	1	AY135778S1	ACCESSION:AY135778S1	C 230	17.8	0.9	1077	1	AY030095	ACCESSION:AY030095
C 158	18.6	0.9	200	1	AR047835	ACCESSION:AR047835	C 231	17.8	0.9	1125	1	AB056161	ACCESSION:AB056161
C 159	18.6	0.9	222	1	AR047835	ACCESSION:AR047835	C 232	17.8	0.9	1278	1	AF465268	ACCESSION:AF465268
C 160	18.6	0.9	241	1	HS88A12P	ACCESSION:HS88A12P	C 233	17.8	0.9	1543	1	AX401899	ACCESSION:AX401899
C 161	18.6	0.9	241	1	HS88A12P	ACCESSION:HS88A12P	C 234	17.8	0.9	1543	1	BNP3OC	ACCESSION:BNP3OC
C 162	18.6	0.9	427	1	AX524284	ACCESSION:AX524284	C 235	17.8	0.9	1551	1	AX147505	ACCESSION:AX147505
C 163	18.6	0.9	427	1	AX524284	ACCESSION:AX524284	C 236	17.6	0.9	121	1	AX264997	ACCESSION:AX264997
C 164	18.6	0.9	439	1	AX277349	ACCESSION:AX277349	C 237	17.6	0.9	121	1	AX264998	ACCESSION:AX264998
C 165	18.6	0.9	439	1	AX277375	ACCESSION:AX277375	C 238	17.6	0.9	121	1	AX265001	ACCESSION:AX265001
C 166	18.6	0.9	484	1	MACCFX	ACCESSION:MACCFX	C 239	17.6	0.9	121	1	AX265002	ACCESSION:AX265002
C 167	18.6	0.9	546	1	AX775014	ACCESSION:AX775014	C 240	17.6	0.9	121	1	AX265005	ACCESSION:AX265005
C 168	18.6	0.9	624	1	AX335885	ACCESSION:AX335885	C 241	17.6	0.9	121	1	AX265006	ACCESSION:AX265006
C 169	18.6	0.9	711	1	BD173590	ACCESSION:BD173590	C 242	17.6	0.9	121	1	AX265009	ACCESSION:AX265009
C 170	18.6	0.9	773	1	AX827818	ACCESSION:AX827818	C 243	17.6	0.9	121	1	AX265010	ACCESSION:AX265010
C 171	18.6	0.9	773	1	RNTRY2	ACCESSION:RNTRY2	C 244	17.6	0.9	121	1	AX265013	ACCESSION:AX265013
C 172	18.6	0.9	819	1	DOGRYPA	ACCESSION:DOGRYPA	C 245	17.6	0.9	121	1	AX265014	ACCESSION:AX265014
C 173	18.6	0.9	854	1	PVTRYPIN	ACCESSION:PVTRYPIN	C 246	17.6	0.9	121	1	AX265025	ACCESSION:AX265025
C 174	18.6	0.9	1278	1	AF465268	ACCESSION:AF465268	C 247	17.6	0.9	121	1	AX265017	ACCESSION:AX265017
C 175	18.6	0.9	1443	1	HUMFXM	ACCESSION:HUMFXM	C 248	17.6	0.9	121	1	AX265018	ACCESSION:AX265018
C 176	18.6	0.9	1467	1	AB6859	ACCESSION:AB6859	C 249	17.6	0.9	121	1	AX265019	ACCESSION:AX265019
C 177	18.6	0.9	1467	1	AB6886	ACCESSION:AB6886	C 250	17.6	0.9	121	1	AX265030	ACCESSION:AX265030
C 178	18.6	0.9	1467	1	AR316969	ACCESSION:AR316969							
C 179	18.6	0.9	1467	1	AR340866	ACCESSION:AR340866							

ALIGNMENTS

[illegible]

RESULT 3
 ARQ030786/c
 LOCUS
 DEFINITION
 ARQ030786
 ACCESSION
 ARQ030786
 VERSION
 ARQ030786.1
 KEYWORDS
 GI:5944000
 SOURCE
 Unknown.
 ORGANISM
 Unknown.
 Unclassified.
 1 (bases 1 to 2422)
 Bekner, K.L., Petersen, L.Christian. and Hart, C.E.
 Modified Factor VII
 Patent: US 5861374-A 1 19-JAN-1999;
 Location/Qualifiers
 1..2422
 /organism="unknown"
 /mol_type="unassigned DNA"
 source

```

RESULT 4
LOCUS      ARO45090/c
DEFINITION Sequence 1 from patent US 5817788.
ACCESSION  ARO45090
VERSION     ARO45090.1
KEYWORDS   GI:5966555
SOURCE      Unknown.
ORGANISM    Unknown.
REFERENCE   1 (bases 1 to 2422)
AUTHORS     Berkner,K.L., Petersen,L.Christian., Hart,C.E., Hedner,U. and
              Bregengaard,C.
TITLE        Modified factor VII
JOURNAL      Patent: US 5817788-A 1 06-OCT-1998;
FEATURES
            Location/Qualifiers
                source          1..2422
                                /organism="unknown"
                                /mol_type="unassigned DNA"

```

```

Query Match      2.1%; Score 43; DB 1; Length 2422;
Best Local Similarity 58.0%; Pred. No. 9.9e-05;
Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 952 TGTGTGAGAAATATCAATGACGACAGCTGTTTGTGGATCTTTGTTATCTTGCACTTGGAAGTG 1011

Db 1946 TGTGCATATCTATGTGCGTGTGCATCGGTGTGTTTGCGTATCTGTGTGACCATCTG 1887

```


Query Match 2.1%; Score 43; DB 1; Length 2462;
Best Local Similarity 58.0%; Pred. No. 9.9e-05;

RESULT 12	HUMVII	2462 bp	linear	PRI 13-FEB-1996
LOCUS	Human factor VII	serine protease precursor mRNA, complete cds,		
DEFINITION	clone lambda-HVII2463.			
ACCESSION	M12322			
VERSION	M12322.1	GI:182799		
KEYWORDS	factor VII; serine protease; serum glycoprotein.			
SOURCE	Homo sapiens (human)			
ORGANISM	Homo sapiens			
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.			
AUTHORS	Hagen, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C., Woodbury, R.G., Hart, C.E., Insley, M., Kiesel, W., Kurachi, K. and Davie, E.W.			
TITLE	Characterization of a cDNA coding for human factor VII			
JOURNAL	Proc. Natl. Acad. Sci. U.S.A.	83 (8)	2412-2416	(1986)

[illegible]

REFERENCE
AUTHORS
TITLE
JOURNAL

REMARK
COMMENT

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
1 (bases 1 to 1573)
Strausberg, R.
Direct Submission
Submitted (22-NOV-2002) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgc.nci.nih.gov>
Contact: MGC help desk
Email: cgabbs@mail.nih.gov
Tissue Procurement: Life Technologies, Inc.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
<http://www.systemsbio.org>
contact: anadans@systemsbiology.org
Anup Madan, Jessica Fahney, Erin Helton, Mark Kettelman, Anuradha
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAK plate: 84 Row: m Column: 9
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 9961350.
Location/Qualifiers
1..1573
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="IMAGE:5764698"
/tissue_type="Brain", adult, 6 pooled whole brains"
/clone_id="NIH MGC_114"
/lab_host="DH10B"
/note="Vector: pCMV-SPORT6"

Query Match 1.9%; Score 37.4; DB 1; Length 1573;
Best Local Similarity 51.5%; Pred. No. 0.0028;
Matches 86; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

QY 1412 TTATATGTTAATGCTTTTCCCTTGCATCTTTATATCTTTCTTCTTCTATA 1471
Db 1564 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1505
QY 1472 CTTTGTAGTATGATTTATGACATGCTGGGAGTTCTTTCCGTCCTCAATCTATTG 1531
Db 1504 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTG 1445
QY 1532 GTGTTTGTATCTTCTTGTACCTGATAGGACATCTTTCTCAAG 1578
Db 1444 CTCGGGGGATGCTCTTGTGGCTTGGGCAAGCCCTGCTTCTATGG 1398

RESULT 18
BD211952
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BD211952 300 bp DNA linear PAT 17-JUL-2003
Novel human genes and gene expression products ii.
BD211952.1 GI:33021722
JP 2002519000-A/94.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
Williams, L.T., Escobedo, J., Innis, M.A., Garcia, P.D., Klinger, J.S.,
Reinhard, C., Giese, K., Randazzo, F., Kennedy, G.C., Pot, D.,
Kassam, A., Lamson, G., Drmanac, R., Crkvenjakov, R., Dickson, M.,
Drmanac, S., Labat, I., Leshkowitz, D., Kita, D., Garcia, V., Jones, L.W.
and Crain, B.S.
Novel human genes and gene expression products ii
Patent: JP 2002519000-A 94 02-JUL-2002;
CHIRON CORP, HYSEQ INC

COMMENT

OS Homo sapiens (human)
PN JP 2002519000-A/94
PF 02-JUL-2002
PR 28-JAN-1998 JP 2000556580 60/072910,24-FEB-1998 US 60/075954 PR
31-MAR-1998 US 60/080114,03-APR-1998 US 60/080515 PR
03-APR-1998 US 60/080666,21-OCT-1998 US 60/105234 PR
28-OCT-1998 US 60/105877
PI LOUIS T WILLIAMS, JAIME ESCOBEDO, MICHAEL A INNIS, PABLO PI
DOMINGUEZ GARCIA,
PI JULIE SUDDUTH KLINGER, CHRISTOPH REINHARD, KLAUSE GIESE, FILIPPO
PI RANDAZZO,
PI GIULIA C KENNEDY, DAVID POT, ALPAF KASSAM, GEORGE LAMSON, RADOJE
PI DRMANAC,
PI RADOMIR CRKVENJAKOV, MARK DICKSON, SNEZANA DRMANAC, IVAN LABAT,
PI DENA LESHKOWITZ, DAVID KITA, VERONICA GARCIA, LEE WILLIAM JONES,
PI BIRJIT STACHE CRAIN
PC C12N15/09, C12N15/09, C07K14/47, C07K14/82, C07K16/18, C12N1/15, PC
C12N1/19,
PC C12N1/21, C12N5/10, C12Q1/68, C12N15/00, C12N5/00, C12N15/00 CC
= A, T, C or G
FH Key Location/Qualifiers
FT misc feature (1)..(300). Location/Qualifiers
1..300
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

FEATURES
source

Query Match 1.6%; Score 32.4; DB 1; Length 300;
Best Local Similarity 78.0%; Pred. No. 0.047;
Matches 39; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 997 TGCACCTGTGAAGT 1046
Db 89 TCCCTAGGCGCGCTGT 138

RESULT 19
BC009726/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BC009726 1403 bp mRNA linear PSI 12-NOV-2003
Homo sapiens protease, serine, 22, mRNA (cdna clone MGC:9599
IMAGE:3899480), complete cds.
BC009726
GI:16307274
MGC.
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.
Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Sapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Schetz, T.E., Brownstein, M.J., Usdin, T.B., Tschiyuki, S.,
Carninci, P., Prange, C., Raja, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Wotley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalon, D.K., Murray, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahney, J., Helton, E., Kettelman, M., Madan, A., Young, A.C., Shevchenko, Y.,
Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywicki, M.I., Skalski, U., Smallus, D.E.,
Schnerker, A., Schein, J.E., Jones, S.J. and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257

TITLE
JOURNAL
MEDLINE

VIIia), mRNA (cdna clone MGC:34565 IMAGE:5188604), complete cds. BC034377 VERSION BC034377.1 GI:21707770 MGC. Homo sapiens (human) Homo sapiens (human) ORGANISM REFERENCE AUTHORS Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G., Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D., Altshuler,S.F., Zeeberg,S., Buetow,K.H., Schaefer,C.F., Bhat,N.K., Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F., Diatchenko,L., Marisina,K., Palmer,A.A., Rubin,G.M., Hong,L., Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L., Scheetz,T.E., Brownstein,M.J., Uedin,T.B., Teohiyuki,S., Carninci,P., Prange,C., Raha,S.S., Loquellano,N.A., Peters,G.J., Abramson,R.D., Mullany,S.O., Bosak,S.A., McEwan,P.J., McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S., Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W., Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A., Fahney,J., Helton,E., Kettaman,M., Madan,A., Rodrigues,S., Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y., Bonfard,G.G., Blakesley,R.W., Touchman,J.W., Green,E.D., Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M., Butterfield,Y.S., Krzywinski,M.I., Skalski,U., Smaitis,D.E., Schnerch,A., Schein,J.E., Jones,S.J. and Marra,M.A.
NIH-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgabbs-remail.nih.gov
Tissue Procurement: Life Technologies, Inc.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNL)
DNA Sequencing by: Baylor College of Medicine Human Genome Sequencing Center
Center code: BCM-HGSC
Web site: http://www.hgsc.bcm.tmc.edu/cdna/ Contact: amghbcm.tmc.edu
Guanarane, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Louseseg, H., Kowls, C.R., Snead, A.J., Martin, R.G., Muzny, D.M., Nanavati, A.N., Gibbs, R.A.
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov Series: IRAP Plate: 50 Row: h Column: 4 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 4506114.
Location/Qualifiers 1..1792 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone=MGC:34565 IMAGE:5188604" /tissue type="Colon, Kidney, Stomach, adult, whole pooled" /clone.lib="NIH_MGC_116" /lab host="DHIOB" /note=vector: PCMV-SPORT6"
1..1792 /gene="PROC" /db_xref="LocusID:5624" /db_xref="MIM:176860"
gene
REMARK COMMENT
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/ILNL at: http://image.llnl.gov Series: IRAP Plate: 14 Row: l Column: 15 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 21614535.
Location/Qualifiers 1..1403 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone=MGC:9599 IMAGE:3899480" /tissue type="Pancreas, epithelioid carcinoma" /clone.lib="NIH_MGC_70" /lab host="DHIOB" /note=vector: PCMV-SPORT6"
1..1403 /gene="PRSS22" /note=synonyms: BSSP-4, MGC9599, SP001LA, hbSSP-4" /db_xref="LocusID:64063" 39..992 /codon_start=1 /product="protease, serine, 22" /protein_id="AAH03726.1" /db_xref="GI:16307278" /db_xref="LocusID:64063" /translation="MVSGAPPALGGCGLTGTSLLLASTAINARIPVPACGPK QQLNRVGEDSTDSSEPWISIQKHGTHGAGSLTTSRWITVAHCCKDNKNPLVF SVLLGAWGLNGPSRQKVAVYHPHVVSKEGACADIALVLERSIOFSRVLP CLPDASHLNPTCHWISGWGSIODGPLPHPTLOKLKVIPIIDSEVCVSHLYVRGAQ GPITDMLCACVLEGRDCGLDGSGBLMGVDGANLAGLIISWGEGCAERNPVYI SLSAHSRWEVKIVQGVQLRGRAQGGAIRAFPSQSGAARS"
misc_feature 186..902 /note="Tryp SpC; Region: Trypsin-like serine protease" /db_xref="CDD:c00190"
Query Match 1.4%; Score 28; DB 1; Length 1403; Best Local Similarity 63.2%; Pred. No. 0.78; Matches 43; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 1424 TTGGCTTTTCCTTGCACTTTATATCTCTTCTTCTTCTATCTTTAGTATT 1483 Db 1402 TTTTTTTTTTTTGTGTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGAGAAT 1343 QY 1484 TGATTATT 1491 Db 1342 AAAATAATT 1335
RESULT 20 BC034377/c LOCUS DEFINITION Homo sapiens protein C (inactivator of coagulation factors Va and VIIIa), mRNA (cdna clone MGC:34565 IMAGE:5188604), complete cds.


```
mat_peptide      /product="activation peptide"
644..1393
/product="serine protease"

Query Match      1.2%; Score 24; DB 1; Length 1499;
Best Local Similarity 46.9%; Pred. No. 8.7;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1785 CTATCTCTTGTATCTGTCAGTCAGGCTGTCTCTGAGGTCCTGTCGGTCTTAATTT 1844
Db 715 CTCTCTCTTGGAGTCAGAGGATTCCTGCGCAAGAGTCAACCTGCTTCGTCAGCGT 656
QY 1845 TTTCATTTCCAGATTTCCCTTCAGTTGGGTTTGTGTTTATTAATTTCAATTTCCAGTTTCAG 1904
Db 655 TCGGTGACTATCTTGGATCTGGTTCAGTTTCATCTTCTAAGCTGTGTCGTTTGAG 596
QY 1905 GTCTCTGAATGTTTACTCATTTTCTCTCCAGTATTTTACA 1944
Db 595 GATCTTGGCTTCTTCTCTATCCATCCCTCCAGTTTCCCA 556

RESULT 26
AF318182/c      1580 bp mRNA linear ROD 14-FEB-2001
LOCUS
DEFINITION
MUS musculus anticoagulant protein C mRNA, complete cds.
ACCESSION
AF318182.1 GI:12802522
KEYWORDS
MUS musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 (bases 1 to 1580)
Korf, I.
Complete sequence of UC72A01
Unpublished
REFERENCE
2 (bases 1 to 1580)
Korf, I.
Direct Submission
Submitted (02-NOV-2000) Genetics, Washington University, 4444
Forest Park Avenue, St. Louis, MO 63108, USA
FEATURES
Location/Qualifiers
1..1580
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="dbEST:AA986009"
/db_xref="taxon:10090"
72..1454
/codon_start=1
/product="anticoagulant protein C"
/protein_id="AAK07918.1"
/db_xref="GI:12802523"
/tranlation="MWQPRVFLLMSTWGISSPAHPDPVFSSEHAHQVLRVRANS
FLEMRPGSLRECMESICDLEAEQIFQVQEDTAFWIKYFDGDCSAPPLDHCDS
PCGHGTCTDGIQSGFSCSKDWGKFCQQLRFPQCVNNGCLHYCLEENGRCA
CAPGVLLADHWRCSTWNPCKGLRWIKKILKRLTDELEPPRIVNGTIL
KQGSPPWAILLDKKLLACGGVLIHFSWVLAHCVGKLTVALGEYDURRDHW
ELDDKEILVHPNTRESSNDIALRLAQPATLSKTIIVPICLPNGLAQTLQAG
ETVVTGYSQSDR.KDGRNRNFTLFIPLVARNCEVKNVYSENMLCAGTIGD
TRDADGDSGSGPMVVFPRGTWFLVGLVSGEGCGHTNNYGIYTKVGSYLKWHISYGE
KGVSLKSQKL"

CDS
1..1580
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="dbEST:AA986009"
/db_xref="taxon:10090"
72..1454
/codon_start=1
/product="anticoagulant protein C"
/protein_id="AAK07918.1"
/db_xref="GI:12802523"
/tranlation="MWQPRVFLLMSTWGISSPAHPDPVFSSEHAHQVLRVRANS
FLEMRPGSLRECMESICDLEAEQIFQVQEDTAFWIKYFDGDCSAPPLDHCDS
PCGHGTCTDGIQSGFSCSKDWGKFCQQLRFPQCVNNGCLHYCLEENGRCA
CAPGVLLADHWRCSTWNPCKGLRWIKKILKRLTDELEPPRIVNGTIL
KQGSPPWAILLDKKLLACGGVLIHFSWVLAHCVGKLTVALGEYDURRDHW
ELDDKEILVHPNTRESSNDIALRLAQPATLSKTIIVPICLPNGLAQTLQAG
ETVVTGYSQSDR.KDGRNRNFTLFIPLVARNCEVKNVYSENMLCAGTIGD
TRDADGDSGSGPMVVFPRGTWFLVGLVSGEGCGHTNNYGIYTKVGSYLKWHISYGE
KGVSLKSQKL"

Query Match      1.2%; Score 24; DB 1; Length 1580;
Best Local Similarity 46.9%; Pred. No. 8.8;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1785 CTATCTCTTGTATCTGTCAGTCAGGCTGTCTCTGAGGTCCTGTCGGTCTTAATTT 1844
Db 776 CTCTCTCTTGGAGTCAGAGGATTCCTGCGCAAGAGTCAACCTGCTTCGTCAGCGT 717
QY 1845 TTTCATTTCCAGATTTCCCTTCAGTTGGGTTTGTGTTTATTAATTTCAATTTCCAGTTTCAG 1904
```

```
Db 716 TCCGTTGACTATCCCTTGGATCTGTTCCAGTTCATCTTAAAGTCGTGTCGTTTGAG 657
QY 1905 GTCCTGAAATGTTTACTCTCATTTTCTCTCCAGTATTTTACA 1944
Db 656 GATCTTGGCTTCTTCTCTATCCACCTCCAGTTTCCCA 617

RESULT 27
BC013896/c      1603 bp mRNA linear ROD 03-OCT-2003
LOCUS
DEFINITION
MUS musculus protein C, mRNA (cdna clone MGC:13870 IMAGE:4211329),
complete cds.
ACCESSION
BC013896.1 GI:15530229
KEYWORDS
MGC.
SOURCE
Mus musculus (house mouse)
ORGANISM
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE
1 (bases 1 to 1603)
Strausberg, R.D., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altschul, S.F., Zeeberg, B., Buotow, K.H., Schaefer, C.F., Bat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stepleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Stapleton, T.E., Brownstein, M.J., Udwin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullen, S.J., Bosak, S.A., McEwan, P.J.,
Korner, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Sanchez, A., Whitting, M., Madan, A., Young, A.C., Rodriguez, S.,
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalls, D.E.,
Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
2338257
MEDLINE
12477932
REFERENCE
2 (bases 1 to 1603)
Strausberg, R.
Direct Submission
Submitted (07-SEP-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK
NHI-MGC Project URL: http://mgc.nci.nih.gov
Contact: MGC help desk
Email: cgaps@imail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
CDNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbio.org
contact: amadan@systemsbiology.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettman, Anuradha
Madan, Stephanie Rodriguez, Amy Sanchez and Michelle Whiting
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAC Plate: 18 Row: n Column: 8
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 6679476.
Location/Qualifiers
1..1603
/organism="Mus musculus"
/mol_type="mRNA"
/strain="FVB/N"
/db_xref="taxon:10090"
```

```
/clones="MGC:13870 IMAGE:4211329"
/tissue type="Liver, normal. 5 month old male mouse."
/clone lib="NCI CGAP_L19"
/lab host="DH10B"
/notes="vector: pCMV-SPORT6"
1..1603
/gene="proc"
/notes="synonym: PC"
/db_xref="LocusID:19123"
/db_xref="MGI:19771"
100..1482
/cds_start=1
/product="protein C"
/protein_id="AAH13896.1"
/db_xref="GI:15530210"
/db_xref="LocusID:19123"
/translaction="MMOFVFLLLMTWGISIPAPHPDPVFSSSEHAHVLVRRANS
PCCMRGSLRECEMCEICFEQAQIFQVETDLAFWKYFDGDCSAPPLDHOCDS
FCCGHGTICDIGIFSCDCGKEGFCQOELRFOCRVNNGGFCLHVCLEESNGRCA
CAPVELADHMRCKSVNFCCKGLRWIEKILKEDTDLDELEPDRIVNGTLLT
KQGSPPHQAILLDSKLAGGVLIHTSVLTAHCVETGKLTLYGIDYDRLRRDHW
ELDDIDKELLVHNYTSSNDNIALRLAQPATLSKTIYFICPLNNGAQLTQNGQ
ETVVGWGYSDRIKDGRRNRTFILFIRPLVARNECVEMKNVSENMCLAGLIGD
TRDACDGSQGPVVFRGTWFLVGLVSGEGCGHTNNGYIYTKGSLYKWHISYIGE
KGVSLKSQL"
175..357
/notes="GLA; Region: Domain containing Gla
(gamma-carboxylglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
/notes="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
730..1431
/misc_feature
/notes="Tryp SP; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"
Query Match 1.2%; Score 24; DB 1; Length 1603;
Best Local Similarity 46.9%; Pred. No. 8.8;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;
QY 1785 CTATCTTGATCTGTGACGTGAGGCTGTCTCTGAGGTCCTGTGGTCTTATTT 1844
DB 804 CTTCTCTTGAGTCCAGAGGATGCTGCCAAGGACTGTACCCCTGCTCTGAGCGT 745
QY 1845 TTTCATTTCCAGATTCCTTCAGTTGGGTTTGTATTATTTATTTCCACTTCAG 1904
DB 744 TCCGTTGACTATCTTGGATCTGGTCCAGTTCATCTTAAAGTGTGTCTGCTTGAG 685
QY 1905 GTCCTGAATGTTTACATTTTCTCCCAAGTATTACA 1944
DB 684 GATCTTGCTTCTCTCTATCCACCTCCCAAGTTCCCA 645
RESULT 28
AR425705 364 bp DNA linear PAT 18-DEC-2003
LOCUS
DEFINITION
Sequence 17202 from patent US 6639063.
AR425705
ACCESSION
AR425705.1 GI:40180815
VERSION
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unknown.
Unclassified.
REFERENCE
1 (bases 1 to 364)
```

```
Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
EST's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES
Location/Qualifiers
source
1..364
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.2%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 8.5;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;
QY 88 CTTAGGCTGAGGTTACCACTGCTCTCTCTCCCTTCTCTTAACACTTCTGGCCAGG 147
DB 27 MCKSRSYGRRSSCCGSMGWSGCCSKRSWSRCRCKMSWMMWYMRSMKYKRCSTCASCK 86
QY 148 TAGGGCACTACCGCATTCCTCTCTCTTCCAAACACTTCTATTCTTG 196
DB 87 YKGGMACMTCWSTGMYRMASVGYWCYSYMARVYTCYSKYRWKCYR 135
RESULT 29
BD121258 364 bp DNA linear PAT 18-SEP-2002
LOCUS
DEFINITION
EST and encoded human protein.
ACCESSION
BD121258
VERSION
BD121258.1 GI:23216169
KEYWORDS
JP 2002010789-A/13335.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 364)
AUTHORS
Edwards,J.B.D.M., Jobert,S. and Giordano,J.E.
TITLE
EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 13335 15-JAN-2002;
COMMENT
OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PR 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPUIST DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09,C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,PC
C12N1/21,
PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68,C12N15/00,C12N5/00,PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source
1..364
/organism="Homo sapiens (human)"
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.2%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 8.5;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;
QY 88 CTTAGGCTGAGGTTACCACTGCTCTCTCTCCCTTCTCTTAACACTTCTGGCCAGG 147
DB 27 MCKSRSYGRRSSCCGSMGWSGCCSKRSWSRCRCKMSWMMWYMRSMKYKRCSTCASCK 86
QY 148 TAGGGCACTACCGCATTCCTCTCTTCCAAACACTTCTATTCTTG 196
DB 87 YKGGMACMTCWSTGMYRMASVGYWCYSYMARVYTCYSKYRWKCYR 135
RESULT 30
AX839180
```



```
AY040345/c
LOCUS AY040345 1671 bp mRNA linear VRT 25-JUL-2001
DEFINITION Danio rerio coagulation factor VII mRNA, complete cds.
ACCESSION AY040345
VERSION AY040345.1 GI:15020317
KEYWORDS Danio rerio (zebrafish)
SOURCE Danio rerio
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
Cypriniformes; Cyprinidae; Danio.
REFERENCE 1 (bases 1 to 1671)
AUTHORS Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
Phan,T., Thankavel,B. and Jagadeeswaran,P.
TITLE Direct Submission
JOURNAL Submitted (14-JUN-2001) Cellular and Structural Biology, University
MEDLINE of Texas Health Science Center at San Antonio, 7703 Floyd Curl
PUBMED Drive, San Antonio, TX 78229, USA
21353085 Location/Qualifiers
REFERENCE 2 (bases 1 to 1671)
AUTHORS Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
Phan,T., Thankavel,B. and Jagadeeswaran,P.
TITLE Direct Submission
JOURNAL Submitted (14-JUN-2001) Cellular and Structural Biology, University
MEDLINE of Texas Health Science Center at San Antonio, 7703 Floyd Curl
PUBMED Drive, San Antonio, TX 78229, USA
11459993 Location/Qualifiers
REFERENCE 3 (bases 1 to 1671)
AUTHORS Sheehan,J., Templer,M., Gregory,M., Hanumanthaiah,R., Troyer,D.,
Phan,T., Thankavel,B. and Jagadeeswaran,P.
TITLE Direct Submission
JOURNAL Submitted (14-JUN-2001) Cellular and Structural Biology, University
MEDLINE of Texas Health Science Center at San Antonio, 7703 Floyd Curl
PUBMED Drive, San Antonio, TX 78229, USA
11459993 Location/Qualifiers
FEATURES
source
1..1671
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
1..1302
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAK74192.1"
/db_xref="GI:15020318"
/translation="MSLLVFLSLMSLVHYSCHSAVVRDEAHEVLISKANSWFE
ELKTNLEKCEKESVEEAREVEFEHTAETNEFWKIDVDKHCASSPCEHDLCTTQ
NADSYNCLCAPGFSGRHCESQIGDLVDSCLHDNGCEHFTEQDQGRSCADGYLD
NSGQCRSEHPGCKVPLQAGKAADHQVLRIVGSECEPKGHCPCWVLKYGKEK
GFCGVYKPTILTAACHLEKLVKFLRIVAGEHDLVEDETEOLIQVDWFTHPAY
VSETADSDIALRLPTPIVSVYAVPVCPLPREMAERELWAVSKHTVSGWKRSDGP
TSRLRLRLVPIRQECQVQVSNLILTSNMFACGIEGQDSCKGDSGGPLVTRVDT
AFLGLGVSGKCARPGSYGIYRVSNIQWIRQITNTIIT"
Query Match 1.2%; Score 23.6; DB 1; Length 1671;
Best Local Similarity 54.7%; Pred. No. 11;
Matches 47; Conservative 0; Mismatches 39; Indels 0; Gaps 0;
AY 1213 TGAAGATAGATATCTTCACTGATTTTATCTTATCTTATGATGCTTTCTTCTCCCACTAT 1272
DB 1436 TTAATATAATATTTTTTTTATTTTCAATAATTTTCTTATTTTACAAACATTAACAT 1377
QY 1273 TGTGACAGAAAGTTTCTAAGTGCA 1298
DB 1376 AATAGTTAATATTTGTTAATGTTCA 1351
RESULT 34
LOCUS AR425705/c
DEFINITION AR425705 364 bp DNA linear PAT 18-DEC-2003
SEQUENCE AR425705 Sequence 17202 from patent US 6639063.
ACCESSION AR425705
VERSION AR425705.1 GI:40180815
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards,J.-B.D.M., Jobert,S. and Giordano,J.-Y.
TITLE EST's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES Location/Qualifiers
source
1..364
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.1%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred. No. 14;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;
AY 554 TTGAAGTAGCCCACTATCTGTGTGAGGTCACATATGATTTAGCTGTAGCTGTGCTT 613
DB 277 WTGRSMWMSKTYKRWRSRAGSWMTGYRMSKMWGTGSTRCTSKKKKGGTSSKYASTSGK 218
QY 614 GTTTTATGAACCTTGGGTGACATTTGTTGGTGTCATAGACATTAAAGATTGCAATGCTT 673
DB 217 SSKYMSKCRSKKCRYSATYYSCMMWKKYCMMSATYSGCMWWRWYCYSCMMSRYSCT 158
QY 674 CTTCGTCGATTTT 686
DB 157 SYSRKCSCCTGK 145
RESULT 35
LOCUS BD121258/c
DEFINITION BD121258 364 bp DNA linear PAT 18-SEP-2002
ACCESSION BD121258
VERSION BD121258.1 GI:23216168
KEYWORDS JP 2002010789-A/13335.
SOURCE Homo sapiens (human)
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards,J.-B.D.M., Jobert,S. and Giordano,J.E.
TITLE EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 13335 15-JAN-2002;
COMMENT GENSET CORP
OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PF 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09, C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, PC
C12N1/21,
PC C12N5/10, C12P21/02, C12P21/08, C12Q1/68, C12N15/00, C12N5/00, PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source 1..364
/organism="Homo sapiens (human)"
/ft_id="F_1"
/ft_type="text"
/ft_version="1"
/ft_date="2002010789-A/13335"
/ft_xref="taxon:9606"
FEATURES
source
1..364
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
Query Match 1.1%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred. No. 14;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;
AY 554 TTGAAGTAGCCCACTATCTGTGTGAGGTCACATATGATTTAGCTGTAGCTGTGCTT 613
DB 277 WTGRSMWMSKTYKRWRSRAGSWMTGYRMSKMWGTGSTRCTSKKKKGGTSSKYASTSGK 218
QY 614 GTTTTATGAACCTTGGGTGACATTTGTTGGTGTCATAGACATTAAAGATTGCAATGCTT 673
DB 217 SSKYMSKCRSKKCRYSATYYSCMMWKKYCMMSATYSGCMWWRWYCYSCMMSRYSCT 158
QY 674 CTTCGTCGATTTT 686
DB 157 SYSRKCSCCTGK 145
```

```

RESULT 36
AF465274
LOCUS
DEFINITION
  Takifugu rubripes coagulation factor VIIb precursor, mRNA, complete
  cds.
ACCESSION
  AF465274
VERSION
  AF465274.1 GI:28194019
KEYWORDS
  Takifugu rubripes (Fugu rubripes)
SOURCE
  Takifugu rubripes
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
  Acanthomorpha; Acanthopterygii; Percomorpha; Tetraodontiformes;
  Tetraodontidae; Tetraodontidae; Takifugu.
REFERENCE
  1 (bases 1 to 1329)
  Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
  Tuddenham,E.G.D. and McVey,J.H.
  Comparative sequence analysis and molecular evolution of blood
  coagulation genes from Gallus gallus and Fugu rubripes
  Unpublished
  2 (bases 1 to 1329)
  McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
  Direct Submission
  Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
  Centre, The Faculty of Medicine, Imperial College, Hammersmith
  Campus, Du Cane Road, London W12 0NN, UK
FEATURES
  source
    1..1329
    /organism="Takifugu rubripes"
    /mol_type="mRNA"
    /db_xref="taxon:31033"
  CDS
    1..1329
    /EC_number="3.4.21.21"
    /function="serum prothrombin conversion accelerator"
    /note="vitamin K dependent serine protease; similar to
    Fugu rubripes FVII; synthesized in liver; contains 2
    EGF-like domains; member of peptidase family S1/trypsin
    family"
    /codon_start=1
    /product="coagulation factor VIIb precursor"
    /protein_id="AA033369.1"
    /db_xref="GI:28194020"
    /translations="MLIR.CCTVILFSATAAAVFERDDASTVLQRRRRANSQGLE
    EMQGNLKEBIEICNYBEAREVEDDAQTRKFWETYNRHPDPCSVMPONNGVCVSM
    GNTYCHQCPGFGGQRCETKAEDFLKLYQNGCOHFCDSGASRKCPCALGYTLASD
    GROCIAEVEFPCCQLPPEPTGPDVTVGOTRLVGNHCPKGCPCQVVLVLHGQSHCG
    GVLRDPWITARACVYTKQPHLSVVAEHLNDDGTEQKIPVARFAHEGYVSET
    GDKDIALHLNASVTVNGRIVPCLPTKOLARELLMTRHYTVSGKRTNGNBDHG
    VNTAPVSPFLRFKFSVPIIPNQCQSHRSQNFNTDMFCAGYLEGQQSCRGDGDGPLV
    TLYGSHFLLGVVGRGCGCFYGYGYVTNMGFVDMWANGIMVAANKIST"
  Query Match
    1.1%; Score 23; DB 1; Length 1329;
  Best Local Similarity
    74.4%; Pred. No. 16;
  Matches
    29; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 1479 TGATTGATTATATGACACTGTGGGAGTTCCTTTCCG 1517
|||||
Db 5 TGATTAGGATTTCGCACTGTTTGATCTCTTTCCG 43

RESULT 37
AX174765/c
LOCUS
DEFINITION
  Sequence 81 from Patent WO03038129.
ACCESSION
  AX174765
VERSION
  AX174765.1 GI:32486281
KEYWORDS
  Homo sapiens (human)
SOURCE
  Homo sapiens
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

```

```

REFERENCE
  1
  Raponi,M.
  Methods for assessing and treating leukemia
  TITLE
  Patent: WO 03038129-A 81 08-MAY-2003;
  JOURNAL
  Ortho-Clinical Diagnostics, Inc. (US)
  Location/Qualifiers
  1..1507
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"
  Query Match
    1.1%; Score 23; DB 1; Length 1507;
  Best Local Similarity
    60.3%; Pred. No. 16;
  Matches
    38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;

QY 1528 TTGTGTTTCTATGCTTCTTGTACCTGTAGGCATCTCTTCTCAAGTTAGGAAT 1587
|||||
Db 1506 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1587
|||||
QY 1588 TTT 1590
Db 1446 TAT 1444

RESULT 38
HUMFACX
LOCUS
DEFINITION
  Human coagulation factor X (F10) mRNA, complete cds.
ACCESSION
  M57285
VERSION
  M57285.1 GI:182389
KEYWORDS
  coagulation factor X.
SOURCE
  Homo sapiens (human)
  ORGANISM
    Homo sapiens
    Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE
    1 (bases 1 to 1507)
    Messier,T.L., Pittman,D.D., Long,G.L., Kaufman,R.J. and Church,W.R.
    Cloning and expression in COS-1 cells of a full-length cDNA
    encoding human coagulation factor X
    JOURNAL
    Gene 99 (2), 291-294 (1991)
    MEDLINE
    91216473
    PUBMED
    1902434
    COMMENT
    Original
    FEATURES
      source
        1..1507
        /organism="Homo sapiens"
        /mol_type="mRNA"
        /db_xref="taxon:9606"
        /map="13q34"
        /tissue_type="liver"
      gene
        1..1507
        /gene="F10"
      CDS
        1..1467
        /gene="F10"
        /EC_number="3.4.21.6"
        /codon_start=1
        /product="coagulation factor X"
        /protein_id="AAA52421.1"
        /db_xref="GI:182390"
        /db_xref="GDB:G00-119-890"
        /translations="MGRPLHLVLSASLAGLLLSLFRREQANNILARVTRANSF
        LEEMKHLRECEMEETSYEARVEFSDKTFNEFNKYKDGQDQETPCQNGKCK
        DGLGYTCCTGCEGKNCLETRKLCSLNDGDCDQFCHBEQNSVVCARGVTLADN
        GKACITGPYPCQKTLERKRSVAQATSSGEAPDSITWKPVDADLDPTENPFLL
        DFNQTOPEDNNLITRIVGQCKGCECPQALLINEENGFCGGTILSEFVILTAH
        CLYQARFKRVGRDNRTEQEGEAEVHEVVIKNNRFTKTFYDFDIARVLRKPTTF
        RNNVAPACLPEDPAESTLMTQKTVISGFGTHKGROSTRKLMLEVEFYVDRNSCKL
        SSSFLITQNFNGADTKQEDACQSGSGFHFRTKDTFYFTVTGIVSWGEGCARKGYK
        IYTKVTAFLKWDIRDSMKTRGLPKAKSHAPEVITSSPLK"
        /genes="F10"
        /notes="putative Bacteriophage lambda
        (J02459); putative"
      misc_feature
        1004..1060

```

ORGANISM	Homo sapiens
REFERENCE	1
AUTHORS	Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE	Expressed sequence tags and encoded human proteins
JOURNAL	Patent: EP 1033401-A 8650 06-SEP-2000;
FEATURES	Genset (FR)
source	Location/Qualifiers
	1..385
	/organism="Homo sapiens"
	/mol_type="unassigned DNA"
	/db_xref="taxon:9606"
Query Match	1.1%; Score 22; DB 1; Length 385;
Best Local Similarity	57.1%; Pred.No.25;
Matches	40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY	111 TCCTCTCTCCCTTTCTCTAACACTTCTGGCCAGGTAGGGGCACTACCGCATTCCTCC 170
Db	135 TCTCACACTCCAGCCTCCCAATCCGAGACTGGATGAGGGGCAAGCCAGTGCACC 76
QY	171 TCTCTTCCAA 180
Db	75 CCACAGACAA 66
RESULT 41	
BD028320/c	
LOCUS	BD028320 385 bp DNA linear PAT 27-AUG-2002
DEFINITION	Sequence tag and encoded human protein.
ACCESSION	BD028320
VERSION	BD028320.1 GI:22570062
KEYWORDS	JP 2001269182-A/4566.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
	Mammalia; Euthera; Primates; Catarrhini; Hominiidae; Homo.
REFERENCE	1 (bases 1 to 385)
AUTHORS	Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE	Sequence tag and encoded human protein
JOURNAL	Patent: JP 2001269182-A 4566 02-OCT-2001;
COMMENT	GENSET
	OS Homo sapiens (human)
	PN JP 2001269182-A/4566
	PD 02-OCT-2001
	PF 24-FEB-2000 JP 2000118773
	PR 26-FEB-1999 US 60/122487
	PI JEAN BAPTISTE DUMAS MILNE EDWARDS, EIMERIC DUCLAIR, JEAN YVES
	PI JORDAN
	PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21, PC
	C12N5/10,
	PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N15/00,C12N5/00, PC
	G06F15/40
CC	Key
FH	Location/Qualifiers.
FEATURES	source
	1..385
	/organism="Homo sapiens"
	/mol_type="genomic DNA"
	/db_xref="taxon:9606"
Query Match	1.1%; Score 22; DB 1; Length 385;
Best Local Similarity	57.1%; Pred.No.25;
Matches	40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
QY	111 TCCTCTCTCCCTTTCTCTAACACTTCTGGCCAGGTAGGGGCACTACCGCATTCCTCC 170
Db	135 TCTCACACTCCAGCCTCCCAATCCGAGACTGGATGAGGGGCAAGCCAGTGCACC 76
QY	171 TCTCTTCCAA 180
Db	75 CCACAGACAA 66

AF011352.1 GI:2293477
 Petromyzon marinus (sea lamprey)
 Petromyzon marinus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
 Petromyzontiformes; Petromyzontidae; Petromyzon.
 1 (bases 1 to 861)
 Roach, J.C.
 The molecular evolution of the vertebrate trypsinogenase
 Unpublished
 2 (bases 1 to 861)
 Roach, J.C.
 Direct Submission
 Submitted (25-JUN-1997) Molecular Biotechnology, University of
 Washington, Seattle, WA 98185, USA
 Location/Qualifiers
 1. .861
 /organism="petromyzon marinus"
 /mol_type="mRNA"
 /db_xref="taxon:7757"
 /tissue_type="anterior intestine"
 /dev_stage="ammocoete"
 6. .749
 /codon_start=1
 /product="trypsinogen A1"
 /protein_id="AAB65411.1"
 /db_xref="GI:2293478"
 /translation="MHGLILALLGVAAAPVYEDHIVGGECIAHSPQWVSLNIG
 YHFGGSLINSQWVSAHCYQASRISVIEGHNFVNEGTQOIQAKAIOHPQYN
 SWTIDNIMLIKLSPPATLQYQAATLPSVCNTGVMCTISGKETQTSVGSPPVLM
 CVPQVLSDSICRSNYSFGDINNMICLGLLEGKSCQSDSGGFPVVCNGELQGISWG
 RGCAPLNPYGVYKVCNNAWIAQTAA"
 6. .50
 /evidence=not_experimental
 51. .746
 /product="trypsin A1"
 /evidence=not_experimental
 sig_peptide
 1.1; Score 21.6; DB 1; Length 861;
 Best Local Similarity 68.2; Pred. No. 35;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 QY 1446 TTTTAAATCTCTTCTTGTTCTATCTTTAGTGATTTGATTA 1489
 DB 860 TTTTITTTTATATGTTTCACATTTTATTCATTTGTTA 817
 Query Match 1.1; Score 21.6; DB 1; Length 861;
 Best Local Similarity 68.2; Pred. No. 35;
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
 RESULT 46
 BC061149/c
 LOCUS
 DEFINITION Mus musculus coagulation factor VII, mRNA (cdna clone MGC:74281
 IMAGE:30305571), complete cds.
 ACCESSION BC061149
 VERSION BC061149.1 GI:38511701
 KEYWORDS MGC.
 SOURCE Mus musculus (house mouse)
 ORGANISM Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
 1 (bases 1 to 1869)
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.P., Bhat, N.K.,
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
 Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L.,
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
 Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
 Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Huiyk, S.W.,
 Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
 Fahey, J., Helton, E., Kettman, M., Mada, A., Rodriguez, S.,

Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butterfield, Y.S., Krzyzanski, M.I., Skalska, U., Smalley, D.E.,
 Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 23388257
 12477932
 2 (bases 1 to 1869)
 Strausberg, R.
 Direct Submission
 Submitted (03-NOV-2003) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 NIH-MGC Project URL: http://mgc.nci.nih.gov
 Contact: MGC help desk
 Email: cgapbs@mail.nih.gov
 Tissue Procurement: Dr. Michael Brownstein
 cDNA Library Preparation: Michael Brownstein / Ted Usdin
 Laboratory
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome
 Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: http://www-shgc.stanford.edu
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.
 Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
 Series: IRAL Plate: 53 Row: n Column: 1
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 6753805.
 FEATURES
 Location/Qualifiers
 1. .1869
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="MGC:74281 IMAGE:30305571"
 /tissue_type="Liver, mouse"
 /clone_1b="NIH MGC_177"
 /lab_host="DH10B"
 /notes="vector: pDNR-LIB"
 1. .1869
 /gene="F7"
 /note="synonyms: FVII, mfVII"
 /db_xref="LocusID:14068"
 /db_xref="MGI:109325"
 10..1350
 /codon_start=1
 /product="coagulation factor VII"
 /protein_id="AAH61149.1"
 /db_xref="GI:38511702"
 /db_xref="LocusID:14068"
 /translations="MVPQAGLLLCFLQLQPLGTAVFTQEEAHGVLRQRANS
 LLELPGLSLRECNCEOCSEAREIFKSPRTKQFWIVSDGQCSANPCONGTC
 QDLKVSFCFLDPKRCCKSKNQLCANENGDCDOYCRDHVTKETCSCHDYT
 LQDEVSCKPKVEYPCGRIPVVEKNSRQCRVGVNCPKGECPQAVLKLGLLL
 CGVLLDARWIVTAACHFNIRYGNITVWGEHDFSEKDGQVRVQVIMPKYI
 RGLNIDIEVRLMTQDLERAKHSNTPKITENMFCAGMDGTCKACKDSCGPHATH
 YHGTWLTGVSWGEGCAAIGHGVYTRVSVQIDVLRHMDSKLQGVFRLPL"
 79..264
 /notes="GLA; Region: Domain containing Gla
 (gamma-carboxyglutamate) residues"
 /db_xref="CDD:smar00069"
 268..378
 /note="EGF CA; Region: Calcium-binding EGF-like domain,
 present in a large number of membrane-bound and
 extracellular (mostly animal) proteins. Many of these

proteins require calcium for their biological function and calcium-binding sites have been found to be located at the N-terminus of particular EGF-like domains"

misc_feature

589..1302
/db_xref="CDD:cd00054"
/note="Tryp SPG; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"

Query Match 1.1%; Score 21.6; DB 1; Length 1869;
Best Local Similarity 68.2%; Pred. No. 37;
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1587 TTTTCTTTTGGTTTCTTGAATAATTTCCCTGTTTGA 1630
|||||
Db 1860 TTTTCTTTTGGTTTCTTGAATAATTTCCATTAATGA 1817
|||||

RESULT 47
AX464088/c 1129 bp DNA linear PAT 16-JUL-2002
LOCUS
DEFINITION Sequence 221 from Patent WO0140466.
ACCESSION AX464088
VERSION AX464088.1 GI:21899060
KEYWORDS Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E.,
Cao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L.,
Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K.,
Wood, W.L. and Zhang, Z.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding
same
JOURNAL Patent: WO 0140466-A 221 07-JUN-2001;
Genentech Inc. (US)
FEATURES
source
1..1129
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 40;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTCTTT 1881
|||||
Db 1129 TTTTCTTTTTCATTTTCAGCTGGCACAGGCTGGTTTATT 1083
|||||

RESULT 48
AY359106/c 1129 bp mRNA linear PRI 03-OCT-2003
LOCUS
DEFINITION Homo sapiens clone DNA99391 MFN (UNQ1884); mRNA, complete cds.
ACCESSION AY359106
VERSION AY359106.1 GI:37183328
KEYWORDS FLI-CDNA
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens

REFERENCE
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J.,
Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B.,
Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E.,
Heidens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S.,
Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C.,
Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V.,
Stinson, J., Vagts, A., Wandlen, R., Watanabe, C., Wieand, D., Woods, K.,
Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z.,
Goddard, A., Wood, W.L. and Godowski, P.

TITLE The Secreted Protein Discovery Initiative (SPDI), a Large-Scale
Effort to Identify Novel Human Secreted and Transmembrane Proteins:
A Bioinformatics Assessment
Genome Res. 13 (10), 2265-2270 (2003)
12975309

REFERENCE 2 (bases 1 to 1129)

AUTHORS Clark, H.F.

TITLE Direct Submission

JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech,
Inc., 1 DNA Way, South San Francisco, CA 94080, USA

FEATURES

source
1..1129
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="DNA99391"

gene

1..1129
/locus_tag="UNQ1884"
36..908
/locus_tag="UNQ1884"
/note="PRO4327"
/codon_start=1
/product="MPN"
/protein_id="AAQ89464.1"
/db_xref="GI:37183329"

CDS

1..1129
/translation="MRPRAVPLLLLLCTGSPAKATACGRPMLENVGGDTQEG
EWPQVQIQNGSHFCCGSLIAQWVLTAAHCFRNTSETSLVQVLLGARQLVQGPCHA
MYARQVSNPLPQGTASSADVALVELAPVFTNIDPVLCPDPSPVIFGMCNHW
TGWSPSEDLLEPRLQKLVFIIDTKNLLYSKDTFQGPQPTIKNDMLCAGFE
EGKSDACKGSDGGPLVCLVQSWLQAGVISWEGCARQNRPGVYIRVTAHNWIRII
PKLQFQPARLGQK"

Query Match

Best Local Similarity 1.1%; Score 21.4; DB 1; Length 1129;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTCTTT 1881
|||||
Db 1129 TTTTCTTTTTCATTTTCAGCTGGCACAGGCTGGTTTATT 1083
|||||

RESULT 49

AX565990

LOCUS AX565990 6098 bp DNA linear PAT 29-NOV-2002
DEFINITION Sequence 2 from Patent WO02077218.
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.

REFERENCE

1

Persson, E.

Coagulation factor vii derivatives

TITLE Patent: WO 02077218-A 2 03-OCT-2002;

NOVO NORDISK A/S (DK)

FEATURES

source

1..6098
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Plasmid DNA pLN174"

Query Match

Best Local Similarity 1.1%; Score 21.4; DB 1; Length 6098;
Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 1536 TTTGTATGCTTCTGTACCTTGATAGGCATCTCTTCTCAAGTTAGGAATTTCTTT 1595
|||||

Db 4429 TTTTACGGTTCCTGGGCTTTTCTGCGCTTTTGCATGTTCTTCTCGGTATCC 4488
|||||

Qy 1596 TTTGGTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTCTTCCCT 1646
|||||

Db 4489 CCGTATCTGTGATGAACCGTATTACCGCTTTGAGTGAGTGATACCGCT 4539

RESULT 50
BC046125/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BC046125 1541 bp mRNA linear PRI 07-OCT-2003
IMAGE:5723510, Complete cds.
BC046125
MGC.
BC046125.1 GI:28374355
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 1541)
Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,
Hopkins R.F., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,
Stapleton M., Soares M.B., Bonaldo M.P., Casavant J.L.,
Schaeetz T.E., Brownstein M.J., Ustin T.B., Tohiyuki S.,
Carinci P., Prange C., Raha S.S., Loquellano N.A., Peters G.J.,
Abramson R.D., Mullaly S.J., Bosak S.A., McEwan P.J.,
McKernan K.J., Malek J.A., Gunaratne P.H., Richards S.,
Worley K.C., Hale S., Garcia A.M., Gay D.J., Hulyk S.W.,
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,
Fahey J., Helton E., Kettner M., Madan A., Rodriguez S.,
Santchez A., Whitting M., Madan A., Young A.C., Shevchenko Y.,
Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D.,
Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,
Butterfield Y.S., Krzyzanski M.I., Skalska U., Smalios D.E.,
Schuerch A., Schein J.E., Jones S.J. and Marra M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
2338257
12477932
2 (bases 1 to 1541)
Straussberg R.
Direct Submission
Submitted (31-JAN-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
NIH-MGC Project URL: <http://mgi.nci.nih.gov>
Contact: MGC help desk
Email: cgabbs@mail.nih.gov
Tissue Procurement: Invitrogen
CDNA Library Preparation: Life Technologies, Inc.
DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: <http://www-shgc.stanford.edu>
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>
Series: IRAC Plate: 107 Row: h Column: 24
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 9961350.
Location/Qualifiers
1. 1541
/organism="Homo sapiens"
/mcl_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:57588 IMAGE:5723510"
/tissue_type="Ovary, pooled from 3 adults"
/clone_lib="NIH MGC_125"
/lab_host="DH10B"

gene
CDS
misc_feature
misc_feature
misc_feature

/note="Vector: pCMV-SPORT6"
1. 1541
/gene="F10"
/note="synonyms: FX, FXA"
/db_xref="LocusID:2159"
/db_xref="MIM:227600"
39. 1505
/codon_start=1
/product="coagulation factor X precursor"
/protein_id="AAH46125.1"
/db_xref="GI:28374356"
/db_xref="LocusID:2159"
/translation="MGRPLHLVLSASLAGLLIGLESFIRREQANNILARVTRANS
LESMKGLHRECEWSTCSVEAREVFEDSDKTNFVWKYKDGDCETSPCONCKCK
DGLGVETCTCLEGEGKNGELFRKLCSLDNGDCDFCHEONSVVACAGAYTADN
GKACIFGPPYCGKQLERKRSVAQATSSGEAFDSITWKYDAADDPENPDLL
DFNQTQERDNNLTRIVGQCKGECQVALLINEENEGFCGGTILISEFVILLTAH
CLQAKRFRVGRDNTREGEAEVHEVVKHNRFTKTYDIDIAVLKRTITF
RMVAPALPERDWAESTLMTOKTIVSGFGRHEKGRQSTRKMLEVYVDRNSCKL
SSSFLITQNNFCAGYDTKQEDACQDGGPHVTRFKDYFTVTGIVSWEGGCARKGYG
IYTKVFLAWIDRSMKTRGLPKAKSHAPEVITSSPLK"
111. 293
/note="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
318. 401
/note="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
738. 1424
/note="Tryp SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 1.1%; Score 21.2; DB 1; Length 1541;
Best Local Similarity 60.3%; Pred. No. 46;
Matches 35; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 1533 TGTTCCTGCTCTCTGATGATGAGTCATCTTCTCAAGTTAGGAATTTT 1590
DB 1539 TTTTTCCTGCTCTCTGATGATGAGTCATCTTCTCAAGTTAGGAATTTT 1482

RESULT 51
BD060364/c
LOCUS
DEFINITION
ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

BD060364 267 bp DNA linear PAT 27-AUG-2002
Secreted expressed sequence tags (seSTs).
BD060364
BD060364.1 GI:22605970
JP 2001518793-A/724.
Zea mays
Zea mays
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD
clade; Panicoideae; Andropogoneae; Zea.
1 (bases 1 to 267)
Jacobs, K., Mccoy, J.M., Lavallie, E.R., Racie, L.A., Merberg, D.,
Treacy, M., Spaulding V. and Agostino M.J.
Secreted expressed sequence tags (seSTs)
Patent: JP 2001518793-A 724 16-OCT-2001;
GENETICS INSTITUTE INC
PN JP 2001518793-A/724
PD 16-OCT-2001
PF 10-APR-1998 JP 1998543070
PR 10-APR-1997 US 08/837312
PI KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI

DAVID MERBERG,
PI NAURICE TREACY, VIKKI SPAULDING, MICHAEL J AGOSTINO PC
C12N15/12, C12N5/10, C07K14/47, C12Q1/68, A61K38/17 CC Strandedness:
Double;
CC Topology: Linear; Location/Qualifiers.

FEATURES
source

1. .267
/organism="Zea mays"
/mol_type="genomic DNA"
/db_xref="taxon:4577"

Query Match 1.0%; Score 21; DB 1; Length 267;
Best Local Similarity 49.5%; Pred. No. 44;
Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
QY 1543 GCTCTGTGACCTGTAGGACATCTCTCTTCAAGGTAGGAAATTTCTTTTGGTT 1602
DB 243 GATGATGACCTCAACACATCTCTCAGTATCCCATTTCTGTGATTTCTTTCTCAATC 184
QY 1603 TTCTTGAAATATTTCCCTGCTTTTGGACCTGCTCTTCCCTTCCTC 1651
DB 183 TTCTTCAAAAGTCCACTTGGCTGTCTCTTTCTTCGCGCATGCAC 135

RESULT 52
AR162089
LOCUS AR162089 289 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6258558.
ACCESSION AR162089
VERSION AR162089.1 GI:16229155
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 289)
AUTHORS Szostak, J.W., Roberts, R.W. and Liu, R.
TITLE Method for selection of proteins using RNA-protein fusions
JOURNAL Patent: US 6258558-A 17 10-JUL-2001;
FEATURES Location/Qualifiers
source 1. .289
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.0%; Score 21; DB 1; Length 289;
Best Local Similarity 17.6%; Pred. No. 44;
Matches 12; Conservative 33; Mismatches 23; Indels 0; Gaps 0;
QY 1004 GTGAAGTG 1063
DB 4 GRGARCRARARTRTRARCTRTTRTRARCRARARTRTRARCRARARTRGRNRNR 63

QY 1064 TGTGTGTG 1071
DB 64 NNRNRNR 71

RESULT 53
AR166614
LOCUS AR166614 289 bp DNA linear PAT 17-OCT-2001
DEFINITION Sequence 17 from patent US 6261344.
ACCESSION AR166614
VERSION AR166614.1 GI:16242009
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 289)
AUTHORS Szostak, J.W., Roberts, R.W. and Liu, R.
TITLE Nucleic acid-protein fusion molecules and libraries
JOURNAL Patent: US 6261344-A 17 28-AUG-2001;
FEATURES Location/Qualifiers
source 1. .289

/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1.0%; Score 21; DB 1; Length 289;
Best Local Similarity 17.6%; Pred. No. 44;
Matches 12; Conservative 33; Mismatches 23; Indels 0; Gaps 0;
QY 1004 GTGAAGTG 1063
DB 4 GRGARCRARARTRTRARCTRTTRTRARCRARARTRTRARCRARARTRGRNRNR 63

QY 1064 TGTGTGTG 1071
DB 64 NNRNRNR 71

RESULT 54
AFS15269
LOCUS AFS15269 1722 bp mRNA linear VRT 15-NOV-2002
DEFINITION Danio rerio coagulation factor VIII mRNA, complete cds.
ACCESSION AFS15269
VERSION AFS15269.1 GI:25005098
KEYWORDS
SOURCE Danio rerio (zebrafish)
ORGANISM Danio rerio

REFERENCE 1 (bases 1 to 1722)
AUTHORS Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.
TITLE Comprehensive analysis of blood coagulation pathways in teleostei:
Evolution of coagulation factor genes and identification of
zebrafish factor VIII

JOURNAL Blood Cells Mol. Dis. (2002) In press
REFERENCE 2 (bases 1 to 1722)
AUTHORS Jagadeeswaran, P. and Hanumanthaiah, R.
TITLE Direct Submission

JOURNAL Submitted (24-MAY-2002) Cellular & Structural Biology, University
of Texas Health Science Center at San Antonio, 7703 Floyd Curl
Drive, San Antonio, TX 78229, USA

FEATURES
source

1. .1722
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
27. .1358
/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AA071000.1"
/db_xref="GI:25005098"

CDS

EMKAGNLERECVEEICDYEAREVEFDDDRDQFVLSYNKEPCLTNPENNGTCVYL
ADSYCLCSSEYEGKYCEKGLBETLKCQVNGGCEQFCDCGARSCEGAYALAD
GTSVSOVDYPCGKIPIVQNTSONQFQVGHGCPWVLIDYNGESVCGGALLEG
PWLITAHCHVKDTRFLKAVTGEDHLDVLDGSEPEYSAVFIHPNVDPETLSDLA
LLRLRVPORSLYAVPICLPTQLARSELAAARFHTLSMGTRFAGHNLREKGLKP
ASGTLORLAVPLPAAQCCNANTTANMFCAGTGEDHASCGRHDSGLVTRIGTSFL
TGVVSGRGCGPGPYIWIYTKVENFLIMDTVMKNTDSEQIANVSTKN"

Query Match 1.0%; Score 21; DB 1; Length 1722;
Best Local Similarity 56.5%; Pred. No. 52;
Matches 39; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 1356 TTCTTACATTTTTCAGTTTCTTATTTGGAAGTACAGGTGAATTTCTAATCATCTGCTTTA 1415
DB 1464 TACITCCACCTCATCTCTGGATGGAATATGATATATATATATATATATATAT 1523
QY 1416 TATCTTAAT 1424
DB 1524 AATCTTAGT 1532


```

RESULT 55
RATCFX/c
LOCUS      484 bp      DNA      linear      ROD 05-FEB-1999
DEFINITION Rat gene for coagulation factors X, partial cds.
ACCESSION D21215
VERSION    D21215.1 GI:415309
KEYWORDS   coagulation factor X.
SOURCE     Rattus norvegicus (Norway rat)
ORGANISM   Rattus norvegicus

REFERENCE
AUTHORS    Murakawa,M., Okamura,T., Kamura,T., Kuroiwa,M., Harada,M. and
            Niho,Y.
TITLE      Analysis of the partial nucleotide sequences and deduced primary
            structures of the protease domains of mammalian blood coagulation
            factors VII and X
JOURNAL    Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE    94222160
PUBMED     8168596
REFERENCE  2 (bases 1 to 484)
AUTHORS    Murakawa,M.
TITLE      Direct Submission
JOURNAL    Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General
            Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
            Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
            Submitted (18-Oct-1993) to DDBJ by:
            Masahiro Murakawa
            Division of Hematology
            Harasanshin General Hospital
            1-8 Taihaku-machi, Hakata-ku
            Fukuoka, Fukuoka 812
            Japan
            Phone: 092-291-3434
            Fax : 092-291-3266.
FEATURES   source
            Location/Qualifiers
            1..484
            /organism="Rattus norvegicus"
            /mol_type="genomic DNA"
            /db_xref="taxon:10116"
            <1..>484
            /codon_start=2
            /product="coagulation factor X"
            /protein_id="BAA04756.1"
            /db_xref="GI:455396"
            /translation="PDGEMVHEVDMIIKKNKFORDTYDFDIAMLRKLTBITRENVAP
            ACLPKQDAEATLMTQKTIQVSGFRTHERGQSKVLKMEVYVGNTRCLSTSFSI
            TQNMFCAGYDAKQEDACQSDSGGFHVFRTDYFTVTVGSWEGECARQKGYITKVT
            A"
CDS
            1..484
            /product="coagulation factor VII modification"
            /protein_id="BAA04756.1"
            /db_xref="GI:455396"
            /translation="PDGEMVHEVDMIIKKNKFORDTYDFDIAMLRKLTBITRENVAP
            ACLPKQDAEATLMTQKTIQVSGFRTHERGQSKVLKMEVYVGNTRCLSTSFSI
            TQNMFCAGYDAKQEDACQSDSGGFHVFRTDYFTVTVGSWEGECARQKGYITKVT
            A"
Query Match      1.0%; Score 20.8; DB 1; Length 484;
Best Local Similarity 57.8%; Pred. No. 53;
Matches 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 637 GTGTTGGTGATGACATTAAGATGCAATGCTCTGGTGGGATTTCCCTTGATGC 636
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 111 GTGATGGGGGCTTTCAGCCTCAGCATGCAATGCTGAAGTCGTAGGTGTCCTCTGAAC 52
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 697 CTAT 700
      |||
Db 51 TTGT 48

RESULT 56
E63001/c
LOCUS      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63001
VERSION    E63001.1 GI:18633643
KEYWORDS   JP 2001061479-A/5.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
PATENT: JP 2001061479-A 5 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
OS Artificial Sequence
PN JP 2001061479-A/5
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YAGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1206
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
FEATURES   source
            Location/Qualifiers
            1..1206
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
Query Match      1.0%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACATGCTGTTTGAATATATATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

RESULT 57
E63002/c
LOCUS      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63002
VERSION    E63002.1 GI:18633644
KEYWORDS   JP 2001061479-A/6.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
PATENT: JP 2001061479-A 6 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
OS Artificial Sequence
PN JP 2001061479-A/6
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YAGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1206
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
FEATURES   source
            Location/Qualifiers
            1..1206
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
Query Match      1.0%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACATGCTGTTTGAATATATATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||

```

```

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 58
LOCUS E62997 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62997
VERSION E62997.1 GI:18633639
KEYWORDS JP 2001061479-A/1.
SOURCE unidentified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 1 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS blood coagulation factor VII
PN JP 2001061479-A/1
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC FH Key Location/Qualifiers
FT source 1..1221
FT /organism="blood coagulation factor VII"
FEATURES
source
1..1221
Location/Qualifiers
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 59
LOCUS E62998 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62998
VERSION E62998.1 GI:18633640
KEYWORDS JP 2001061479-A/2.
SOURCE synthetic construct
ORGANISM artificial sequences
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 2 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/2
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC FH Key Location/Qualifiers
FT source 1..1221
FT /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 60
LOCUS E62999 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM artificial sequences
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 3 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/3
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC FH Key Location/Qualifiers
FT source 1..1221
FT /organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 61
LOCUS E63000 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63000
VERSION E63000.1 GI:18633642
KEYWORDS JP 2001061479-A/4.
SOURCE synthetic construct

```

```

PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC FH Key Location/Qualifiers
FT source 1..1221
FT /organism="Artificial Sequence"
FEATURES
source
1..1221
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 60
LOCUS E62999 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM artificial sequences
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 3 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/3
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YUGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC FH Key Location/Qualifiers
FT source 1..1221
FT /organism="Artificial Sequence"
FEATURES
source
1..1221
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATAATGTAATCAATTTGG 392
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 444 TTTCGTCGCAATTTCTTTTCTAGATAGGTATTTTCCACATGGATATCAACTGTGG 386

RESULT 61
LOCUS E63000 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63000
VERSION E63000.1 GI:18633642
KEYWORDS JP 2001061479-A/4.
SOURCE synthetic construct

```

ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima, K., Mizuguchi, J., Yaguchi, M., Nakagaki, T. and Iwanaga, S.
TITLE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 4 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/4
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YAGUCHI, TOMOHIRO
PI NAKAGAKI, I
PI SADAOKI IWANAGA
PC C12N15/09, A61K38/43, A61P7/04, C07K14/755, C12N9/76, C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism="Artificial Sequence".
FEATURES
source
1..1221
Location/Qualifiers
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCACATTTGG 392
Db 444 TTTCCTGGCATTCTTTTCTAGATAGGATATTTTCCACATGGATATTCACACTGG 386
RESULT 62
LOCUS AR112953 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132729.
ACCESSION AR112953
VERSION AR112953.1 GI:14093275
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe, P.E., King, S.W. and Gao, B.
TITLE Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
JOURNAL Patent: US 6132729-A 13 17-OCT-2000;
FEATURES
source
1..1440
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCACATTTGG 392
Db 659 TTTCCTGGCATTCTTTTCTAGATAGGATATTTTCCACATGGATATTCACACTGG 601
RESULT 63
LOCUS AR112969 1440 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 13 from patent US 6132730.
ACCESSION AR112969
VERSION AR112969.1 GI:14093291
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe, P.E., King, S.W. and Gao, B.
TITLE Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment
JOURNAL Patent: US 6132730-A 13 17-OCT-2000;
FEATURES
source
1..1440
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCACATTTGG 392
Db 659 TTTCCTGGCATTCTTTTCTAGATAGGATATTTTCCACATGGATATTCACACTGG 601
RESULT 64
LOCUS I19358/c 1440 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 3 from patent US 5504064.
ACCESSION I19358
VERSION I19358.1 GI:1599713
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Morrissey, J.H. and Comp, P.C.
TITLE Treatment of bleeding with modified tissue factor in combination with an activator of FVII
JOURNAL Patent: US 5504064-A 3 02-APR-1996;
FEATURES
source
1..1440
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGTTTGAATATGATTCACATTTGG 392
Db 659 TTTCCTGGCATTCTTTTCTAGATAGGATATTTTCCACATGGATATTCACACTGG 601
RESULT 65
LOCUS I19360/c 1440 bp DNA linear PAT 07-OCT-1996
DEFINITION Sequence 3 from patent US 5504067.
ACCESSION I19360
VERSION I19360.1 GI:1599715
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Morrissey, J.H. and Comp, P.C.
TITLE Treatment of bleeding with modified tissue factor in combination with FVII
JOURNAL Patent: US 5504067-A 3 02-APR-1996;
FEATURES
source
1..1440
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

```

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTGG 392
  |||
Db 659 TTGCTGGCATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGG 601

RESULT 66
BD194674 1440 bp DNA linear PAT 17-JUL-2003
LOCUS Tissue factor methods and compositions for coagulation and tumor
DEFINITION treatment.
ACCESSION BD194674
VERSION BD194674.1 GI:33004420
KEYWORDS JP 2002514201-A/3.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Tissue factor methods and compositions for coagulation and tumor
JOURNAL treatment
COMMENT BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PF 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920,27-JAN-1997 US 60/036205 PR
PI PHILIP E THORPE,STEVEN W KING,BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
FH Key tumor treatment
FT source
FEATURES
  source
    Location/Qualifiers
    1..1440
    /organism="Mammalian".
    /mol_type="genomic DNA"
    /db_xref="taxon:32644"

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTGG 392
  |||
Db 659 TTGCTGGCATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGG 601

RESULT 67
AX565990/c 5098 bp DNA linear PAT 29-NOV-2002
LOCUS Sequence 2 from Patent WO20077218.
DEFINITION
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Persson,E.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)
FEATURES
  source
    Location/Qualifiers
    1..6098
    /organism="synthetic construct"
    /mol_type="unassigned DNA"
    /db_xref="taxon:32630"
    /note="Plasmid DNA pLN174"

```

```

Query Match 1.0%; Score 20.6; DB 1; Length 6098;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGATTCATTTGG 392
  |||
Db 728 TTGCTGGCATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGG 670

RESULT 68
AX908508 223 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 24371 from Patent EP1033401.
DEFINITION
ACCESSION AX908508
VERSION AX908508.1 GI:40064588
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 24371 06-SEP-2000;
Genset (FR)
FEATURES
  source
    Location/Qualifiers
    1..223
    /organism="Homo sapiens"
    /mol_type="unassigned DNA"
    /db_xref="taxon:9606"

Query Match 1.0%; Score 20.4; DB 1; Length 223;
Best Local Similarity 58.1%; Pred. No. 62;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 996 TTGCACCTGTGCAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1055
  |||
Db 4 TTGCACCTGTGTGGAGTTGTGGAGACGGCTTGTAGTCTAGTACGAGTGTGGTGTG 63

QY 1056 TG 1057
  |||
Db 64 AG 65

RESULT 69
BD044041 223 bp DNA linear PAT 27-AUG-2002
LOCUS Sequence tag and encoded human protein.
DEFINITION
ACCESSION BD044041
VERSION BD044041.1 GI:22585783
KEYWORDS JP 2001269182-A/20287.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 223)
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 20287 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/20287
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PR 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCLAIR,JEAN YVES
PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N1/5/00,C12N5/00, PC
G06F15/40
CC
FH Key Location/Qualifiers.

```

[illegible]

[illegible]


```

/mol_type="genomic DNA"
/db_xref="taxon:4530"
1. .227
repeat_region
/notes="microsatellite MRS5546"
/rpt_type="standem"
/rpt_unit="gct"

Query Match
Best Local Similarity 1.0%; Score 20.2; DB 1; Length 227;
Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 34 TGAAGCTCTCTGCGCAATACCTTCTGGGCTGCTGCTGCTTCTCCCGTTC 82
DB 103 TGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTC 151

RESULT 81
HUMPROS01/c
LOCUS Homo sapiens protein S alpha (PROS1) gene, exon 2.
DEFINITION Homo sapiens protein S alpha (PROS1) gene, exon 2.
ACCESSION M35551 J02918
VERSION M35551.1 GI:190427
KEYWORDS
SEGMENT
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 272)
AUTHORS Bertina R.M.
Ploos van Amstel,H.K., Reitsma,P.H., van der Logt,C.P. and
Intron-exon organization of the active human protein S gene PS
alpha and its pseudogene PS beta: duplication and silencing during
primate evolution
Biochemistry 29 (34), 7853-7861 (1990)
JOURNAL
MEDLINE 91084445
PUBMED 2148111
COMMENT Original source text: Human DNA.
Draft entry and computer-readable sequence for [Biochemistry 29,
7853-4861 (1990)] kindly submitted
by H.K.Ploos van Amstel, 13-JUL-1990.
FEATURES
Location/Qualifiers
1. .272
exon
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="3"
/map="3p11-q11.2"
28. .185
/gene="PROS1"
/notes="protein S alpha; G00-120-721; putative"
/number=2

Query Match
Best Local Similarity 1.0%; Score 20.2; DB 1; Length 272;
Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 184 CTTCTATTCTTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTACGTTGTTT 243
DB 153 CTTCTCTTTTATTCACAGATTTCTCGAGTATCTCTTCAAGATTACCTGTTGGTTT 94

QY 244 CCATAAGTTTGTAAAGTTTCTGTTGTTTC 272
DB 93 CTTCAAGTAAGAATTTCACGACGCTC 65

RESULT 82
HUMPS02/c
LOCUS Human S protein-alpha (PS-alpha) gene, exon 2.
DEFINITION Human S protein-alpha (PS-alpha) gene, exon 2.
ACCESSION M57841 J02917
VERSION M57841.1 GI:190535
KEYWORDS S protein; anticoagulant cofactor; vitamin K-dependent protein.

```

```

2 of 14
Homo sapiens (human)
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 352)
AUTHORS Schmidel,D.K., Tatro,A.V., Phelps,L.G., Tomczak,J.A. and Long,G.L.
TITLE Organization of the human protein S genes
JOURNAL Biochemistry 29 (34), 7845-7852 (1990)
MEDLINE 91084444
PUBMED 2148110
COMMENT Original source text: Human liver DNA.
FEATURES
Location/Qualifiers
1. .352
source
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="3p11-q11.2"
/tissue_type="liver"
join(M57840.1:837..912,135..181)
/gene="PS-alpha"
order(M57840.1:913..1014,1..134)
/gene="PROS1"
number=1
number=1
135..252
/gene="PROS1"
/notes="G00-120-721"
/number=2

Query Match
Best Local Similarity 1.0%; Score 20.2; DB 1; Length 352;
Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 184 CTTCTATTCTTGATTTCTATCTTGGCTCATTTTAACTCAGTAGTACGTTGTTT 243
DB 260 CTTCTCTTTTATTCACAGATTTCTCGAGTATCTCTTCAAGATTACCTGTTGGTTT 201

QY 244 CCATAAGTTTGTAAAGTTTCTGTTGTTTC 272
DB 200 CTTCAAGTAAGAATTTCACGACGCTC 172

RESULT 83
AR108139/c
LOCUS Sequence 1 from patent US 6110721.
DEFINITION Sequence 1 from patent US 6110721.
ACCESSION AR108139
VERSION AR108139.1 GI:12823626
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE
1 (bases 1 to 885)
AUTHORS Gibbs,C.S., Leung,L.L.K. and Tsiang,M.
TITLE Polypeptides and coagulation therapy
JOURNAL Patent: US 6110721-A 1 29-AUG-2000;
FEATURES
Location/Qualifiers
1. .885
source
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 1.0%; Score 20.2; DB 1; Length 885;
Matches 31; Conservative 0; Mismatches 18; Indels 0; Gaps 0;

QY 61 GGCTGGCTGCTTTCCTCCCTGCTGTTCTTAGGGTGGGTTTACCACCTG 109
DB 489 GGCTGGCTGCTTTCCTCCCTGCTGTTCTTAGGGTGGGTTTACCACCTG 441

RESULT 84
AX401899/c
LOCUS AX401899
1543 bp DNA linear PAT 06-JUN-2002

```


Db 855 TTTTCTTTTTCATTAGTTCACATTTTATTCATTGGTTA 812

RESULT 87
AR234337
LOCUS 1130 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 8 from patent US 6458564.
ACCESSION AR234337
VERSION AR234337.1 GI:27277021
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1130)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE DNA encoding the human serine protease T
JOURNAL Patent: US 6458564-A 8 01-OCT-2002;
FEATURES Location/Qualifiers
source 1..1130
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1130;
Best Local Similarity 58.3%; Pred. No. 91;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 609 TGCTTTTATGAACTTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668
Db 1059 TGCTTTTATGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1118

RESULT 88
AR219285
LOCUS 1142 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 8 from patent US 6420157.
ACCESSION AR219285
VERSION AR219285.1 GI:23320255
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1142)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;
FEATURES Location/Qualifiers
source 1..1142
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1142;
Best Local Similarity 58.3%; Pred. No. 91;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 609 TGCTTTTATGAACTTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668
Db 1071 TGCTTTTATGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1130

RESULT 89
AR221273
LOCUS 1166 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 2 from patent US 6426199.
ACCESSION AR221273
VERSION AR221273.1 GI:23320188
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1166)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE DNA

JOURNAL Patent: US 6426199-A 2 10-JUL-2002;
FEATURES Location/Qualifiers
source 1..1166
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1166;
Best Local Similarity 58.3%; Pred. No. 91;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 609 TGCTTTTATGAACTTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668
Db 1095 TGCTTTTATGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1154

RESULT 90
AR219284
LOCUS 1169 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 7 from patent US 6420157.
ACCESSION AR219284
VERSION AR219284.1 GI:23320254
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1169)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 7 16-JUL-2002;
FEATURES Location/Qualifiers
source 1..1169
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1169;
Best Local Similarity 58.3%; Pred. No. 91;
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 609 TGCTTTTATGAACTTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668
Db 1098 TGCTTTTATGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1157

RESULT 91
AF515269/c
LOCUS 1722 bp mRNA linear VRT 15-NOV-2002
DEFINITION Danio rerio coagulation factor VII mRNA, complete cds.
ACCESSION AF515269
VERSION AF515269.1 GI:25005098
KEYWORDS
SOURCE Danio rerio (zebrafish)
ORGANISM Danio rerio
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;
Cypriniformes; Cyprinidae; Danio.

REFERENCE 1 (bases 1 to 1722)
AUTHORS Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.
TITLE Evolution of coagulation pathways in teleostei:
zebrafish factor VII.
JOURNAL Blood Cells Mol. Dis. (2002) In press
REFERENCE 2 (bases 1 to 1722)
AUTHORS Jagadeeswaran, P. and Hanumanthaiah, R.
TITLE Direct Submission
JOURNAL Submitted (24-MAY-2002) Cellular & Structural Biology, University
of Texas Health Science Center at San Antonio, 7703 Floyd Curl
Drive, San Antonio, TX 78229, USA
FEATURES Location/Qualifiers
source 1..1722
/organism="Danio rerio"
/mol_type="mRNA"
/db_xref="taxon:7955"
27..1358
CDS

```
/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AAN71000.1"
/db_xref="GI:25003099"
/translation="MTLGAVALLCVLTSLTSAVFLSKDASALLQRRFRANSGLFE
EMKAGNLESECVEELCDVEAREVEFDDRTKQWLSYKNEPCLTNPENNGTCVYL
ADSYCLCEGEGYKCKGLEETLKQYVNGGCEQCDGSGARRSCSCEGVALADD
GRSCSVQDYFGCKIPVQKNTSQNGLFGHICPRGCFWQVLIDINGESVCGGALLEG
PMLTAAHCVHQRDFRFLKAVTGEDHLDVDSBEPYEVSAVFIFHNYDETLDSLA
LRLRVFVORSYAPVILCLPTPOLARSELNAARFHTLSGWTGRTAGHNLREKGLKGP
ASGTLQRLAVPLPAACQGNANTTANMFCAGYTEGHASCRHDSGLVTRYGETSFL
TGVVSGRGCGPPGYIYIKVENFLIMWDTVMKNTEDKSEQIANVSTKN"

Query Match
  1.0%; Score 20; DB 1; Length 1722;
Best Local Similarity 50.0%; Pred. No. 92;
Matches 50; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

Qy 858 TTTTGGATGCACGATAGATGATCTTTTTCATATCATCTCTGTACCCAGTATCT 917
Db 1354 TTTTGTAGTGAACATAGCAATCTGCTGCTCTTATCTTCAGTGTGTGTTCATAAC 1295

Qy 918 TTTTCTAGAGAAATTAAGATCATGATGATGATGGA 957
Db 1294 GTGTCCATCCAGATCAGGAGTCTCCACTTTAGTGATGA 1255

RESULT 92
AX587861/c
LOCUS AX587861 254 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 331 from Patent WO0246467.
ACCESSION AX587861
VERSION AX587861.1 GI:27656555
KEYWORDS
SOURCE synthetic construct
          synthetic construct
          artificial sequences.
REFERENCE
  1 Bertucci,F., Houlgatte,R., Birnbaum,D., Nguyen,C., Wiens,P. and
    Fert,V.
  2 Gene expression profiling of primary breast carcinomas using arrays
    of candidate genes
  3 Patent: WO 0246467-A 331 13-JUN-2002;
  4 Ipsogen (FR)
FEATURES
  source
    Location/Qualifiers
      1..254
        /organism="synthetic construct"
        /mol_type="unassigned DNA"
        /db_xref="taxon:32630"
        /note="primer"
      misc_feature
        1..254
          /note="3' terminal sequence, macrophage stimulating
            (hepatocyte growth factor-like) (MSR1) gene."

Query Match
  1.0%; Score 19.8; DB 1; Length 254;
Best Local Similarity 51.7%; Pred. No. 90;
Matches 45; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1042 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1101
Db 136 TGTCTTACGCGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 77

Qy 1102 TCTCCCTCTTTGATTTTTCCTGG 1128
Db 76 GCCACGCTTGATGCAATGCTTGG 50

RESULT 93
HSLKBP7/c
LOCUS HSLKBP7 268 bp DNA linear PRI 02-MAY-1998
DEFINITION Homo sapiens Peutz-Jeghers syndrome protein (LKB1) gene, exon 8.
ACCESSION AF055326
VERSION AF055326.1 GI:3063582
```

```
KEYWORDS 7 of 8
SEGMENT Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE
  1 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  2 (bases 1 to 268)
AUTHORS Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Lothe,R.A.,
  Stenwig,A.E., Fossa,S.D., Salovaara,R.E. and Aaltonen,L.A.
  3 Sonatic mutations in LKB1 are rare in sporadic colorectal and
    testicular tumors
  4 Cancer Res. (1998)
  5 (bases 1 to 268)
  6 In press
  7 Bignell,G.R., Barfoot,R., Seal,S., Collins,N., Warren,W. and
    Stratton,M.R.
  8 Low frequency of somatic mutations in the LKB1/Peutz-Jeghers
    syndrome gene in sporadic breast cancer
  9 Cancer Res. 58 (7), 1384-1386 (1998)
  10 9537235-
  11 9537235-
  12 (bases 1 to 268)
  13 Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Bignell,G.R.,
    Warren,W., Stratton,M.R. and Aaltonen,L.A.
  14 Direct Submission
  15 Submitted (25-MAR-1998) Department of Medical Genetics, Haartman
    Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3),
    Helsinki FIN-00014, Finland
  16 Location/Qualifiers
    1..268
      /organism="Homo sapiens"
      /mol_type="genomic DNA"
      /db_xref="taxon:9606"
      /chromosomes="19"
      /map="19p13.3"
      41..228
        /gene="LKB1"
        /number=8

exon

Query Match
  1.0%; Score 19.8; DB 1; Length 268;
Best Local Similarity 60.0%; Pred. No. 90;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 832 TGATGCTATCCATGATGATGCTCTTTTGGATGCACGATGATGATGATGATGAT 886
Db 105 TGGTGCTCGGCTCGGTGGATGGCACTGGTCTCAGCCGAGGATGTTCTT 51

RESULT 94
BD095271/c
LOCUS BD095271 384 bp DNA linear PAT 27-AUG-2002
DEFINITION Structural coordinate and NMR chemical shift of protein and
  utilization thereof.
ACCESSION BD095271
VERSION BD095271.1 GI:22640859
KEYWORDS WO 0142453-A/3.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE
  1 Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
    Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  2 (bases 1 to 384)
  3 Koda,D., Hiroaki,H. and Sumimoto,H.
  4 Structural coordinate and NMR chemical shift of protein and
    utilization thereof
  5 Patent: WO 0142453-A 3 14-JUN-2001;
  6 BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU
    HIROAKI, HIDEKI SUMIMOTO
  7 OS Homo sapiens (human)
  8 PN WO 0142453-A/3
  9 PD 14-JUN-2001
  10 PF 01-DEC-2000 WO 2000JP008501
  11 PR 06-DEC-1999 JP 99P 346193
  12 PI DAISUKE KODA,HIDEKAZU HIROAKI,HIDEKI SUMIMOTO PC
    C12N05/50 C12N06/28 C12N06/28
```


NIFLKGSGVSGRVENGRSRTILQYLKVLVDRATCLRSKTVISNMFCAGPH
EGGKDSCLGDSGGPHVEGTSFLTGISWGECAVKGYITKVSRYVW"

Query Match 1.0%; Score 19.8; DB 1; Length 813;
Best Local Similarity 49.5%; Pred. No. 99;
Matches 51; Conservative 0; Mismatches 52; Indels 0; Gaps 0;
QY 192 TCTGATTTCTACTTGGTCTATTTTAACTCAGTAGGAGTGTGTTGGTTTCCATAGT 251
DB 156 TTTGGCGTTTCTCCACCAACAATTCGAATAAGTCGTCAGATGTTGTTTTCAGT 97
QY 252 TTTGATGTTTCTGTTTGTGTTGTTGTTGTTGTTGTTTATCTAG 294
DB 96 GAGGCTATCCAAAATGGTTCAACTTCAGTAGAATTTTCATAG 54

RESULT 98
LOCUS MMU44795/c 1850 bp mRNA linear ROD 23-MAY-1996
DEFINITION Mus musculus coagulation factor VII (fVII) mRNA, complete cds.
ACCESSION U44795
VERSION U44795.1 GI:1184738
KEYWORDS Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 1850)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and Castellino, F.J.
JOURNAL Characterization of a cDNA encoding murine coagulation factor VII
MEDLINE Thromb. Haemost. 75 (3), 481-487 (1996)
PUBMED 8701412
REFERENCE 2 (bases 1 to 1850)
AUTHORS Rosen, E.D., Idusogie, E., Carmeliet, P., Collen, D. and Castellino, F.J.
TITLE Direct Submission
JOURNAL Submitted (05-JAN-1996) Elliot D. Rosen, Chemistry, Univ. of Notre Dame, Notre Dame, IN 46556, USA
FEATURES
source 1. .1850
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/tissue_type="liver"
gene 1. .1850
/gene="fVII"
CDS 16. .1356
/note="initiation of extrinsic pathway of blood coagulation; serine protease"
/codon_start=1
/product="coagulation factor VII"
/protein_id="AAC52570.1"
/db_xref="GI:1184739"

translation="MVPAQHGLLLCFLQLQGLGTAFTVTOEAGHVLHRRRANS
LLELWPSLEECNEECSEFEAREIFKSPERTKQFWIVSDGDQCAINPCQVGTIC
QHLKSYVFCFLDFEGRNCSEKNEQLICANENGDCDQYCRDHVGTKRTCSCHEDYT
LQPEVSKCPKVEYPCGRIPVVEKNSRSSRQGRIVGNGVCPKCECPQAVLKIINGLL
CGAVLLDARWITAAHCFDNIWGNITVWGEHDFSEKDGDEQVRVTVQVIMDKYI
RGKINHDLALRLRPVFTDYVPLCLPEKSFSENTLARIFFSRVSGWGLDRGAT
ALELMSIEVPLMTODCLLEHAKHSNTPKITENMFCAGYMDGTCDKAGDSGSPHATH
ALELMSIEVPLMTODCLLEHAKHSNTPKITENMFCAGYMDGTCDKAGDSGSPHATH
YHGTWLTGVSNGECCAAIGHGYTVTSQVLDLWVRHMSKLVQGVRLPLGSAE
FKSCDKHTVCPCPAPELGLGGSVFPPKPKDILMISRTPEVICVVDVSHEDPEYK
FNIVDGEVHNAKTPREEQYNSTRVSVLTVLHQLWNLNGKTKYCKVSKNALPAPI
EKYISAKQPEPQVYTLPPSRDLTKNQVSLTCLVKGFPYPSDIANEWESNGPENN
YKTPPVLSDSGSFFLYSKLTVDKRWQGNVFCSCVMHEALHNHYTKRSLSPGK"

polyA_site 1850
/gene="fVII"
/note="54 A nucleotides"
Query Match 1.0%; Score 19.8; DB 1; Length 1850;
Best Local Similarity 69.2%; Pred. No. 1e+02;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 1766 CTCGCTGAGATCTCTCTCTATCTCTGATCTGTCATCTGTC 1804

DB 581 CTGCTGAGATCTCTCTCTATCTCTGATCTGTCATCTGTC 543

RESULT 99
LOCUS AF272773/c 2078 bp mRNA linear SYN 17-AUG-2000
DEFINITION Synthetic construct mutated mouse factor VII molecule immunocognate mRNA, complete cds.
ACCESSION AF272773
VERSION AF272773.1 GI:9837149
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM Hu, Z., Sun, Y. and Garen, A.
REFERENCE 1 (bases 1 to 2078)
AUTHORS Targeting tumor vasculature endothelial cells and tumor cells for immunotherapy of human melanoma in a mouse xenograft model
TITLE Proc. Natl. Acad. Sci. U.S.A. 96 (14), 8161-8166 (1999)
JOURNAL 9924206
MEDLINE 10393965
PUBMED 20381364
REFERENCE 2 (bases 1 to 2078)
AUTHORS Hu, Z. and Garen, A.
TITLE Intratumoral injection of adenoviral vectors encoding tumor-targeted immunocognates for cancer immunotherapy
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 97 (16), 9221-9225 (2000)
MEDLINE 10922073
PUBMED 20381364
REFERENCE 3 (bases 1 to 2078)
AUTHORS Hu, Z. and Garen, A.
TITLE Direct Submission
JOURNAL Submitted (26-MAY-2000) Molecular Biophysics and Biochemistry, Yale University, 266 Whitney Ave, New Haven, CT 06520, USA
FEATURES
source 1. .2078
/organism="synthetic construct"
/mol_type="mRNA"
/db_xref="taxon:32630"
CDS 22. .2067
/note="mfVIIasm; contains active site mutation"
/codon_start=1
/transl_table=1
/product="mutated mouse factor VII molecule immunocognate"
/protein_id="AAG00449.1"
/db_xref="GI:9837150"

translation="WVPAQHGLLLCFLQLQGLGTAFTVTOEAGHVLHRRRANS
LLELWPSLEECNEECSEFEAREIFKSPERTKQFWIVSDGDQCAINPCQVGTIC
QHLKSYVFCFLDFEGRNCSEKNEQLICANENGDCDQYCRDHVGTKRTCSCHEDYT
LQPEVSKCPKVEYPCGRIPVVEKNSRSSRQGRIVGNGVCPKCECPQAVLKIINGLL
CGAVLLDARWITAAHCFDNIWGNITVWGEHDFSEKDGDEQVRVTVQVIMDKYI
RGKINHDLALRLRPVFTDYVPLCLPEKSFSENTLARIFFSRVSGWGLDRGAT
ALELMSIEVPLMTODCLLEHAKHSNTPKITENMFCAGYMDGTCDKAGDSGSPHATH
YHGTWLTGVSNGECCAAIGHGYTVTSQVLDLWVRHMSKLVQGVRLPLGSAE
FKSCDKHTVCPCPAPELGLGGSVFPPKPKDILMISRTPEVICVVDVSHEDPEYK
FNIVDGEVHNAKTPREEQYNSTRVSVLTVLHQLWNLNGKTKYCKVSKNALPAPI
EKYISAKQPEPQVYTLPPSRDLTKNQVSLTCLVKGFPYPSDIANEWESNGPENN
YKTPPVLSDSGSFFLYSKLTVDKRWQGNVFCSCVMHEALHNHYTKRSLSPGK"

Query Match 1.0%; Score 19.8; DB 1; Length 2078;
Best Local Similarity 69.2%; Pred. No. 1e+02;
Matches 27; Conservative 0; Mismatches 12; Indels 0; Gaps 0;
QY 1766 CTCGCTGAGATCTCTCTCTATCTCTGATCTGTCATCTGTC 1804
DB 587 CTGCTGAGATCTCTCTCTATCTCTGATCTGTCATCTGTC 549
RESULT 100
LOCUS HAMCFX/c 484 bp DNA linear ROD 05-FEB-1999
DEFINITION Syrian hamster gene for coagulation factor X, partial

ACCESSION D21216
 VERSION D21216.1 GI:415304
 KEYWORDS coagulation factor X.
 SOURCE Mesocricetus auratus (golden hamster)
 ORGANISM Mesocricetus auratus
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;
 Mesocricetus.
 REFERENCE 1 (bases 1 to 484)
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.
 TITLE Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X
 JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)
 MEDLINE 94222160
 PUBMED 8168596
 REFERENCE 2 (bases 1 to 484)
 AUTHORS Murakawa, M.
 TITLE Direct Submission
 JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
 COMMENT Submitted (18-Oct-1993) to DDBJ by:
 Masahiro Murakawa
 Division of Hematology
 Harasanshin General Hospital
 1-8 Taihaku-machi, Hakata-ku
 Fukuoka, Fukuoka 812
 Japan
 Phone: 092-291-3434
 Fax: 092-291-3266
 FEATURES
 source
 1. 484
 /organism="Mesocricetus auratus"
 /mol_type="genomic DNA"
 /db_xref="taxon:10036"
 <1..>484
 /codon_start=2
 /product="coagulation factor X"
 /protein_id="BAA04757.1"
 /db_xref="GI:415304"
 /translation="EGNETHVEDVVKHKNFVREYDFDIIVRLKTPPIIFRMNVAP
 ACPKDWAEATLMTQSGIVSGFGRTHKQSHLKKLEVPYVDRNTCKLSFTI
 TONMFCAGYDAKEDACQDSGGPHVTRFDYFVTVGVSWEGGCRKGYIYKVT
 A"
 CDS
 Query Match 1.0%; Score 19.6; DB 1; Length 484;
 Best Local Similarity 50.0%; Pred. No. 1.1e+02;
 Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;
 QY 634 ATTGTTGTTGGTCATAGACATTAAAGATTGCAATGCTCTCTTGGTGGATTTCCTTTCA 693
 Db 114 AATGATGGGGTCTTCACCTGAGCAGCGCGATGTCGAAGTCGTAGTCTCCCTCACA 55
 QY 694 TGCCTATGTAGTATCTTCCCAATCTCATCTGCTTAGT 731
 Db 54 AACTTGTGTGTTTATGACCAAGTCCACCTCATGTGT 17
 RESULT 101
 AX193364
 LOCUS AX193364 596 bp DNA linear PAT 15-AUG-2001
 DEFINITION Sequence 931 from Patent WO0149716.
 ACCESSION AX193364
 VERSION AX193364.1 GI:15211315
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J.,

Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.
 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
 Patent: WO 0149716-A 931 12-JUL-2001;
 CORIXA CORPORATION (US)
 FEATURES
 source
 1. 596
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 1.0%; Score 19.6; DB 1; Length 596;
 Best Local Similarity 58.6%; Pred. No. 1.1e+02;
 Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
 QY 621 GAACCTGGGTGACATGCTTTGGTGCATAGACATTAGAAATGCAATGCTCTTGG 678
 Db 122 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTGGAGAGTGCATGTCGCCCTGG 179
 RESULT 102
 AX763043
 LOCUS AX763043 609 bp DNA linear PAT 25-JUN-2003
 DEFINITION Sequence 37 from Patent WO03040393.
 ACCESSION AX763043
 VERSION AX763043.1 GI:32257659
 KEYWORDS
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Martinez, R.A. and Sigurdsson, G.T.
 TITLE Nucleic acids encoding proteases
 JOURNAL Patent: WO 03040393-A 37 15-MAY-2003;
 Decode Genetics EHF. (IS)
 FEATURES
 source
 1. 609
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"
 Query Match 1.0%; Score 19.6; DB 1; Length 609;
 Best Local Similarity 54.1%; Pred. No. 1.1e+02;
 Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;
 QY 329 ATTATTTCAATGCTCTTTATCTGTGAGACTGCTTGTGTTTGAATATGTTCAATT 388
 Db 142 ATTATTTGCCATATATAGATCATGCTGTGGCCCTTTGTTTTCGAAATTTCTTCATT 201
 QY 389 TTGGAGAGTTTCAT 402
 Db 202 TGGATGGGAACAT 215
 RESULT 103
 HUMCFIX/c
 LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994
 DEFINITION Human coagulation factor IX mRNA, partial cds.
 ACCESSION M35672
 VERSION M35672.1 GI:180287
 KEYWORDS coagulation factor IX; serine protease.
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 873)
 AUTHORS Jagadeeswaran, P., Lavelle, D.E., Kaul, R., Mohandas, T. and Warren, S.T.
 TITLE Isolation and characterization of human factor IX cDNA:
 identification of Tag I polymorphism and regional assignment
 JOURNAL Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)
 MEDLINE 84300526

PUBMED 6089357
COMMENT Original source text: Human adult liver, cDNA to mRNA.
FEATURES

source
1. .873
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="Xq26.3-q27.1"
1. .873
/gene="P9"
/db_xref="GDB:600-119-900"
/gene="P9"
/note="Coagulation factor IX"
/codon_start=1
/protein_id="AA51981.1"
/db_xref="GI:180288"
/translation="NANKILRPRKYSKLEEFVQGNLRERECMEKCFEAREVFE
NTERTEPMKQVDDQCEPCLNGSKDDINSYECWPCFEGKNCGLDVTGNK
NGRCQFCNKSADNVCSCTEGYRLAENQKCEPAPVPPGGRVSVQSKLTRAETV
FDDVYVNSTAEATILDNITQSTQSFNDFTRVVGGEDAKQGPFWQVWLNKQVAFPG
GSIVNEKMTVTAACHVETGVKITVVAEHNIEETHEQXNVIRIIPHNNYNAINK
YNHDALELDELPLV"
Query Match 1.0%; Score 19.6; DB 1; Length 873;
Best Local Similarity 56.1%; Pred. No. 1.1e+02;
Matches 37; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1830 TTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGTGTTTATTATTC 1889
DB 552 TTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGTGTTTATTATTC 1889
QY 1890 TATTTTC 1895
DB 492 CACATC 487

RESULT 104
AX675583/c
LOCUS AX675583 882 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 33 from Patent WO02055704.
ACCESSION AX675583
VERSION AX675583.1 GI:29333568
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens

REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Baldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rotherberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 33 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1. .882
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 19.6; DB 1; Length 882;
Best Local Similarity 58.6%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATTTGTTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678
DB 369 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTGAATGTCGCCCTGG 312

RESULT 105
AR219285/c
LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 8 from patent US 6420157.
ACCESSION AR219285
VERSION AR219285.1 GI:23320255
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE 1 (bases 1 to 1142)
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;
FEATURES Location/Qualifiers
source 1. .1142
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.0%; Score 19.6; DB 1; Length 1142;
Best Local Similarity 58.6%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATTTGTTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678
DB 456 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTGAATGTCGCCCTGG 399

RESULT 106
AX675581/c
LOCUS AX675581 1161 bp DNA linear PAT 27-MAR-2003
DEFINITION Sequence 31 from Patent WO02055704.
ACCESSION AX675581
VERSION AX675581.1 GI:29333567
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens

ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,
Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,
Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,
Baldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,
Edingermark, S., Rotherberg, M.E., Ellerman, K., Macdougall, J.,
Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and
Stone, D.J.
TITLE Proteins, polynucleotides encoding them and methods of using the
same
JOURNAL Patent: WO 02055704-A 31 18-JUL-2002;
Curagen Corporation (US)
FEATURES Location/Qualifiers
source 1. .1161
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 19.6; DB 1; Length 1161;
Best Local Similarity 58.6%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATTTGTTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678
DB 657 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTGAATGTCGCCCTGG 600

RESULT 107
AR219284/c
LOCUS AR219284 1169 bp DNA linear PAT 25-SEP-2002
DEFINITION Sequence 7 from patent US 6420157.
ACCESSION AR219284


```
VERSION AR219284.1 GI:23320254
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1169)
AUTHORS Darrow,A., Qi,J. and Andrade-Grodon,P.
TITLE Zymogen activation system
JOURNAL Patent: US 6420157-A 7 16-JUL-2002;
FEATURES Location/Qualifiers
source
1. .1169
/mol_type="genomic DNA"

Query Match 1.0%; Score 19.6; DB 1; Length 1169;
Best Local Similarity 58.6%; Pred. No. 1.1e+02;
Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTTTGGTGACATTTGTTGGTCATAGACATTAAGAATTCGAATGCTCTCTTGG 678
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
483 GATGTAGCGGAGAGAGTGATGGTGTCTGCTGAGTGGAGGAGTGCAATGCGCCCTGG 426

RESULT 108
AR109618
LOCUS AR109618 177 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 30 from patent US 6114139.
ACCESSION AR109618
VERSION AR109618.1 GI:12825994
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma,S., Hosoya,M., Fujii,R., Ohtaki,T., Fukusumi,S. and Ohgi,K.
TITLE G-protein coupled receptor protein and a DNA encoding the receptor
JOURNAL Patent: US 6114139-A 30 05-SEP-2000;
FEATURES Location/Qualifiers
source
1. .177
/mol_type="unknown"

Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1621 CTCGTTTACCTGCCTTCTCCCTCTCTATTCCTTGTGTTTTCATAGTGTCTCT 1680
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTCGTGGTCACTACCTACCTGCTCCCTCTCTGCTGTCATCTCTCTCTTACGTCGGGTGCA 66

1681 G 1681
67 G 67

RESULT 109
AR150638
LOCUS AR150638 177 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 25 from patent US 6228984.
ACCESSION AR150638
VERSION AR150638.1 GI:15115229
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma,S., Habata,Y., Kawamata,Y., Hosoya,M., Fujii,R., Fukusumi,S. and Kitada,C.
TITLE Polypeptides their production and use
JOURNAL Patent: US 6228984-A 25 08-MAY-2001;
FEATURES Location/Qualifiers
source
1. .177
/mol_type="unknown"

Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1621 CTCGTTTACCTGCCTTCTCCCTCTCTATTCCTTGTGTTTTCATAGTGTCTCT 1680
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTCGTGGTCACTACCTACCTGCTCCCTCTCTGCTGTCATCTCTCTCTTACGTCGGGTGCA 66

1681 G 1681
67 G 67

/mol_type="unassigned DNA"

Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1621 CTCGTTTACCTGCCTTCTCCCTCTCTATTCCTTGTGTTTTCATAGTGTCTCT 1680
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTCGTGGTCACTACCTACCTGCTCCCTCTCTGCTGTCATCTCTCTCTTACGTCGGGTGCA 66

1681 G 1681
67 G 67

RESULT 110
E16187
LOCUS E16187 177 bp DNA linear PAT 28-JUL-1999
DEFINITION Partial sequence of cDNA encoding G protein-coupled receptor.
ACCESSION E16187
VERSION E16187.1 GI:5710870
KEYWORDS JP 1998146192-A/11.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma,K., Habatake,Y., Kawamata,Y., Hosoya,M., Fujii,A.,
Fukuzumi,M. and Kitada,C.
TITLE NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE, ITS PRODUCTION AND USE
JOURNAL Patent: JP 1998146192-A 11 02-JUN-1998;
COMMENT TAKEDA CHEM IND LTD
OS Homo sapiens (human)
PN JP 1998146192-A/11
PD 02-JUN-1998
PF 26-DEC-1996 JP 1996348328
PR 28-DEC-1995 JP 95P 34371.15-MAR-1996 JP 96P 59419, PR
12-AUG-1996 JP 96P 211805, 18-SEP-1996 JP 96P 246573 PI
HINUMA KUNIJU, HABATAKE YUUGO, KAWAMATA YUJI, HOSoya MASAKI, PI
FUJII AKIRA,
PI FUKUZUMI MASASHI, KITADA CHIEKO
PC C12N15/09,A61K31/70,A61K31/70,A61K31/70,A61K31/70,A61K31/70,
PC A61K31/70,
PC A61K35/76,A61K38/00,A61K48/00,C07H21/00,C07K14/47,C12N5/10, PC
C12P21/02,
PC C12Q1/02,G01N33/566,(C12N5/10,C12R1:91),(C12P21/02,C12R1:91);
CC strandedness: Double;
CC topology: linear;
CC hypothetical: No;
CC anti-sense: No;
FH Key Location/Qualifiers
FT source 1. .177
FT /organism="Homo sapiens"
FT /tissue_type="pituitary gland".
FEATURES
source
1. .177
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1621 CTCGTTTACCTGCCTTCTCCCTCTCTATTCCTTGTGTTTTCATAGTGTCTCT 1680
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
7 CTCGTGGTCACTACCTACCTGCTCCCTCTCTGCTGTCATCTCTCTCTTACGTCGGGTGCA 66

1681 G 1681
67 G 67
```

```
RESULT 111
E27213
LOCUS
DEFINITION Novel physiologically active substance, process for producing the
same and utilization thereof.
ACCESSION E27213
VERSION E27213.1 GI:13025230
KEYWORDS JP 1999009286-A/4.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 177)
AUTHORS Shuji H. and Shoji F.
TITLE Novel physiologically active substance, process for producing the
same and utilization thereof
JOURNAL TAKEDA CHEM IND LTD
COMMENT PN JP 1999009286-A/4
PD 19-JAN-1999
PF 27-APR-1998 JP 1998117189
PR SHUJI HINUMA, SHUJI FUKUZUMI
PI C12N15/09, A01K67/027, A61K38/00, A61K38/00, C07K14/47, C07K16/18,
PC C12N1/21,
PC C12N5/10, C12P21/02, G01N33/53, G01N33/577, C12P21/08, (C12N15/09,
PC C12R1:91),
PC (C12N1/21, C12R1:19), (C12N5/10, C12R1:91), (C12P21/02, C12R1:19),
PC C12N15/00,
PC A61K37/02, A61K37/02, C12N5/00, (C12N15/00, C12R1:91), (C12N5/00,
PC C12R1:91)
CC Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..177
FEATURES
source
Location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTCTTCCCTTCCTCTATTCCTTTGTTTGCATAGTGTCTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCCTCTCTCTTACGTCGGGTGTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 113
AR300928
LOCUS
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION AR300928.1 GI:31688601
KEYWORDS Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma, S., Ito, Y. and Fujii, R.
TITLE G protein coupled receptor protein production, and use thereof
JOURNAL Patent: US 6538107-A 30.25-MAR-2003;
FEATURES
source
Location/Qualifiers
/mol_type="unknown"
/mol_type="mRNA"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTCTTCCCTTCCTCTATTCCTTTGTTTGCATAGTGTCTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCCTCTCTCTTACGTCGGGTGTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 114
AR109885
LOCUS
DEFINITION Sequence 310 from patent US 6114139.
ACCESSION AR109885
VERSION AR109885.1 GI:12826161
KEYWORDS AR109885
PD 16-MAR-1999
PF 22-JUN-1998 JP 1998175007
PR SHUJI HINUMA, RYO FUJII, YUJI KAWAMATA, HIROKAZU MATSUMOTO
PI A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, PC
A61K38/00,
PC A61K38/00, A61K38/00, C07K7/08, C07K14/705, (C12N15/09, C12P21/02,
PC (C12P21/02, C12R1:91), A61K37/02, A61K37/02, A61K37/02, A61K37/02,
PC A61K37/02,
PC A61K37/02, A61K37/02, A61K37/02, C12N15/00 CC
Strandedness: Double;
CC Topology: Linear;
FH Key Location/Qualifiers
FT source 1..177
FEATURES
source
Location/Qualifiers
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTCTTCCCTTCCTCTATTCCTTTGTTTGCATAGTGTCTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCCTCTCTCTTACGTCGGGTGTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 115
E28271
LOCUS
DEFINITION Utilization of peptide.
ACCESSION E28271
VERSION E28271.1 GI:13025305
KEYWORDS JP 1999071300-A/11.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 177)
AUTHORS Shuji H., Ryo F., Yuji K. and Hirokazu, M.
TITLE Utilization of peptide
JOURNAL Patent: JP 1999071300-A 11 16-MAR-1999;
JOURNAL TAKEDA CHEM IND LTD
COMMENT OS Unidentified
PN JP 1999071300-A/11
```

TITLE	cDNA and genomic clones of Festuca arundinacea and Lolium multiflorum	
JOURNAL	Unpublished	
REFERENCE	2 (bases 1 to 249)	
AUTHORS	Bettany,A.J.E.	
TITLE	Direct Submission	
JOURNAL	Submitted (13-OCT-2003) Bettany A.J.E., Plant, Animal & Microbial Science, Inst. Grassland & Environmental Research, Plas Gogerddan, Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM	
FEATURES	Location/Qualifiers	
source	1..249	
	/organism="Lolium multiflorum"	
	/mol_type="mRNA"	
	/cultivar="Trident"	
	/db_xref="taxon:4521"	
	/tissue_type="young leaves with leaf bases"	
	/dev_stage="seedlings"	
gene	1..249	
	/gene="4cl"	
CDS	<1..>249	
	/gene="4cl"	
	/EC_number="6.2.1.12"	
	/function="activation of thioester substrates for phenylpropanoid synthesis"	
	/codon_start=3	
	/product="putative 4-coumarate coA ligase"	
	/protein_id="CAE51882.1"	
	/db_xref="GI:37805459"	
	/translation="PFVKVSGSGCTVVRNAELKVPDPTGASLGRNQPGECVVRGKQI MLGYLNDPESTXNTIDKDWLWLTGIDGLVDDDDDEIFV"	
Query Match	1.0%; Score 19.4; DB 1; Length 249;	
Best Local Similarity	60.4%; Pred. No. 1.1e+02;	
Matches	32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;	
QY	1786 TATCTCTTTGATTCGTGCAGTGAGCGTCTGTCTCGAGGTTCTCTGTGGGTCT 1838	
DBS	210 TGTCTCCGGTGCACGACCGCGTCTTGTGATGGTGTCTTGGTGGACTCT 158	
RESULT 117		
AX839191/c		
LOCUS	AX839191 290 bp DNA linear PAT 15-DEC-2003	
DEFINITION	Sequence 34 from Patent WO03076610.	
ACCESSION	AX839191	
VERSION	AX839191.1 GI:39922640	
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Homo sapiens	
REFERENCE	1 Bracco,L., Brinkman,B. and Coignard,F.	
AUTHORS	Variants of human kallikrein-2 and kallikrein-3 and uses thereof	
TITLE	Patent: WO 03076610-A 34 18-SEP-2003;	
JOURNAL	Exonhit Therapeutics S.A. (FR)	
FEATURES	Location/Qualifiers	
source	1..290	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	1.0%; Score 19.4; DB 1; Length 290;	
Best Local Similarity	55.1%; Pred. No. 1.2e+02;	
Matches	39; Conservative 0; Mismatches 31; Indels 0; Gaps 0;	
QY	111 TCTCTCTCTCCCTTCTTCTACACTCTTGGCCAGGCTAGGGGCACTACCGCATTCCTC 170	
DBS	113 TCTCGACTCCGACGCTCCCACTCCGAGACAGATGAGGGGTGCAGACCAATCCAG 54	
QY	171 TCTCTTCCA 179	
DB	53 TCACGGACA 45	


```

ACCESSION M26233
VERSION M26233.1
KEYWORDS factor IX, Ovis aries (sheep)
SOURCE Ovis aries
ORGANISM Ovis aries
REFERENCE 1 (bases 1 to 823)
AUTHORS Sarkar, G., Koerber, D.D. and Sommer, S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL Genomics 6 (1), 133-143 (1990)
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
FEATURES
source
1..823
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/notes="factor IX"
/codon_start=1
/protein_id="AA31520.1"
/db_xref="GI:552419"
/translation="RASVHTSKLTRAETIFSNMNYNSSEAEIWDNVTSQNSQFD
DFNRVGGEDAAAGQFPWQLLHGEIAAFCGGSIVNEKVVTAHCIKPGKIVTVAG
EHNTKEPTQKRNIVRAIPHYGNASINKYSHDLALLEDEPLELNSYVTPICIA
REYTNIKFTGYGVSGWVRNRSASILQYKVLVDRAVDRCLASTFTIYHMF
AGYHEGKDCQSGDGGPHVTEVGTSTFLGIIISWGEACAMKKGYGIYTKVSRVEY"
Query Match 1.0%; Score 19.4; DB 1; Length 823;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
Qy 1569 TTTCTCAAGGTACGAATTTTCTTTTGGTTTCTTCAAAATATTTCCCTGCTTT 1628
Db 93 TATTTGAGTTCAGAGAAATTTTATAGTTCATATTCGAAATAATAGTCTCAGCAGG 34
Qy 1629 GACCTGGCT 1637
Db 33 GAGCTTCTT 25
RESULT 122
BC061135/c 829 bp mRNA linear ROD 25-NOV-2003
LOCUS Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),
DEFINITION complete cds.
ACCESSION BC061135
VERSION BC061135.1
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 829)
Straussberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klauser, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altshuler, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullany, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahey, J., Helton, E., Kettelman, M., Madan, A., Rodriguez, S.,

```

```

TITLE
JOURNAL MEDLINE
PUBMED 12477932
REFERENCE 2 (bases 1 to 829)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgabs-r@mail.nih.gov
Tissue procurement: Dr. Michael Brownstein
CDNA Library Preparation: Michael Brownstein / Ted Usdin
Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www.shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IZAL Plate: 53 Row: 0 Column: 2
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 6755892.
FEATURES
source
1..829
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:74265 IMAGE:30306436"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10B"
/notes="Vector: pDNR-LIB"
1..829
/genes="Try4"
/notes="synonyms: 0910001B19rik, Tc"
/db_xref="locusid:22074"
/db_xref="MGI:102757"
14..754
/codon_start=1
/product="trypsin 4"
/protein_id="AAH61135.1"
/db_xref="GI:38511693"
/db_xref="Locusid:22074"
/translation="VRALLFLALVGAAVFPVDDDKLVGGTCTENSVPYQVSLNSG
YHFCGSGTINDQWVYSAARCYKSRIOVRLGHNINVLGEQFVNSAKIHKPFNSR
TLNNIDMLIKLASPVTLNARVATVALPSSCAPAGTQCLTISGMTLSFGVNPDLQ
LDAIPLOADCEASYPGKITNNMICVGFLEGGKSCQGDSPGVPVCGNQLQIVSWGY
GCALLKDPGVYTKVCNVYDWIQTIAAN"
misc_feature 83..739
/notes="tryp_SPC; Region: Trypsin-like serine protease"
/db_xref="CDD:cd00190"
Query Match 1.0%; Score 19.4; DB 1; Length 829;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Qy 1587 TTTTCTTTTGGTTTCTTGAATAATATTTCCCTGCTTTTACCTGCCTTC 1639
Db 817 TTTTCTTTTGGTTTCTTGAATAATATTTCCCTGCTTTTACCTGCCTTC 765

```

Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,
 Bouffard, G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
 Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalish, D.E.,
 Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.
 Generation and initial analysis of more than 15,000 full-length
 human and mouse cDNA sequences
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
 23388257
 12477932
 2 (bases 1 to 829)
 Strausberg, R.
 Direct Submission
 Submitted (03-NOV-2003) National Institutes of Health, Mammalian
 Gene Collection (MGC), Cancer Genomics Office, National Cancer
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
 USA
 NIH-MGC Project URL: http://mgc.nci.nih.gov
 Contact: MGC help desk
 Email: cgabs-r@mail.nih.gov
 Tissue procurement: Dr. Michael Brownstein
 CDNA Library Preparation: Michael Brownstein / Ted Usdin
 Laboratory
 CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome
 Center, Stanford University School of Medicine, Stanford, CA 94305
 Web site: http://www.shgc.stanford.edu
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
 R. M.
 Clone distribution: MGC clone distribution information can be found
 through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
 Series: IZAL Plate: 53 Row: 0 Column: 2
 This clone was selected for full length sequencing because it
 passed the following selection criteria: matched mRNA gi: 6755892.
 Location/Qualifiers
 1..829
 /organism="Mus musculus"
 /mol_type="mRNA"
 /db_xref="taxon:10090"
 /clone="MGC:74265 IMAGE:30306436"
 /tissue_type="Liver, mouse"
 /clone_lib="NIH MGC_177"
 /lab_host="DH10B"
 /notes="Vector: pDNR-LIB"
 1..829
 /genes="Try4"
 /notes="synonyms: 0910001B19rik, Tc"
 /db_xref="locusid:22074"
 /db_xref="MGI:102757"
 14..754
 /codon_start=1
 /product="trypsin 4"
 /protein_id="AAH61135.1"
 /db_xref="GI:38511693"
 /db_xref="Locusid:22074"
 /translation="VRALLFLALVGAAVFPVDDDKLVGGTCTENSVPYQVSLNSG
 YHFCGSGTINDQWVYSAARCYKSRIOVRLGHNINVLGEQFVNSAKIHKPFNSR
 TLNNIDMLIKLASPVTLNARVATVALPSSCAPAGTQCLTISGMTLSFGVNPDLQ
 LDAIPLOADCEASYPGKITNNMICVGFLEGGKSCQGDSPGVPVCGNQLQIVSWGY
 GCALLKDPGVYTKVCNVYDWIQTIAAN"

RESULT 123
LOCUS AR095306/c 1126 bp DNA linear PAT 08-SEP-2000
DEFINITION Sequence 27 from patent US 6004555.
ACCESSION AR095306
VERSION AR095306.1 GI:10023064
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1126)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods for the specific coagulation of vasculature
JOURNAL Patent: US 6004555-A 27 21-DEC-1999;
FEATURES
Location/Qualifiers
source 1..1126
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGCCACTTGGTTTATGACATCAGTTAGCTCC 495
Db 596 TTGTGAACCGTTGTGCTTGTGATGACACCTCCACCTCGTGACCGGCTCACCGCCCTCC 537
QY 496 AGCATTTCTGTTTCGTTTGTGATGATGACCTAACTCTTGGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480
RESULT 124
LOCUS AR103990/c 1126 bp DNA linear PAT 14-FEB-2001
DEFINITION Sequence 27 from patent US 6093399.
ACCESSION AR103990
VERSION AR103990.1 GI:12816698
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 1126)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods and compositions for the specific coagulation of vasculature
JOURNAL Patent: US 6093399-A 27 25-JUL-2000;
FEATURES
Location/Qualifiers
source 1..1126
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.0%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGCCACTTGGTTTATGACATCAGTTAGCTCC 495
Db 596 TTGTGAACCGTTGTGCTTGTGATGACACCTCCACCTCGTGACCGGCTCACCGCCCTCC 537
QY 496 AGCATTTCTGTTTCGTTTGTGATGATGACCTAACTCTTGGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480
RESULT 125
LOCUS HUMEX/c 1126 bp mRNA linear PRI 08-NOV-1994
DEFINITION Human factor X mRNA.
ACCESSION K01886
VERSION K01886.1 GI:182820
KEYWORDS
SOURCE HumEX
ORGANISM Homo sapiens (human)
REFERENCE 1 (bases 1 to 1126)
AUTHORS Leytus,S.P., Chung,D.W., Kiesel,W., Kurachi,K. and Davie,E.W.
TITLE Characterization of a cDNA coding for human factor X
JOURNAL Proc Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)
FEATURES
Location/Qualifiers
source 1..1126
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="13q34"
gene 1..1126
mRNA <1..1126
/gene="F10"
/product="factor X mRNA"
CDS <1..1116
/gene="F10"
/note="factor X precursor peptide"
/codon_start=1
/protein_id="AAA52486.1"
/db_xref="GI:182821"
/db_xref="GDB:G00-119-890"
/translation="GFEKNCLELPTKLCSLDNGDCDFCHEQNSVVCSCARGVTLA
DNGKACIPTGYPCKQKQLERRKSVAGATSSSEAPDSITWKFIDADLDPTENPFD
LLDFNQTPERGDNNLIRIVGGCKGCEQWQALLINEEGFCGGTILSEFVLTA
AHCLYQARFEGDRNTEQEGGEAVHEVVEVVKINRFTKETYDFDIAVRLKPTIFR
MNVAPACLPERDWAESTLMTQKTVGIVGTHKRGQSRKLMLEVPYVDRNSCKLS
SSFIITQNMFCAGYDTKQEDACQDGSQSPHVRFKDITYFTVITVSWGEGCARKKYGI
YTKVTAFLKWDIRSMKTRGLPKAKSHAPEVITSSPLK"
mat_peptide <1..195
/gene="F10"
/product="factor X light chain"
mat_peptide 205..1113
/gene="F10"
/product="factor X heavy chain"
mat_peptide 361..1113
/gene="F10"
/product="factor Xa heavy chain"
Query Match 1.0%; Score 19.4; DB 1; Length 1126;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGCCACTTGGTTTATGACATCAGTTAGCTCC 495
Db 596 TTGTGAACCGTTGTGCTTGTGATGACACCTCCACCTCGTGACCGGCTCACCGCCCTCC 537
QY 496 AGCATTTCTGTTTCGTTTGTGATGATGACCTAACTCTTGGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480
RESULT 126
LOCUS A93124/c 1404 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 15 from Patent WO9747737.
ACCESSION A93124
VERSION A93124.1 GI:6741514
KEYWORDS
SOURCE unidentified

```

ORGANISM      unidentified
REFERENCE      1 (bases 1 to 1404)
AUTHORS        Kopeckzi, E. and Hopfner, K.
TITLE          RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL        Patent: WO 9747737-A 15 DEC-1997;
                KOPETZKI ERHARD (DE); BOEHRINGER MANNHEIM GMBH (DE)
FEATURES       Location/Qualifiers
                1..1404
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match   1.0%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 436 TTGGTGAATAGTCTGTAATATCTCTAGGTCACCTTGTGTTATGACATCAGTTAGTCC 495
      |||||
DB 884 TTGTGAACCGGTGTGCTGTGATGACACCTCCACCTGTCGACCGCTCCACCGCCCTCC 825
      |||||
QY 496 AGCATTTCTCTGTTGCTGTTTTTGTGATGACCTAACTCTTGAGAGAAATGGGGT 552
      |||||
DB 824 TCTGCTCCGTGTTCCGGTCCCTTCGAATCTCTGCTTGGTGTAGACAGTGGGCT 768
      |||||

RESULT 127
HUMCFX/c      HUMCFX      1414 bp      mRNA      linear      PRI 01-NOV-1994
LOCUS         Human blood-coagulation factor X mRNA, complete cds.
DEFINITION    M22613
ACCESSION     M22613
VERSION       M22613.1 GI:180335
KEYWORDS      coagulation factor X.
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE     1 (bases 1 to 1414)
AUTHORS       Kaul, R.K., Hildebrand, B., Roberts, S. and Jagadeeswaran, P.
TITLE         Isolation and characterization of human blood-coagulation factor X
              cDNA
JOURNAL       Gene 41 (2-3), 311-314 (1986)
MEDLINE       86221713
PUBMED        3011603
COMMENT       Original
FEATURES      Location/Qualifiers
                1..1414
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /map="13q34"
                1..1414
                /gene="F10"
                <1..1414
                /genes="F10"
                /product="coagulation factor X mRNA"
                <1..1404
                /gene="F10"
                /note="coagulation factor X precursor"
                /codon_start=1
                /protein_id="AA51984.1"
                /db_xref="GI:180336"
                /db_xref="GDB:G00-119-890"
                /translation="LIGESLFIHQANNILARVTRANSFLEEMKXHLRECEMEETC
                SYEAREVPEVDSDXTNEFWNKYDQDQETSPQONQKCKDGLGEYTCCTCLEGFEGKN
                CELFLKSLDNGDCDFCHEEONSVVCARGVTLADNGKACIPTPGYPCKGQTLK
                RRERSVAQTSSSGEAPDSITWKPYDAADLPTEPNFDLLFNQTPERGDNLTRIV
                GGCEKDGCPQWALLINEENEGCGGILSEFYILFAHCLYQAKSEGDNRNTEOEE
                GGSAVEVEVGNHNRFTKETDYFDIAPVLRKTPITFRNVAAPACLFERDWAESTLMT
                QKTGVISGVRGTHKQRSLRKLMEVFPVDRNSCKLSSFIITONMFCAGYDTKQBD
                ACQSGSGPHVTRFKDQTVFTGIVSWGEGCAKRGKYIYTKVTAFLKWDIRSMKTRGL
                PKAKSHAPEVITSSPLK"
                <1..56
sig_peptide

```

```

/gene="F10"
/note="coagulation factor X signal peptide"
67..483
/gene="F10"
/product="coagulation factor X light chain"
493..1401
/gene="F10"
/product="coagulation factor X heavy chain"
493..648
/gene="F10"
/product="coagulation factor X activation peptide"

Query Match   1.0%; Score 19.4; DB 1; Length 1414;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 436 TTGGTGAATAGTCTGTAATATCTCTAGGTCACCTTGTGTTATGACATCAGTTAGTCC 495
      |||||
DB 884 TTGTGAACCGGTGTGCTGTGATGACACCTCCACCTGTCGACCGCTCCACCGCCCTCC 825
      |||||
QY 496 AGCATTTCTCTGTTGCTGTTTTTGTGATGACCTAACTCTTGAGAGAAATGGGGT 552
      |||||
DB 824 TCTGCTCCGTGTTCCGGTCCCTTCGAATCTCTGCTTGGTGTAGACAGTGGGCT 768
      |||||

RESULT 128
AXI47505      AXI47505      1551 bp      DNA      linear      PAT 08-JUN-2001
LOCUS         Sequence 59 from Patent WO0136632.
DEFINITION    AXI47505
ACCESSION     AXI47505
VERSION       AXI47505.1 GI:14346662
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
ORGANISM      Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE     1
AUTHORS       Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
TITLE         Variants of alternative splicing
JOURNAL       Patent: WO 0136632-A 59 25-MAY-2001;
              Compugen Ltd. (IL)
FEATURES      Location/Qualifiers
                1..1551
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match   1.0%; Score 19.4; DB 1; Length 1551;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1042 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1094
      |||||
DB 1448 TGCATGCGGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1500
      |||||

RESULT 129
MMU44795      MMU44795      1850 bp      mRNA      linear      ROD 23-MAY-1996
LOCUS         Mus musculus coagulation factor VII (FVII) mRNA, complete cds.
DEFINITION    U44795
ACCESSION     U44795
VERSION       U44795.1 GI:1184738
KEYWORDS      Mus musculus (house mouse)
SOURCE        Mus musculus
ORGANISM      Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.
REFERENCE     1 (bases 1 to 1850)
AUTHORS       Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and
              Cascellino, F.J.
TITLE         Characterization of a cDNA encoding murine coagulation factor VII
JOURNAL       Thromb. Haemost. 75 (3), 481-487 (1996)
MEDLINE       96276538

```


[illegible]

```

/map="18-10064-9474-AC126686.3.1.232817"
/clone.lib="Roche Palo Alto"
/notes="SNPs developed from assay sequences derived from 15
different strains-of mice (as of October 1, 2003). Those
strains include A/J, A/HeJ, -129/Sv, AKR/J, B10.D2-H2/OsNj,
BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J,
MEL/MpJ, NZB/BinJ, NZW/LaC, SPRET/Ei, -"
<1..5596

STS
Query Match 1.0%; Score 19.2; DB 1; Length 596;
Best Local Similarity 49.5%; Pred. No. 1.4e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 191 TTCTGATTTCTATCTTGGCTCAATTTAACTAGTAGTGGTGTGGTTCCTAAG 250
Db 555 TTCTGGCTTAAGGAGACACCTTTTCCCAATGTAAGTGAATCCATTGAGGTAG 496
QY 251 TTGTGAAGTTTCTGTTCTTCTGTTGTTGTTGTTGT 287
Db 495 CTCCCACTTGGTGTAGTCCATAGTTGTTGTTGT 459

RESULT 134
LOCUS RAETHRO 826 bp mRNA linear MAM 08-MAY-1993
DEFINITION Oryctolagus cuniculus thrombin mRNA, 3' end.
ACCESSION M81396
VERSION M81396.1 GI:165740
KEYWORDS thrombin.
SOURCE Oryctolagus cuniculus (rabbit)
ORGANISM Oryctolagus cuniculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
REFERENCE 1 (bases 1 to 826)
AUTHORS Bankfield,D.K. and MacGillivray,R.T.
TITLE Partial characterization of vertebrate prothrombin cDNAs:
amplification and sequence analysis of the B chain of thrombin from
nine different species
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2779-2783 (1992)
MEDLINE 92212913
PUBMED 1557383
COMMENT Original source text: Oryctolagus cuniculus adult liver cDNA to
mRNA.
FEATURES
source
Location/Qualifiers
1..826
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"
/dev_stage="adult"
1..826
/gene="thrombin"
<1..708
/gene="thrombin"
/codon_start=1
/product="thrombin"
/protein_id="AAA31477.1"
/db_xref="GI:165741"
/translation="QELLCAASLSRDLWLTAAHCLLYPFPDKNFTVNDILVRIGKYA
RSRYRNNEKISTLEKIIHPGYNRENLDRIALMKLKKPVAFSDYHPVCLPKQKI
VTSLLQAGHKRVTGWNKEMVNNVNEQPSVLQVNLPLVERPICKASTGIRVTD
NMFCAGYKPEEGKGDCEGSGGPFVMKNPNYRNWYQMGIVSWGEGCDRDKGYFT
HVERLKKWIRKWDREFG"
706..816
/gene="thrombin"
3'UTR

Query Match 1.0%; Score 19.2; DB 1; Length 826;
Best Local Similarity 51.1%; Pred. No. 1.4e+02;
Matches 45; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 892 CATATCCATTCTGTACCCAGTACTTTTCTAGAGAAATTAAGATTCATTGAGTCA 951
Db 714 CACACACATTTGGGCTCTCTCACTCCGATGTGTACAGAAACCAACCCAGTCAAGATTGT 773

```

```

QY 952 TGTGGAATATCATGAGCAGTGT 979
Db 774 TTTTGTGTTGTGCGCTAAACGGTGT 801

RESULT 135
LOCUS AP465270 1302 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus anticoagulant protein C precursor (PROC) mRNA,
complete cds.
ACCESSION AP465270
VERSION AP465270.1 GI:28194011
KEYWORDS
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
REFERENCE 1 (bases 1 to 1302)
AUTHORS Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
TITLE Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1302)
AUTHORS McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
TITLE Direct Submission
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
source
Location/Qualifiers
1..1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1302
/gene="PROC"
1..1302
/gene="PROC"
/BC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/note="vitamin K dependent serine protease;
autoprothrombin IIf; coagulation factor XIV, contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AAO33365.1"
/db_xref="GI:28194012"
/translation="MWKLITGVLLAACSSPVCHASIFYSKYKDAQNVKIRKANSFL
ELKPGSVRECNBERCFEASRIFETKATLEFWSKYVDGQCAQKPCSGACKDN
IGSYSCIDKMGWGAQCNVYKNGKVDNGGCHQCKEDPAKQCYCSCAGYQLTN
DHWCTPVYPCSGVMDVTEGKAERNILGNGSGGSGSPRYVNLONLAKGFLCG
GVLIHPSNLTAACHVETGETLKVRLGKYHRLRIENSEQRIKRVKVRHNTKLSD
NDIAMLHLAEPVMNKYALPCLFTRDLAHELTITKGRQMLVTGWSTDEMRNYSAL
LSYIETIPVPCNECAQVNTISDNLCAAGSLGDRKDCSGDSGGSGGWATKIDTWFLV
GLVSWGCGCKKKEKFGVYTSQYSLVLIQHINKSGSWFG"

Query Match 1.0%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.4e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 949 TGATGTTGAGATTATCATGAGCAGTGTTCGTGATCTCTGTTATCTTCATCTGGA 1008
Db 617 TTATGCTCAAAATCTGAAGGAGATTCTGTGTGGAGGTCTCATCCCTCCCT 676

QY 1009 GTGT 1012
Db 677 GGT 680

```

RESULT 136
 BOVPRBC
 LOCUS Bovine protein C mRNA.
 DEFINITION K02435
 ACCESSION K02435.1 GI:163486
 VERSION autothrombin IIA; protein C; serine protease.
 KEYWORDS Bos taurus (cow)
 SOURCE Bos taurus
 ORGANISM Bos taurus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
 Bovidae; Bovinae; Bos.
 1 (bases 1 to 1373)
 Long, G.L., Balagaje, R.M. and MacGillivray, R.T.
 Cloning and sequencing of liver cDNA coding for bovine protein C
 Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)
 MEDLINE 85014826
 PUBMED 6091108
 COMMENT Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and
 pBC-7.
 The sequence reported in [1] included homopolymeric tails on the 5'
 and 3' ends (not shown here).
 Location/Qualifiers
 1..1373
 /organism="Bos taurus"
 /mol_type="mRNA"
 /db_xref="taxon:9913"
 <1..1370
 /note="protein C prepropeptide"
 /codon_start=3
 /protein_id="AAA30685.1"
 /db_xref="GI:163487"
 /translation="TGLLLFVITWINGISSTPAPPDSVFSSORAHVLRIRKANGSFLP
 ELRGNVERSCSEVCEFEAREIFONTEDTMAFSKYSDDGDCEDRPSGSPCDLPSC
 GRGCDLGLGFRGDCACGWEGRFCLEHVFENCSAENGCAHVCMEERGRHSCAP
 GYRLDDHQLCVSKVTFPCRGLGKMEKRRILARDINQVDDQKLDLPRIVDGCEAGV
 GESPWQVLDSKKKLVCGAVLIHVSMTVAHLDSRKKLIVRLGEYDMRRWSEWV
 DLDKEVLIHENTKTSNDIALRLAKPATLSQTVIPICLPDPSGSKKLTQVQGE
 TVVTGWRDTERNTFVLSIKVFPVFNACVHAKENKISNMLCAGILGSPRDAC
 EGDGSGPMVTFEFGTFLVGLVSGWEGGCRLYNYGVTVKSVRYLDMYIIGHIKAEAPL
 ESQVP"
 <1..86
 /note="protein C signal peptide"
 117..581
 /product="protein C light chain"
 588..1367
 /product="protein C inactive heavy chain"
 630..1367
 /product="protein C active heavy chain"

Query Match 1.08; Score 19.2; DB 1; Length 1373;
 Best Local Similarity 50.08; Pred.No.1.4e+02;
 Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;

QY 1732 GACCAAGATATCCATTCTTCTATCTGTCTCAGTGCCTGAGATCTCTTCTATCTC 1791
 Db 1061 GACGAAGTGCGGTTTCTCTGTGTCGTGACGTTGCCACAGAGGCC 1002
 QY 1792 TTGTATTCTGTCAGTGGCTTCTCTCAGGTTCC 1827
 Db 1001 CTGGCGACCTGGTGGTGGCTTGGCTCAGAGGCC 966

RESULT 137
 OCUT7477/c
 LOCUS Oryctolagus cuniculus (rabbit)
 DEFINITION Oryctolagus cuniculus coagulation factor VII mRNA, complete cds.
 ACCESSION U77477.1 GI:1698964
 VERSION U77477.1
 KEYWORDS Oryctolagus cuniculus (rabbit)
 SOURCE Oryctolagus cuniculus
 ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;


```

VERSION      AR141647.1  GI:15101163
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 168)
              Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and
              Stiegler,G.L.
TITLE        Flea protease proteins
JOURNAL      Patent: US 6146870-A 28 14-NOV-2000;
FEATURES     Location/Qualifiers
              1..168
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.9%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 1.8e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY      1552 ACCTTGATAGGACATCTTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTGGAA 1611
DB      150 ATCAGGATAACAGCAGCAAAATCATATTTTGGGTAAATTATTAGTCCTTCATTTCCATATAT 91
QY      1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCCTCTATTCCTTTGGTT 1664
DB      90 AGTTTGCACGTAGTCAGTCAATCAATAGGTACCTTTACATATATGTCAGTTGTT 38

RESULT 153
LOCUS        AR151537/c
DEFINITION   Sequence 28 from patent US 6232096.
ACCESSION    AR151537
VERSION      AR151537.1  GI:15127587
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 168)
              Gaines,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R., Stiegler,G.L.,
              Gaines,P.J. and Silver,G.
TITLE        Flea serine protease nucleic acid molecules and uses thereof
JOURNAL      Patent: US 6232095-A 28 15-MAY-2001;
FEATURES     Location/Qualifiers
              1..168
               /organism="unknown"
               /mol_type="unassigned DNA"

Query Match      0.9%; Score 18.6; DB 1; Length 168;
Best Local Similarity 47.8%; Pred. No. 1.8e+02;
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

QY      1552 ACCTTGATAGGACATCTTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTGGAA 1611
DB      150 ATCAGGATAACAGCAGCAAAATCATATTTTGGGTAAATTATTAGTCCTTCATTTCCATATAT 91
QY      1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCCTCTATTCCTTTGGTT 1664
DB      90 AGTTTGCACGTAGTCAGTCAATCAATAGGTACCTTTACATATATGTCAGTTGTT 38

RESULT 154
LOCUS        I82435/c
DEFINITION   Sequence 28 from patent US 5712143.
ACCESSION    I82435
VERSION      I82435.1  GI:3210732
KEYWORDS     .
SOURCE       Unknown.
ORGANISM     Unknown.
REFERENCE    Unclassified.
AUTHORS      1 (bases 1 to 168)
              Grieve,R.B., Rushlow,K.E., Hunter,S.Wu., Frank,G.R. and

```


PUBMED 8168596
 REFERENCE 2 (bases 1 to 484)
 AUTHORS Murakawa, M.
 TITLE Direct Submission
 JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology, 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
 COMMENT Submitted (18-Oct-1993) to DDBJ by: Masahiro Murakawa
 Division of Hematology
 Harasanshin General Hospital
 1-8 Taihaku-machi, Hakata-ku
 Fukuoka, Fukuoka 812
 Japan
 Phone: 092-291-3434
 Fax : 092-291-3266.

FEATURES
 source
 1. 484
 /organism="Macaca mulatta"
 /mol_type="genomic DNA"
 /db_xref="taxon:9544"
 <1..>484
 /product="coagulation factor X"
 /protein_id="BAA04755.1"
 /db_xref="GI:455395"
 /translation="EGGEAVHEVLIKHREFTKTYDDEIDAVLRKSPITPRMNVAP
 ACLERWASSTLMTQGTGIVSGFGRHEKRGQSTRLKMLEVPPYVDRNSCKLSSFFII
 TQNNFCAGYHAKQEDACQDSGGPHVTRFKDITFTVIGVSGEGCARKGKIYTKVT
 A"

Query Match 0.9%; Score 18.6; DB 1; Length 484;
 Best Local Similarity 61.2%; Pred. No. 1.9e+02;
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAGCTGTCGTC 312
 Db 317 TGTCTGGTGATGATGAAGCTGCTGGAGAGCTTGCAGCTGTGCGGTC 269

RESULT 166
 AX775014/c
 LOCUS 546 bp DNA linear PAT 09-JUL-2003
 DEFINITION Sequence 330 from Patent WO03038129.
 ACCESSION AX775014
 VERSION AX775014.1 GI:32486530
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Raponi, M.
 TITLE Methods for assessing and treating leukemia
 JOURNAL Patent: WO 03038129-A 330 08-MAY-2003;
 Ortho-Clinical Diagnostics, Inc. (US)
 FEATURES
 source
 1. 546
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9608"

Query Match 0.9%; Score 18.6; DB 1; Length 546;
 Best Local Similarity 57.9%; Pred. No. 1.9e+02;
 Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 37 AGCCCTCTCTGCGAATCTTCTGGGGTGCTGCTTCTCCCTGTTGATTCCTAGG 93
 Db 336 AGCCCTCTCTTGTGACACACAGGGGGCCCCCGCTGTCCCTCTGGAGCTGTCACG 280

RESULT 167
 AX335885/c
 LOCUS 624 bp DNA linear PAT 09-JAN-2002
 DEFINITION Sequence 6394 from Patent WO0194629.
 ACCESSION AX335885
 VERSION AX335885.1 GI:18126604
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1
 AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,
 Horrigan, S., Soppet, D.R. and Weaver, Z.
 TITLE Cancer gene determination and therapeutic screening using signature
 gene sets
 JOURNAL Patent: WO 0194629-A 6394 13-DEC-2001;
 Avalon Pharmaceuticals (US)
 FEATURES
 source
 1. 624
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 18.6; DB 1; Length 624;
 Best Local Similarity 61.2%; Pred. No. 2e+02;
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTCGTC 312
 Db 351 TGTCTGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTGCGGTC 303

RESULT 168
 HUMFX8/c
 LOCUS 624 bp DNA linear PRI 09-NOV-1994
 DEFINITION Human factor X (blood coagulation factor) gene, exon 8.
 ACCESSION L29433 M14327 N00045
 VERSION L29433.1 GI:459809
 KEYWORDS Stuart factor; blood coagulation factor; factor X; glycoprotein;
 serine protease.
 SEGMENT 8 of 8
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 624)
 AUTHORS Leytus, S.P., Foster, D.C., Kurachi, K. and Davie, E.W.
 TITLE Gene for human factor X: a blood coagulation factor whose gene
 organization is essentially identical with that of factor IX and
 protein C
 JOURNAL Biochemistry 25 (18), 5098-5102 (1986)
 MEDLINE 87026600
 PUBMED 3768336
 COMMENT Original source text: Homo sapiens (tissue library: of Lawn et al.,
 matp + 13 + 458 factor Xa heavy chain.
 FEATURES
 source
 1. 624
 Location/Qualifiers
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /map="15q34"
 /tissue_lib="of Lawn et al., and Yoshitake et al."
 Join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,
 L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,
 L00396.1:13..130,13..614)
 /notes="preprofactor X"
 /codon_start=1
 /product="coagulation factor X"
 /protein_id="AA52764.1"
 /db_xref="GI:182831"
 /translation="MGRELHVLLSASLGLLLGESLFIIRQANNILARVTRANSF
 LEMKTKHLRECEMEETCSYSEARVFDSDKTNEFWNKYQDQCSYPCQNGKCK
 DGLGEYTCLEGEFGKNCLELFRKLCSLDNGDCDQCFHEBQNSWVCARGYTLADN

db_xref="SWISS-PROT:P00763"
 /translations="LVGAFAVFDVDDDKIVGGTYCOENSVYQVSLNSGYHFCGSL
 INQWVSAACHVKSRIVRLGHEINVLGNEQFVNAKIIKHENPDKTLNNDIML
 IKLSVPKLNARVATVALPSSCAAGTQCLISGNGTLLSSGYNEDLLQCLDAPLLPQ
 ADCEASYPKLTIDNMVGVFLEGGKDCSCGDSGGPVCNGELQGLVSGYGCALPDNP
 GVTIKVNYVDWIQDTIAAN"
 <1..25
 /notes="signal peptide"
 773
 /note="polyA addition site"

Query Match 0.9%; Score 18.6; DB 1; Length 773;
 Best Local Similarity 45.5%; Pred. No. 2e+02;
 Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;
 Qy 1552 ACCTGTAGGATCTCTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTGAAA 1611
 Db 315 AGCTTGATCAGCATGATGTCATTTGAGGTCCTCTCGAAGTTGGATGCTGATG 256
 Qy 1612 ATATTTTCCCTGCTTTGACCTGCCCTCTCCCTCTTCTCTTCTTCTTGGTTTGCAT 1671
 Db 255 ATCTGCGACATTCACAACTGCTCATTCCTCCCTCAGGACATGATGTTGCTCTCC 196
 Qy 1672 AGTCTCTCTGCTTCTCTGATGTTT 1696
 Db 195 AGTCTCATTGGATGGGGACTTAT 171

RESULT 172
 DOGTRYPA DOGTRYPA 819 bp mRNA linear MAM 27-APR-1993
 LOCUS Dog pancreatic anionic trypsinogen mRNA.
 ACCESSION M11589
 VERSION M11589.1 GI:164094
 KEYWORDS
 SOURCE Canis sp.

REFERENCE Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.
 1 (bases 1 to 819)
 AUTHORS Pinsky, S.D., LaForce, K.S. and Scheele, G.
 TITLE Differential regulation of trypsinogen mRNA translation:
 full-length mRNA sequences encoding two oppositely charged
 trypsinogen isoenzymes in the dog pancreas
 Mol. Cell. Biol. 5 (10), 2669-2676 (1985)

JOURNAL 86284628
 MEDLINE 3841794
 PUBMED
 COMMENT Original source text: Dog pancreas, cDNA to mRNA, clone pT1.
 FEATURES Location/Qualifiers
 source 1..819
 /organism="Canis sp."
 /mol_type="mRNA"
 /db_xref="taxon:9616"

mRNA 1..819
 CDS 15..758
 /product="anionic trypsinogen mRNA"
 /note="anionic trypsinogen precursor"
 /codon_start=1
 /protein_id="AAA30899.1"
 /db_xref="GI:164095"
 /translation="MNPILLAFGLAAVPTDDDKIVGGTYCOENSVYQVSLNSG
 YHFCGSLIDQWVAACHVKSRIVRLGHEINVLGNEQFINSKVRHPNYSW
 ILNDIMLIKSSPAVILNARVATISLPACAPGTQCLISGNGTLLSSGYNEDLLQCLDAPLLPQ
 LDAPILTAQCEASYPQITENMICAGFLGEGKDCSCGDSGGPVCNGELQGLVSGY
 GCAQKRPYGVTVKCNFVDWIQDTIAANS"

Query Match 0.9%; Score 18.6; DB 1; Length 819;
 Best Local Similarity 50.6%; Pred. No. 2e+02;
 Matches 45; Conservative 0; Mismatches 44; Indels 0; Gaps 0;
 Qy 776 GCTTCTCTTAGGGCCATTGTTAGATATCTTTTCCATCTCTTTTACTCTAAGTGAT 835
 Db 531 GCCTCTTACCCGCCAGATCACGAGAACATGATTGCGCGGCTTCTTGTAGGGAGGC 590

Qy 836 GTCTATCCATGGTAGGTTGCTCTTTTGG 864
 Db 591 AAGACTCTCCAGGAGGTGACTCTGCTGG 619

RESULT 173
 PVTRYPSIN PVTRYPSIN 854 bp mRNA linear INV 01-OCT-1996
 LOCUS P.vannamei mRNA for trypsin.
 DEFINITION X86359
 ACCESSION X86359.1 GI:785034
 VERSION
 KEYWORDS trypsin.
 SOURCE Litopenaeus vannamei (Pacific white shrimp)
 ORGANISM Litopenaeus vannamei
 Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;
 Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;
 Penaeidae; Litopenaeus.

REFERENCE Klein, B., Le Moullac, G., Sellos, D. and Van Wormhoudt, A.
 AUTHORS Molecular cloning and sequencing of trypsin cDNAs from *Penaeus*
 TITLE vannamei (Crustacea, Decapoda): use in assessing gene expression
 during the moult cycle
 Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)

JOURNAL 96252881
 MEDLINE 8697100
 PUBMED
 REFERENCE 2 (bases 1 to 854)
 AUTHORS Van Wormhoudt, A.E.
 TITLE Direct Submission

JOURNAL Submitted (18-APR-1995) A.E. Van Wormhoudt, College de France /
 CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,
 FRANCE

FEATURES Location/Qualifiers
 source 1..854
 /organism="Litopenaeus vannamei"
 /mol_type="mRNA"
 /db_xref="taxon:6689"
 /tissue_type="hepatopancreas"
 /dev_stage="adult"
 3..803
 /EC_number="3.4.21.4"
 /codon_start=1
 /product="trypsin"
 /protein_id="CAA60129.1"
 /db_xref="GI:785035"
 /db_xref="GOA:Q27761"
 /db_xref="SPTREMBL:Q27761"
 /translation="MKTLILCVLLAGFAAPSRKPTFRRLGKLVGGTDTATPGLPYQ
 LSPQDISFGFAHFCGASINENWAIACGHCVCQGEDMNNPDYLVQVAGELNDVDEGT
 EOTVILSKIIQHEHDYNGFTISNDILKLSQPLSNDNVRADIPACGHAASGDCIVS
 GAGTTSSEGSTSVLQKVTVPVIVSDDECDAYGQSDIEDSMICAGVPSGKDCSCQDS
 GGPLASDITASTYLAGIVSWGICGAPFGYGVYAEVSHVDWIKNAV"

sig_peptide 3..41

Query Match 0.9%; Score 18.6; DB 1; Length 854;
 Best Local Similarity 61.2%; Pred. No. 2e+02;
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 613 TGTTTATGAACTTGGGTGACATTTGTTGGTGATGACATTAAGAA 661
 Db 797 TGTTTATCAAGTTGTTTACATGTTACTTACCTTGAACCAATAAGAA 845

RESULT 174
 LOCUS AP465268/c
 DEFINITION Gallus gallus coagulation factor VII precursor (F7) mRNA, complete
 cds.
 ACCESSION AP465268
 VERSION AP465268.1 GI:28194007
 KEYWORDS Gallus gallus (chicken)
 SOURCE Gallus gallus
 ORGANISM Gallus gallus


```
source
1. .1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1. .1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69367.1"
/db_xref="GI:6735651"
/db_xref="REVIEW:MBL: CAB69367"
/translation="MGRPLHLVLSASLAGLLLGESLPIREQANNILARVTRANSF
LEEMKGLHRECMETCSYEAREVFEDSKTNFHWKYKDGOCETSPCONQKCK
DGGEYTCCTCEGFEKNCLEFTRKLCSDNDGDCQFCHEEQNSVVCSCARGYTLADN
GRACITPTGPPCKQTLERRKRSVAQATSSGEAPDSITWKPYDAADLDPTENPFDLL
DFNQTQPERGDNLLTRIVGQCKDECPQALLINEENEGFCGTTILSEFYILTAH
CLYQAKRVKVRGDRNTEQEGEAVHEVVEVVKINRFTKETYDFDIIVLRKPTIF
RMNVAACLPERDWAESTLMTOKTGVSGFGRTEKGRSTELKMLVYVVDNRSKL
SSSFILITQNMFCAGYTKOEDACQDSGGPHVTRFKDYFVTGIVSWGESCARCKGYG
IYTKVAFPLKWDISMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 312
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 177
A86886/c
LOCUS A86886 1467 bp DNA linear PAT 22-JAN-2000
DEFINITION Sequence 26 from Patent WO9838317.
ACCESSION A86886
VERSION A86886.1 GI:6735677
KEYWORDS unidentified
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M. and Eibl,J.
TITLE FACTOR X ANALOGUES WITH A MODIFIED PROTEASE CLEAVAGE SITE
JOURNAL Himmelspach MICHELE (AT); EIBL JOHANN (AT)
FEATURES
Location/Qualifiers
1. .1467
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"
1. .1467
/notes="unnamed protein product"
/codon_start=1
/protein_id="CAB69368.1"
/db_xref="GI:6735678"
/db_xref="REVIEW:MBL: CAB69368"
/translation="MGRPLHLVLSASLAGLLLGESLPIREQANNILARVTRANSF
LEEMKGLHRECMETCSYEAREVFEDSKTNFHWKYKDGOCETSPCONQKCK
DGGEYTCCTCEGFEKNCLEFTRKLCSDNDGDCQFCHEEQNSVVCSCARGYTLADN
GRACITPTGPPCKQTLERRKRSVAQATSSGEAPDSITWKPYDAADLDPTENPFDLL
DFNQTQPERGDNLLTRIVGQCKDECPQALLINEENEGFCGTTILSEFYILTAH
CLYQAKRVKVRGDRNTEQEGEAVHEVVEVVKINRFTKETYDFDIIVLRKPTIF
RMNVAACLPERDWAESTLMTOKTGVSGFGRTEKGRSTELKMLVYVVDNRSKL
SSSFILITQNMFCAGYTKOEDACQDSGGPHVTRFKDYFVTGIVSWGESCARCKGYG
IYTKVAFPLKWDISMKTRGLPKAKSHAPEVITSSPLK"

Query Match 0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 312
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 178
A86886/c
LOCUS A86886 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 43 from patent US 6562598.
ACCESSION A86886
VERSION A86886.1 GI:33696092
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Pfeleiderer,M., Falkner,F.-G., Eibl,J., Dörner,F. and Schlokot,U.
TITLE Factor X deletion mutants and analogues thereof
JOURNAL Patent: US 6562598-A 43 13-MAY-2003;
FEATURES
Location/Qualifiers
1. .1467
/organism="unknown"
/mol_type="mRNA"

Query Match 0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 312
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 179
A86886/c
LOCUS A86886 1467 bp mRNA linear PAT 17-AUG-2003
DEFINITION Sequence 26 from patent US 6573071.
ACCESSION A86886
VERSION A86886.1 GI:33732713
KEYWORDS Unknown.
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 1467)
AUTHORS Himmelspach,M., Schlokot,U., Dörner,F., Fisch,A. and Eibl,J.
TITLE Factor X analogues with a modified protease cleavage site
JOURNAL Patent: US 6573071-A 26 03-JUN-2003;
FEATURES
Location/Qualifiers
1. .1467
/organism="unknown"
/mol_type="mRNA"

Query Match 0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTTAAGCTGTGGTGC 312
|||||
Db 1204 TGTCTGGGTGATGATGAAGCTGCTGGACAGCTTGCAGCTGTTCGGTC 1156

RESULT 180
A86886/c
LOCUS A86886 1467 bp DNA linear PAT 28-FEB-2001
DEFINITION Sequence 1 from Patent WO0110896.
ACCESSION A86886
VERSION A86886.1 GI:13184880
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Himmelspach,M. and Schlokot,U.
TITLE Factor X analog with an improved ability to be activated
JOURNAL Patent: WO 0110896-A 1 15-FEB-2001;
```

```

FEATURES             Baxter Aktiengesellschaft (AT)
source               1..1467
                    /organism="Homo sapiens"
                    /mol_type="unassigned DNA"
                    /db_xref="taxon:9606"

Query Match          0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGATGAAGCTGTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 181
BD070392/c          1467 bp DNA linear PAT 27-AUG-2002
LOCUS               Factor X-analogues with modified protease cleavage site.
DEFINITION          BD070392
ACCESSION            BD070392.1 GI:22615995
VERSION              JP 2001513631-A/26.
KEYWORDS              unclassified.
SOURCE               unclassified.
ORGANISM             unclassified.
REFERENCE             1 (bases 1 to 1467)
AUTHORS              Himmelsbach,M., Schlokot,U., Dörner,F., Andreas, Fisch and Eibl,J.
TITLE                Factor X-analogues with modified protease cleavage site
JOURNAL              Patent: JP 2001513631-A 26 04-SEP-2001;
                     BAXTER AG
COMMENT              OS Unidentified
                     PN JP 2001513631-A/26
                     PD 04-SEP-2001
                     PR 27-FEB-1998 JP 1998537062
                     PI MICHELE HIMMELSPACH,UWE SCHLOKAT,FRIEDRICH DÖRNER,ANDREAS PI
                     FISCH,JOHANN EIBL
                     PC Cl2N15/57,Cl2N9/64,A61K38/48
                     CC Strandedness: Single;
                     CC Topology: Linear;
                     CC Factor X-analogues with modified protease cleavage site FH
                     Key
                     FT CDS
                        Location/Qualifiers
                        1..1467
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"

Query Match          0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGATGAAGCTGTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 182
BD070435/c          1467 bp DNA linear PAT 27-AUG-2002
LOCUS               Factor X deletion mutants and analogues thereof.
DEFINITION          BD070435
ACCESSION            BD070435.1 GI:22616038
VERSION              JP 2001513632-A/43.
KEYWORDS              unclassified.
SOURCE               unclassified.
ORGANISM             unclassified.
REFERENCE             1 (bases 1 to 1467)
AUTHORS              Himmelsbach,M., Pfeleiderer,M., Falkner,F.G., Eibl,J., Dörner,F. and
                     Schlokot,U.
TITLE                Factor X deletion mutants and analogues thereof

JOURNAL              Patent: JP 2001513632-A 43 04-SEP-2001;
                     BAXTER AG
COMMENT              OS Unidentified
                     PN JP 2001513632-A/43
                     PD 04-SEP-2001
                     PR 27-FEB-1998 JP 1998537063
                     PI MICHELE HIMMELSPACH,MICHAEL PFELEIDERER,FALKO GUNTER FALKNER,
                     JOHANN EIBL,
                     PC Cl2N15/57,Cl2N9/64,A61K38/48
                     CC Strandedness: Single;
                     CC Topology: Linear;
                     CC Factor X deletion mutants and analogues thereof FH
                     Key
                     FT CDS
                        Location/Qualifiers
                        1..1467
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"

Query Match          0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGATGAAGCTGTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 183
AF191307/c          1514 bp mRNA linear MAM 01-NOV-2000
LOCUS               Sus scrofa protein C mRNA, complete cds.
DEFINITION          AF191307
ACCESSION            AF191307
VERSION              AF191307.1 GI:11065893
KEYWORDS              Sus scrofa (pig)
SOURCE               Sus scrofa
ORGANISM             Sus scrofa
REFERENCE             1 (bases 1 to 1514)
AUTHORS              Grimm,D.R., Colter,M.B. and Kim,H.
TITLE                Cloning of the complete cDNA sequences encoding porcine factor V
                     and protein C
JOURNAL              Unpublished
REFERENCE             2 (bases 1 to 1514)
AUTHORS              Grimm,D.R., Colter,M.B. and Kim,H.
TITLE                Direct Submission
JOURNAL              Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
                     North Pine Drive, Tampa, FL 33612, USA
FEATURES             Location/Qualifiers
source               1..1514
                    /organism="Sus scrofa"
                    /mol_type="mRNA"
                    /db_xref="taxon:9823"
                    /clone="92N.4; 58/86.2; 12N3.1"
                    /tissue_type="liver"
                    22..1401
                    /note="serine protease"
                    /codon_start=1
                    /product="protein C"
                    /protein_id="AAG28380.1"
                    /db_xref="GI:11065894"
                    /translation="MWQLASLLLLLIWVSSSTVPDPSVSSQRAHQMLRSKRANS
                     FLEELRPSLSERECKEETCDDEEARIFONTENAFWSKIHGDQCAVSPPEHLCD
                     PCGGRTGIDGLGFRCDCAQWEGRCFLHEVFNCSNGTNGGCAHYCLSEEGRRCA
                     QPGYRLGDDHLQCFKVRSPCGRLNMRKKNLKRDTQVDKDDQDLPRLVNGK
                     QSPWESQWVILLDSKKLACGAVLIHVSWLTAARCLDDYKLTAVRLGEYDLRRE
                     KVEVDLDIKFVLVHPNTRSTSDNDIALRLAEPATFSQIVPICLPDLSGLSRELTR
                     VQCVTVTGVGYRSEAKTRNSRFLNFVKVPVAPNECVQAMHNKISNMCLCAGLGD
                     RDACGDSGPGMVASFRGTWELVGLVSGEGCGRLHNYGVYTKVSRVLDWIHGHRME"

JOURNAL              Patent: JP 2001513632-A 43 04-SEP-2001;
                     BAXTER AG
COMMENT              OS Unidentified
                     PN JP 2001513632-A/43
                     PD 04-SEP-2001
                     PR 27-FEB-1998 JP 1998537063
                     PI MICHELE HIMMELSPACH,MICHAEL PFELEIDERER,FALKO GUNTER FALKNER,
                     JOHANN EIBL,
                     PC Cl2N15/57,Cl2N9/64,A61K38/48
                     CC Strandedness: Single;
                     CC Topology: Linear;
                     CC Factor X deletion mutants and analogues thereof FH
                     Key
                     FT CDS
                        Location/Qualifiers
                        1..1467
                        /organism="unidentified"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:32644"

Query Match          0.9%; Score 18.6; DB 1; Length 1467;
Best Local Similarity 61.2%; Pred. No. 2e+02;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGATGAAGCTGTGGACAGCTTGCAGCTGTTCGGGTC 1156

RESULT 184
AF191307/c          1514 bp mRNA linear MAM 01-NOV-2000
LOCUS               Sus scrofa protein C mRNA, complete cds.
DEFINITION          AF191307
ACCESSION            AF191307
VERSION              AF191307.1 GI:11065893
KEYWORDS              Sus scrofa (pig)
SOURCE               Sus scrofa
ORGANISM             Sus scrofa
REFERENCE             1 (bases 1 to 1514)
AUTHORS              Grimm,D.R., Colter,M.B. and Kim,H.
TITLE                Cloning of the complete cDNA sequences encoding porcine factor V
                     and protein C
JOURNAL              Unpublished
REFERENCE             2 (bases 1 to 1514)
AUTHORS              Grimm,D.R., Colter,M.B. and Kim,H.
TITLE                Direct Submission
JOURNAL              Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
                     North Pine Drive, Tampa, FL 33612, USA
FEATURES             Location/Qualifiers
source               1..1514
                    /organism="Sus scrofa"
                    /mol_type="mRNA"
                    /db_xref="taxon:9823"
                    /clone="92N.4; 58/86.2; 12N3.1"
                    /tissue_type="liver"
                    22..1401
                    /note="serine protease"
                    /codon_start=1
                    /product="protein C"
                    /protein_id="AAG28380.1"
                    /db_xref="GI:11065894"
                    /translation="MWQLASLLLLLIWVSSSTVPDPSVSSQRAHQMLRSKRANS
                     FLEELRPSLSERECKEETCDDEEARIFONTENAFWSKIHGDQCAVSPPEHLCD
                     PCGGRTGIDGLGFRCDCAQWEGRCFLHEVFNCSNGTNGGCAHYCLSEEGRRCA
                     QPGYRLGDDHLQCFKVRSPCGRLNMRKKNLKRDTQVDKDDQDLPRLVNGK
                     QSPWESQWVILLDSKKLACGAVLIHVSWLTAARCLDDYKLTAVRLGEYDLRRE
                     KVEVDLDIKFVLVHPNTRSTSDNDIALRLAEPATFSQIVPICLPDLSGLSRELTR
                     VQCVTVTGVGYRSEAKTRNSRFLNFVKVPVAPNECVQAMHNKISNMCLCAGLGD
                     RDACGDSGPGMVASFRGTWELVGLVSGEGCGRLHNYGVYTKVSRVLDWIHGHRME"

```



```

EAFHKNQVP"
Query Match      0.9%; Score 18.6; DB 1; Length 1514;
Best Local Similarity 51.9%; Pred. No. 2e+02;
Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;

Qy 1854 CAGATTCCTTCAGTTGGTTTGGTTTAAATCTATTCACATTCAGTCTCGAAA 1913
      |||||
Db 657 CGGATCATTTGGTCTCTCTTTTGGTTCACATTTGGTCTGTATCACGCTTCAAGTCTTCGCG 598
      |||||

Qy 1914 TGTCTTACTCATTTCTCTCC 1934
      |||||
Db 597 TTCTCTTCATCGGATTCCTCC 577

RESULT 184
HUMKALR4
LOCUS      Human renal kallikrein, exon 4.          linear          PRI 06-JAN-1995
DEFINITION
ACCESSION  M33108
VERSION     M33108.1 GI:186648
KEYWORDS   kallikrein; kininogenase.
SEGMENT    4 of 5
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 193)
AUTHORS    Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N.,
            Nakanishi,S., Callen,D.F., Baker,E., Hyland,V.J., Sutherland,G.R.
            and Richards,R.I.
TITLE      Structure and chromosomal localization of the human renal
            kallikrein gene
JOURNAL    Biochemistry 27 (9), 3124-3129 (1988)
MEDLINE    88269498
PUBMED     2898948
COMMENT    Original source text: Human parotid gland, cDNA to mRNA.
FEATURES   source
            Location/Qualifiers
            1..193
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="19q13.3"
            /note="19q13.3"
            prim_transcript <1..>193
            /gene="KLK1"
            /notes="kallikrein mRNA and introns"
            intron <1..>29
            /gene="KLK1"
            /notes="kallikrein intron C"
            exon 30..166
            /gene="KLK1"
            /note="G00-120-118"
            intron 167..>193
            /gene="KLK1"
            /notes="kallikrein intron D"

Query Match      0.9%; Score 18.4; DB 1; Length 193;
Best Local Similarity 69.4%; Pred. No. 2e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 1838 TTAATTTTTCATTCACATTCCTTCCTTCAGTTGGG 1873
      |||||
Db 23 TTCTAGTCATTCATTCACATGATCTCCAGTGTGG 58
      |||||

RESULT 185
HUMDPB1A/c
LOCUS      Human DPB1 protein gene, partial cds.    linear          PRI 07-NOV-1994
DEFINITION
ACCESSION  M77674
VERSION     M77674.1 GI:181735
KEYWORDS   DPB1 protein.

Homo sapiens (human)
Homo sapiens
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (bases 1 to 249)
AUTHORS    Cao,X., Veale,A. and Serjeantson,S.
TITLE      ABI: a novel HLA-DPB1 allele found in one third of an Australian
            population
JOURNAL    Immunogenetics 36 (1), 64-66 (1992)
MEDLINE    92267574
PUBMED     1587554
COMMENT    Original source text: Homo sapiens blood DNA.
FEATURES   source
            Location/Qualifiers
            1..249
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /db_xref="taxon:9606"
            /map="6p21.3"
            /cell_type="lymphocyte"
            /tissue_type="blood"
            gene 1..249
            /gene="HLA-DPB1"
            misc_feature 1..249
            /gene="HLA-DPB1"
            /note="G00-120-636"

Query Match      0.9%; Score 18.4; DB 1; Length 249;
Best Local Similarity 56.7%; Pred. No. 2.1e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTCTCTCAGGTTCTGTGGTCTTAATTTTTCATTTCCAGATTCCTTCAGTTG 1871
      |||||
Db 218 TTGTGTGCATCTCTGTCGGCACTCCCGCTTCTCTCCAGATGTCTCTTGCTG 159
      |||||

RESULT 186
HUMDPBA/c
LOCUS      Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK1. linear          PRI 14-APR-2000
DEFINITION
ACCESSION  D10478
VERSION     D10478.1 GI:219604
KEYWORDS   HLA-DP beta; DPB1; MHC; human leukocyte antigen; major
            histocompatibility complex class II molecule.
SOURCE     Homo sapiens (human)
ORGANISM   Homo sapiens
            Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1 (sites)
            Akaza,T., Mitomi,Y. and Juji,T.
            Family study on HLA-DPB1 polymorphism: linkage analysis with
            HLA-DR/DQ and two 'new' alleles
            Hum. Immunol. 34 (3), 203-211 (1992)
JOURNAL    Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE    93053849
PUBMED     1358967
REFERENCE  2 (bases 1 to 249)
AUTHORS    Mitsuunaga,S.
JOURNAL    Unpublished
COMMENT    Submitted (17-Feb-1992) to DDBJ by:
            Katsushi Mitsuunaga
            Dept. of Transfusion Medicine and
            Immunohematology, Faculty of Medicine
            The University of Tokyo
            7-3-1 Hongo, Bunkyo-ku
            Tokyo 113
            Japan
            Phone: 03-3815-5411 x8880
            Fax: 03-3816-2516
            Location/Qualifiers
            1..249
            /organism="Homo sapiens"
            /mol_type="genomic DNA"
            /isolate="THK"

```

```

/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK1"
/cell_type="peripheral blood mononuclear cell"
1..249
/gene="DPB1"
<1..>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01281.1"
/db_xref="GI:219605"
/translation="LFGQRCYAFNGTQFLERYINREELVRFDSVGEFRAVTEL
GRPEAYWNSQKILEKRAVPDRMCRHNYELDEAVTLQ"
1..249
/gene="DPB1"
/number=2
1
/gene="DPB1"
/citation=[1]
/replace="cctcccgagagaattac"
249
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgaggct"

```

Query Match 0.9%; Score 18.4; DB 1; Length 249;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

```

Qy 1812 TTGTCCTGAGGTCCTGTCGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 1871
Db 218 TTGTCCTGACATCTGTCGGACTCGCCGCTTCTCTCCAGATGTCCTTCGGCTG 159

```

```

RESULT 187
HUMDPBB/c HUMDPBB 249 bp DNA linear PRI 14-APR-2000
LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK2.
DEFINITION D10479
ACCESSION D10479
VERSION D10479.1 GI:219606
KEYWORDS HLA-DP beta; DPB1; MHC; human leukocyte antigen; major histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (sites)
REFERENCE Mitsuana,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K., Akaza,T., Mitoma,Y. and Ojui,T.
AUTHORS Family study on HLA-DPB1 polymorphism: linkage analysis with HLA-DR/DQ and two 'new' alleles
TITLE Hum. Immunol. 34 (3), 203-211 (1992)
JOURNAL MEDLINE 93053849
PUBMED 1358867
REFERENCE 2 (bases 1 to 249)
AUTHORS Mitsuana,S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DBJ by: Katsushi Tokunaga
Dept. of Transfusion Medicine and Immunohematology, Faculty of Medicine The University of Tokyo
7-3-1 Hongo, Bunkyo-ku Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.
Location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THM"

```

```

/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK2"
/cell_type="peripheral blood mononuclear cell"
1..249
/gene="DPB1"
<1..>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01282.1"
/db_xref="GI:219607"
/translation="VYQLRQCYAFNGTQFLERYINREELVRFDSVGEFRAVTEL
GRPEAYWNSQKILEKRAVPDRMCRHNYELDEAVTLQ"
1..249
/gene="DPB1"
/number=2
1
/gene="DPB1"
/citation=[1]
/replace="cctcccgagagaattac"
249
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgaggct"

```

Query Match 0.9%; Score 18.4; DB 1; Length 249;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

```

Qy 1812 TTGTCCTGAGGTCCTGTCGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 1871
Db 218 TTGTCCTGACATCTGTCGGACTCGCCGCTTCTCTCCAGATGTCCTTCGGCTG 159

```

```

RESULT 188
HUMDPBB/c HUMDPBB 249 bp DNA linear PRI 07-JAN-1995
LOCUS Human MHC class II HLA DP-beta gene, exon 2 allele DPB5.
DEFINITION M23680
ACCESSION M23680
VERSION M23680.1 GI:188070
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 249)
REFERENCE Bugawan,T.L., Horn,G.T., Long,C.M., Mickelson,E., Hansen,J.A., Ferrara,G.B., Angelini,G. and Erlich,H.A.
AUTHORS Analysis of HLA-DP allelic sequence polymorphism using the in vitro enzymatic DNA amplification of DP-alpha and DP-beta loci
TITLE J. Immunol. 141 (11), 4024-4030 (1988)
JOURNAL MEDLINE 89035547
PUBMED 2460556
REFERENCE Original
COMMENT source text: Human DNA allele DPB5.
Location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1..249
/gene="HLA-DPB1"
<1..>249
/gene="HLA-DPB1"
/number=2
/number=2
/codon_start=1
/protein_id="AAA59745.1"
/db_xref="GI:188071"
/db_xref="GDB:G00-120-636"
/translation="LFGQRCYAFNGTQFLERYINREELVRFDSVGEFRAVTEL"

```

GRPEAEYWNQKDLLEKRAVPRMCRHNYELDEAVTLQ"

Query Match 0.98; Score 18.4; DB 1; Length 249;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTGCTCTGAGGTTCTGTTGGTTCTTAATTTTTCATTCCAGATTTCTTCAGTTTG 1871
 |||||
 Db 218 TTGCTCTGACATCTCTGTCGGCACTGCCGGCTTCTCTCCAGGATGTCCTCTGGCTG 159
 |||||

RESULT 189
 HUMDPB1KT/C
 LOCUS Human MHC class II HLA DP-beta 256 bp DNA linear PRI 07-JAN-1995
 DEFINITION
 ACCESSION M62333
 VERSION M62333.1 GI:188026
 KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane glycoprotein; major histocompatibility complex.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 256)
 AUTHORS Bugawan, T.L., Begovich, A.B. and Erlich, H.A.
 TITLE Rapid HLA-DPB typing using enzymatically amplified DNA and nonradioactive sequence-specific oligonucleotide probes
 JOURNAL Immunogenetics 32 (4), 231-241 (1990)
 MEDLINE 91055805
 PUBMED 2242906
 COMMENT Original source text: Human DNA allele DPB5.
 FEATURES Location/Qualifiers
 1..256
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /map="6p21.3"
 1..256
 /gene="HLA-DPB1"
 1..256
 /gene="HLA-DPB1"
 /codon_start=1
 /product="MHC class II HLA-DP-beta-1"
 /protein_id="AAAS9726.1"
 /db_xref="GI:553549"
 /db_xref="GDB:G00-120-636"
 /translations="LFGQROECYAFNGTQFLERYIYNREELVRFDSVGEFRAVTEL
 GRPEAEYWNQKDLLEKRAVPRMCRHNYELDEAVTLQRR"

Query Match 0.98; Score 18.4; DB 1; Length 256;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTGCTCTGAGGTTCTGTTGGTTCTTAATTTTTCATTCCAGATTTCTTCAGTTTG 1871
 |||||
 Db 218 TTGCTCTGACATCTCTGTCGGCACTGCCGGCTTCTCTCCAGGATGTCCTCTGGCTG 159
 |||||

Query Match 0.98; Score 18.4; DB 1; Length 256;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTGCTCTGAGGTTCTGTTGGTTCTTAATTTTTCATTCCAGATTTCTTCAGTTTG 1871
 |||||
 Db 218 TTGCTCTGACATCTCTGTCGGCACTGCCGGCTTCTCTCCAGGATGTCCTCTGGCTG 159
 |||||

RESULT 190
 AF180970/C
 LOCUS Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1 variant allele, partial cds.
 DEFINITION
 ACCESSION AF180970
 VERSION AF180970.1 GI:14279142
 KEYWORDS Homo sapiens (human)
 SOURCE Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 257)
 AUTHORS Xu, A., Huang, H., Liu, Z., Chen, W., Pan, D., Lin, J., Xu, K., Chen, S., Wang, X. and Chen, R.

TITLE A novel HLA-DPB1 allele in Chinese people
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 257)
 AUTHORS Xu, A., Huang, H., Liu, Z., Chen, W., Pan, D., Lin, J., Xu, K., Chen, S., Wang, X. and Chen, R.
 TITLE Direct Submission
 JOURNAL Submitted (26-AUG-1999) Biochemistry, School of Life Science, 135 Xingangxi Road, Guangzhou, Guangdong 510275, P.R.China
 FEATURES Location/Qualifiers
 1..257
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
 /chromosomes="6"
 /map="6p21.3"
 <1..>257
 /gene="HLA-DPB1"
 /allele="HLA-DPB1 variant"
 <1..>257
 /genes="HLA-DPB1"
 /product="MHC class II antigen"
 <1..>257
 /genes="HLA-DPB1"
 /notes="membrane protein"
 /codon_start=3
 /product="MHC class II antigen"
 /protein_id="AAK53508.1"
 /db_xref="GI:14279143"
 /translation="NLFQGRQECYAFNGTQFLERYIYNREELVRFDSVGEFRAVTELQ
 ELGRPEAEYWNQKDLLEKRAVPRMCRHNYELDEAVTLQ"

Query Match 0.9%; Score 18.4; DB 1; Length 257;
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTGCTCTGAGGTTCTGTTGGTTCTTAATTTTTCATTCCAGATTTCTTCAGTTTG 1871
 |||||
 Db 226 TTGCTCTGACATCTCTGTCGGCACTGCCGGCTTCTCTCCAGGATGTCCTCTGGCTG 167
 |||||

RESULT 191
 HUMDPB1KT/C
 LOCUS Human MHC class II HLA-DPB1 gene allele DPB1*KT.
 DEFINITION
 ACCESSION D10882
 VERSION D10882.1 GI:219602
 KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.
 SOURCE Homo sapiens (human)
 ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 264)
 AUTHORS Ozawa, K., Icho, H., Nakajyo, S., Kobayashi, K., Sekiguchi, S., Koshizaka, T., Taguchi, M., Onishi, H., Kobayashi, S. and Inoko, H.
 TITLE A novel HLA-DPB1 allele, DPB1*3601 (DPB1*KT)
 JOURNAL Tissue Antigens 44 (2), 134-136 (1994)
 MEDLINE 95117110
 PUBMED 7817379
 REFERENCE 2 (bases 1 to 264)
 AUTHORS Koshizaka, T.
 TITLE Direct Submission
 JOURNAL Submitted (06-APR-1992) Takuya Koshizaka, Sumitomo Metal Industries, Ltd., 14-15 Kobuchi 2-chome, Sagami-hara, Kanagawa 229, Japan (Tel:0427-51-7568, Fax:0427-51-7519)
 COMMENT Submitted (06-Apr-1992) to DDBJ by: Takuya Koshizaka
 Sumitomo Metal Industries, Ltd.
 14-15 Kobuchi 2-chome
 Sagami-hara, Kanagawa 229


```

/isolate="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1
<20..283
/codon_start=3
/label=exon.2
/product="MHC HLA DPB1"
/protein_id="AAA36266.1"
/db_xref="GI:553571"
/translation="NVVQLRQECVAFNGTQRLVRYNREELVRFDSVDGFRFVAT
ELGRPEAEYNNQKLLLEKRAVPRMCRHNYELDEAVTLQRR"
284..285
/number=2

intron

Query Match      0.9%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.1e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 1812 TTCTCTCAGGTCCTGTTGGTCTTAATTTTCATTTCCAGATTCTCTCAGTTG 1871
      |||||
Db 245 TTGTGTGCATCTGTGCGCACTGCCGCTTCTCTCCAGAGTCTCTTGTGCTG 186

RESULT 198
AF312826/c      804 bp      mRNA      linear      INV 02-MAR-2001
LOCUS          Luidia foliolata sea star regeneration-associated protease SRAP
DEFINITION     AF312826.1 GI:13183619
ACCESSION      AF312826
VERSION        AF312826
KEYWORDS       Luidia foliolata
SOURCE         Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;
               Asteoidea; Valvatacea; Paxillosida; Luidiidae; Luidia.
REFERENCE      1 (bases 1 to 804)
AUTHORS        Vickery,M.C., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE          Utilization of a novel deuterostome model for the study of
               regeneration genetics: molecular cloning of genes that are
               differentially expressed during early stages of larval sea star
               regeneration
JOURNAL        Gene 262 (1-2), 73-80 (2001)
MEDLINE        21100442
PubMed        11179669
REFERENCE      2 (bases 1 to 804)
AUTHORS        Vickery,M.C.L., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE          Direct Submission
JOURNAL        Submitted (12-OCT-2000) Department of Biology, University of
               Alabama at Birmingham, 1300 University Blvd., Birmingham, AL
               35294-1170, USA

FEATURES       Location/Qualifiers
source         1..804
               /organism="Luidia foliolata"
               /mol_type="mRNA"
               /db_xref="taxon:105861"
               /dev_stage="larva"
               1..804
               /note="serine protease"
               /codon_start=1
               /product="sea star regeneration-associated protease SRAP"
               /protein_id="AAK15274.1"
               /db_xref="GI:13183620"
               /translation="MLRLILVLCALAAFYVADCGVQVNPVNLKINGDSEAVGSGHPWQ
               VNRKRYWAGDIFCGGLILSDAWAACHFNIGNINHTAVGAHRDSDVSTQT
               TVLGGKVFVHSDYITLNDLIALIKLSSPVSMNYSNVCLEPTAATPTGTCVVTGW
               GQCEVADVDPLQQVVPITISQCNATRYGGEINDNMNCAFGKREGGDCQGGSGG
               PFVCSAGEYELGVVSWGVCADARKPGYAKLVNYSWNNLVARN"

Query Match      0.9%; Score 18.4; DB 1; Length 804;
Best Local Similarity 59.6%; Pred. No. 2.2e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 189 ATTTCCTGATTTCTATCTGGCTCATTTTAACTCACTAGTAGAGTTGTTGTTCCATA 248
      |||||
Db 207 AATTGCTGCATTTCTGTGGAGGTTCCATCGTTAATGAAAATGGTTGTAAGTGTGCCCA 266

Query Match      0.9%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.2e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 249 AGTTTGTAAGTTTCTGTTGTTCTCTGTTGTTGTTGTTGTT 288
      |||||
Db 267 CTGCATCAACCTGGTGTAAATAATCTGTTGTCAGGT 306

RESULT 200
AF011900/c      832 bp      mRNA      linear      VRT 09-SEP-1997
LOCUS          Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
DEFINITION     AF011900
ACCESSION      AF011900
VERSION        AF011900.1 GI:2367498
KEYWORDS       Petromyzon marinus (sea lamprey)
SOURCE         Petromyzon marinus
ORGANISM       Petromyzon marinus
REFERENCE      1 (bases 1 to 832)
AUTHORS        Roach,J.C.
TITLE          The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL        Unpublished

```

```

Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 517 TTGTTGAGTACCTAATCTTGGAGAGATGGGTATTGAAGTAGCCCACT 568
      |||||
Db 251 TGGTTGATGTGCCATAGTTATGGAAGCAATGGGCAGACAGACGCCCACT 200

RESULT 199
SHPFIXA
LOCUS          Sheep factor IX mRNA, partial cds.
DEFINITION     M26233
ACCESSION      M26233
VERSION        M26233.1 GI:165878
KEYWORDS       factor IX. (sheep)
SOURCE         Ovis aries (sheep)
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
               Bovidae; Caprinae; Ovis.
REFERENCE      1 (bases 1 to 823)
AUTHORS        Sarkar,G., Koerber,D.D. and Sommer,S.S.
TITLE          Direct sequencing of the activation peptide and the catalytic
               domain of the factor IX gene in six species
JOURNAL        Genomics 6 (1), 133-143 (1990)
MEDLINE        90152675
PubMed        2303254
COMMENT        Original source text: Sheep liver, cDNA to mRNA.
               Draft entry and computer-readable sequence for [1] kindly provided
               by G.Sarkar, 18-JUL-1989.

FEATURES       Location/Qualifiers
source         1..823
               /organism="Ovis aries"
               /mol_type="mRNA"
               /db_xref="taxon:9940"
               <1..823
               /note="factor IX"
               /codon_start=1
               /protein_id="AA31520.1"
               /db_xref="GI:552413"
               /translation="RASVLHSTSKLTATETFSNNVNSSEARLIWDNVTSQCSFD
               DNRVVGSDAARQPFQVQLHGEIAAFCGSVINRWVVAACHKPGKRVTVAG
               ENHTEKPEPTEQRNVIRAIPIHYGNASINKYSHDIALLEDELELNSVYTPICID
               REYTNIFLKGFGYVSGWRVFNRSASIIQYLKVLPLDRATCLRTKFTIYNMFC
               AGYHGGKDCQCGDGGPHVTEGTSFLTGTIISWGECAMKKGIVTKVRYEV"

Query Match      0.9%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.2e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 189 ATTTCCTGATTTCTATCTGGCTCATTTTAACTCACTAGTAGAGTTGTTGTTCCATA 248
      |||||
Db 207 AATTGCTGCATTTCTGTGGAGGTTCCATCGTTAATGAAAATGGTTGTAAGTGTGCCCA 266

Query Match      0.9%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.2e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

QY 249 AGTTTGTAAGTTTCTGTTGTTCTCTGTTGTTGTTGTTGTT 288
      |||||
Db 267 CTGCATCAACCTGGTGTAAATAATCTGTTGTCAGGT 306

RESULT 200
AF011900/c      832 bp      mRNA      linear      VRT 09-SEP-1997
LOCUS          Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
DEFINITION     AF011900
ACCESSION      AF011900
VERSION        AF011900.1 GI:2367498
KEYWORDS       Petromyzon marinus (sea lamprey)
SOURCE         Petromyzon marinus
ORGANISM       Petromyzon marinus
REFERENCE      1 (bases 1 to 832)
AUTHORS        Roach,J.C.
TITLE          The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL        Unpublished

```

REFERENCE 2 (bases 1 to 832)
Roach, J.C.
Direct Submission
Submitted (01-JUL-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA
JOURNAL Location/Qualifiers
FEATURES
source
1..832
/organism="Petrotyzon marinus"
/mol_type="mRNA"
/db_xref="taxon:7757"
/dev_stage="amocoete"
/tissue_lib="anterior intestine"
<1..832
/genes="TRYPB1"
/db_xref="GI:2367499"
<1..736
/genes="TRYPB1"
/codon_start=2
/product="trypsinogen B1"
/protein_id="AAB69856.1"
/db_xref="GI:2367499"
/translation="LIFALLVGTAAAPWYEDHIVGYECAAHQVQVSLNIGYHF CGSLSSWYVAAHYQATASRISVRIGEHNFVTEGTEQRIQAKAIRPQYSSAT INDIMLILSSPATLNOVAQVPLPSSCGVTGVMCTISGNETQTSVSGPDVLMVQ APVLSSTCRNSVPGDITNNMICLGLYEGGKDSQCGSGPVCNQLQGVSNWGRG. ALPNYGVVTKVCNYSNWSIASTMAAN"
<1..37
/genes="TRYPB1"
/evidence=not_experimental
38..733
/genes="TRYPB1"
/product="trypsin b1"
/evidence=not_experimental
sig_peptide
mat_peptide
Query Match 0.9%; Score 18.4; DB 1; Length 832;
Best Local Similarity 78.8%; Pred. No. 2.2e+02;
Matches 22; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 1591 TCTTTTGGTTTCTTGAAATATTTT 1618
Db 832 TTTTITTTTTTTTATTTCAATATTTT 805
RESULT 201
AF465275/c
LOCUS 1293 bp mRNA linear VRT 02-FEB-2003
DEFINITION Takifugu rubripes coagulation factor VIIC precursor, mRNA, complete cds.
ACCESSION AF465275
VERSION AF465275.1 GI:28194021
KEYWORDS Takifugu rubripes (Fugu rubripes)
SOURCE Takifugu rubripes
ORGANISM Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Actinopterygii; Percomorpha; Tetraodontiformes; Tetraodontidae; Takifugu.
REFERENCE 1 (bases 1 to 1293)
Davidson, C.J., Hitt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G.D. and McVey, J.H.
Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1293)
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
Direct Submission
TITLE Direct Submission
AUTHORS McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.
JOURNAL Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK
FEATURES
source
1..1293
/organism="Takifugu rubripes"
/mol_type="mRNA"
/db_xref="taxon:31033"

CDS
1..1293
/SC_number="3.4.21.21"
/function="serum prothrombin conversion accelerator"
/note="vitamin K dependent serine protease; similar to factor VII precursor; synthesized in liver; similar to Fugu rubripes FVII and FVIII; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"
/codon_start=1
/product="coagulation factor VIIC precursor"
/protein_id="AA033370.1"
/db_xref="GI:28194021"
/translation="WASFRGKXRLFFIKLFIIVPVCSPFAGVFNKEPEANVFLH RTRANFLPELKAAGNERIEEKSEYEEAKEIFALPQLEAFWRTYAVDQCKLSP CNGATCTRRFTYACKANGHCNDKVALTNGCRNGGCEHFEPDRSYVC FKAPGYRLDKNSTCLPQVPCGRQLQILFSPRVINGLICPKGHCPCWAMLSNNIYT CQTIIILSEOMVLTAAHCVKRVKFLNVTVEGHDREIPEKTEQHRVTKVLIHSGYNN TSSDXDLAMKLHVRPVLGLVWPICLPAONSTISRTIANIROSTVSGMGLSRFGPP AFILQRLTLPVPELOECBLHTNENLWLCAGLKTGGRDACEGDSGSLVTVYEKTV FLTGVSNGKGCANENLVYVVRVNFIDWIGNIATN"
Query Match 0.9%; Score 18.4; DB 1; Length 1293;
Best Local Similarity 69.4%; Pred. No. 2.2e+02;
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1656 CCTTTCGTTTTCATAGTGTCTCTGGCTTCTCTGGA 1691
Db 115 CCTCGGTTTTTCCATATAAACTCCGCTTCGGAA 80
RESULT 202
AX523898
LOCUS 1505 bp DNA linear PAT 24-OCT-2002
DEFINITION Sequence 105 from Patent WO02064799.
ACCESSION AX523898
VERSION AX523898.1 GI:24412662
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
Seldon, R.F., Miller, A.M. and Treco, D.S.
Optimized messenger rna
Patent: WO 02064799-A 105 22-AUG-2002;
JOURNAL TRANSGENOTIC THERAPIES, INC. (US)
FEATURES
source
1..1505
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 18.4; DB 1; Length 1505;
Best Local Similarity 59.6%; Pred. No. 2.2e+02;
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
QY 1709 ATTTAGACTTAACATTTTCTTTGACCAAGGTATCCATTTCTTCTTGT 1760
Db 1425 AATTGAATTAACAGGCGCTCTCACTAATCACTTCCATCTTTTGT 1476
RESULT 203
S78934
LOCUS 171 nt DNA linear PRI 07-MAY-1993
DEFINITION (Factor IX Madrid 2) (exon IV and intron d) [human, Genomic Mutant, 171 nt].
ACCESSION S78934
VERSION S78934.1 GI:244109
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1 (bases 1 to 171)

AUTHORS Solera,J., Magallon,M., Martin-Villiar,J. and Coloma,A.
TITLE Factor IXMadrid 2: a deletion/insertion in factor IX gene which abolishes the sequence of the donor junction at the exon IV-intron d splice site
JOURNAL Am.J. Hum. Genet. 50 (2), 434-437 (1992)
MEDLINE 92133619
PUBMED 1346483
REMARK GenBank staff at the National Library of Medicine created this entry [NCBI gisbq 78934] from the original journal article. This sequence comes from Fig 3A.

FEATURES

source
 1..171
 /organism="Homo sapiens"
 /mol_type="genomic DNA"
 /db_xref="taxon:9606"
Query Match 0.9%; Score 18.2; DB 1; Length 171;
Best Local Similarity 51.9%; Pred. No. 2.2e+02;
Matches 41; Conservative 0; Mismatches 38; Indels 0; Gaps 0;
QY 427 CTTTGTGTTTGGTCAATAGCTCTGTAATATCTCTAGGTCCACTTGGTTATGACATCA 486
 |||||
Db 84 CTTTGGATTGGAAGGAAGAACTGTGAATTTCCAGTTTCAACTGTTTTCAGAGGAAA 143
 |||||
QY 487 GTTAGCTCCAGCAATTTCTC 505
 |||||
Db 144 CTTTGAACCATGAGTATTC 162
 |||||

RESULT 204
AX318568
LOCUS AX318568 240 bp DNA linear PAT 06-JUL-2002
DEFINITION Sequence 73 from Patent WO0177155.
ACCESSION AX318568
VERSION AX318568.2 GI:21713338
KEYWORDS
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS 1 Fernandes,E., Vernet,C.A., Mishnu,V.S., Leach,M.D., Shimkets,R.A., Zerhusen,B.D. and Kekuda,R.
TITLE Orfx polynucleotides and polypeptides
JOURNAL Patent: WO 0177155-A 73 18-OCT-2001;
 Curagen Corporation (US)

COMMENT On Jul 8, 2002 this sequence version replaced gi:17900986.

FEATURES

source
 1..240
 /organism="Homo sapiens"
 /mol_type="unassigned DNA"
 /db_xref="taxon:9606"

Query Match 0.9%; Score 18.2; DB 1; Length 240;
Best Local Similarity 58.2%; Pred. No. 2.3e+02;
Matches 32; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 1646 TTCCTCTATTCTCTGTTTTCATAGTCTCTCGCTTCCTCGGATGTTTATG 1700
 |||||
Db 26 TCCCTCAGATGCTCTGAGTGTGGAGCGAGCCCTCGCTTCGCGATAGTTGGT 80
 |||||

RESULT 205
AY083553
LOCUS AY083553 251 bp DNA linear PRI 13-APR-2002
DEFINITION Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.
ACCESSION AY083553
VERSION AY083553.1 GI:20146915
KEYWORDS
SOURCE Macaca mulatta (rhesus monkey)
ORGANISM Macaca mulatta
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;

REFERENCE Cercopitheidae; Macaca.
 1 (bases 1 to 251)
AUTHORS Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
TITLE Construction of a targeted rhesus macaque microarray
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 251)
AUTHORS Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.
TITLE Direct Submission
JOURNAL Submitted (11-MAR-2002) Molecular and Cellular Biology Core, Oregon Regional Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA

FEATURES

Location/Qualifiers
 1..251
 /organism="Macaca mulatta"
 /mol_type="genomic DNA"
 /db_xref="taxon:9544"
 <1..>251
 /genes="GAP43"
 <1..>251
 /genes="GAP43"
 /product="growth associated protein 43"
 <1..>251
 /genes="GAP43"

Query Match 0.9%; Score 18.2; DB 1; Length 251;
Best Local Similarity 55.6%; Pred. No. 2.3e+02;
Matches 35; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 900 TTCTGTACCCAGTATCTTTTCTAGAGAAATAGATCAATTCATTCATTCATTCGGA 959
 |||||
Db 147 TTTTGTCTCTGTGTGTGTATGGCGAGTTTGTGTAATGATGATCAATTCATTCGGA 206
 |||||
QY 960 ATT 962
 |||||
Db 207 AAT 209
 |||||

RESULT 206

HSTCRB9
LOCUS HSTCRB9 265 bp mRNA linear PRI 22-DEC-1993
DEFINITION H.sapiens (3.2) mRNA for T-cell receptor beta chain.
ACCESSION X74849
VERSION X74849.1 GI:407455

KEYWORDS T-cell receptor beta chain; TCR-b gene.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Jores,R. and Neo,T.
TITLE Few V gene segments dominate the T cell receptor beta-chain repertoire of the human thymus

JOURNAL J. Immunol. 151 (11), 6110-6122 (1993)
MEDLINE 94065165
PUBMED 8245454
REFERENCE 2 (bases 1 to 265)
AUTHORS Jores,R.
TITLE Direct Submission
JOURNAL Submitted (11-AUG-1993) R. Jores, Institut Pasteur, Unite d'Immunogenetique, Dept d'Immunologie, 25, rue du Dr. Roux, 75015 Paris, FRANCE

FEATURES

source
 1..265
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="3.2"
 /issue_type="thymus"
 /clone_lib="human thymus cdna"
 1..265
 /gene="TCR-b"
 38..>265
 /genes="TCR-b"

Db 548 TTTCGACGACCGGTGGTTGGTAGTCGGTCTTCTTCACTGG 506

RESULT 209
OCU49933/c
LOCUS
DEFINITION
CRYOTOLAGUS CUNICULUS VITAMIN K-DEPENDENT PROTEIN C PRECURSOR mRNA,
PARTIAL CDS.
ACCESSION
U49933
VERSION
U49933.1 GI:1236620

ORGANISM
CRYOTOLAGUS CUNICULUS (RABBIT)
CRYOTOLAGUS CUNICULUS
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.
1 (bases 1 to 1558)
Shen, L., He, X. and Dahlback, B.
Molecular cloning of rabbit vitamin K-dependent protein C and
demonstration of its mRNA in the reproductive organs
Unpublished
2 (bases 1 to 1558)
Shen, L., He, X. and Dahlback, B.
Direct Submission
Submitted (26-FEB-1996) Lei Shen, Clinical Chemistry, Lund
University, University Hospital, Malmö S-205 02, Sweden
Location/Qualifiers
1..1558
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"
/dev_stage="adult"
<1..1377
/codon_start=1
/product="vitamin K-dependent protein C precursor"
/protein_id="AA92956.1"
/db_xref="GI:1236621"
/translation="IPDVGVRNOKTASKEGVSVKQCDGPNTLPRKANSFLBEL
RPSLERECSEVCDLEAKEIFQSVDDTLAFWYVDGQCAALPEHPSCSQCGH
GTCADISGFCQCHGEGFQCEVFRFNSVDNGCAHYCLEEAGRSCGCAFGY
ELADHLCQPAVRPFCGRGKWKRIKKRGVNRKDLSDVDEMDVDPRLIDGKLTTRG
DSPQCVILLDSKKLACGAVILHVSWLTAHCMEEPKLFLVRLGYDVLPRKRWEL
LNIQVLLHPNYSSTTNDIALRLAGPATLSQTIPIGLPDLNGLAERLMAGQET
VVTGMYHSREKAKRNTIFLNFITVPAPQNECEQVMSNIISENLCAGLIGRR
DACDSDGSPVMSAFRGFTWFLVGLVSWGEGCGDLNNYGVYTKRVSLDMLHSHIEKE
RAPESPAP"

CDS
sig_peptide
mat_peptide
109..1374
/note="putative; leader peptide"
/product="vitamin K-dependent protein C"
/note="putative"

Query Match 0.9%; Score 18.2; DB 1; Length 1558;
Best Local Similarity 66.7%; Pred. No. 2.4e+02;
Matches 26; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 814 CATCTTTTACCTAAGGTGATGTCTATCCATGGTAGGT 852
DB 1351 CTTCTTTTCTCGATGTCGCTGGATCCAGTCAGGT 1313

RESULT 210
S68634/c
LOCUS
DEFINITION
CRM+ factor IX Strasbourg 2-cross reacting material positive factor
IX Strasbourg 2 {exon 2} [human, hemophilia B patient J-C L, blood,
Genomic Mutant, 199 nt].
ACCESSION
S68634
VERSION
S68634.1 GI:545020

ORGANISM
Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 199)
de la Salle, C., Charman-tier, J.L., Ravanat, C., Ohlmann, P.,
Hartmann, M.L., Schueller, S., Bischoff, R., Ebel, C., Roeklin, D.,
Balland, A. et al.
The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation
by factor Xla
Nouv. Rev. Fr. Hematol. 35 (5), 473-480 (1993)
94126308
8295821
GensBank staff at the National Library of Medicine created this
entry [NCBI gisseq 143652] from the original journal article.
G6365 to A transition.
Location/Qualifiers
1..199
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="hemophilia B patient J-C L"
/db_xref="taxon:9606"
/tissue_type="blood"
<4..>168
/note="cross reacting material positive factor IX
Strasbourg 2; Arg-4 to Gln transition; Method: conceptual
translation with partial peptide sequencing"
/codon_start=1
/product="CRM+ factor IX Strasbourg 2"
/protein_id="AAB29758.1"
/db_xref="GI:545021"
/translation="VFLDENANKILNQPKYNSGLKEFVQGNLERECMEKCSPEE
AREVFENTERT"

CDS
Query Match 0.9%; Score 18; DB 1; Length 199;
Best Local Similarity 45.2%; Pred. No. 2.5e+02;
Matches 66; Conservative 0; Mismatches 80; Indels 0; Gaps 0;

QY 1540 TATGCTTTTGTACCTGATAGGATCTCTTCTCAAGGTAGGAATTTTCTTTT 1599
DB 168 TGTCTTTTCACTGTTTCAAAAACCTCTCGTGTCTTCTCAAACTACACATTTTCTTCCAT 109
QY 1600 GTTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATCTT 1659
DB 108 ACAITCTCTCTCAAGTTCCTTGAACAACCTCTTCCAATTACCTGAATTATACCTCTT 49
QY 1660 TGGTTTTTGCATAGTGTCTTGGCTT 1685
DB 48 TGGCTGATTCAGAAATTTTGTGGCGT 23

RESULT 211
I14646/c
LOCUS
DEFINITION
Sequence 123 from patent US 5451512.
ACCESSION
I14646
VERSION
I14646.1 GI:997129
KEYWORDS
Unknown.
SOURCE
ORGANISM
Unclassified.
1 (bases 1 to 276)
Apple, R.J., Bugawan, T.L. and Erlich, H.A.
Methods and reagents for HLA class I A locus DNA typing
Patent: US 5451512-A 123 19-SEP-1995;
Location/Qualifiers
1..276
/organism="unknown"
/mol_type="unassigned DNA"

REFERENCE
AUTHORS
TITLE
JOURNAL
PUBLISHED
1993
source

QY 63 CTGCTGCTTTTCTCCCTGTCTGATTCCTAGGTCAGGTTACCACTGCTCTCTCTCC 122
DB 108 ACAITCTCTCTCAAGTTCCTTGAACAACCTCTTCCAATTACCTGAATTATACCTCTT 49
QY 1660 TGGTTTTTGCATAGTGTCTTGGCTT 1685
DB 48 TGGCTGATTCAGAAATTTTGTGGCGT 23

Db 238 CTGGGAGCCACTCCAGCAGCGTCCCTCCAGGTAGGCTCTCCAGTCTCCAGCTCCGCTCATGG 179

Qy 123 TTCTCTTAACACTT 136

Db 178 GCCGTCTCCCACTT 165

RESULT 212
AV267909S2/c
LOCUS Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A*3401 variant
DEFINITION allele, exon 3 and partial cds.
ACCESSION AY267910
VERSION AY267910.1 GI:30525804
KEYWORDS
SEGMENT
SOURCE 2 of 2
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 276)
AUTHORS Steinert N.K., Fernandez-Vina, M. and Hurley, C.K.
TITLE Novel HLA-A Allele
JOURNAL Unpublished
AUTHORS Steinert N.K., Fernandez-Vina, M. and Hurley, C.K.
TITLE Direct Submission
JOURNAL Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC
20007, USA

FEATURES
source
1. .276
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="GN00431"
/db_xref="taxon:9606"
order(AY267909.1:<1..270,1..>276)
/gene="HLA-A"
/allele="HLA-A*3401 variant"
join(AY267909.1:<1..270,1..>276)
/gene="HLA-A"
/product="MHC class I antigen"
join(AY267909.1:<1..270,1..>276)
/gene="HLA-A"
/codon_start=3
/product="MHC class I antigen"
/protein_id="AAP32699.1"
/db_xref="GI:30525805"
translation="SSMRVFTVSVPGRGPRFTAVGVDDTQFVRFSDAASORM
EPAPRTQCPYWRNTRKYKQSQTRVLDGLRGLYNSQSGSHTIQRMVGGDY
GPDGRFGRGQQDAYDKGKTISLNEDESRWTADMAAQITQRKWTAEAGWRAYLE
GTCVWMLRRVYLENGKETLQRT"
exon
1. .276
/gene="HLA-A"
/number=3

Query Match 0.9%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.6e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 63 CTGCTGCTTTCCCTGTCTGATCTAGGGTGAGGGTTACACGTCTCTCTCTCC 122
|||||
Db 238 CTGGGAGCCACTCCAGCAGCGTCCCTCCAGGTAGGCTCTCCAGTCTCCGCTCATGG 179
|||||

Qy 123 TTCTCTTAACACTT 136
|||||
Db 178 GCCGTCTCCCACTT 165
|||||

RESULT 214
HSHLAAGN2/c
LOCUS Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
DEFINITION partial cds.
ACCESSION U90243
VERSION U90243.1 GI:1905858
KEYWORDS
SEGMENT
SOURCE 2 of 2
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 276)
AUTHORS Hurley, C.K., Steiner, N., Kosman, C., Mitton, W., Koester, R., Bei, M.,
Bush, J., McCormack, J., Hahn, A., Hanson, V., Hoyer, R., Wade, J.A.,
Hartzman, R.J. and Ng, J.
TITLE Novel HLA-A and HLA-B alleles
JOURNAL Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE 98378282
PUBMED 9714480
REFERENCE 2 (bases 1 to 276)
AUTHORS Bei, M. and Hurley, C.K.
TITLE Direct Submission
JOURNAL Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC

allele, exon 3.
AJ507648
AJ507648.1 GI:23304865
HLA-A gene; HLA-A*34 allele; human leucocyte antigen A; major
histocompatibility complex; MHC class I antigen.
Homo sapiens (human)
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Lebedeva, T.V., Huang, A., Janzen, M. and Yu, N.
TITLE Identification of novel HLA Class I alleles using single allele
sequencing
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 276)
AUTHORS Lebedeva, T.V.
TITLE Direct Submission
JOURNAL Submitted (10-SEP-2002) Lebedeva T.V., HLA laboratory, American Red
Cross New England Region, 180 Rustcraft Rd, Dedham, MA 02026, USA

FEATURES
source
1. .276
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"
1. .276
/genes="HLA-A"
1. .276
/gene="HLA-A"
/number=3
/allele="HLA-A*34"
/usedin=AJ507647:HLA-A*34_CDS

Query Match 0.9%; Score 18; DB 1; Length 276;
Best Local Similarity 52.7%; Pred. No. 2.6e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 63 CTGCTGCTTTCCCTGTCTGATCTAGGGTGAGGGTTACACGTCTCTCTCTCC 122
|||||
Db 238 CTGGGAGCCACTCCAGCAGCGTCCCTCCAGGTAGGCTCTCCAGTCTCCGCTCATGG 179
|||||

Qy 123 TTCTCTTAACACTT 136
|||||
Db 178 GCCGTCTCCCACTT 165
|||||

RESULT 214
HSHLAAGN2/c
LOCUS Human MHC class I antigen HLA-A gene (A*2601 variant), exon 3 and
DEFINITION partial cds.
ACCESSION U90243
VERSION U90243.1 GI:1905858
KEYWORDS
SEGMENT
SOURCE 2 of 2
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 276)
AUTHORS Hurley, C.K., Steiner, N., Kosman, C., Mitton, W., Koester, R., Bei, M.,
Bush, J., McCormack, J., Hahn, A., Hanson, V., Hoyer, R., Wade, J.A.,
Hartzman, R.J. and Ng, J.
TITLE Novel HLA-A and HLA-B alleles
JOURNAL Tissue Antigens 52 (1), 84-87 (1998)
MEDLINE 98378282
PUBMED 9714480
REFERENCE 2 (bases 1 to 276)
AUTHORS Bei, M. and Hurley, C.K.
TITLE Direct Submission
JOURNAL Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC

```

20007, USA
FEATURES
  source
    Location/Qualifiers
      1..276
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /isolate="GNO0158"
        /db_xref="taxon:9606"
        join(U90242.1:1..270,1..>276)
        /gene="HLA-A"
        join(U90242.1:1..270,1..>276)
        /gene="HLA-A"
        /product="MHC class I antigen"
        join(U90242.1:1..270,1..>276)
        /gene="HLA-A"
        /note="variant A*2601"
        /codon_start=3
        /product="MHC class I antigen"
        /protein_id="AAB50149.1"
        /db_xref="GI:1903860"
        /translation="SHSMRYFTSVSPGRGEPRFVAVGVDDTQFVREDSDAASORM
        EPRAPWISQEGPEYWDNRNKAHSOTDRANLGTLEGYNQSDSGSHIQRYMGCDV
        GTFGRFLRGYQDDAYDGRDIALNEDRSWTADMAAQITQRKWTAEAEQWRVYLE
        GTGVWELRYRLNKGKTLQRT"
      1..276
        /gene="HLA-A"
        /number=3
  exon
    Query Match
      0.9%; Score 18; DB 1; Length 276;
    Best Local Similarity
      52.7%; Pred. No. 2.6e+02;
    Matches
      39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
  QY
    63 CTGCGCCTTTCTCCCTCTGATTCCTAGGAGGAGGTTACCACTGCTCTCTCTCCC 122
  Db
    238 CTGCGAGCACTCCACGACGTCGCTCCAGGAGGCTCTCCACTGCTCCGCTCATGG 179
  QY
    123 TTCTCTACACTT 136
  Db
    178 GCCGCTCCACTT 165
  RESULT 215
  AR249144/c
  LOCUS
    AR249144
  DEFINITION
    Sequence 4503 from patent US 6476212.
  ACCESSION
    AR249144
  VERSION
    AR249144.1 GI:27297018
  KEYWORDS
    Unknown.
  SOURCE
    Unknown.
  ORGANISM
    Unclassified.
  REFERENCE
    1 (bases 1 to 290)
    Lalquidi, R.V., Ito, L.Y. and Sherman, B.K.
    Polynucleotides and polypeptides derived from corn ear
    Patent: US 6476212-A 4503 05-NOV-2002;
  TITLE
    Location/Qualifiers
  JOURNAL
    source
      1..290
        /organism="unknown"
        /mol_type="genomic DNA"
  Query Match
    0.9%; Score 18; DB 1; Length 290;
  Best Local Similarity
    51.2%; Pred. No. 2.6e+02;
  Matches
    42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;
  QY
    1577 GGTAGGAATTTTCTTTTGTGTTTCTTGAAATATTTCCTCGCTTTGACCTGCC 1636
  Db
    218 GCGCGGAGATCTTGCCCTCTGCTGCTCCAGGAGGCTCGGCTCTCCAGGGGTGAC 159
  QY
    1637 TTCTTCCCTTCCCTCTATTCCT 1658
  Db
    158 TGCAGCTCCATCTTCTCGGCT 137
  RESULT 216

```

```

AX312474
LOCUS
  AX312474
  DEFINITION
    Sequence 5459 from Patent WO0190366.
  ACCESSION
    AX312474
  VERSION
    AX312474.1 GI:17897467
  KEYWORDS
    Homo sapiens (human)
  SOURCE
    Homo sapiens
  ORGANISM
    Homo sapiens
  Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
  REFERENCE
    1
    Leach, M.D. and Shinkets, R.A.
    Human polynucleotides and polypeptides encoded thereby
    Patent: WO 0190366-A 5459 29-NOV-2001;
    Curagen Corporation (US)
  LOCATION/Qualifiers
    1..299
      /organism="Homo sapiens"
      /mol_type="unassigned DNA"
      /db_xref="taxon:9606"
  Query Match
    0.9%; Score 18; DB 1; Length 299;
  Best Local Similarity
    54.5%; Pred. No. 2.6e+02;
  Matches
    36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
  QY
    1626 TTGACCTGCTTCTTCCCTCTCTATTCCTTGGTTTTCATAGTCTCTGGCTT 1685
  Db
    220 TTGACCTGCTTCTTCCCTCTCTATTCCTTGGTTTTCATAGTCTCTGGCTT 1685
  QY
    1686 CCTGGA 1691
  Db
    280 CCTGGA 285
  RESULT 217
  BTA271156/c
  LOCUS
    BTA271156
  DEFINITION
    Bos taurus partial mRNA for haptoglobin (hp gene).
  ACCESSION
    BTA271156
  VERSION
    BTA271156.1 GI:9581738
  KEYWORDS
    haptoglobin; hp gene.
  SOURCE
    Bos taurus (cow)
  ORGANISM
    Bos taurus
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
  Bovidae; Bovinae; Bos.
  REFERENCE
    1
    Lavery, K.S., Gabler, C. and Killian, G.J.
    Expression and localization of haptoglobin in the bovine female
    reproductive tract
    Unpublished
    2 (bases 1 to 302)
    Lavery, K.S.
    Direct Submission
    Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science,
    Pennsylvania State University, The John O. Almquist Research
    Center, Fox Hollow Road, University Park, USA
  LOCATION/Qualifiers
    1..302
      /organism="Bos taurus"
      /mol_type="mRNA"
      /db_xref="taxon:9913"
      /sex="female"
      /cell_type="epithelial cell"
      /tissue_type="oviduct"
      /dev stage="adult"
    1..302
      /gene="hp"
      /genes="hp"
      /function="acute phase protein"
      /codon_start=3
      /product="haptoglobin"
  gene
  CDS

```

/protein_id="CAC00531.1"
/db_xref="GI:9581739"
/db_xref="GOA:Q9MYV8"
/db_xref="SPTREMBL:Q9MYV8"
/translation="KGSFQWQAKWVSHNLSGATLINERWLLTTAKNLYLGHSSDKK
AKDITPLRLVGVGNQLVEVEKVLHPDHSKVDIGLIKLRQKVPVNDKVMPCILPS"
Query Match 0.9%; Score 18; DB 1; Length 302;
Best Local Similarity 52.7%; Pred. No. 2.7e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 1550 GTACCTTCATAGGATCTCTTTCTCAAGGTAGGAATTTCTTTTGGTTTCTTGA 1609
DB 297 GTAGCAGATGGGCAATTTCTTCATGACAGTACCTTCCTCGAGTTGATGAGCC 238
QY 1610 AAATATTTCCCTG 1623
DB 237 CAATGCTACCTTG 224
RESULT 218
LOCUS AF266240 383 bp mRNA linear VRT 15-FEB-2001
DEFINITION Gillichthys seta trypsinogen 2 precursor, mRNA, partial cds.
ACCESSION AF266240
VERSION AF266240.1 GI:10121759
KEYWORDS Gillichthys seta
ORGANISM Gillichthys seta
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei;
Acanthomorpha; Acanthopterygii; Percormorpha; Perciformes;
Gobioidae; Gobiidae; Gillichthys.
REFERENCE 1 (bases 1 to 383)
AUTHORS Gracey,A.Y., Troll,J.V. and Somero,G.N.
TITLE Hypoxia-induced gene expression profiling in the euryoxic fish
Gillichthys mirabilis
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 98 (4), 1993-1998 (2001)
MEDLINE 21117151
PUBMED 11172064
REFERENCE 2 (bases 1 to 383)
AUTHORS Gracey,A.Y., Troll,J.V. and Somero,G.N.
TITLE Direct Submission
JOURNAL Submitted (10-MAY-2000) Biological Sciences, Stanford University,
Hopkins Marine Station, Oceanview Blvd., Pacific Grove, CA 93950,
USA
FEATURES
source Location/Qualifiers
1..383
/organism="Gillichthys seta"
/mol_type="mRNA"
/db_xref="taxon:79693"
/tissue_type="liver"
33..>383
/codon_start=1
/product="trypsinogen 2 precursor"
/protein_id="AAG13359.1"
/db_xref="GI:10121750"
/translation="MRLCLVFIILIGAAFAEDDKIVGVYECPHSAHQVSLNSGYHFC
GGSLVNAEWVYSAHCVKSRVEVRLGHEHNLRTGTEQFISSSRVIRHENVSSYNID
DIMLIKLSKPNLNL"
CDS
Query Match 0.9%; Score 18; DB 1; Length 383;
Best Local Similarity 52.7%; Pred. No. 2.7e+02;
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;
QY 195 TCATTTCATCTCGCTCAITTTTAACTCAGTAGTAGTGGTTGTTGTTCCATAAGTTTG 254
DB 155 TCATTTCATCTCGCTCAITTTTAACTCAGTAGTAGTGGTTGTTGTTCCATAAGTTTG 254
QY 255 TAAGTTTCCTGTTG 268
DB 215 CAAGTCTCGTGTGTTG 228

RESULT 219
AX921761
LOCUS AX921761 815 bp DNA linear PAT 18-DEC-2003
DEFINITION Sequence 101 from Patent WO02068649.
ACCESSION AX921761
VERSION AX921761.1 GI:40215332
KEYWORDS Homo sapiens (human)
SOURCE Curagen Corporation (US)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Patent: WO 02068649-A 101 06-SEP-2002;
JOURNAL Curagen Corporation (US)
FEATURES
source Location/Qualifiers
1..815
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
Query Match 0.9%; Score 18; DB 1; Length 815;
Best Local Similarity 54.3%; Pred. No. 2.7e+02;
Matches 27; Conservative 0; Mismatches 15; Indels 0; Gaps 0;
QY 1664 TTTTCATAGTCTCTGCTTCTCGATGTTTATGCTGG 1705
DB 39 TCTTCAGAGTGGCTTTCAGCTCCTCGAGAGTGGCGG 80
RESULT 220
LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994
DEFINITION Human coagulation factor IX mRNA, partial cds.
ACCESSION M35672
VERSION M35672.1 GI:180287
KEYWORDS coagulation factor IX; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 873)
AUTHORS Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and
Warren,S.T.
TITLE Isolation and characterization of human factor IX cDNA:
identification of Tag I polymorphism and regional assignment
Sonat. Cell Mol. Genet. 10 (5), 465-473 (1984)
JOURNAL MEDLINE 84300526
PUBMED 6089357
COMMENT Original
FEATURES
source Location/Qualifiers
1..873
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="Xq26.3-q27.1"
1..873
/genes="F9"
<1..>873
/genes="F9"
/notes="coagulation factor IX"
/codon_start=1
/protein_id="AAA51981.1"
/db_xref="GI:180288"
/translation="NANKILNRPKRYNSKLEEFVQGNLERECMBEKCSEFEAREVFE
NTRTTFWKQYVDGQCSNCLGSKDDINSYECWCWCFEGKNCCLDTVCNIK
NGRCEQKNSADNKVCSCTEGYRLAENQKCEPAVPPCGRVSVQTSKLTAEIV
FPDYVYNSTAEITLLDNTQTSFNDFTRVVGGEDAKEGQFPQVVLNGKVDACG
GSIVNEKIVTAHCVGTGKTVVAGENIEETHETEQKRNVIIRPHNNYNAINK
YNHIALLELDEPLV"

Organism= Homo sapiens
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.8; DB 1; Length 177;
Best Local Similarity 58.5%; Pred. No. 2.8e+02;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 42 CTGTGGCAATACCTCTGGGGGTGTGCTCTTCTCCCTGTCTGATTCCTAGGG 94
DB 93 CCGCAGGTGTCTTGTGTGTGCGCTTCCACGCGCTGCTCTCTCATTAGGG 41

RESULT 224
AX52169/C
LOCUS AR152169 239 bp DNA linear PAT 08-AUG-2001
DEFINITION Sequence 3 from patent US 6232456.
ACCESSION AR152169
VERSION AR152169.1 GI:15118219
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.

REFERENCE
AUTHORS Cohen, M., Colpitts, T.L., Friedman, P.N., Granados, E., Klass, M.R.,
Russell, J.C., Stewart, K.D. and Stroupe, S.D.
TITLE Serine protease reagents and methods useful for detecting and
treating diseases of the prostate
JOURNAL Patent: US 6232456-A 3 15-MAY-2001;
FEATURES
source
1..239
Location/Qualifiers
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.9%; Score 17.8; DB 1; Length 239;
Best Local Similarity 55.7%; Pred. No. 2.9e+02;
Matches 34; Conservative 0; Mismatches 27; Indels 0; Gaps 0;

QY 137 CTGGCCAGGTAGGGCACTACCGATTCCTCTCTCCAAACACTCTATTTCTTG 196
DB 196 CCGGGTGGGGAAGACTCAGTGCTGTCGGGTCTGCTCACAGCCCTCTCTCTG 137

QY 197 A 197
DB 136 A 136

RESULT 225
AX040017
LOCUS AX040017 315 bp DNA linear PAT 18-NOV-2000
DEFINITION Sequence 33 from Patent WO0063435.
ACCESSION AX040017
VERSION AX040017.1 GI:11230031
KEYWORDS Rattus sp.
SOURCE Rattus sp.
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;
Rattus.

REFERENCE
AUTHORS Gould-Rothberg, B.E. and Dipippo, V.A.
TITLE Method of identifying toxic agents using differential gene expres
ion
JOURNAL Patent: WO 0063435-A 33 26-OCT-2000;
Curagen Corporation (US)
FEATURES
source
1..315
Location/Qualifiers
/organism="Rattus sp."
/mol_type="unassigned DNA"
/db_xref="taxon:10118"

QY 688 CTTTGATCGCTATGTAGTATCTTCCCAATCTCATCTGCTTAGTT 732
DB 163 CTTTCATTCGAGTGTAGTTTCTCCAAATCCAGTCCACATCTT 207

RESULT 226
AX524243
LOCUS AX524243 341 bp DNA linear PAT 21-NOV-2002
DEFINITION Sequence 273 from Patent EP1236798.
ACCESSION AX524243
VERSION AX524243.1 GI:25169339
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
Schlueter, T.
TITLE Gene library and method for its production
JOURNAL Patent: EP 1236798-A 273 04-SEP-2002;
FEATURES
source
1..341
Location/Qualifiers
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 17.8; DB 1; Length 341;
Best Local Similarity 58.5%; Pred. No. 3e+02;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 448 TCTGTAATATCTCTAGGTCCACTTCGTTTATGACATCATCTAGTCCAGCAT 500
DB 254 TCTGTGACTTCTGTAGTAGACTTTGGCACAGTTCTCATTGGCGAGGCGT 306

RESULT 227
AX552981
LOCUS AX552981 341 bp DNA linear PAT 27-NOV-2002
DEFINITION Sequence 273 from Patent WO02074953.
ACCESSION AX552981
VERSION AX552981.1 GI:25896981
KEYWORDS
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE
AUTHORS Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and
Schlueter, T.
TITLE Gene library and a method for producing the same
JOURNAL Patent: WO 02074953-A 273 26-SEP-2002;
FEATURES
source
1..341
Location/Qualifiers
/organism="Mus musculus"
/mol_type="unassigned DNA"
/db_xref="taxon:10090"

Query Match 0.9%; Score 17.8; DB 1; Length 341;
Best Local Similarity 58.5%; Pred. No. 3e+02;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 448 TCTGTAATATCTCTAGGTCCACTTCGTTTATGACATCATCTAGTCCAGCAT 500
DB 254 TCTGTGACTTCTGTAGTAGACTTTGGCACAGTTCTCATTGGCGAGGCGT 306

```

RESULT 228
AX375719/c
LOCUS AX375719 927 bp DNA linear PAT 01-MAR-2002
DEFINITION Sequence 26 from Patent WO0196378.
ACCESSION AX375719
VERSION AX375719.1 GI:19170240
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Xiao,Y.
Regulation of human epithin-like serine protease
Patent: WO 0196378-A 26 20-DEC-2001;
Bayer Aktiengesellschaft (DE)
Location/Qualifiers
1..927
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
FEATURES
source
Query Match 0.9%; Score 17.8; DB 1; Length 927;
Best Local Similarity 67.6%; Pred. No. 3.1e-02;
Matches 25; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 35 GAAGCCTCTGCTGGCAATCTTCTGGGGCTGCTGCT 71
|||||
Db 54 GAAACTCAGCAGGAAAGGACACTGGGCTGCTGCTT 28
|||||

RESULT 229
AY030095
LOCUS AY030095 1077 bp mRNA linear PRI 24-JAN-2003
DEFINITION Homo sapiens pancreasin mRNA, complete cds.
ACCESSION AY030095
VERSION AY030095.1 GI:20384683
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 1077)
Bhagwandin,V.J., Hau,L.W.T., Mallen-St. Clair,J., Walters,P.J. and
Caughey,G.H.
Structure and activity of human pancreasin, a novel tryptic serine
peptidase expressed primarily by the pancreas
J. Biol. Chem. 278 (5), 3363-3371 (2003)
12441343
JOURNAL
PUBMED 12441343
REFERENCE
2 (bases 1 to 1077)
Hau,L.W.T. and Caughey,G.H.
Direct Submission
TITLE Submitted (11-APR-2001) Medicine, UCSF, 90 Medical Center Way, San
Francisco, CA 94143-0911, USA
JOURNAL
Location/Qualifiers
1..1077
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="16"
/map="16p"
1..873
/feature="CAP2: channel-activating protease 2; tryptic
serine protease; similar to marapsin"
/codon_start=1
/product="pancreasin"
/protein_id="AAK168.1"
CDS

```

```

PKLQFPARLGGOK"
Query Match 0.9%; Score 17.8; DB 1; Length 1077;
Best Local Similarity 53.6%; Pred. No. 3e-02;
Matches 37; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 1225 TTCTTACATCTGATTTTATCTTAGAATGCTTTCTTCTCCAACTATTGTGACAGAAG 1284
|||||
Db 1005 TTCTCCCTCTCAATACCTTATTATTATGTTTCTCCAAATAAAACCCAGCCTG 1064
|||||

Qy 1285 TTTTCTTAA 1293
Db 1065 TGTGCCAAA 1073

RESULT 230
AB056161
LOCUS AB056161 1125 bp mRNA linear PRI 04-MAR-2003
DEFINITION Homo sapiens PRSS27 mRNA for serine protease 27, complete cds.
ACCESSION AB056161
VERSION AB056161.1 GI:18916397
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 Okaze,H., Hayashi,A., Kozuma,S. and Saito,T.
G3VTS2083
JOURNAL
PUBMED G3VTS2083
REFERENCE
2 (bases 1 to 1125)
Okaze,H., Hayashi,A., Kozuma,S. and Saito,T.
Direct Submission
TITLE Submitted (23-FEB-2001) Toshiyuki Saito, National Institute of
Radiological Sciences, Genome Research Group, 4-9-1, Anagawa,
Inage-ku, Chiba, Chiba 263-8555, Japan (E-mail:ts_saito@nirs.go.jp,
Tel:81-43-206-3135, Fax:81-43-251-9818)
JOURNAL
Location/Qualifiers
1..1125
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="16"
/cell_type="pool"
1..1125
/feature="PRSS27"
51..923
/gene="PRSS27"
/codon_start=1
/product="serine protease 27"
/protein_id="BAB85497.1"
/db_xref="GI:18916398"
/translators="MRRPAAPVLLLLCGSORAATAACGPRMLNRMVGGQDTEG
EMQVSIORNGSHFCGSLIAEOMVLAHCFRTSETSLYQVLGRLQVQGPRA
MYARVQESNPXYQGTASSADVALVEAPVPTNYILPCLPDPSPVIFETGNCWV
TGMGSEEDLLPEPRILQKLAVIDTPKMLLYSKOTEFQYQPTIKNDMLCAGFE
EGKKDACKGGGGLVCLVQSWLQAGVISWEGGCARONRPGVYIRVTAHENVHRII
PKLQFPARLGGOK"
1098..1103
/gene="PRSS27"
1120
/gene="PRSS27"
polyA_signal
polyA_site
Query Match 0.9%; Score 17.8; DB 1; Length 1125;
Best Local Similarity 53.6%; Pred. No. 3e-02;
Matches 37; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

```


WELDLIDIKELVHNYRNSNDIALRLSQPATLSKTIPICLPNSGLAQLSQAG
QETVVTGMYGQSDKVKDGRNRRTFILFIRIPLAARNDCMVNNVVSENMLCAGIIG
DTRDACDGDSDGPMVFFRGTFWFLVGLVSMGEGCGHLNNYGVTVKGVSLKWIHSVIG
ERDVLKSPKL"
49..147
169..1431
/product="protein C"
1514..1519

Query Match 0.9%; Score 17.8; DB 1; Length 1543;
Best Local Similarity 62.2%; Pred. No. 2.9e+02;
Matches 28; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 1792 TTGTAATTCGACGAGCGCTGCTCTGAGGTCCTGTTGGGTT 1836
Db 1268 TGGTCTCTTTGCGGGTACCTGGTTCTCTGCGGCGCTGGTGGCT 1312

RESULT 234
AX147505/c
LOCUS AX147505 1551 bp DNA linear PAT 08-JUN-2001
DEFINITION Sequence 59 from Patent WO0136632.
ACCESSION AX147505
VERSION AX147505.1 GI:14346662
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
TITLE Variants of alternative splicing
JOURNAL Patent: WO 0136632-A 59 25-MAY-2001;
COMPUGEN LTD. (IL)
FEATURES
source
1..1551
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.8; DB 1; Length 1551;
Best Local Similarity 45.0%; Pred. No. 2.9e+02;
Matches 67; Conservative 0; Mismatches 82; Indels 0; Gaps 0;

QY 1242 TATCTAGAACTCTTCTTCTCCACTATTGTGACAGAAAGTTTCTTAAGTCAGTA 1301
Db 1208 TTTCACGCTCTCTCAATACCTCCCTCTGTTCTTCTCACTCTCTTTATCTCAT 1149
QY 1302 GTCTGCGCTGACATCTGAGTCTCTTGAGTCTGTAGCATCTGTGCGGCTCTTA 1361
Db 1148 CTCCTCCCTTACACAGAAATGACAGAAAGTCCATGACAGCTTCACAGCGGTAGCT 1089
QY 1362 CATTGTGATTTCTATTGAAAGTCAGG 1390
Db 1088 CTTCTTGGAGCGGTGGGCTATCCAG 1060

RESULT 235
AX264997/c
LOCUS AX264997 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2388 from Patent WO0173002.
ACCESSION AX264997
VERSION AX264997.1 GI:16513796
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 2388 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGTTTCTTTAATGGATTTCATTT 1978
Db 121 TACTCAGTCTTCTTCAGTGTTCCTTCAAAACTTCTCGTCTTCTTCAAACTACACTTT 62
QY 1979 CCTC 1982
Db 61 CTTC 58

RESULT 236
AX264998
LOCUS AX264998 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2389 from Patent WO0173002.
ACCESSION AX264998
VERSION AX264998.1 GI:16513797
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 2389 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGTTTCTTTAATGGATTTCATTT 1978
Db 1 TACTCAGTCTTCTTCAGTGTTCCTTCAAAACTTCTCGTCTTCTTCAAACTACACTTT 60
QY 1979 CCTC 1982
Db 61 CTTC 64

RESULT 237
AX265001/c
LOCUS AX265001 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2392 from Patent WO0173002.
ACCESSION AX265001
VERSION AX265001.1 GI:16513800
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL Patent: WO 0173002-A 2392 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)


```
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 108 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 49
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 48 CTTC 45

RESULT 242
AX265010
LOCUS AX265010 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2401 from Patent WO0173002.
ACCESSION AX265010
VERSION AX265010.1 GI:16513809
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2401 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 14 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 73
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 74 CTTC 77

RESULT 243
AX265013/c
LOCUS AX265013 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2404 from Patent WO0173002.
ACCESSION AX265013
VERSION AX265013.1 GI:16513812
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2404 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 14 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 73
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 74 CTTC 77

RESULT 244
AX265014
LOCUS AX265014 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2405 from Patent WO0173002.
ACCESSION AX265014
VERSION AX265014.1 GI:16513813
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2405 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 106 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 47
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 46 CTTC 43
```

```
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 106 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 47
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 46 CTTC 43

RESULT 244
AX265014
LOCUS AX265014 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2405 from Patent WO0173002.
ACCESSION AX265014
VERSION AX265014.1 GI:16513813
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2405 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 16 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 75
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 76 CTTC 79

RESULT 245
AX265025/c
LOCUS AX265025 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2416 from Patent WO0173002.
ACCESSION AX265025
VERSION AX265025.1 GI:16513824
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2416 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 16 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 75
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 76 CTTC 79

RESULT 245
AX265025/c
LOCUS AX265025 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2416 from Patent WO0173002.
ACCESSION AX265025
VERSION AX265025.1 GI:16513824
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
JOURNAL stranded oligonucleotides
PATENT: WO 0173002-A 2416 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source
Location/Qualifiers
1..121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 16 TACTCAGTGTCTTTCAGTGTCTTCAAAAACCTCTCGTGTCTTCTTCAAAACTACACTTTT 75
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
      |||
Db 76 CTTC 79
```

/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

Qy 1919 TACTCATTTCCTCCAGATTATACATTTCATAGGTTCTTTAATGGATTATTCATT 1978
|||||
Db 103 TACTCAGTCTCTTCAGTCTTTTCAAAACTTCCTCGTCTCTTCAAAACTACACTTT 44
|||||

Qy 1979 CCTC 1982
|||
Db 43 CTTC 40

RESULT 246
AX265026
LOCUS AX265026 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2417 from Patent WO0173002.
ACCESSION AX265026
VERSION AX265026.1 GI:16513825
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2417 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

Qy 1919 TACTCATTTCCTCCAGATTATACATTTCATAGGTTCTTTAATGGATTATTCATT 1978
|||||
Db 19 TACTCAGTCTCTTCAGTCTTTTCAAAACTTCCTCGTCTCTTCAAAACTACACTTT 78
|||||

Qy 1979 CCTC 1982
|||
Db 79 CTTC 82

RESULT 247
AX265017/c
LOCUS AX265017 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2408 from Patent WO0173002.
ACCESSION AX265017
VERSION AX265017.1 GI:16513816
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2408 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

Qy 1919 TACTCATTTCCTCCAGATTATACATTTCATAGGTTCTTTAATGGATTATTCATT 1978
|||||
Db 102 TACTCAGTCTCTTCAGTCTTTTCAAAACTTCCTCGTCTCTTCAAAACTACACTTT 43
|||||

Qy 1979 CCTC 1982
|||
Db 42 CTTC 39

RESULT 248
AX265018
LOCUS AX265018 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2409 from Patent WO0173002.
ACCESSION AX265018
VERSION AX265018.1 GI:16513817
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2409 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

Qy 1919 TACTCATTTCCTCCAGATTATACATTTCATAGGTTCTTTAATGGATTATTCATT 1978
|||||
Db 20 TACTCAGTCTCTTCAGTCTTTTCAAAACTTCCTCGTCTCTTCAAAACTACACTTT 79
|||||

Qy 1979 CCTC 1982
|||
Db 80 CTTC 83

RESULT 249
AX265029/c
LOCUS AX265029 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2420 from Patent WO0173002.
ACCESSION AX265029
VERSION AX265029.1 GI:16513828
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2420 04-OCT-2001;
UNIVERSITY OF DELAWARE (US)
FEATURES
source Location/Qualifiers
1. .121
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:48:23 ; Search time 786 Seconds

(without alignments)
3.881 Million cell updates/sec

Title: us-10-664-775-3

Perfect score: 2003

Sequence: 1 agcttccagagagacttca.....tcaaggaccttttatgaatt 2003

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 segs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	43	2.1	2422	1	AAQ80296
C 2	43	2.1	2422	1	AAV02230
C 3	43	2.1	2422	1	AAZ57385
C 4	43	2.1	2422	1	AAZ57099
C 5	43	2.1	2422	1	ADC24226
C 6	43	2.1	2422	1	AAZ15425
C 7	43	2.1	2422	1	AAZ15298
C 8	43	2.1	2422	1	AAZ56118
C 9	43	2.1	2422	1	AAZ54032
C 10	43	2.1	2422	1	AAZ89784
C 11	43	2.1	2422	1	AB167255
C 12	43	2.1	2422	1	AAZ95753
C 13	43	2.1	2422	1	AAZ60054
C 14	41.6	2.1	2177	1	AAZ60063
C 15	41.6	2.1	2438	1	AAZ60085
C 16	32.4	1.6	300	1	AAZ12625
C 17	25.6	1.3	254	1	AAZ16179
C 18	25.4	1.3	237	1	AAZ68947
C 19	25.2	1.3	1843	1	AAZ54035
C 20	25.2	1.3	1843	1	AAZ54035
C 21	25.2	1.3	1843	1	AAZ97175
C 22	24.2	1.2	267	1	AAZ45604
C 23	24.2	1.2	267	1	AAZ19599
C 24	24.2	1.2	267	1	ABZ45294
C 25	24.2	1.2	267	1	ABZ19876
C 26	23.8	1.2	868	1	AAZ93580
C 27	23.8	1.2	868	1	AAZ93580
C 28	23.4	1.2	612	1	ABQ47966
C 29	23.4	1.2	612	1	ABQ47966
C 30	23	1.1	306	1	AAZ40850
C 31	23	1.1	1507	1	AAZ54031
C 32	23	1.1	1507	1	ABZ35332
C 33	23	1.1	1507	1	ADE84862

34	22.8	1.1	433	1	ACH20452	Human adult liver
C 35	22.8	1.1	1151	1	AAQ08286	Human secreted pro
C 36	22.2	1.1	301	1	AAI19676	Probe #9609 for ge
C 37	22.2	1.1	301	1	ABA64702	Human fetal liver
C 38	22.2	1.1	301	1	AAI44871	Probe #13557 used
C 39	22.2	1.1	301	1	ABA46822	Human breast cell
C 40	22.2	1.1	301	1	ABA31826	Probe #10292 for g
C 41	22.2	1.1	301	1	AAK38868	Human bone marrow
C 42	22.2	1.1	301	1	AAK13137	Human brain expres
C 43	22.2	1.1	301	1	ABS38453	Human liver single
C 44	22.2	1.1	301	1	AAI05395	Probe #5386 used t
C 45	22.2	1.1	301	1	ABS12949	Human genome-deriv
C 46	22	1.1	385	1	AAC04575	Human secreted pro
C 47	22	1.1	612	1	ABQ47969	Oligonucleotide fo
C 48	22	1.1	512	1	ABQ47968	Oligonucleotide fo
C 49	21.6	1.1	253	1	AAQ70944	Single nucleotide
C 50	21.6	1.1	254	1	ABV98470	Human pancreatic c
C 51	21.4	1.1	283	1	AAV28290	Galanin receptor G
C 52	21.4	1.1	283	1	AAV32651	Galanin receptor G
C 53	21.4	1.1	283	1	AAV44930	Galanin receptor G
C 54	21.4	1.1	283	1	ABK14060	Rat galanin recept
C 55	21.4	1.1	1129	1	AAZ21354	Human cDNA sequenc
C 56	21.4	1.1	1129	1	ACD23963	Novel human secret
C 57	21.4	1.1	1129	1	ACA67104	cDNA encoding huma
C 58	21.4	1.1	1129	1	ACA03713	cDNA encoding huma
C 59	21.4	1.1	1129	1	ABX89251	cDNA encoding novel
C 60	21.4	1.1	1129	1	ACD41905	Human secreted/tra
C 61	21.4	1.1	1129	1	ACA04134	Human cDNA encodi
C 62	21.4	1.1	1129	1	ADA45740	Novel human secret
C 63	21.4	1.1	1129	1	ADA76171	Human PRO polynucl
C 64	21.4	1.1	1129	1	ADA18821	Human PRO polynucl
C 65	21.4	1.1	1129	1	ADA61444	Homo sapiens. Nov
C 66	21.4	1.1	1129	1	ADB19229	Novel human secret
C 67	21.4	1.1	1129	1	ADB27770	cDNA encoding huma
C 68	21.4	1.1	1129	1	ADA86249	Novel human secret
C 69	21.4	1.1	1129	1	ADB15813	Human PRO polynucl
C 70	21.4	1.1	1129	1	ADA47599	Human PRO polynucl
C 71	21.4	1.1	1129	1	ADA67394	Human PRO polynucl
C 72	21.4	1.1	1129	1	ADB30401	cDNA encoding huma
C 73	21.4	1.1	1129	1	ADA85897	Novel human secret
C 74	21.4	1.1	1129	1	ADA96909	Human PRO polynucl
C 75	21.4	1.1	1129	1	ADA79213	Human PRO polynucl
C 76	21.4	1.1	1129	1	ADA87352	Novel human secret
C 77	21.4	1.1	1129	1	ADA16554	Human PRO polynucl
C 78	21.4	1.1	1129	1	ADA91646	Novel human secret
C 79	21.4	1.1	1129	1	ADA14709	Human PRO polynucl
C 80	21.4	1.1	1129	1	ADB18670	Novel human secret
C 81	21.4	1.1	1129	1	ADA93885	Human PRO polynucl
C 82	21.4	1.1	1129	1	ADB19781	Novel human secret
C 83	21.4	1.1	1129	1	ADB13093	Human PRO polynucl
C 84	21.4	1.1	1129	1	ACD98534	Novel human secret
C 85	21.4	1.1	1129	1	ADA74347	Human PRO polynucl
C 86	21.4	1.1	1129	1	ADB24580	Human PRO polynucl
C 87	21.4	1.1	1129	1	ADA82104	Human PRO polynucl
C 88	21.4	1.1	1129	1	ADA75067	Human PRO polynucl
C 89	21.4	1.1	1129	1	ADA85145	Novel human secret
C 90	21.4	1.1	1129	1	ADA84593	Novel human secret
C 91	21.4	1.1	1129	1	ADB29849	cDNA encoding huma
C 92	21.4	1.1	1129	1	ADA80377	Human PRO polynucl
C 93	21.4	1.1	1129	1	ADA75619	Human PRO polynucl
C 94	21.4	1.1	1129	1	ADA46844	Human PRO polynucl
C 95	21.4	1.1	1129	1	ADB25140	Human PRO polynucl
C 96	21.4	1.1	1129	1	ADA93316	Human PRO polynucl
C 97	21.4	1.1	1129	1	ADB26666	cDNA encoding huma
C 98	21.4	1.1	1129	1	ADB30953	cDNA encoding huma
C 99	21.4	1.1	1129	1	ADA60881	Homo sapiens. Nov
C 100	21.4	1.1	1129	1	ADB24028	Human PRO polynucl
C 101	21.4	1.1	1129	1	ADA96357	Human PRO polynucl
C 102	21.4	1.1	1129	1	ADA80929	Human PRO polynucl
C 103	21.4	1.1	1129	1	ADA95805	Human PRO polynucl
C 104	21.4	1.1	1129	1	ADB26114	cDNA encoding huma
C 105	21.4	1.1	1129	1	ADB21599	Novel human secret
C 106	21.4	1.1	1129	1	ADA77378	Human PRO polynucl

C 107	1.1	21.4	1.1	1129	1	ADB18118	cdNA encoding huma
C 108	1.1	21.4	1.1	1129	1	ADA86801	Novel human secret
C 109	1.1	21.4	1.1	1129	1	ADA87904	Novel human secret
C 110	1.1	21.4	1.1	1129	1	ADA46292	Novel human secret
C 111	1.1	21.4	1.1	1129	1	ADB28232	cdNA encoding huma
C 112	1.1	21.4	1.1	1129	1	ADB28874	cdNA encoding huma
C 113	1.1	21.4	1.1	1129	1	ADB476826	Human PRO polynucl
C 114	1.1	21.4	1.1	1129	1	ADB48456	Novel human secret
C 115	1.1	21.4	1.1	1129	1	ADA97461	Human PRO polynucl
C 116	1.1	21.4	1.1	1129	1	ADB27218	cdNA encoding huma
C 117	1.1	21.4	1.1	1129	1	ADB22151	Novel human secret
C 118	1.1	21.4	1.1	1129	1	ADA56842	Human PRO polynucl
C 119	1.1	21.4	1.1	1129	1	ADB23703	Human PRO polynucl
C 120	1.1	21.4	1.1	1129	1	ADB23476	Human PRO polynucl
C 121	1.1	21.4	1.1	1129	1	ADB23705	Human PRO polynucl
C 122	1.1	21.4	1.1	1129	1	ADB32198	Novel human secret
C 123	1.1	21.4	1.1	1129	1	ADB35261	Novel human secret
C 124	1.1	21.4	1.1	1129	1	ADB38513	Novel human secret
C 125	1.1	21.4	1.1	1129	1	ADB37961	Novel human secret
C 126	1.1	21.4	1.1	1129	1	ADB66433	Novel human secret
C 127	1.1	21.4	1.1	1129	1	ADB89513	Human PRO polynucl
C 128	1.1	21.4	1.1	1129	1	ADB90245	Human PRO polynucl
C 129	1.1	21.4	1.1	1129	1	ADB39346	Novel human secret
C 130	1.1	21.4	1.1	1129	1	ADB46969	Novel human secret
C 131	1.1	21.4	1.1	1129	1	ADB65796	Human PRO polynucl
C 132	1.1	21.4	1.1	1129	1	ADB77181	Novel human secret
C 133	1.1	21.4	1.1	1129	1	ADB34338	Human PRO polynucl
C 134	1.1	21.4	1.1	1129	1	ADB35442	Human PRO polynucl
C 135	1.1	21.4	1.1	1129	1	ADB33786	Human PRO polynucl
C 136	1.1	21.4	1.1	1129	1	ADB34890	Human PRO polynucl
C 137	1.1	21.4	1.1	1129	1	ADB35994	Human PRO polynucl
C 138	1.1	21.4	1.1	1129	1	ADB46389	Novel human secret
C 139	1.1	21.4	1.1	1129	1	ADC50262	Novel human secret
C 140	1.1	21.4	1.1	1129	1	ADC71809	Novel human secret
C 141	1.1	21.4	1.1	1129	1	ADC59788	Novel human secret
C 142	1.1	21.4	1.1	1129	1	ADC52795	Novel human secret
C 143	1.1	21.4	1.1	1129	1	ADC57149	Novel human secret
C 144	1.1	21.4	1.1	1129	1	ADC60340	Novel human secret
C 145	1.1	21.4	1.1	1129	1	ADC50815	Novel human secret
C 146	1.1	21.4	1.1	1129	1	ADC65342	Human PRO polynucl
C 147	1.1	21.4	1.1	1129	1	ADC54440	Novel human secret
C 148	1.1	21.4	1.1	1129	1	ADC32401	Novel human secret
C 149	1.1	21.4	1.1	1129	1	ADC58924	Novel human secret
C 150	1.1	21.4	1.1	1129	1	ADC55802	Novel human secret
C 151	1.1	21.4	1.1	1129	1	ADC58372	Novel human secret
C 152	1.1	21.4	1.1	1129	1	ADC03046	Novel human secret
C 153	1.1	21.4	1.1	1129	1	ADC90038	cdNA encoding huma
C 154	1.1	21.4	1.1	1129	1	ADC69457	Human PRO polynucl
C 155	1.1	21.4	1.1	1129	1	ADC48346	Human PRO polynucl
C 156	1.1	21.4	1.1	1129	1	ADD09875	Human PRO polynucl
C 157	1.1	21.4	1.1	1129	1	ADD04450	Novel human secret
C 158	1.1	21.4	1.1	1129	1	ADC60406	Novel human secret
C 159	1.1	21.4	1.1	1129	1	ADD10913	Human PRO polynucl
C 160	1.1	21.4	1.1	1129	1	ADC47794	Human PRO polynucl
C 161	1.1	21.4	1.1	1129	1	ADC79854	Nov

[illegible]

QY 1072 TCTGTGTCTGT 1082
 DB 1887 TCCATGTGTGT 1877

RESULT 8
 AA256118/c
 ID AA256118 standard; DNA; 2462 BP.
 XX
 AC AA256118;
 XX
 XX
 DT 15-SEP-2003 (revised)
 DT 27-MAR-2000 (first entry)
 XX
 XX Vitamin-K dependent coagulation factor VII/VIIa coding sequence.
 XX
 XX Vitamin-K-dependent coagulation factor; tumour associated vasculature;
 KW carcinoma; benign prostatic hyperplasia; diabetic retinopathy;
 KW vascular restenosis; arteriovenous malformation; meningioma; haemangioma;
 KW neovascular glaucoma; psoriasis; cytostatic; antidiabetic; vasotrophic;
 KW ophthalmological; antipsoriatic; factor VII/VIIa; ss.
 XX
 OS unidentified.
 XX
 XX US6004555-A.
 XX
 XX 21-DEC-1999.
 XX
 XX 07-JUN-1995; 95US-00487427.
 XX
 XX 05-MAR-1992; 92US-00846349.
 PR 02-MAR-1994; 94US-00205330.
 PR 11-JUL-1994; 94US-00273567.
 XX
 XX (SCRI) SCRIPPS RES INST.
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 XX Edgington TS, Thorpe PB;
 XX
 XX WPI; 2000-072047/06.
 DR
 XX
 XX Bispecific binding ligands for promoting blood coagulation in a tumor
 PT associated vasculature are useful for treating cancer.
 XX
 XX Example 9; Col 127-130; 83pp; English.
 XX
 XX This is the coding sequence for Factor VII/VIIa, a vitamin-K-dependent
 CC coagulation factor. This coagulation factor can be used in the formation
 CC of coaguligands. Mutated versions of this sequence can be used in the
 CC method for delivering a coagulant to a tumour-associated vasculature
 CC using bispecific binding ligands which promote blood coagulation. The
 CC binding ligand consists of a binding region that binds to a surface-
 CC expressed, surface accessible or surface-localised component of a tumour
 CC cell, intratumoural vasculature or tumour associated stroma. The binding
 CC region is linked to a coagulating agent which is a coagulation factor
 CC (e.g. tissue factor). The second binding region comprises an antibody or
 CC an antigen binding region of an antibody. The method is used for
 CC delivering an exogenous or an endogenous coagulation factor to tumour-
 CC associated vasculature which is benign or malignant. The method can be
 CC used to treat cancer by promoting specific blood coagulation in the
 CC vasculature of the tumour relative to the vasculature in nontumour sites.
 CC Vascularised tumours are usually solid tumours, particularly carcinomas
 CC which require a vascular component to provide oxygen and nutrients. The
 CC ligands are suitable to treat benign and malignant diseases with a
 CC vascular component, including benign prostatic hyperplasia, diabetic
 CC retinopathy, vascular restenosis, arteriovenous malformations,
 CC meningioma, haemangioma, neovascular glaucoma and psoriasis. The ligands
 CC can also be used in standard binding assays in vitro. Bispecific ligands
 CC can be designed which are capable of binding to vascular endothelial
 CC cells and disease-associated agents such as activated platelets. Certain
 CC disease-associated agents are similar in different diseases and in
 CC different tumours, making it possible to treat numerous diseases and
 CC different types of cancer with one pharmaceutical, therefore an agent

CC does not need to be tailored to each individual disease or specific
 CC tumour type. (Updated on 15-SEP-2003 to standardise OS field)
 XX
 XX Sequence 2462 BP; 530 A; 724 C; 721 G; 427 T; 0 U; 0 Other;
 SQ

Query Match 2.1%; Score 43; DB 1; Length 2462;
 Best Local Similarity 58.0%; Pred. No. 4.3e-05;
 Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 952 TGTGAGAAATATCAATGACGACGATGTTGTGGATTCCTGTATCTTGCACCTGTGAAGTG 1011
 DB 2007 TGTGCATATCTCTATGTGGGTGTCATCGGTGTTGCGTATCTCTGTGTGACCATCTG 1948
 QY 1012 TG 1071
 DB 1947 TGTGTGATCCGTG 1877
 QY 1072 TCTGTGTCTGT 1082
 DB 1887 TCCATGTGTGT 1877

RESULT 9
 AA54032/c
 ID AA54032 standard; DNA; 2462 BP.
 XX
 AC AA54032;
 XX
 DT 08-FEB-2001 (first entry)
 XX
 XX Human factor VII coding sequence.
 DE
 XX Vitamin K dependent protein; VKDF; gamma-carboxylation; chimeric protein;
 KW fusion protein; coagulation factor; Factor X; Factor VII; Protein S;
 KW Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
 KW ds.
 XX
 OS Homo sapiens.
 XX
 XX WO200054787-A1.
 XX
 XX 21-SEP-2000.
 XX
 XX 16-MAR-2000; 2000WO-US006934.
 XX
 XX 16-MAR-1999; 99US-0124609P.
 XX
 XX (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
 PA (UYNC-) UNIV NORTH CAROLINA.
 XX
 XX High KA, Camire RM, Larson PJ, Stafford DW;
 XX
 XX WPI; 2000-638152/61.
 DR
 XX Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent
 PT protein useful for treating diseases associated with the protein,
 PT comprises sequence encoding propeptide fused to sequence encoding the
 PT protein.
 XX
 XX Disclosure; Fig 6Bi-ii; 60pp; English.
 PS
 XX Efficient processing and release of mature two-chain factor X into the
 CC circulation requires: removal of the signal sequence; formation of
 CC disulfide bonds; modification of amino terminal glutamic acid residues,
 CC to gamma-carboxylglutamic acid; modification of one aspartic acid in the
 CC first epimeral growth factor (EGF) domain to Beta-hydroxyaspartic acid;
 CC addition of N- and O-linked oligosaccharides to the activation peptide;
 CC removal of an internal tripeptide to yield two-chain factor X and removal
 CC of the propeptide just prior to secretion. While some of these
 CC modifications do not appear essential for factor X function the removal
 CC of the signal sequence, propeptide, internal tripeptide and full gamma-
 CC carboxylation are all steps which are important requisites for the
 CC production of biologically active factor X/Fxa. Isolated chimeric

2007 TGTCATATCTCTATGTGCGTGTGCATCGGTGTTTGGTATCTCTGTGTGACCATCTG 1948

[illegible]

2007 TGTCATATCTCTATGTGCGTGTCATCGGTGCTTTGCCATCTCTGTG

Ddb 236 CATTTTGGTTTCATGCGGTCTGCCTGGAGAACAAATGCTCCTGGACGACTTCTTGTC 17

Oy 1422 AATTGGTCTTTTTCCCTGCCAICTTTTAATAATCTTTCTTTGTTCTATACATTT 1476
 | | | | | | |||
Ddb 176 CAGTAATCCTTCT 122

RESULT 19

AAA54035/c

ID AAA54035 standard; DNA; 1843 BP.

AC AC AAAS4035;

XX XX

DT DT 08-FEB-2001 (first entry)

XX XX Human protein C coding sequence.

KW KW Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;
KX KX fusion protein; coagulation factor; Factor X; Factor VII; Protein S;
KW KW Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
KK KK ds.
OS OS Homo sapiens.
XX XX WO200054787-A1.
PN PN 21-SEP-2000.
PD PD
XX XX 16-MAR-2000; 200OWO-US06934.
XX XX 16-MAR-1999; 9SUS-0124609P.
PP PR (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
PA PBA (UYNC-) UNIV NORTH CAROLINA.
XX XX High KA, Canire RM, Larson PJ, Stafford DW;
FI FI WPI; 2000-638152/61.
XX XX Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent
PT PT protein useful for treating diseases associated with the protein,
PT PT comprises sequence encoding propeptide fused to sequence encoding the
PT PT protein.

XX PS Disclosure; Fig 6E-i; ii; 6opp; English.

XX CC Efficient processing and release of mature two-chain factor X into the
CCC CCC circulation requires: removal of the signal sequence; formation of
CCC CCC disulfide bonds; modification of amino terminal glucamic acid residues,
CCC CCC to gamma-carboxylglutamic acid; modification of one aspartic acid in the
CCC CCC first epidermal growth factor (EGF) domain to Beta-hydroxyaspartic acid;
CCC CCC addition of N- and O-linked oligosaccharides to the activation peptide;
CCC CCC removal of an internal tripeptide to yield two-chain factor X and removal
CCC CCC of the propeptide just prior to secretion. While some of these
CCC CCC modifications do not appear essential for factor X function the removal
CCC CCC of the signal sequence, propeptide, internal tripeptide and full gamma-
CCC CCC carboxylation are all steps which are important requisites for the
CCC CCC production of biologically active factor X/Fxa. Isolated chimeric
CCC CCC polynucleotides are described which encode a propeptide fused to a
CCC CCC nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The
CCC CCC fusion proteins encoded are vitamin K-dependent protein gamma-
CCC CCC carboxylation enhancers and are useful for optimising the gamma-
CCC CCC carboxylation of a VKDP to produce a fully gamma-carboxylated VKDP. The
CCC CCC fusion proteins and recombinant cells expressing them are useful for
CCC CCC alleviating a VKDP associated disease. The fusion constructs result in
CCC CCC the production of fully gamma-carboxylated mature VKDPs, which are
CCC CCC biologically active. The invention encompasses all combinations of
CCC CCC propeptide sequences (modified or not) and VKDP's. This sequence encodes
CCC CCC the signal, propeptide and mature protein sequence of human protein C

XX SQ Sequence 1843 BP; 417 A; 530 C; 564 G; 332 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 25.2; DB 1; Length 1843;

[illegible]

Disclosure; Fig 6Ei-ii: 60pp; English.

Query Match
1.3%; Score 25.2; DB 1; Length 1843;

[illegible]

RESULT 24	
ABS45294	
ID	ABS45294 standard; DNA; 267 BP.
XX	
XX	
XX	ABS45294;
XX	AC
XX	
XX	25-FEB-2003 (first entry)
XX	
DE	Human liver single exon probe, SEQ ID NO 20284.
XX	
XX	Human; single exon nucleic acid probe; liver; cirrhosis;
KW	hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW	coronary heart disease; ss.
XX	
XX	
OS	Homo sapiens.
XX	
XX	WO200157273-A2.
PN	
XX	
XX	09-AUG-2001.
PP	
XX	
XX	30-JAN-2001; 2001WO-US000664.
XX	
PR	04-FEB-2000; 2000US-0180312P.
PR	26-MAY-2000; 2000US-0207456P.
PR	30-JUN-2000; 2000US-0060840B.
PR	03-AUG-2000; 2000US-00632366.
PR	21-SEP-2000; 2000US-0234687P.
PR	27-SEP-2000; 2000US-0236359P.
PR	04-OCT-2000; 2000GB-00024263.
XX	
XX	(MOLE-) MOLECULAR DYNAMICS INC.
PA	
XX	
PI	Penn SG, Hanzel DK, Chen W, Rank DR;
XX	
DR	WPI; 2001-488898/53.

Human genome-derived single exon nucleic acid probes useful for analyzing gene expression in human adult liver.

Claim 4; SEQ ID NO 20284; 658bp; English.

The invention relates to a single exon nucleic acid probe (SENP) (I) for measuring human gene expression in a sample derived from human adult liver, comprising one of 13109 defined nucleotide sequences given in the specification (or complements/ fragments). The probe hybridises at high stringency to a nucleic acid molecule expressed in the human adult liver. (I) may be used for predicting, measuring and displaying gene expression in samples derived from human adult liver. The genes identified may be involved in genetic liver diseases such as cirrhosis, hnerliproteinemia, hnerlipidemia and hnercholesterolamia which is

XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
 XX DR WPI; 2002-371829/40.
 XX
 XX PT Determining the degree of cytosine methylation in genomic DNA, useful for
 XX PT diagnosis and prognosis, comprises selective hybridization of amplicons
 XX PT from chemically treated DNA.
 XX PS
 XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.
 XX
 XX CC This invention describes a novel method for determining the degree of
 CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
 CC genomic sample of DNA. The sample is treated chemically to convert
 CC cytosine (C) but not methylated C, to uracil, then part of the genomic
 CC DNA that contains the target C is amplified to form a labeled amplicon.
 CC The amplicon is hybridised to two classes, each with at least one member,
 CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
 CC degree of hybridisation to both classes is determined from the label on
 CC the amplicon. From the ratio of labels hybridised to the two classes of
 CC oligomers, the degree of methylation is calculated. The method is used:
 CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
 CC and of a wide range of diseases, e.g. cancer, disorders of the central
 CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
 CC particularly by detecting mutations or single nucleotide polymorphisms
 CC (SNP's); and (ii) for differentiation of cell or tissue types and for
 CC investigating cell differentiation. The method allows the methylation
 CC status of many C residues to be determined simultaneously. ABQ13410-
 CC ABQ54121 represent genomic DNA sequences used to illustrate the method
 CC for determining the degree of cytosine methylation described in the
 CC disclosure of the invention
 XX
 XX SQ Sequence 612 BP; 88 A; 72 C; 216 G; 236 T; 0 U; 0 Other;

Query Match 1.2%; Score 23.4; DB 1; Length 612;
 Best Local Similarity 46.2%; Pred. No. 11;
 Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;
 QY 1499 GTGGGGAGTTTCTTTCCGGTCCCAATCTATTGGGTGTTTGTATGCTTCTTGTACCTTGA 1558
 DB 431 GGGGGTCTGTTTTCGTTTCGGGGTATTCGTTTTCGGCGATGTTTTTATTTTAGG 490
 QY 1559 TAGGCATCTCTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTCTGAAATATTTT 1618
 DB 491 TACGCGTTTTTTCGTCGGTCTGATCGGTATGTCGGTTTTTATATTAGAAATACGAT 550
 QY 1619 CCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCTCTTCTTGGTTTTT 1667
 DB 551 TTGTAAGTATATTAGGGTGTTTTTTTAAATTTTAAAGGAGTTTTT 599

RESULT 29
 ABQ47967/c
 ID ABQ47967 standard; DNA; 612 BP.
 XX AC ABQ47967;
 XX
 XX DT 12-JUL-2002 (first entry)
 XX
 XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34558.
 XX
 XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
 KW drug; side effect; cancer; central nervous system; cardiovascular;
 KW gastrointestinal; respiratory system; single nucleotide polymorphism;
 KW SNP; cell differentiation; ds.
 XX
 XX OS Homo sapiens.
 XX
 XX PN WO200218632-A2.
 XX
 XX PD 07-MAR-2002.

XX PF 01-SEP-2001; 2001WO-EP010074.
 XX PR 01-SEP-2000; 2000DE-01043826.
 XX PR 05-SEP-2000; 2000DE-01044543.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;
 XX DR WPI; 2002-371829/40.
 XX
 XX PT Determining the degree of cytosine methylation in genomic DNA, useful for
 XX PT diagnosis and prognosis, comprises selective hybridization of amplicons
 XX PT from chemically treated DNA.
 XX PS
 XX PS Claim 12; 56pp + Sequence Listing; 56pp; German.
 XX
 XX CC This invention describes a novel method for determining the degree of
 CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a
 CC genomic sample of DNA. The sample is treated chemically to convert
 CC cytosine (C) but not methylated C, to uracil, then part of the genomic
 CC DNA that contains the target C is amplified to form a labeled amplicon.
 CC The amplicon is hybridised to two classes, each with at least one member,
 CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
 CC degree of hybridisation to both classes is determined from the label on
 CC the amplicon. From the ratio of labels hybridised to the two classes of
 CC oligomers, the degree of methylation is calculated. The method is used:
 CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
 CC and of a wide range of diseases, e.g. cancer, disorders of the central
 CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
 CC particularly by detecting mutations or single nucleotide polymorphisms
 CC (SNP's); and (ii) for differentiation of cell or tissue types and for
 CC investigating cell differentiation. The method allows the methylation
 CC status of many C residues to be determined simultaneously. ABQ13410-
 CC ABQ54121 represent genomic DNA sequences used to illustrate the method
 CC for determining the degree of cytosine methylation described in the
 CC disclosure of the invention
 XX
 XX SQ Sequence 612 BP; 236 A; 216 C; 72 G; 88 T; 0 U; 0 Other;

Query Match 1.2%; Score 23.4; DB 1; Length 612;
 Best Local Similarity 46.2%; Pred. No. 11;
 Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;
 QY 1499 GTGGGGAGTTTCTTTCCGGTCCCAATCTATTGGGTGTTTGTATGCTTCTTGTACCTTGA 1558
 DB 182 GGGGGTCTGTTTTCGTTTCGGGGTATTCGTTTTCGGCGATGTTTTTATTTTAGG 123
 QY 1559 TAGGCATCTCTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTCTGAAATATTTT 1618
 DB 122 TACGCGTTTTTTCGTCGGTCTGATCGGTATGTCGGTTTTTATATTAGAAATACGAT 63
 QY 1619 CCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCTCTTCTTGGTTTTT 1667
 DB 62 TTGTAAGTATATTAGGGTGTTTTTTTAAATTTTAAAGGAGTTTTT 14

RESULT 30
 AAT40850/c
 ID AAT40850 standard; cDNA; 306 BP.
 XX AC AAT40850;
 XX
 XX DT 16-MAR-1997 (first entry)
 XX
 XX DE Serine protease nfsP8-299 gene.
 XX
 XX KW Flea; midgut; serine protease; nfsP8-299; recombinant vaccine;
 KW domestic animal; infestation; insecticide; protease-inhibitor;
 KW controlled release formulation; synergist; ss.
 XX
 XX OS Siphonaptera sp.

AC	AAA54031;
XX	
DT	08-FEB-2001 (first entry)
XX	
DE	Human factor X coding sequence.
XX	
KW	Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;
KX	fusion protein; coagulation factor; factor X; factor VII; Protein S;
KW	Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;
XW	ds.
XX	
OS	Homo sapiens.
XX	
WO	WO200054787-A1.
PN	
PD	21-SEP-2000.
XX	
FF	16-MAR-2000; 2000WO-US006934.
XX	
PR	16-MAR-1999; 99US-0124609P.
XX	
PA	(CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
PA	(UYNC-) UNIV NORTH CAROLINA.
PI	High KA, Camire RM, Larson PJ, Stafford DW;
XX	
DR	WPI; 2000-638452/61.
XX	
PS	Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent
PT	protein useful for treating diseases associated with the protein,
PT	comprisses sequence encoding propeptide fused to sequence encoding the
PT	protein.
XX	
PS	Disclosure; Fig 6a; 60pp; English.
XX	
CC	Efficient processing and release of mature two-chain factor X into the
CC	circulation requires: removal of the signal sequence; formation of
CC	disulfide bonds; modification of amino terminal glutamic acid residues,
CC	to gamma-carboxyglutamic acid; modification of one aspartic acid in the
CC	first epidermal growth factor (EGF) domain to beta-hydroxyaspartic acid;
CC	addition of N- and O-linked oligosaccharides to the activation peptide;
CC	removal of an internal tripeptide to yield two-chain factor X and removal
CC	of the propeptide just prior to secretion. While some of these
CC	modifications do not appear essential for factor X function the removal
CC	of the signal sequence, propeptide, internal tripeptide and full gamma-
CC	carboxylation are all steps which are important requisites for the
CC	production of biologically active factor X/Fxa. Isolated chimeric
CC	polynucleotides are described which encode a propeptide fused to a
CC	nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The
CC	fusion proteins encoded are vitamin K-dependent protein gamma-
CC	carboxylation enhancers and are useful for optimising the gamma-
CC	carboxylation of a VKDP to produce a fully gamma-carboxylated VKDP. The
CC	fusion proteins and recombinant cells expressing them are useful for
CC	alleviating a VKDP associated disease. The fusion constructs result in
CC	the production of fully gamma-carboxylated mature VKDPe, which are
CC	biologically active. The invention encompasses all combinations of
CC	propeptide sequences (modified or not) and VKDP's. This sequence encodes
CC	the signal, propeptide and mature protein sequence of human Factor X
XX	
SQ	Sequence 1507 BP; 394 A; 429 C; 446 G; 238 T; 0 U; 0 Other;
	Query Match 1.1%; Score 23; DB 1; Length 1507;
	Best Local Similarity 60.3%; Pred. No. 17;
	Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY	1528 TTGTGGTGTTCGATCGCTCTTGTTACCCTGATAGGCATCTCTTTCTCAGGTTAGGAAT 1587
DB	1506 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGATGGATCTCACTTTATGGAGAGACGT 1447
QY	1588 TTT 1590
DB	1446 TAT 1448

[illegible]

ID:

AC	AA080286;
XX	
XX	08-AUG-2001 (first entry)
XX	
DE	Human secreted protein-encoding gene 4 cDNA clone HWHIH10, SEQ ID NO: 14.
XX	
KW	Human; secreted protein; proliferative disorder; Cancer; tumour; asthma;
KW	foetal abnormality; developmental abnormality; haematopoietic disorder;
KW	immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis;
KW	Parkinson's disease; cognitive disorder; schizophrenia; skin disorder;
KW	psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder;
KW	inflammation; neurological disorder; Alzheimer's disease; food additive;
KW	angiogenic disorder; kidney disorder; gastrointestinal disorder; allergy;
KW	pregnancy-related disorder; endocrine disorder; infection; wound healing;
KW	cell culture; chemotaxis; vulvovaginitis; binding partner identification;
KW	gene therapy; ss.
XX	
XX	Homo sapiens.
XX	
FT	Key Location/Qualifiers
FT	CDS 42..914
FT	/*tag= a
FT	/product= "Human secreted protein precursor"
FT	sig_peptide 42..107
FT	/*tag= b
FT	mat_peptide 108..911
FT	/*tag= c
FT	/product= "Mature human secreted protein"
XX	
XX	WO200136440-A1.
PN	
XX	25-MAY-2001.
PD	
XX	
XX	15-NOV-2000; 2000WO-US031282.
PF	
XX	
XX	19-NOV-1999; 99US-0166414P.
PR	
PR	21-JUL-2000; 2000US-0219665P.
XX	
XX	(HUMA-) HUMAN GENOME SCI INC.
PA	
XX	
PI	Ruben SM, Komatsoulis GA, Birse CE, Moore PA;
DR	
DR	WPI: 2001-343795/36.
DR	P-PSDB; AA033821.
XX	
XX	Isolated nucleic acid molecule encoding a human secreted protein is used
XX	in preventing, treating or ameliorating a medical condition.
XX	
XX	Claim 1; Page 440-441; 553pp; English.
XX	
XX	AA080283-RA080355 represent cDNAs corresponding to 23 human secreted
CC	protein genes, and AA033818-AA033870 represent the proteins they encode.
CC	AA033871-AA033896 represent human secreted protein fragments or variants.
CC	The secreted proteins and their genes are useful for preventing, treating
CC	or ameliorating medical conditions, e.g., by protein or gene therapy.
CC	Pathological conditions can be diagnosed by determining the amount of the
CC	new protein in a sample or by determining the presence of mutations in
CC	the new genes. Specific uses are described for each of the 23 genes,
CC	based on the tissues in which they are most highly expressed, and include
CC	developing products for the diagnosis or treatment of proliferative
CC	disorders, cancer, tumours, foetal and developmental abnormalities,
CC	haematopoietic disorders, diseases of the immune system, AIDS, autoimmune
CC	diseases (e.g., rheumatoid arthritis), inflammation, allergies,
CC	neurological disorders (e.g., Alzheimer's disease, Parkinson's disease),
CC	cognitive disorders, schizophrenia, asthma, skin disorders (e.g.,
CC	psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders,
CC	angiogenic disorders, kidney disorders, gastrointestinal disorders,
CC	pregnancy-related disorders, endocrine disorders, and infectious diseases.
CC	Proteins can also be used to aid wound healing and epithelial cell
CC	proliferation, to prevent skin aging due to culture, to maintain organs
CC	before transplantation, for supporting cell culture of primary tissues,
CC	to regenerate tissues, to identify their cognate ligands or binding
CC	partners, and in chemotaxis, and can be used as a food additive or


```
QY 1696 CCTGGAT 1692
DB 217 TCTAGCT 211

RESULT 39
AAI44871/c
ID AAI44871 standard; DNA; 301 BP.
XX
AC AAI44871;
XX
DT 17-OCT-2001 (first entry)
XX
DE Probe #13557 used to measure gene expression in human placenta sample.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder; ss.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-48897/53.
XX
DR WPI; 2001-48897/53.
XX
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 25; SEQ ID NO 13557; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP).
CC The present sequence is one such probe. The probes are useful for
CC producing a microarray for predicting, measuring and displaying gene
CC expression in samples derived from human placenta. The probes are useful
CC for antenatal diagnosis of human genetic disorders
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCCTTCTCCCTCTCTATTCCTTTGCTTTTGCATAGTGTCTCGGCTT 1685
DB 277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCT 218
QY 1686 CCTGGAT 1692
DB 217 TCTAGCT 211

RESULT 39
ABA46822/c
ID ABA46822 standard; DNA; 301 BP.
XX
AC ABA46822;
XX
DT 01-FEB-2002 (first entry)
```

```
XX Human breast cell single exon nucleic acid probe #5517.
DE Human; microarray; single exon probe; gene expression; breast; disease;
XX cancer; ss.
KW Homo sapiens.
XX
PN WO200157271-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000662.
XX
PR 04-FEB-2000; 2000US-0180312P.
XX
PR 26-MAY-2000; 2000US-0207456P.
XX
PR 30-JUN-2000; 2000US-00608408.
XX
PR 03-AUG-2000; 2000US-00632366.
XX
PR 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
XX
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
WPI; 2001-496933/54.
XX
DR WPI; 2001-496933/54.
XX
PT New spatially-addressable set of single exon nucleic acid probes, useful
PT for measuring gene expression in sample derived from human breast,
PT comprises number of single exon nucleic acid probes.
XX
PS Claim 4; SEQ ID NO 5517; 327pp + Sequence Listing; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting the
CC probes with a collection of detectably labelled nucleic acids derived
CC from mRNA of human breast, and then measuring the label bound to each
CC probe of the microarray. The probes are useful for verifying the
CC expression of regions of genomic DNA predicted to encode proteins. They
CC are useful for gene discovery, and for determining predisposition and/or
CC prognosing breast disease. Gene expression analysis is useful for
CC assessing the toxicity of chemical agents on cells. The microarray of
CC this invention presents a far greater diversity of probes for measuring
CC gene expression, with far less bias than expressed sequence tag
CC microarrays. The method is suitable for rapid production of functional
CC information from genomic sequence. The present sequence is a single exon
CC nucleic acid probe of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCCTTCTCCCTCTCTATTCCTTTGCTTTTGCATAGTGTCTCGGCTT 1685
DB 277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCTCGCT 218
QY 1686 CCTGGAT 1692
DB 217 TCTAGCT 211

RESULT 40
ABA31826/c
ID ABA31826 standard; DNA; 301 BP.
XX
AC ABA31826;
XX
```


XX 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
PA Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
PI brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCTTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685
DB 277 TCTGCGCTGTACCTCTGCGCTCTCAATTTCTTCTCTCTCTCTCTGCGGT 218
QY 1686 CTTGGAT 1692
DB 217 TCTAGCT 211
RESULT 43
ABS38453/C
ID ABS38453 standard; DNA; 301 BP.
XX
AC ABS38453;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver single exon probe, SEQ ID No 13443.
XX
KW Human; single exon nucleic acid probe; liver; cirrhosis;
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW coronary heart disease; ss.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-483446/52.
XX Single exon nucleic acid probes for analyzing gene expression in human
PI brains.
XX Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.
XX The present invention provides a number of single exon nucleic acid
CC probes which are derived from genomic sequences expressed in the human
CC brain. They can be used to measure gene expression in brain cell samples,
CC which may enable the diagnosis and improved treatment of nervous system
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC epilepsy and cancers. The present sequence is one of the probes of the
CC invention
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCTTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685
DB 277 TCTGCGCTGTACCTCTGCGCTCTCAATTTCTTCTCTCTCTCTGCGGT 218
QY 1686 CTTGGAT 1692
DB 217 TCTAGCT 211

PA (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.
XX Human genome-derived single exon nucleic acid probes useful for analyzing
PI gene expression in human adult liver.
XX Claim 4; SEQ ID NO 13443; 658pp; English.
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABS25011-ABS51005 represent human
CC liver single exon nucleic acid probes of the invention. Note: The
CC sequence information for this patent does not appear in the printed
CC specification but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCTTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685
DB 277 TCTGCGCTGTACCTCTGCGCTCTCAATTTCTTCTCTCTCTCTGCGGT 218
QY 1686 CTTGGAT 1692
DB 217 TCTAGCT 211
RESULT 44
AAI05395/C
ID AAI05395 standard; DNA; 301 BP.
XX
AC AAI05395;
XX
DT 09-OCT-2001 (first entry)
XX
DE Probe #5396 used to measure gene expression in human breast sample.
XX
KW Probe; human; breast disease; breast cancer; development disorder; ss;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX WPI; 2001-488898/53.

```

XX DR WPI; 2001-476286/51.
XX PT Novel single exon nucleic acid probe used to measuring gene expression in
XX PT a human breast.
XX PS Claim 25; SEQ ID NO 5386; 322pp; English.
XX CC The present invention relates to novel single exon nucleic acid probes.
XX CC The present sequence is one such probe. The probes are useful for
XX CC measuring human gene expression in a human breast sample, where the probe
XX CC hybridizes at high stringency to a nucleic acid expressed in the human
XX CC breast. The probes are useful for predicting, diagnosing, grading,
XX CC staging, monitoring and prognosing diseases of the human breast,
XX CC particularly those diseases with polygenic aetiology. The diseases
XX CC include: breast cancer, disorders of development, inflammatory diseases
XX CC of the breast, fibrocystic changes, proliferative breast disease and non-
XX CC carcinoma tumours. Note: The sequence data for this patent did not form
XX CC part of the printed specification, but was obtained in electronic format
XX CC directly from WIFO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCTTCTCCCTCTCTATTCCTTGGTTTTCATAGTCTCTGCGCTT 1685
DB 277 TCTGCGCTGCTTACTCTGCGCTCTCAATTCTCTCTCTCTCTCTCTCTCTCT 218
QY 1686 CTTGGAT 1692
DB 217 TCTAGCT 211
RESULT 45
ABS12949/C
ID ABS12949 standard; DNA; 301 BP.
AC ABS12949;
XX 19-AUG-2002 (first entry)
DE Human genome-derived single exon probe ORF from lung SEQ ID NO 12940.
XX Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;
XX chronic obstructive pulmonary disease; interstitial lung disease;
XX familial idiopathic pulmonary fibrosis; neurofibromatosis;
XX tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
XX Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
XX pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;
XX pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
XX primary ciliary dyskinesia; pulmonary hypertension;
XX hyaline membrane disease; open reading frame; ORF.
XX OS Homo sapiens.
XX WO200186003-A2.
XX 15-NOV-2001.
XX 30-JAN-2001; 2001WO-US0000665.
XX 04-FEB-2000; 2000US-0180312P.
XX 26-MAY-2000; 2000US-0207456P.
XX 30-JUN-2000; 2000US-00608408.
XX 03-AUG-2000; 2000US-00632366.
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.

```

```

XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX DR WPI; 2002-114183/15.
XX PT Spatially-addressable set of single exon nucleic acid probes, used to
XX PT measure gene expression in human lung samples.
XX PS Claim 4; SEQ ID NO 12940; 634pp; English.
XX CC The invention relates to a spatially-addressable set of single exon
XX CC nucleic acid probes for measuring gene expression in a sample derived
XX CC from human lung comprising single exon nucleic acid probes having one of
XX CC 12614 nucleic acid sequences mentioned in the specification, or their
XX CC complements or the 12387 open reading frames derived from the 12614
XX CC probes. Also included are a microarray comprising the novel set of probes
XX CC ; the novel set of probes which hybridise at high stringency to a nucleic
XX CC acid expressed in the human lung; measuring gene expression in a sample
XX CC derived from human lung, comprising (a) contacting the array with a
XX CC collection of detectably labeled nucleic acids derived from human lung
XX CC mRNA, and (b) measuring the label detectably bound to each probe of the
XX CC array; identifying exons in a eukaryotic genome, comprising (a)
XX CC algorithmically predicting at least one exon from genomic sequences of
XX CC the eukaryote; and (b) detecting specific hybridisation of detectably
XX CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
XX CC having a fragment identical to the predicted exon, the probe is included
XX CC in the above mentioned microarray; assigning exons to a single gene,
XX CC comprising (a) identifying exons from genomic sequence by the method
XX CC above and (b) measuring the expression of each of the exons in several
XX CC tissues and/or cell types using hybridisation to a single exon
XX CC microarrays having a probe with the exon, where a common pattern of
XX CC expression of the exons in the tissues and/or cell types indicates that
XX CC the exons should be assigned to a single gene; a peptide comprising one
XX CC of 12011 sequences, mentioned in the specification, or encoded by the
XX CC probes/open reading frames (ORF). The probes are used for gene expression
XX CC analysis, and for identifying exons in a gene, particularly using human
XX CC lung derived mRNA and for the study of lung diseases such as asthma, lung
XX CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
XX CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
XX CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
XX CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
XX CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
XX CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
XX CC dyskinesia, pulmonary hypertension and hyaline membrane disease. The
XX CC present sequence is a single exon probe open reading frame of the
XX CC invention. Note: The sequence data for this patent did not form part of
XX CC the printed specification, but was obtained in electronic format directly
XX CC from WIFO at ftp.wipo.int/pub/published_pct_sequences
XX SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
Query Match 1.1%; Score 22.2; DB 1; Length 301;
Best Local Similarity 58.2%; Pred. No. 20;
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;
QY 1626 TTGACCTGCTTCTCCCTCTCTATTCCTTGGTTTTCATAGTCTCTGCGCTT 1685
DB 277 TCTGCGCTGCTTACTCTGCGCTCTCAATTCTCTCTCTCTCTCTCTCTCTCT 218
QY 1686 CTTGGAT 1692
DB 217 TCTAGCT 211
RESULT 46
AAC04575/C
ID AAC04575 standard; cDNA; 385 BP.
AC AAC04575;
XX 06-OCT-2000 (first entry)
XX Human secreted protein 5' EST, SEQ ID NO: 8650.

```



```
XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;
KW gene therapy; chromosome mapping; ss.
XX Homo sapiens.
XX EP1033401-A2.
XX 06-SEP-2000.
XX 21-FEB-2000; 2000EP-00200610.
XX 26-FEB-1999; 99US-0122487P.
XX (GSET ) GENSET.
XX Dumas Milne Edwards J, Duclert A, Giordano J;
XX MPI; 2000-500381/45.
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for
XX obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for
XX diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX Claim 1; SEQ ID NO 8650; 71pp + Sequence Listing; English.
XX The present sequence is one of a large number of 5' ESTs derived from
XX mRNAs encoding secreted proteins. No ORF has yet been conclusively
XX identified within the present sequence. The 5' ESTs were prepared from
XX total human RNAs or polyA+ RNAs derived from 30 different tissues. EST
XX sequences usually correspond mainly to the 3' untranslated region (UTR)
XX of the mRNA because they are often obtained from oligo-dT primed cDNA
XX libraries. Such ESTs are not well suited for isolating cDNA sequences
XX derived from the 5' ends of mRNAs and even in those cases where longer
XX cDNA sequences have been obtained, the full 5' UTR is rarely included. 5'
XX ESTs are derived from mRNAs with intact 5' ends and can therefore be used
XX to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used in
XX diagnostic, forensic, gene therapy and chromosome mapping procedures.
XX They are used to obtain upstream regulatory sequences and to design
XX expression and secretion vectors
XX
XX Sequence 385 BP; 69 A; 105 C; 126 G; 80 T; 0 U; 5 Other;
XX
Query Match 1.1%; Score 22; DB 1; Length 385;
Best Local Similarity 57.1%; Pred. No. 24;
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;
OY 111 TCTCTCTCCCTTCTCTAACAACITCTGGGCCAGGCTAGGGGCACTACCGCATTCCTC 170
Db 135 TCTCACATCCCGAGCTCCCAACATCCGAGACTGGATGATGGGGGCAACGACATGGACC 76
OY 171 TCTCTTCCAA 180
Db 75 CCACAGACAA 66
RESULT 47
ABQ47969/c
ID ABQ47969 standard; DNA; 612 BP.
XX AC ABQ47969;
XX 12-JUL-2002 (first entry)
XX Oligonucleotide for detecting cytosine methylation SEQ ID NO 34560.
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX Homo sapiens.
OS
```

```
PN WO200218632-A2.
XX 07-MAR-2002.
XX 01-SEP-2001; 2001WO-EP010074.
XX 01-SEP-2000; 2000DE-01043826.
XX 05-SEP-2000; 2000DE-01044543.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K, Guetig D;
XX MPI; 2002-371829/40.
XX Determining the degree of cytosine methylation in genomic DNA, useful for
XX diagnosis and prognosis, comprises selective hybridization of amplicons
XX from chemically treated DNA.
XX Claim 12; 56pp + Sequence Listing; 56pp; German.
XX This invention describes a novel method for determining the degree of
XX methylation of a particular cytosine in a motif 5'-CpG-3', present in a
XX genomic sample of DNA. The sample is treated chemically to convert
XX cytosine (C) but not methylated C, to uracil, then part of the genomic
XX DNA that contains the target C is amplified to form a labeled amplicon.
XX The amplicon is hybridised to two classes, each with at least one member,
XX of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the
XX degree of hybridisation to both classes is determined from the label on
XX the amplicon. From the ratio of labels hybridised to the two classes of
XX oligomers, the degree of methylation is calculated. The method is used:
XX (i) for diagnosis and/or prognosis of side effects of therapeutic drugs
XX and of a wide range of diseases, e.g. cancer, disorders of the central
XX nervous, cardiovascular, gastrointestinal and respiratory systems etc.,
XX particularly by detecting mutations or single nucleotide polymorphisms
XX (SNPs); and (ii) for differentiation of cell or tissue types and for
XX investigating cell differentiation. The method allows the methylation
XX status of many C residues to be determined simultaneously. ABQ13410-
XX ABQ54121 represent genomic DNA sequences used to illustrate the method
XX for determining the degree of cytosine methylation described in the
XX disclosure of the invention
XX
XX Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;
XX
Query Match 1.1%; Score 22; DB 1; Length 612;
Best Local Similarity 49.2%; Pred. No. 27;
Matches 58; Conservative 0; Mismatches 50; Indels 0; Gaps 0;
OY 961 TTATCAATGACGAGTGTGTTGTCGATCTCTGTTATCTTTCGACTGTGAGTGTGTGTGT 1020
Db 258 TTTCGAGGAGTATTGTTTTTTTGTATTTTTTTTAGGAGTTCGGTCGTAGTTTTT 199
OY 1021 GTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1078
Db 198 TTAGGAACGGCTTGGCGCTCGGCTCGGTAGACGTCGTGGGTTTTTTTTTTGGGT 141
RESULT 48
ABQ47968
ID ABQ47968 standard; DNA; 612 BP.
XX AC ABQ47968;
XX 12-JUL-2002 (first entry)
XX Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;
KW drug; side effect; cancer; central nervous system; cardiovascular;
KW gastrointestinal; respiratory system; single nucleotide polymorphism;
KW SNP; cell differentiation; ds.
XX Homo sapiens.
OS
```


RESULT 51	
AAV28290	
ID	AAV28290 standard; cDNA; 283 BP.
XX	
AC	AAV28290;
XX	
DT	24-NOV-1998 (first entry)
XX	
DE	Galanin receptor GALR2 DNA probe.
XX	
KW	Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
XX	cognitive disorder; therapy; probe; ss.
XX	
OS	Rattus sp.
XX	

RESULT 52	
AAV32651	
IID	AAV32651 standard; cDNA; 283 BP.
XX	
XX	AAV32651;
XX	
DT	24-NOV-1998 (first entry)
XX	
XX	Galanin receptor GALR2 DNA probe.
XX	
KW	Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;
KW	cognitive disorder; therapy; probe; ss.
XX	
OS	Rattus sp.
XX	
PN	W09829439-A1.
XX	
PD	09-JUL-1998.
XX	
PF	18-DEC-1997; 97WO-US023890.
XX	
PR	27-DEC-1996; 96US-0033851P.
XX	
PA	(MERI) MERCK & CO INC.
XX	
PI	Tan C, Sullivan K;
XX	
DR	WPI; 1998-388037/33.
XX	
PT	New galanin receptor, GALR2 - useful, e.g. to identify agonists and
PT	antagonists. therapeutically to treat conditions involving excess or

PT insufficient galanin such as obesity.

PS Example 1; Fig 6; 57pp; English.

XX This PCR fragment was used as a probe to screen a rat hypothalamus cDNA library. 2 independent clones, named 27A (see AAV42648) and 16.6, were obtained. Clone 27A codes for a novel full-length rat galanin receptor, designated GALR2 (see AAW49002). The invention provides methods for identifying ligands particular to GALR2. Such ligands may be useful therapeutically e.g. to treat obesity or cognitive disorders involving excess galanin or to treat pain or anorexia involving insufficient galanin

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 283;

Best Local Similarity 61.8%; Pred. No. 33; Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTGCTGCGCCTGCTCCTTACGTGGGGGAGGCTGCACCTACGC 166

RESULT 53

AAV4930

ID AAV4930 standard; cDNA; 283 BP.

XX AAV4930;

XX 24-NOV-1998 (first entry)

XX Galanin receptor GALR2 DNA probe.

XX Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;

XX cognitive disorder; therapy; probe; ss.

XX Rattus sp.

XX WO9829441-A1.

XX 09-JUL-1998.

XX 18-DEC-1997; 97WO-US023892.

XX 27-DEC-1996; 96US-0033851P.

XX (MERI) MERCK & CO INC.

XX (UYTE-) UNIV TEXAS HEALTH SCI CENT SAN ANTONIO.

XX (UTOR) UNIV TORONTO.

XX Sullivan K. Kolakowski LF, Odowd B;

XX WPI; 1998-388039/33.

XX New human galanin receptor, GALR2, - useful to identify agonists and

XX antagonists to treat conditions involving galanin, e.g. for treatment of

XX obesity or cognitive disorders.

XX Example 1; Fig 6; 57pp; English.

XX This PCR fragment was used as a probe to screen a rat hypothalamus cDNA

XX library. 2 independent clones, named 27A (see AAV4929) and 16.6, were

XX obtained. Clone 27A codes for a novel full-length rat galanin receptor,

XX designated GALR2 (see AAW61385). The invention provides methods for

XX identifying ligands particular to human GALR2 (see AAW61386). Such

XX ligands may be useful therapeutically e.g. to treat obesity or cognitive

XX disorders involving excess galanin or to treat pain or anorexia involving

XX insufficient galanin

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

XX Query Match 1.1%; Score 21.4; DB 1; Length 283;

XX Best Local Similarity 61.8%; Pred. No. 33;

XX Mismatches 34; Conservative 0; Indels 21; Gaps 0;

XX QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

XX Db 112 TCGGGCCGCTGCTGCTGCGCCTGCTCCTTACGTGGGGGAGGCTGCACCTACGC 166

RESULT 55

AAS21354/C

ID AAS21354 standard; cDNA; 1129 BP.

XX AAS21354;

XX 24-OCT-2001 (first entry)

XX Human cDNA sequence encoding for PRO4327 polypeptide.

XX

Best Local Similarity 61.8%; Pred. No. 33; Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTGCTGCGCCTGCTCCTTACGTGGGGGAGGCTGCACCTACGC 166

RESULT 54

ABK14060

ID ABK14060 standard; cDNA; 283 BP.

XX ABK14060;

XX 08-MAY-2002 (first entry)

XX Rat galanin receptor 2 (GALR2) cDNA probe.

XX Galanin receptor 2; GALR2; probe; ss; rat; obesity; pain; anorectic;

XX cognitive disorder; analgesic; neuroprotective.

XX Rattus sp.

XX US6337206-B1.

XX 08-JAN-2002.

XX 18-DEC-1997; 97US-00993424.

XX 18-DEC-1997; 97US-00993424.

XX (MERI) MERCK & CO INC.

XX (TEXA) UNIV TEXAS SYSTEM.

XX Tan C. Kolakowski LF;

XX WPI; 2002-163241/21.

XX New nucleic acid encoding mouse galanin receptor 2, useful in assays for

XX identifying galanin receptor 2 ligands for treating obesity, pain and

XX cognitive disorders.

XX Disclosure; Fig 6; 48pp; English.

XX The invention relates to mouse galanin receptor 2 (GALR2) and the nucleic

XX acid encoding the novel polypeptide. The sequences are useful in assays

XX for identifying GALR2 ligands that are useful for treating obesity, pain

XX and cognitive disorders. The sequences are also useful for identifying

XX agonists, antagonists, suppressors or inducers of GALR2. This sequence

XX represents a cDNA probe used to isolate rat GALR2, used in the methods of

XX the invention

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

XX Query Match 1.1%; Score 21.4; DB 1; Length 283;

XX Best Local Similarity 61.8%; Pred. No. 33;

XX Mismatches 34; Conservative 0; Indels 21; Gaps 0;

XX QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

XX Db 112 TCGGGCCGCTGCTGCTGCGCCTGCTCCTTACGTGGGGGAGGCTGCACCTACGC 166

RESULT 55

AAS21354/C

ID AAS21354 standard; cDNA; 1129 BP.

XX AAS21354;

XX 24-OCT-2001 (first entry)

XX Human cDNA sequence encoding for PRO4327 polypeptide.

XX

Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
 prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
 ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
 A-peptide; factor VIIa; gene therapy; ss.

Homo sapiens.

WO200140466-A2.

07-JUN-2001.

01-DEC-2000; 2000WO-US032678.

01-DEC-1999; 99WO-US028301.

01-DEC-1999; 99WO-US028634.

02-DEC-1999; 99WO-US028551.

02-DEC-1999; 99WO-US028564.

02-DEC-1999; 99WO-US028565.

09-DEC-1999; 99US-0170362P.

16-DEC-1999; 99WO-US030095.

20-DEC-1999; 99WO-US030911.

20-DEC-1999; 99WO-US030999.

30-DEC-1999; 99WO-US031243.

30-DEC-1999; 99WO-US031274.

05-JAN-2000; 2000WO-US000219.

06-JAN-2000; 2000WO-US000277.

11-FEB-2000; 2000WO-US000356.

18-FEB-2000; 2000WO-US004341.

22-FEB-2000; 2000WO-US004342.

24-FEB-2000; 2000WO-US004914.

24-FEB-2000; 2000WO-US005004.

01-MAR-2000; 2000WO-US005601.

02-MAR-2000; 2000WO-US005841.

03-MAR-2000; 2000US-0187202P.

10-MAR-2000; 2000WO-US006319.

15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.

21-MAR-2000; 2000WO-US007532.

30-MAR-2000; 2000WO-US008439.

17-MAY-2000; 2000WO-US013705.

22-MAY-2000; 2000WO-US014042.

30-MAY-2000; 2000WO-US014941.

02-JUN-2000; 2000WO-US015264.

05-JUN-2000; 2000US-0209832P.

28-JUL-2000; 2000WO-US020710.

11-AUG-2000; 2000WO-US022031.

23-AUG-2000; 2000WO-US023522.

24-AUG-2000; 2000WO-US023328.

08-NOV-2000; 2000WO-US030952.

10-NOV-2000; 2000WO-US030973.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Deanoyers L, Filvaroff E, Gao W;

Geritsen ME, Gaddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2001-408281/43.

P-PSDB; AAU12282.

Isolated, secretory and transmembrane PRO polypeptide used to detect
 other PRO polypeptides, link bioactive molecules to cells expressing PRO
 polypeptides, and detect the presence of mammalian tumors e.g. lung,
 breast, prostate, cervical.

Claim 3; Fig 221; 813pp; English.

AAG21244-AAS21518 encode for novel human secretory and transmembrane PRO
 polypeptides. The PRO polypeptides are useful to detect other PRO
 polypeptides, to link bioactive molecules to cells expressing PRO
 polypeptides, to modulate biological activities of cells expressing PRO

polypeptides, and to detect the presence of mammalian lung, colon,
 breast, prostate, rectal, cervical or liver tumours by comparing PRO
 polypeptide expression in a cell sample to that in a control sample. Some
 of the 275 sequences are also useful to stimulate the release of tumour
 necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
 differentiation of chondrocytes, the proliferation or gene expression in
 pericyte cells, the release of proteoglycans from cartilage, the
 proliferation of inner ear utricular supporting cells or of T-
 lymphocytes, the release of a cytokine from peripheral blood monocytes
 (BMCs), or the proliferation of endothelial cells. Some of the PRO
 polypeptides may modulate glucose or free fatty acid uptake by skeletal
 muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
 VIIa. The PRO polypeptides can be used in assays to identify molecules
 involved in binding interactions. The polynucleotides encoding PRO
 polypeptides can be used to generate probes, antisense RNA/DNA,
 transgenic or knock out animals and can be used in gene therapy

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. NO. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1835 TTCTTAATTTTTCATTTCACAGATTTCCTTCAGTTTGGGTTTGT 1881

Db 1129 TTTTITTTTTTTTTTTCAGCTGCGCACAGGCTGGGTTTATT 1083

RESULT 56

ACD23963/C

ID ACD23963 standard; cDNA; 1129 BP.

XX ACD23963;

XX 26-AUG-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

Human; secreted and transmembrane protein; PRO; antiinflammatory;
 antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
 antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
 TNF-alpha release; cell proliferation; cell differentiation;
 gene expression modulator; proteoglycan release; cytokine release;
 tumour; inflammatory disease; organ failure; atherosclerosis;
 cardiac injury; infertility; birth defect; premature aging; AIDS;
 acquired immunodeficiency syndrome; cancer; diabetic complication;
 chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
 bioreactor; tissue typing; gene; ss.

XX Homo sapiens.

XX US2003032156-A1.

XX 13-FEB-2003.

XX 06-MAY-2002; 2002US-00140474.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US007733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 23-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020231.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006656.
 PR 05-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00806889.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI: 2003-341980/32.
 DR P-PSDB; ABO17726.
 DR
 XX
 PS Claim 2; Fig 221; 660pp; English.
 CC The invention describes an isolated nucleic acid (I) comprising, or which
 has 80 % sequence identity to, or the full-length coding sequence of, one
 of 275 nucleotide sequences, and which encodes a corresponding
 polypeptide selected from 275 amino acid sequences, where all sequences
 are given in the specification. The polypeptide encoded by (I) is used to
 detect PRO polypeptides, link a bioactive molecule to a cell expressing a
 PRO polypeptide, modulate a biological activity of a cell, stimulate the
 release of tumour necrosis factor (TNF)-alpha from human blood, modulate
 the uptake of glucose or free fatty acid by cells, stimulate or inhibit
 the proliferation or differentiation of cells or gene expression,
 CC stimulate the release of proteoglycans, stimulate the release of cytokine
 from peripheral blood mononuclear cells, inhibit the binding of A-peptide
 to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
 acid and polypeptide encoded by it, are useful for treating inflammatory
 diseases, organ failure, atherosclerosis, cardiac injury, infertility,
 CC birth defects, premature aging, acquired immunodeficiency syndrome
 (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
 hybridisation probes, in chromosome and gene mapping, and in generating
 antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
 CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
 CC This sequence encodes a novel human secreted and transmembrane PRO
 polypeptide
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.4%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1881
 |||||
 Db 1129 TTTTTCATTTTTCATTCAGTGGCACACAGCGTGGTTTATT 1083
 |||||
 RESULT 57
 ACA67104/c
 ID ACA67104 standard; cDNA; 1129 BP.
 XX ACA67104;
 XX
 DT 23-JUN-2003 (first entry)
 XX cDNA encoding human PRO polypeptide #11.
 DE Human; PRO polypeptide; secreted and transmembrane protein;
 KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
 KW

bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
hearing loss; coagulation disorder; stroke; heart attack; cardiac;
anti-diabetic; anorectic; vulnery; antiarthritic; osteopathic;
anti-rheumatic; auditory; cerebroprotective; angiogenic; gene; ss.

Homo sapiens.

US2003004311-A1.

02-JAN-2003.

19-DEC-2001; 2001US-00028072.

18-JUN-1997; 97US-0049911P.

26-AUG-1997; 97US-0056974P.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

19-SEP-1997; 97US-0059332P.

19-SEP-1997; 97US-0059588P.

24-SEP-1997; 97US-0059836P.

17-OCT-1997; 97US-0062250P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

17-OCT-1997; 97US-0063755P.

24-OCT-1997; 97US-0062814P.

24-OCT-1997; 97US-0062816P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063082P.

27-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063350P.

28-OCT-1997; 97US-0063561P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063733P.

29-OCT-1997; 97US-0063735P.

03-NOV-1997; 97US-0063738P.

07-NOV-1997; 97US-0064248P.

12-NOV-1997; 97US-0065186P.

17-NOV-1997; 97US-0065846P.

21-NOV-1997; 97US-0066364P.

24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066770P.

07-OCT-1998; 98WO-US021141.
29-OCT-1998; 98WO-US022991.
29-OCT-1998; 98WO-US022992.
20-NOV-1998; 98WO-US024855.
01-DEC-1998; 98WO-US025108.
05-JAN-1999; 98WO-US000106.
08-MAR-1999; 98WO-US005028.
10-MAR-1999; 98WO-US005190.
20-APR-1999; 98WO-US008615.
14-MAY-1999; 98WO-US010733.
02-JUN-1999; 98WO-US012252.
01-SEP-1999; 98WO-US020111.
08-SEP-1999; 98WO-US020594.
13-SEP-1999; 98WO-US020944.
15-SEP-1999; 98WO-US021090.
15-SEP-1999; 98WO-US021547.
05-OCT-1999; 98WO-US023089.
29-NOV-1999; 98WO-US028214.
30-NOV-1999; 98WO-US028313.
30-NOV-1999; 98WO-US028409.
01-DEC-1999; 98WO-US028301.
01-DEC-1999; 98WO-US028634.
02-DEC-1999; 98WO-US028551.
02-DEC-1999; 98WO-US028564.
16-DEC-1999; 98WO-US028565.
20-DEC-1999; 98WO-US030095.
20-DEC-1999; 98WO-US030911.
20-DEC-1999; 98WO-US030999.
30-DEC-1999; 98WO-US031243.
30-DEC-1999; 98WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US000376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-352836/33.

P-PSDB; ABU80980.

New isolated PRO polypeptide useful for treating diabetes, rheumatoid
arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
heart attack.

Claim 2; Fig 221; 643pp; English.

The present invention relates to the isolation of novel human PRO
polypeptides, and the polynucleotide sequences encoding them. The PRO
polypeptides are secreted and transmembrane proteins. The PRO
polypeptides and polynucleotides are useful for preparing a medicament
useful in the treatment of diabetes, bone and/or cartilage disorders
(e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
(e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
assays for PRO, by detecting its expression in specific cells, tissues or
serum, and for affinity purification of PRO from recombinant cell culture
or natural sources. ACA6894-ACA67268 represent cDNA sequences encoding
the human PRO polypeptides of the invention. Note: The sequence data for
this patent was obtained in electronic format directly from the USPTO web
site at seqdata.uspto.gov/paipsIDEntry.html

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

CC	full-length coding sequence of the nucleotide sequences given in the
CC	specification, or of the DNA deposited under any of the American Type
CC	Culture Collection (ATCC) Accession Numbers listed in the specification.
CC	Also included are a vector comprising the novel nucleic acid, a host cell
CC	comprising the vector, producing a PRO polypeptide, the isolated PRO
CC	polypeptides detailed above, a chimaeric molecule comprising the PRO
CC	polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC	antibody, detecting a PRO polypeptide in a sample suspected of containing
CC	the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC	PRO polypeptide, modulating at least one biological activity of a cell
CC	expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC	factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC	cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC	modulating the uptake of glucose or FFA by skeletal muscle cells or
CC	adipocyte cells, stimulating the proliferation or differentiation of
CC	chondrocyte cells (or proliferation of or gene expression in pericyte
CC	cells), stimulating the proliferation of inner ear utricular supporting
CC	cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC	binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC	cells, detecting the presence of a tumour in a mammal and an
CC	oligonucleotide probe derived from any of the nucleotide sequences given
CC	in the specification. The polynucleotide is useful in molecular biology,
CC	including uses as hybridisation probes, in chromosome and gene mapping,
CC	in generating antisense RNA and DNA, and in gene therapy. The
CC	polynucleotide may also be used in preparing PRO polypeptides by
CC	recombinant techniques, and in generating either transgenic animals or
CC	knock-out animals which, in turn, are useful in the development and
CC	screening of therapeutically useful reagents. The PRO polypeptide or the
CC	antibody is used in preparing a medicament for treating a condition
CC	responsive to the polypeptide or antibody, such as tumours, and in
CC	various diagnostic assays. The present sequence encodes a PRO polypeptide
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match 1.1%; Score 21.4; DB 1; Length 1129;
	Best Local Similarity 66.0%; Pred. No. 45;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1835 TTCTTAATTTCATTTCACGATTTCCTCAGTTGGGTGTTTGT 1881
DB	1129 TTTTITTTTTTTTTTTCAGCTGCACACAGCTGGGTTTTATT 1083
RESULT 61	
ID	ACA04134/c
AC	ACA04134 standard; cDNA; 1129 BP.
XC	ACA04134;
XX	
DT	27-MAY-2003 (first entry)
XX	
DE	Human cDNA encoding a secreted/transmembrane protein, SEQ ID 221.
XX	
KW	Human; ss; Gene; secreted protein; transmembrane protein; PRO;
KW	Inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW	infertility; birth defects; premature aging; AIDS; biosensor;
KW	acquired immunodeficiency syndrome; cancer; diabetic complication;
KW	bioreactor; tumour.
OS	Homo sapiens.
FN	US2003032155-A1.
XX	
PD	13-FEB-2003.
XX	
PF	03-MAY-2002; 2002US-00137865.
XX	
PR	21-MAR-1997; 97WO-US005230.
PR	12-JUN-1998; 98WO-US012456.
PR	28-AUG-1998; 98WO-US014552.
PR	10-SEP-1998; 98WO-US017888.
PR	14-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 27-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022992.
 PR 29-OCT-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 08-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005130.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 11-FEB-2000; 2000WO-US000376.
 PR 18-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 10-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006319.
 PR 20-MAR-2000; 2000WO-US006884.
 PR 21-MAR-2000; 2000WO-US007377.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015284.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.

PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874502.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

XX (GENTECH) GENENTECH INC.
 PA
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-331925/31.
 DR P-PSDB; ABU66956.
 XX
 PT New secreted and transmembrane nucleic acids and polypeptides, designated
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
 PT cancer.
 XX
 PS Claim 2; Fig 221; 659pp; English.

CC The invention relates to an isolated nucleic acid comprising, or which is
 CC at least 80% identical to, or the full-length coding sequence of, any of
 CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
 CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
 CC comprises the full-length coding sequence of the DNA deposited under
 CC American Type Culture Collection (ATCC) accession number in a list given
 CC in the specification. Also included are vectors and host cells for
 CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
 CC extracellular domains and mature sequences, methods of detecting PRO
 CC proteins, methods for stimulating the release of TNF-alpha (tumour
 CC necrosis factor alpha) from human blood, (and the proliferation of
 CC differentiation of chondrocyte cells, the release or proteoglycans from
 CC expression in pericyte cells, the release or proteoglycans from
 CC cartilage, proliferation of inner ear utricular supporting cells, the
 CC proliferation of T-lymphocyte cells, the release of a cytokine from
 CC peripheral blood mononuclear cells (PBMC), or the proliferation of
 CC endothelial cells), a method for modulating the uptake of glucose or free
 CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
 CC binding of A-peptide to factor VIIa, or the differentiation of adipocyte
 CC cells, a method for detecting the presence of a tumour in a mammal and an
 CC oligonucleotide probe derived from any of the nucleotide sequences cited
 CC above. The nucleic acids and polypeptides are useful for treating
 CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
 CC infertility, birth defects, premature aging, AIDS (acquired
 CC immunodeficiency syndrome), cancer, or diabetic complications. The
 CC nucleic acids are useful as hybridisation probes, in chromosome and gene
 CC mapping, and in generating antisense RNA or DNA. The polypeptides are
 CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
 CC are useful in tissue typing. The present sequence encodes a PRO protein
 CC of the invention
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;

Qy 1935 TTCTAATTTTTCATTCAGATTTCCTTCAGTTTGGTTTGT 1881
 Db 1129 TTTTTCATTTTTCATTCAGTTTGGTTTGT 1083

RESULT 62
 ADA45740/c
 ID ADA45740 standard; cDNA; 1129 BP.
 XX
 AC ADA45740;
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 PN US2003022328-A1.
 XX
 PD 30-JAN-2003.
 XX
 PF 16-APR-2002; 2002US-0013904.
 XX
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021144.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US025108.
 PR 01-DEC-1998; 98WO-US025106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 98WO-US005190.
 PR 20-APR-1999; 98WO-US008615.
 PR 01-JUN-1999; 98WO-US010733.
 PR 02-JUN-1999; 98WO-US012252.
 PR 08-SEP-1999; 98WO-US020111.
 PR 13-SEP-1999; 98WO-US020594.
 PR 15-SEP-1999; 98WO-US020944.
 PR 15-SEP-1999; 98WO-US021090.
 PR 15-SEP-1999; 98WO-US021547.
 PR 05-OCT-1999; 98WO-US023089.
 PR 29-NOV-1999; 98WO-US028214.
 PR 30-NOV-1999; 98WO-US028313.
 PR 30-NOV-1999; 98WO-US028409.
 PR 01-DEC-1999; 98WO-US028301.
 PR 01-DEC-1999; 98WO-US028634.
 PR 02-DEC-1999; 98WO-US028551.
 PR 02-DEC-1999; 98WO-US028564.
 PR 02-DEC-1999; 98WO-US028565.
 PR 16-DEC-1999; 98WO-US030095.
 PR 20-DEC-1999; 98WO-US030911.
 PR 20-DEC-1999; 98WO-US030999.
 PR 22-DEC-1999; 98WO-US030720.
 PR 30-DEC-1999; 98WO-US031243.

PR 30-DEC-1999; 98WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.
 PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUN-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US000520.
 PR 01-MAR-2001; 2001WO-US006566.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00860216.
 PR 14-MAY-2001; 2001US-00865028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WJ, Zhang Z;
 XX
 DR WPI: 2003-584997/55.
 DR P-PSDB; ADA45741.
 XX
 XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers.
 XX

PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00871092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882836.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00887879.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001US-00890827.
PR 09-JUL-2001; 2001US-00908827.
PR 18-JUL-2001; 2001US-00924419.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR (GETH) GENENTECH INC.
PR Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;
PR Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PR Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
PR WPI; 2003-687639/65.
PR P-PSDB; ADA76172.
PR New isolated nucleic acid encoding a secreted and transmembrane
PR polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PR gene mapping, in generating antisense RNA and DNA, and in gene therapy.
PR Claim 2; Fig 221; 659pp; English.
PR The invention relates to isolated human PRO polypeptides (secreted and
PR transmembrane polypeptides) and the polynucleotides encoding them. The
PR invention also relates to an antibody which specifically binds to a PRO
PR polypeptide, a method for stimulating the release of tumour necrosis
PR factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR proliferation or differentiation of chondrocyte cells and a method for
PR detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
PR colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR polynucleotides are useful in molecular biology, including uses as
PR hybridisation probes, in chromosome and gene mapping, in generating
PR antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR be used in preparing PRO polypeptides by recombinant techniques and in
PR generating either transgenic animals or knock-out animals which are
PR useful in the development and screening of therapeutically useful
PR reagents. The PRO polypeptides or antibodies are used in preparing a
PR medicament for treating a condition responsive to the polypeptides or
PR antibodies, such as tumours, for stimulating and inhibiting proliferation
PR of human microvascular endothelial cells, for modulating the uptake of
PR glucose or FFA by skeletal muscle cells or adipocyte cells, for
PR stimulating differentiation of adipocyte cells, for stimulating
PR proliferation of or gene expression in pericyte cells, for stimulating
PR the proliferation of inner ear utricular supporting cells or T-lymphocyte
PR cells, for inducing endothelial cell tube formation and for treating
PR various bone and/or cartilage disorders such as sports injuries and
PR arthritis. PRO polypeptides which stimulate the release of proteoglycans
PR from cartilage are useful for treating sports-related joint problems, PRO
PR polypeptides are also useful for treating various mammalian haemoglobin-
PR associated disorders such as various thalassemias and conditions which
PR may benefit from enhanced local immune system cell infiltration. This
PR sequence represents a human PRO polynucleotide of the invention. Note:
PR The sequence data for this patent is also available in electronic format
PR from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
Oy 1835 TTTTAAATTTTTCATTTCCAGATTTTCCTTCAGTTTGGGTTTGT 1881
Db 1129 TTTTAAATTTTTCATTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
RESULT 64
ADA18821/c
ID ADA18821 standard; cDNA; 1129 BP.
XX AC ADA18821;
XX DT 20-NOV-2003 (first entry)
XX DE Human PRO polynucleotide #111.
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX OS Homo sapiens.
XX FN US2003054517-A1.
XX PD 20-MAR-2003.
XX PF 08-MAY-2002; 2002US-00141755.
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 20-NOV-1998; 98WO-US022992.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 02-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 16-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.

XX PD 13-MAR-2003.
XX PF 15-APR-2002; 202US-00123262.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019033.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022291.
PR 29-OCT-1998; 98WO-US022392.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 14-MAR-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021030.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004314.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00803706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00818744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-695892/66.
P-PSDB; ADA61445.

New PRO nucleic acid and encode polypeptides, are useful for
manufacturing a medicament for diagnosing or treating cancer.

Claim 2; Fig 221; 660pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes

CC a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

SQ Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGTGTTT 1881
DB 1129 TTTTITTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083

RESULT 66

ADBI9229/c

ID ADBI9229 standard; cDNA; 1129 BP.

XX

AC ADBI9229;

DT

XX 20-NOV-2003 (first entry)

DE

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

KW Human; secreted and transmembrane protein; PRO; gene; ss;

KW Tumour necrosis factor alpha release; TNF-alpha release;

KW Glucose uptake modulator; FFA uptake modulator;

KW Cell proliferation stimulator; Cell differentiation stimulator;

KW Cell differentiation inhibitor; cytokin.

XX

OS Homo sapiens.

XX

PN US2003068796-A1.

XX

PD 10-APR-2003.

XX

XX 15-APR-2002; 2002US-00123261.

XX

PR 31-MAR-1997; 97WO-US005230.

PR

PR 12-JUN-1998; 98WO-US012456.

PR

PR 14-JUL-1998; 98WO-US014552.

PR

PR 28-AUG-1998; 98WO-US017888.

PR

PR 10-SEP-1998; 98WO-US018824.

PR

PR 14-SEP-1998; 98WO-US019093.

PR

PR 14-SEP-1998; 98WO-US019094.

PR

PR 14-SEP-1998; 98WO-US019177.

PR

PR 16-SEP-1998; 98WO-US019330.

PR

PR 17-SEP-1998; 98WO-US019437.

PR

PR 07-OCT-1998; 98WO-US021141.

PR

PR 29-OCT-1998; 98WO-US022991.

PR

PR 29-OCT-1998; 98WO-US022992.

PR

PR 20-NOV-1998; 98WO-US024855.

PR

PR 01-DEC-1998; 98WO-US025106.

PR

PR 05-JAN-1999; 99WO-US000108.

PR

PR 08-MAR-1999; 99WO-US005028.

PR

PR 10-MAR-1999; 99WO-US005130.

PR

PR 20-APR-1999; 99WO-US008615.

PR

PR 14-MAY-1999; 99WO-US010733.

PR

PR 01-JUN-1999; 99WO-US012252.

PR

PR 01-SEP-1999; 99WO-US020111.

PR

PR 08-SEP-1999; 99WO-US020594.

PR

PR 13-SEP-1999; 99WO-US020944.

PR

PR 15-SEP-1999; 99WO-US021030.

PR

PR 15-SEP-1999; 99WO-US021547.

PR

PR 05-OCT-1999; 99WO-US023089.

PR

PR 29-NOV-1999; 99WO-US028214.

PR

PR 30-NOV-1999; 99WO-US028313.

PR

PR 30-NOV-1999; 99WO-US028409.

PR

PR 01-DEC-1999; 99WO-US028301.

PR

PR 01-DEC-1999; 99WO-US028634.

PR

PR 02-DEC-1999; 99WO-US028551.

PR

PR 02-DEC-1999; 99WO-US028564.

PR

PR 02-DEC-1999; 99WO-US028565.

PR

PR 16-DEC-1999; 99WO-US030085.

PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006319.
PR 20-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US008520.
PR 01-MAR-2001; 2001WO-US008666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00892636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-695927/66.
P-ESDB; ADBI9230.

PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786914/74.
DR P-PSDB; ADA86250.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TCTTAATTTTTCATTCAGATTCTCTTCAGTTTCGGTTTGTTT 1881
DB 1129 TTTTTCATTTTTCATTCAGATTCTCTTCAGTTTCGGTTTGTTT 1083
RESULT 69
ADB15813/c
ID ADB15813 standard; cDNA; 1129 BP.
XX
AC ADB15813;
XX
XX 20-NOV-2003 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX Homo sapiens.
OS
XX US2003087350-A1.
PN
XX 08-MAY-2003.
PD
XX 22-APR-2002; 2002US-00127821.
BF
XX 04-AUG-1998; 98US-0095301P.
PR
XX 02-JUN-1999; 99WO-US012252.
PR
XX 25-AUG-1999; 99US-00380137.
PR
XX 30-MAR-2000; 2000WO-US008439.
PR
XX 01-DEC-2000; 2000WO-US032678.
PR
XX 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786914/74.
DR P-PSDB; ADB15814.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
XX Claim 2; Fig 221; 637pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems.
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

New secreted and transmembrane PRO polypeptides and nucleic acids, useful in gene therapy, detecting the presence of tumor in a mammal, or

KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 XX Homo sapiens.
 OS
 XX US2003082693-A1.
 FN
 XX 01-MAY-2003.
 PD
 XX 22-APR-2002; 2002US-00127843.
 PF
 XX 05-JUN-2000; 2000US-0209832P.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-786907/74.
 DR P-PSDB; ADA85698.
 XX
 XX New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g., tumor or for tissue typing.
 PT
 XX Claim 2; Fig 221; 637pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1935 TTCTATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1881
 DB 1129 TTTTITTTTTTTTTTTCACGTCGACACAGCTGGGTTTATT 1083

RESULT 74

ADA96909/C

ID ADA96909 standard; cDNA; 1129 BP.

XX AC ADA96909;

XX DT 20-NOV-2003 (first entry)

XX DE Human PRO polynucleotide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.

XX OS Homo sapiens.

XX FN US2003082705-A1.

XX PD 01-MAY-2003.

XX PF 24-APR-2002; 2002US-00131829.

XX PR 09-DEC-1999; 99US-0170262P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-755112/71.

XX P-PSDB; ADA96910.

XX New PRO nucleic acid, useful for preparing a composition for treating

PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and

[illegible]

PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-755116/71.
DR P-PSDB; ADA79214.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 2; Fig 221; 659pp; English.
XX
XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129' BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TCTTATTTTTCATTTTCAGATTCTTCAGTTGGGTTTGT 1881
DB 1129 TTTTATTTTTCATTTTTCAGTTGGGTTTGTAT 1083
RESULT 76
ADA87352/c
ID ADA87352 standard; cDNA; 1129 BP.
XX
XX ADA87352;
XX
XX 20-NOV-2003 (first entry)
DI
XX
XX
XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003087345-A1.
XX
XX 08-MAY-2003.
XX
XX 16-APR-2002; 2002US-00129907.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUN-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0003028.
PR 10-MAR-1999; 99WO-US0005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAR-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US022089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.

PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US022031.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808689.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 10-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.
 PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-786937/74.
 DR P-PSDB; ADA87353.

XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.

XX Claim 2; Fig 221; 638pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells, for adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTTT 1861
 |||||
 Db 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTATT 1083
 |||||

RESULT 77

ADBI6554/c

ID ADBI6554 standard; cDNA; 1129 BP.

XX ADBI6554;

DT 20-NOV-2003 (first entry)

DE Human PRO polynucleotide #111.

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

OS Homo sapiens.

PN US2003087349-A1.

XX 08-MAY-2003.

EF 19-APR-2002; 2002US-00125928.

PR 19-JUN-1998; 98US-0089947P.

PR 02-JUN-1999; 99WO-US012252.

PR 25-AUG-1999; 99US-00380137.

PR 02-MAR-2000; 2000WO-US005841.

PR 01-DEC-2000; 2000WO-US032678.

PR 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 DR WPI; 2003-786940/74.

DR P-PSDB; ADBI6555.

XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
 PT and for manufacturing a medicament for diagnosing or treating tumor.

KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; hemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 PN US2003087351-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127822.
 XX
 PR 17-JUN-1998; 98US-0089532P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-NOV-1999; 99WO-US028313.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI: 2003-786942/74.
 DR P-PSDB; ADB14710.
 XX
 XX New PRO nucleic acid, useful for manufacturing a medicament for
 PT diagnosing or treating tumor.
 PT
 XX
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumor necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTTTAAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881
 Db 1129 TTTTAAATTTTTCATTTTCAGTTTCCTTCAGTTGGGTTTGT 1083
 RESULT 80
 ADB18670/c
 ID ADB18670 standard; cDNA; 1129 BP.
 XX
 AC ADB18670;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; Gene; ss;
 KW Tumor necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW Cell proliferation stimulator; cell differentiation stimulator;
 KW Cell differentiation inhibitor; cytokin.
 XX
 OS Homo sapiens.
 XX
 PN US2003073211-A1.
 XX
 PD 17-APR-2003.
 XX
 PF 15-APR-2002; 2002US-00123292.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 16-SEP-1998; 98WO-US019177.
 PR 17-SEP-1998; 98WO-US019330.
 PR 07-OCT-1998; 98WO-US019437.
 PR 29-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 20-NOV-1998; 98WO-US022992.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 05-OCT-1999; 99WO-US021547.
 PR 15-SEP-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028501.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 02-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030939.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.

PR	30-DEC-1999;	99WO-US031274
PR	05-JAN-2000;	2000WO-US000219
PR	06-JAN-2000;	2000WO-US000277
PR	06-JAN-2000;	2000WO-US000376
PR	11-FEB-2000;	2000WO-US000355
PR	18-FEB-2000;	2000WO-US004341
PR	18-FEB-2000;	2000WO-US004342
PR	22-FEB-2000;	2000WO-US004414
PR	24-FEB-2000;	2000WO-US004914
PR	24-FEB-2000;	2000WO-US005004
PR	01-MAR-2000;	2000WO-US005601
PR	02-MAR-2000;	2000WO-US005746
PR	02-MAR-2000;	2000WO-US005841
PR	10-MAR-2000;	2000WO-US006319
PR	15-MAR-2000;	2000WO-US006884
PR	20-MAR-2000;	2000WO-US007377
PR	21-MAR-2000;	2000WO-US007532
PR	30-MAR-2000;	2000WO-US008439
PR	17-MAY-2000;	2000WO-US011705
PR	22-MAY-2000;	2000WO-US011404
PR	30-MAY-2000;	2000WO-US014941
PR	28-JUN-2000;	2000WO-US015254
PR	28-JUN-2000;	2000WO-US020710
PR	11-AUG-2000;	2000WO-US022031
PR	23-AUG-2000;	2000WO-US023522
PR	24-AUG-2000;	2000WO-US023328
PR	08-NOV-2000;	2000WO-US023052
PR	10-NOV-2000;	2000WO-US030273
PR	01-DEC-2000;	2000WO-US032578
PR	20-DEC-2000;	2000US-US0747259
PR	20-DEC-2000;	2000WO-US034956
PR	28-FEB-2001;	2001US-US07964938
PR	28-FEB-2001;	2001WO-US006520
PR	01-MAR-2001;	2001WO-US006666
PR	09-MAR-2001;	2001US-US0802706
PR	14-MAR-2001;	2001US-US0806899
PR	22-MAR-2001;	2001US-US0816744
PR	05-APR-2001;	2001US-US0828368
PR	10-MAY-2001;	2001US-US0854208
PR	18-MAY-2001;	2001US-US0850216
PR	25-MAY-2001;	2001US-US0860238
PR	25-MAY-2001;	2001US-US0866034
PR	25-MAY-2001;	2001WO-US017092
PR	01-JUN-2001;	2001US-US0872035
PR	01-JUN-2001;	2001WO-US0217800
PR	05-JUN-2001;	2001US-US0874503
PR	14-JUN-2001;	2001US-US0826336
PR	19-JUN-2001;	2001US-US0886342
PR	20-JUN-2001;	2001WO-US019692
PR	21-JUN-2001;	2001US-US0887879
PR	22-JUN-2001;	2001WO-US020115
PR	29-JUN-2001;	2001WO-US021066
PR	09-JUL-2001;	2001WO-US008827
PR	06-AUG-2001;	2001US-US0924419
PR	09-AUG-2001;	2001US-US0927796
PR	16-AUG-2001;	2001US-US0931836
PR	19-DEC-2001;	2001US-US098072

[illegible]

XX	ACD98534	standard; cDNA; 1129 BP.
XX	ACD98534;	
XX	26-SEP-2003	(first entry)
XX	Novel human secreted and transmembrane protein PRO4327 cDNA.	
XX	Human; secreted and transmembrane protein; PRO; gene therapy;	
XX	chromosome identification; tissue typing; gene; ss.	
XX	Homo sapiens.	
XX	US2003044945-A1.	
XX	06-MAR-2003.	
XX	10-MAY-2002; 2002US-00142419.	
XX	31-MAR-1997;	97WO-US005230.
XX	12-JUN-1998;	98WO-US012456.
XX	14-JUL-1998;	98WO-US014552.
XX	28-AUG-1998;	98WO-US017898.
XX	10-SEP-1998;	98WO-US018824.
XX	14-SEP-1998;	98WO-US019093.
XX	14-SEP-1998;	98WO-US019094.
XX	14-SEP-1998;	98WO-US019177.
XX	16-SEP-1998;	98WO-US019330.
XX	17-SEP-1998;	98WO-US019437.
XX	07-OCT-1998;	98WO-US021141.
XX	29-OCT-1998;	98WO-US022991.
XX	29-OCT-1998;	98WO-US022992.
XX	20-NOV-1998;	98WO-US024855.
XX	01-DEC-1998;	98WO-US025108.
XX	05-JAN-1999;	99WO-US000106.
XX	08-MAR-1999;	99WO-US005028.
XX	10-MAR-1999;	99WO-US005190.
XX	20-APR-1999;	99WO-US008615.
XX	14-MAY-1999;	99WO-US010733.
XX	02-JUN-1999;	99WO-US012252.
XX	01-SEP-1999;	99WO-US020111.
XX	08-SEP-1999;	99WO-US020594.
XX	13-SEP-1999;	99WO-US020944.
XX	15-SEP-1999;	99WO-US021090.
XX	15-SEP-1999;	99WO-US021547.
XX	05-OCT-1999;	99WO-US023089.
XX	29-NOV-1999;	99WO-US028214.
XX	30-NOV-1999;	99WO-US028313.
XX	30-NOV-1999;	99WO-US028409.
XX	01-DEC-1999;	99WO-US028301.
XX	01-DEC-1999;	99WO-US028634.
XX	02-DEC-1999;	99WO-US028551.
XX	02-DEC-1999;	99WO-US028564.
XX	16-DEC-1999;	99WO-US028565.
XX	20-DEC-1999;	99WO-US0310095.
XX	20-DEC-1999;	99WO-US0310911.
XX	20-DEC-1999;	99WO-US030999.
XX	22-DEC-1999;	99WO-US030720.
XX	30-DEC-1999;	99WO-US031243.
XX	30-DEC-1999;	99WO-US031274.
XX	05-JAN-2000;	2000WO-US000219.
XX	06-JAN-2000;	2000WO-US000277.
XX	11-FEB-2000;	2000WO-US000376.
XX	18-FEB-2000;	2000WO-US003565.
XX	22-FEB-2000;	2000WO-US004341.
XX	22-FEB-2000;	2000WO-US004342.
XX	24-FEB-2000;	2000WO-US004414.
XX	24-FEB-2000;	2000WO-US004914.
XX	01-MAR-2000;	2000WO-US005004.
XX	02-MAR-2000;	2000WO-US005601.
XX		2000WO-US005746.

immune system cell infiltration.

Homo sapiens.

US2003082710-A1.

01-MAY-2003.

16-MAY-2002; 2002US-00147484.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI ; 2003-786913/74.

P-PSDB; ADB13094.

New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide, preparing a composition for treating e.g., tumor, or for tissue typing.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumors, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear uricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at segdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match
Best Local Similarity 1.1%; Score 21.4; DB 1; Length 1129;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

1835 TTCTAAATTTTTCATTCCAGATTCTCAGTTGGGTGTTTT 1881
|||||
1129 TTTTFTTTTTTTTTTTTTCAGCTGGCACACAGCGTGGGTTTATT 1083
|||||

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US034956.
PR 20-DEC-2000; 2000US-00747359.
PR 28-FEB-2001; 2001US-00756498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-492275/46.
DR P-PSDB; ABC43259.
XX New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 2; Fig 221; 660pp; English.
XX The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
XX Anti-PRO antibodies are useful in diagnostic assays for PRO, and in

CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This sequence encodes a novel human secreted and transmembrane
CC PRO polypeptide
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 134 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCACAGATTTTCCTTCAGTTGGGTTTGGTTT 1881
DB 1129 TTTTTCATTTTTCATTTTTCATTTTTCATTTTTCATTTTTCATTTT 1083
RESULT 85
ADA74347/C
ID ADA74347 standard; cDNA; 1129 BP.
XX
AC ADA74347;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
SN US2003068798-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140928.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.

30-NOV-1999; 99WO-US028409.
 01-DEC-1999; 99WO-US028301.
 01-DEC-1999; 99WO-US028634.
 02-DEC-1999; 99WO-US028551.
 02-DEC-1999; 99WO-US028564.
 02-DEC-1999; 99WO-US028565.
 16-DEC-1999; 99WO-US030095.
 20-DEC-1999; 99WO-US030911.
 20-DEC-1999; 99WO-US030999.
 22-DEC-1999; 99WO-US030720.
 30-DEC-1999; 99WO-US031243.
 30-DEC-1999; 99WO-US031274.
 05-JAN-2000; 2000WO-US000219.
 06-JAN-2000; 2000WO-US000277.
 06-JAN-2000; 2000WO-US000376.
 11-FEB-2000; 2000WO-US003765.
 18-FEB-2000; 2000WO-US004341.
 18-FEB-2000; 2000WO-US004342.
 22-FEB-2000; 2000WO-US004414.
 24-FEB-2000; 2000WO-US004914.
 24-FEB-2000; 2000WO-US005004.
 01-MAR-2000; 2000WO-US005501.
 02-MAR-2000; 2000WO-US005746.
 02-MAR-2000; 2000WO-US005841.
 10-MAR-2000; 2000WO-US006319.
 15-MAR-2000; 2000WO-US006884.
 20-MAR-2000; 2000WO-US007377.
 21-MAR-2000; 2000WO-US007532.
 30-MAR-2000; 2000WO-US008439.
 17-MAY-2000; 2000WO-US013705.
 22-MAY-2000; 2000WO-US014042.
 30-MAY-2000; 2000WO-US014941.
 02-JUN-2000; 2000WO-US015264.
 28-JUN-2000; 2000WO-US020710.
 11-AUG-2000; 2000WO-US022031.
 23-AUG-2000; 2000WO-US023522.
 24-AUG-2000; 2000WO-US023328.
 08-NOV-2000; 2000WO-US030952.
 10-NOV-2000; 2000WO-US030873.
 01-DEC-2000; 2000WO-US032678.
 20-DEC-2000; 2000US-00747259.
 20-DEC-2000; 2000WO-US034556.
 28-FEB-2001; 2001US-00796498.
 28-FEB-2001; 2001WO-US006520.
 01-MAR-2001; 2001WO-US006666.
 09-MAR-2001; 2001US-00802706.
 14-MAR-2001; 2001US-00808689.
 22-MAR-2001; 2001US-00816744.
 05-APR-2001; 2001US-00828366.
 10-MAY-2001; 2001US-00854208.
 10-MAY-2001; 2001US-00854280.
 18-MAY-2001; 2001US-00860316.
 25-MAY-2001; 2001US-00866028.
 25-MAY-2001; 2001US-00866034.
 25-MAY-2001; 2001WO-US017092.
 01-JUN-2001; 2001US-00872035.
 01-JUN-2001; 2001WO-US017800.
 05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US021066.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00908827.
 06-AUG-2001; 2001US-00924419.
 09-AUG-2001; 2001US-00927796.
 16-AUG-2001; 2001US-00931836.
 19-DEC-2001; 2001US-00028072.
 (GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-625490/59.
 P-PSDB; ADA74348.
 Novel secreted and transmembrane PRO polypeptides and polynucleotides encoding them, useful for treating bone disorders, arthritis, heart attack, injuries, tumors, and stimulating release of Tumor Necrosis Factor-alpha from human blood.
 Claim 2; Fig 221; 659pp; English.
 The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumor necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.
 Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
 Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1083
 RESULT 86
 ADB24580/c
 ID ADB24580 standard; cDNA; 1129 BP.
 XX
 AC ADB24580;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide SEQ ID NO 221.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA;

(GETH) GENENTECH INC.

KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.

XX Homo sapiens.
 XX US2003077713-A1.
 XX 24-APR-2003.
 XX 22-APR-2002; 2002US-00127839.
 XX 05-JUN-2000; 2000US-0209832P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755068/71.
 XX P-PSDB; ADB24581.

XX New isolated, secreted and transmembrane PRO polypeptides and nucleic
 XX acids, useful for the diagnosis, prevention and/or treatment of tumors,
 XX such as lung, colon, breast, prostate, rectal, cervical and/or liver
 XX tumors.
 XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a
 XX medicament for treating a condition responsive to the polypeptides or
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation
 XX of human microvascular endothelial cells, for modulating the uptake of
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
 XX stimulating differentiation of adipocyte cells, for stimulating
 XX proliferation of or gene expression in pericyte cells, for stimulating
 XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
 XX cells, for inducing endothelial cell tube formation and for treating
 XX various bone and/or cartilage disorders such as sports injuries and
 XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
 XX from cartilage are useful for treating sports-related joint problems,
 XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 XX polypeptides are also useful for treating various mammalian haemoglobin-
 XX associated disorders such as various thalassaemias and conditions which
 XX may benefit from enhanced local immune system cell infiltration. This
 XX sequence represents a human PRO polynucleotide of the invention. Note:
 XX The sequence data for this patent is also available in electronic format
 XX from USPTO at seqdata.uspto.gov/sequence.html.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 XX Best Local Similarity 66.0%; Pred. NO. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTTCTTAATTTTTCATTTCCAGATTTCTTTCAGTTTGGGTTTCTTT 1881
 DB 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1083

RESULT 87
 ADA82104/C
 ID ADA82104 standard; cDNA; 1129 BP.
 XX ADA82104;
 XX 20-NOV-2003 (first entry)
 XX Human PRO polynucleotide #111.
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 XX liver; microvascular endothelial cell; glioma; FFA;
 XX skeletal muscle cell; adipocyte cell; pericyte cell;
 XX inner ear utricular supporting cell; T-lymphocyte cell;
 XX endothelial cell tube formation; bone disorder; cartilage disorder;
 XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 XX immune system cell infiltration.

XX Homo sapiens.
 XX US2003082701-A1.
 XX 01-MAY-2003.
 XX 23-APR-2002; 2002US-00128686.
 XX 31-AUG-1998; 98US-0098525P.
 XX 16-SEP-1998; 98US-0100634P.
 XX 02-JUN-1999; 99WO-US012252.
 XX 25-AUG-1999; 99US-00380137.
 XX 30-MAR-2000; 2000WO-US008439.
 XX 02-JUN-2000; 2000WO-US015264.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755110/71.
 XX P-PSDB; ADA82105.

XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 XX tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful

05-JUN-2001; 2001US-00874503.
 14-JUN-2001; 2001US-00882636.
 19-JUN-2001; 2001US-00886342.
 20-JUN-2001; 2001WO-US019692.
 21-JUN-2001; 2001US-00887879.
 22-JUN-2001; 2001WO-US020116.
 29-JUN-2001; 2001WO-US020166.
 09-JUL-2001; 2001WO-US021735.
 18-JUL-2001; 2001US-00308827.
 06-AUG-2001; 2001US-00324419.
 09-AUG-2001; 2001US-00327796.
 16-AUG-2001; 2001US-00331836.
 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-765392/72.
 P-PSDB; ADA75068.

New secreted and transmembrane PRO polypeptides useful for stimulating
 the release of tumor necrosis factor alpha in human blood and detecting
 the presence of tumor in a mammal.

Claim 2; Fig 22i; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
 transmembrane polypeptides) and the polynucleotides encoding them. The
 invention also relates to an antibody which specifically binds to a PRO
 polypeptide, a method for stimulating the release of tumor necrosis
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 proliferation or differentiation of chondrocyte cells and a method for
 detecting the presence of a tumour in a mammal (e.g. adrenal lung,
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 polynucleotides are useful in molecular biology, including uses as
 hybridisation probes, in chromosome and gene mapping, in generating
 antisense RNA and DNA and in gene therapy. The polynucleotides may also
 be used in preparing PRO polypeptides by recombinant techniques and in
 generating either transgenic animals or knock-out animals which are
 useful in the development and screening of therapeutically useful
 reagents. The PRO polypeptides or antibodies are used in preparing a
 medicament for treating a condition responsive to the polypeptides or
 antibodies, such as tumours, for stimulating and inhibiting proliferation
 of human microvascular endothelial cells, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating differentiation of adipocyte cells, for stimulating
 proliferation of or gene expression in pericyte cells, for stimulating
 the proliferation of inner ear utricular supporting cells or for treating
 various bone and/or cartilage disorders such as sports injuries and
 arthritis. PRO polypeptides which stimulate the release of proteoglycans
 from cartilage are useful for treating sports-related joint problems,
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 polypeptides are also useful for treating various mammalian haemoglobin-
 associated disorders such as various thalassemias and conditions which
 may benefit from enhanced local immune system cell infiltration. This
 sequence represents a human PRO polynucleotide of the invention. Note:
 The sequence data for this patent is also available in electronic format
 from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1835 TTTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1881

1129 TTTTITTTTTTTTTTTTCTACCTGGCACACAGCTGGGTTTATT 1083

RESULT 89
 ADA85145/C
 ID ADA85145 standard; cDNA; 1129 BP.

XX AC ADA85145;

XX DT 20-NOV-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene: ss;

XX KW Tumor necrosis factor alpha release; TNF-alpha release;

XX KW glucose uptake modulator; FFA uptake modulator;

XX KW cell proliferation stimulator; cell differentiation stimulator;

XX KW cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW gene therapy; chromosome identification; chromosome marker.

XX OS Homo sapiens.

XX PN US2003082695-A1.

XX PD 01-MAY-2003.

XX PF 22-APR-2002; 2002US-00127846.

XX PR 03-MAR-2000; 2000US-0187202P.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH) GENENTECH INC.

PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-786909/74.

XX P-PSDB; ADA85146.

XX New nucleic acid encoding a PRO polypeptide, useful for preparing a
 composition for treating e.g. tumor by gene therapy, or for tissue
 typing.

XX Claim 2; Fig 22i; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and
 transmembrane) polypeptides (I). (I) is useful for stimulating the
 release of TNF-alpha from human blood, for modulating the uptake of
 glucose or FFA by skeletal muscle cells or adipocyte cells, for
 stimulating the proliferation or differentiation of chondrocyte cells,
 for stimulating the proliferation of or gene expression in pericyte
 cells, for stimulating the release of proteoglycans from cartilage, for
 stimulating the proliferation of inner ear utricular supporting cells,
 for stimulating the proliferation of r-lymphocyte cells, for stimulating
 the release of a cytokine from PBMC cells, for inhibiting the binding of
 A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 cells, for stimulating proliferation of endothelial cells, for detecting
 the presence of tumour in a mammal. The tumour is lung, colon, breast,
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 are useful for isolating genomic and cDNA nucleotide sequences or
 antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 in assays to identify other proteins or molecules involved in binding
 interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 and gene mapping, in generation of antisense RNA and DNA, in the
 preparation of PRO polypeptide, for generating transgenic animals or
 knockout animals which in turn are useful in the development and
 screening of therapeutically useful reagents, in gene therapy, for
 chromosome identification, as chromosome marker, and for generating
 probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 detecting its expression in specific cells, tissues or serum, and for

CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTTCACAGATTCTTCAGTTGGGTTTGT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
 RESULT 90
 ADA84593/c
 ID ADA84593 standard; cDNA; 1129 BP.
 AC ADA84593;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW Glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 XX US2003082708-A1.
 XX
 PD 01-MAY-2003.
 XX
 PP 15-MAY-2002; 2002US-00146729.
 XX
 PR 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WC-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI: 2003-786911/74.
 DR P-PSDB; ADA84594.
 XX
 PT New PRO nucleic acid, useful for preparing a composition for treating
 PT e.g. tumor or for tissue typing.
 XX
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention describes 105 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation or differentiation of pericyte
 CC cells, for stimulating the release of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from FMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTTCACAGATTCTTCAGTTGGGTTTGT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083
 RESULT 91
 ADB29849/c
 ID ADB29849 standard; cDNA; 1129 BP.
 XX
 AC ADB29849;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE cDNA encoding human PRO polypeptide #111.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003073214-A1.
 XX
 PD 17-APR-2003.
 XX
 PP 17-APR-2002; 2002US-00124822.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022931.
 PR 20-NOV-1998; 98WO-US022932.
 PR 01-DEC-1998; 98WO-US024855.
 PR 05-JAN-1999; 98WO-US000106.
 PR 08-MAR-1999; 98WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.

AC ADA80377; 20-NOV-2003 (first entry) Human PRO polynucleotide #11. Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassaemia; immune system cell infiltration. Homo sapiens. US2003082761-A1. 01-MAY-2003. 12-APR-2002; 2002US-00121061. 31-MAR-1997; 97WO-US005230. 12-JUN-1998; 98WO-US012456. 14-JUL-1998; 98WO-US014552. 28-AUG-1998; 98WO-US017888. 10-SEP-1998; 98WO-US018824. 14-SEP-1998; 98WO-US019093. 14-SEP-1998; 98WO-US019094. 14-SEP-1998; 98WO-US019177. 16-SEP-1998; 98WO-US019330. 17-SEP-1998; 98WO-US019437. 07-OCT-1998; 98WO-US021141. 29-OCT-1998; 98WO-US022391. 29-OCT-1998; 98WO-US022992. 20-NOV-1998; 98WO-US024855. 01-DEC-1998; 98WO-US025108. 05-JAN-1999; 99WO-US000106. 08-MAR-1999; 99WO-US005028. 10-MAR-1999; 99WO-US005190. 20-APR-1999; 99WO-US008615. 14-MAY-1999; 99WO-US010733. 02-JUN-1999; 99WO-US012252. 01-SEP-1999; 99WO-US020111. 08-SEP-1999; 99WO-US020594. 13-SEP-1999; 99WO-US020944. 15-SEP-1999; 99WO-US021090. 15-SEP-1999; 99WO-US021547. 05-OCT-1999; 99WO-US023089. 29-NOV-1999; 99WO-US028214. 30-NOV-1999; 99WO-US028313. 30-NOV-1999; 99WO-US028409. 01-DEC-1999; 99WO-US028301. 01-DEC-1999; 99WO-US028634. 02-DEC-1999; 99WO-US028551. 02-DEC-1999; 99WO-US028564. 02-DEC-1999; 99WO-US028565. 16-DEC-1999; 99WO-US030095. 20-DEC-1999; 99WO-US030311. 20-DEC-1999; 99WO-US030399. 22-DEC-1999; 99WO-US030720. 30-DEC-1999; 99WO-US031243. 30-DEC-1999; 99WO-US031274. 05-JAN-2000; 2000WO-US000219. 06-JAN-2000; 2000WO-US000277. 06-JAN-2000; 2000WO-US000376. 11-FEB-2000; 2000WO-US000356. 18-FEB-2000; 2000WO-US004341. 18-FEB-2000; 2000WO-US004342. 22-FEB-2000; 2000WO-US004414. 24-FEB-2000; 2000WO-US004914. 24-FEB-2000; 2000WO-US005004. 01-MAR-2000; 2000WO-US005601. 02-MAR-2000; 2000WO-US005746. 02-MAR-2000; 2000WO-US005841. 10-MAR-2000; 2000WO-US006319. 15-MAR-2000; 2000WO-US006884. 20-MAR-2000; 2000WO-US007377. 21-MAR-2000; 2000WO-US008439. 30-MAR-2000; 2000WO-US013705. 22-MAY-2000; 2000WO-US014042. 30-MAY-2000; 2000WO-US014941. 02-JUN-2000; 2000WO-US015264. 28-JUL-2000; 2000WO-US020710. 11-AUG-2000; 2000WO-US022031. 23-AUG-2000; 2000WO-US023522. 24-AUG-2000; 2000WO-US023328. 08-NOV-2000; 2000WO-US030952. 10-NOV-2000; 2000WO-US030873. 01-DEC-2000; 2000WO-US032678. 20-DEC-2000; 2000US-00747259. 28-DEC-2000; 2000WO-US034956. 28-FEB-2001; 2001US-00796498. 28-FEB-2001; 2001WO-US006520. 01-MAR-2001; 2001WO-US006666. 09-MAR-2001; 2001US-00803706. 14-MAR-2001; 2001US-00809689. 22-MAR-2001; 2001US-00816744. 05-APR-2001; 2001US-00828366. 10-MAY-2001; 2001US-00854280. 18-MAY-2001; 2001US-00860216. 25-MAY-2001; 2001US-00866028. 25-MAY-2001; 2001US-00866034. 25-MAY-2001; 2001WO-US017092. 01-JUN-2001; 2001US-00872035. 01-JUN-2001; 2001WO-US017800. 05-JUN-2001; 2001US-00874503. 14-JUN-2001; 2001US-00882636. 19-JUN-2001; 2001US-00886342. 20-JUN-2001; 2001WO-US019692. 21-JUN-2001; 2001US-00887879. 22-JUN-2001; 2001WO-US020116. 29-JUN-2001; 2001WO-US021066. 09-JUL-2001; 2001WO-US021735. 18-JUL-2001; 2001US-00908827. 06-AUG-2001; 2001US-00924419. 09-AUG-2001; 2001US-00927796. 16-AUG-2001; 2001US-00931836. 19-DEC-2001; 2001US-00028072. (GETH) GENENTECH INC. Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2003-755115/71. P-FSDB; ADA80378. New PRO polypeptides useful for treating diabetes, hyper- or hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart attack, various coagulation disorders and tumors. Claim 2; Fig 221; 638pp; English. The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for

KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003073210-A1.

XX 17-APR-2003.

XX 11-APR-2002; 2002US-00121045.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 28-AUG-1998; 98WO-US014552.

XX 14-JUL-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US0005028.

XX 10-MAR-1999; 99WO-US0005190.

XX 20-APR-1999; 99WO-US0008615.

XX 14-MAY-1999; 99WO-US010733.

XX 01-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020211.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 02-DEC-1999; 99WO-US028565.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.
XX 20-DEC-1999; 99WO-US030929.
XX 22-DEC-1999; 99WO-US030720.
XX 30-DEC-1999; 99WO-US031243.
XX 30-DEC-1999; 99WO-US031274.
XX 05-JAN-2000; 2000WO-US000219.
XX 06-JAN-2000; 2000WO-US000277.
XX 06-JAN-2000; 2000WO-US000376.
XX 11-FEB-2000; 2000WO-US000356.
XX 18-FEB-2000; 2000WO-US000341.
XX 18-FEB-2000; 2000WO-US000342.
XX 22-FEB-2000; 2000WO-US000414.
XX 24-FEB-2000; 2000WO-US0004914.
XX 24-FEB-2000; 2000WO-US0005004.
XX 01-MAR-2000; 2000WO-US005601.
XX 02-MAR-2000; 2000WO-US005746.
XX 02-MAR-2000; 2000WO-US005841.
XX 10-MAR-2000; 2000WO-US006319.
XX 15-MAR-2000; 2000WO-US006684.
XX 20-MAR-2000; 2000WO-US007377.
XX 21-MAR-2000; 2000WO-US007532.
XX 30-MAR-2000; 2000WO-US008439.
XX 17-MAY-2000; 2000WO-US013705.

PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00909827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski P, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-644800/61.
XX P-PSDB; ADA46845.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 01-DEC-1998; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US012252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 05-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028551.
PR 16-DEC-1999; 98WO-US030099.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 18-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007532.
PR 21-MAR-2000; 2000WO-US007539.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 28-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806899.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001US-00886342.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001US-00887879.
PR 29-JUN-2001; 2001US-00921066.
PR 09-JUL-2001; 2001US-00921735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786990/74.
XX P-PSDB; ADB30954.
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
XX hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
XX attack, various coagulation disorders, tumors.
XX Claim 2; Fig 221; 638pp; English.
XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumor necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating differentiation of adipocyte cells, for stimulating
XX proliferation of or gene expression in pericyte cells, for stimulating
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte
XX cells, for inducing endothelial cell tube formation and for treating
XX various bone and/or cartilage disorders such as sports injuries and
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans
XX from cartilage are useful for treating sports-related joint problems, PRO
XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
XX polypeptides are also useful for treating various mammalian haemoglobin-
XX associated disorders such as various thalassemias and conditions which
XX may benefit from enhanced local immune system cell infiltration. This
XX sequence encodes a human PRO polypeptide of the invention. Note: The
XX sequence data for this patent is also available in electronic format from

CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 359 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCACAGATTCTTCAGTTGGTTTCTTT 1881
DB 1129 TTTTITTTTTTTTTTTCAGTGGCACACAGCTGGTTTATT 1083
RESULT 99
ADA60881/c
ID ADA60881 standard; cDNA; 1129 BP.
XX
AC ADA60881;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO4327.
OS cDNA.
XX
PN US2003049817-A1.
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017886.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 02-JUN-1999; 99WO-US010733.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021050.
PR 15-SEP-1999; 99WO-US021547.
05-OCT-1999; 99WO-US023089.
29-NOV-1999; 99WO-US028214.
30-NOV-1999; 99WO-US028313.
30-NOV-1999; 99WO-US028409.
01-DEC-1999; 99WO-US028301.
01-DEC-1999; 99WO-US028634.
02-DEC-1999; 99WO-US028551.
02-DEC-1999; 99WO-US028564.
16-DEC-1999; 99WO-US030095.
20-DEC-1999; 99WO-US030911.
20-DEC-1999; 99WO-US030999.
22-DEC-1999; 99WO-US030720.
30-DEC-1999; 99WO-US031243.
30-DEC-1999; 99WO-US031274.
05-JAN-2000; 2000WO-US000219.
06-JAN-2000; 2000WO-US000277.
06-JAN-2000; 2000WO-US003376.
11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
21-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014842.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-0074259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
01-MAR-2001; 2001WO-US006520.
09-MAR-2001; 2001WO-US006666.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
18-MAY-2001; 2001US-00854280.
25-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
01-JUN-2001; 2001US-0087092.
01-JUN-2001; 2001US-00872035.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00885342.
20-JUN-2001; 2001WO-US015692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
03-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
10-MAR-2009; 2000WO-US006319.

XX (GETH) GENENTECH INC.

XX Baker KP, Bresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

XX WPI; 2003-695893/66.

XX P-PSDB; ADA60882.

XX DR

XX New secreted and transmembrane PRO polypeptide and nucleic acid, useful

XX PPT for manufacturing a medicament for diagnosing or treating tumor.

XX PPT

XX Claim 2; Fig 221; 658pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and

XX transmembrane) polypeptides (I). (I) is useful for stimulating the

XX release of TNF-alpha from human blood, for modulating the uptake of

XX glucose or PFA by skeletal muscle cells or adipocyte cells, for

XX stimulating the proliferation or differentiation of chondrocyte cells,

XX for stimulating the proliferation of or gene expression in pericyte

XX cells, for stimulating the release of proeoglycans from cartilage, for

XX stimulating the proliferation of inner ear utricular supporting cells,

XX for stimulating the proliferation of T-lymphocyte cells, for stimulating

XX the release of a cytokine from PMNC cells, for inhibiting the binding of

XX A-peptide to factor VIItA, for inhibiting the differentiation of adipocyte

XX cells, for stimulating proliferation of endothelial cells, for detecting

XX the presence of tumour in a mammal. The tumour is lung, colon, breast,

XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes

XX are useful for isolating genomic and cDNA nucleotide sequences or

XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

XX in assays to identify other proteins or molecules involved in binding

XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome

XX and gene mapping. In generation of antisense RNA and DNA, in the

XX preparation of PRO polypeptide, for generating transgenic animals or

XX knockout animals which in turn are useful in the development and

XX screening of therapeutically useful reagents, in gene therapy, for

XX chromosome identification, as chromosome marker, and for generating

XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

XX detecting its expression in specific cells, tissues or serum, and for

XX affinity purification of PRO from recombinant cell culture or natural

XX sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX a novel human secreted and transmembrane PRO polypeptide.

XX SQ

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTGTTT 1881

DB 1129 TTTTITTTTTTTTTTTTTTTCAGTCGGCACACAGGTCGGTTTATT 1083

RESULT 100

ADBE24028/c

ID ADBE24028 standard; cDNA; 1129 BP.

XX

XX ADB24028;

XX

XX 20-NOV-2003 (first entry)

XX

XX Human PRO polynucleotide SEQ ID NO 221.

XX

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal, lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; PFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proeoglycan; articular cartilage defect; osteoarthritis;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1881
 DB 1129 TTTTATTTTATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 101
 ADA96357/c
 ID ADA96357 standard; cDNA; 1129 BP.
 CC ADA96357;
 XX
 CC ADA96357;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Human PRO polynucleotide #111.
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003082690-A1.
 XX
 XX 01-MAY-2003.
 XX
 XX 22-APR-2002; 2002US-00127837.
 XX
 XX 01-SEP-1998; 98US-0098750P.
 XX
 XX 01-SEP-1999; 99WO-US020111.
 XX
 XX 18-OCT-1999; 99US-00403297.
 XX
 XX 18-FEB-2000; 2000WO-US004342.
 XX
 XX 08-NOV-2000; 2000WO-US030952.
 XX
 XX 01-DEC-2000; 2000WO-US032678.
 XX
 XX 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755107/71.
 XX
 XX P-PSDB; ADA96358.
 XX
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,
 XX tumor or for tissue typing.
 XX
 XX Claim 2; Fig 221; 637pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 XX polynucleotides are useful in molecular biology, including uses as
 XX hybridisation probes, in chromosome and gene mapping, in generating
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
 XX be used in preparing PRO polypeptides by recombinant techniques and in
 XX generating either transgenic animals or knock-out animals which are
 XX useful in the development and screening of therapeutically useful
 XX reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems.
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGTTTGT 1881
 DB 1129 TTTTATTTTATTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 102

ADA80929/c

ID ADA80929 standard; cDNA; 1129 BP.

XX ADA80929;

AC ADA80929;

DT 20-NOV-2003 (first entry)

DE Human PRO polynucleotide #111.

XX

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;

tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

liver; microvascular endothelial cell; glucose; FFA;

skeletal muscle cell; adipocyte cell; pericyte cell;

inner ear utricular supporting cell; T-lymphocyte cell;

endothelial cell tube formation; bone disorder; cartilage disorder;

sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

immune system cell infiltration.

XX

OS Homo sapiens.

XX

US2003082702-A1.

XX

01-MAY-2003.

XX

23-APR-2002; 2002US-00128690.

XX

02-MAR-2000; 2000WO-US005841.

XX

30-MAY-2000; 2000WO-US014941.

XX

01-DEC-2000; 2000WO-US032678.

XX

19-DEC-2001; 2001US-00028072.

XX

(GETH) GENENTECH INC.

XX

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755111/71.

XX

P-PSDB; ADA80930.

XX

1

PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005001.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 02-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US011705.
PR 22-MAY-2000; 2000WO-US011402.
PR 30-MAY-2000; 2000WO-US011941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US032679.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00865034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001WO-US0172035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021056.
PR 09-JUL-2001; 2001WO-US021725.
PR 18-JUL-2001; 2001US-00908627.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR (GETH) GENENTECH INC.
PR Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;
PR Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PR Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
PR WPI; 2003-777204/73.
PR P-PSDB; ADB26115.
PR New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PR in gene therapy, detecting the presence of tumor in a mammal, or
PR modulating the uptake of glucose or free fatty acid by skeletal muscle
PR cells or adipocyte cells.
PR Claim 2; Fig 221; 659pp; English.
PR The invention relates to isolated human PRO polypeptides (secreted and
PR transmembrane polypeptides), and the polynucleotides encoding them. The
PR invention also relates to an antibody which specifically binds to a PRO
PR polypeptide, a method for stimulating the release of tumor necrosis
PR factor-alpha (TNF-alpha) from human blood, a method for stimulating the
PR proliferation or differentiation of chondrocyte cells and a method for
PR detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
PR colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
PR polynucleotides are useful in molecular biology, including uses as
PR hybridisation probes, in chromosome and gene mapping, in generating
PR antisense RNA and DNA and in gene therapy. The polynucleotides may also
PR be used in preparing PRO polypeptides by recombinant techniques and in
PR generating either transgenic animals or knock-out animals which are
PR useful in the development and screening of therapeutically useful
PR reagents. The PRO polypeptides or antibodies are used in preparing a
PR medicament for treating a condition responsive to the polypeptides or
PR antibodies, such as tumours, for stimulating and inhibiting proliferation
PR of human microvascular endothelial cells, for modulating the uptake of
PR glucose or FFA by skeletal muscle cells or adipocyte cells, for
PR stimulating differentiation of adipocyte cells, for stimulating
PR the proliferation of or gene expression in pericyte cells, for stimulating
PR the proliferation of inner ear utricular supporting cells or T-lymphocyte
PR cells, for inducing endothelial cell tube formation and for treating
PR various bone and/or cartilage disorders such as sports injuries and
PR arthritis. PRO polypeptides which stimulate the release of proteoglycans
PR from cartilage are useful for treating sports-related joint problems, PRO
PR articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
PR polypeptides are also useful for treating various mammalian haemoglobin-
PR associated disorders such as various thalassaemias and conditions which
PR may benefit from enhanced local immune system cell infiltration. This
PR sequence encodes a human PRO polypeptide of the invention. Note: The
PR sequence data for this patent is also available in electronic format from
PR the USPTO website at seqdata.uspto.gov.
PR Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
PR
PR Query Match 1.1%; Score 21.4; DB 1; Length 1129;
PR Best Local Similarity 66.0%; Pred. No. 45;
PR Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
PR
PR QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTCAGTTGGGTTTGT 1881
PR |||||
PR DB 1129 TTTTITTTTITTTTTCAGCTGCACACAGGCTGGTTTATT 1083
PR
PR RESULT 105
PR ADB21599/c
PR ID ADB21599 standard; cDNA; 1129 BP.
PR XX
PR AC ADB21599;
PR XX
PR DT 20-NOV-2003 (first entry)
PR XX
PR DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; EPA uptake modulator;
KW Cell proliferation stimulator; cell differentiation stimulator;
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW Gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
XX US2003082765-A1.
XX
XX 01-MAY-2003.
XX
XX 17-MAY-2002; 2002US-00147492.
XX
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 23-OCT-1998; 98WO-US022991.
PR 23-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 05-OCT-1999; 99WO-US021547.
PR 23-NOV-1999; 99WO-US023089.
PR 30-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US003376.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747359.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908627.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-786920/74.
XX P-PSDB; ADB21600.
XX
XX New secreted and transmembrane PRO polypeptide useful for detecting the
XX presence of tumor in a mammal, or modulating the uptake of glucose or
XX free fatty acid by skeletal muscle cells or adipocyte cells.
XX
XX Claim 2; Fig 221; 638pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from BMC cells, for inhibiting the binding of
XX a-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,

CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCCTAATTTTCATTTCCAGATTTCTTCAGTTGGTGTGTTT 1881
DB 1129 TTTTITTTTTTTTTTTTCAGCTGCACACAGGCTGGTGTATT 1083

RESULT 106
ADA77378/c
ID ADA77378 standard; cDNA; 1129 BP.
XX
AC ADA77378;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068797-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140921.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808659.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
XX immune system cell infiltration.

OS Homo sapiens.

XX US2003059909-A1.

XX 27-MAR-2003.

XX 10-MAY-2002; 2002US-00143032.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028501.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 30-DEC-1999; 99WO-US031274.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 11-FEB-2000; 2000WO-US000376.

XX 18-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004341.

XX 22-FEB-2000; 2000WO-US004342.

XX 24-FEB-2000; 2000WO-US004414.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005746.

XX 10-MAR-2000; 2000WO-US006319.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX 30-MAY-2000; 2000WO-US014941.

XX 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US008520.
PR 01-MAR-2001; 2001WO-US008666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Pi Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Pi Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-540684/51.
P-PSDB; ADA76827.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 2; Fig 221; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TCTTAATTTTCATTTCCAGATTCTCTCAGTTTCAGTTGGTTTGT 1881
Db 1129 TTTTATTTTTCATTTTCAGTTTCAGTTTCAGTTGGTTTGT 1083

RESULT 114
ADA89456/c
ID ADA89456 standard; cDNA; 1129 BP.
XX
AC ADA89456;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
FN US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 20-APR-1999; 98WO-US008615.
PR 14-MAY-1999; 98WO-US010733.

PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 10-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US008520.
PR 01-MAR-2001; 2001US-00806666.
PR 09-MAR-2001; 2001WO-US0082706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00854280.
PR 25-MAY-2001; 2001US-00866029.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.

PR 09-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931936.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-743816/70.
 DR P-PSDB; ADA88457.
 XX
 PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
 PT in gene therapy, detecting the presence of tumor in a mammal, or
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle
 PT cells or adipocyte cells.
 XX
 PS Claim 2; Fig 221; 659pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from BMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumor. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1935 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881
 Db 1129 TTTTITTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
 RESULT 115
 ID ADA97461/c
 ID ADA97461 standard; cDNA; 1129 BP.
 AC ADA97461;
 XX
 XX 20-NOV-2003 (first entry)
 XX
 XX Human PRO polynucleotide #111.
 XX

KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS
 XX US2003082686-A1.
 PN
 XX 01-MAY-2003.
 PD
 XX 19-APR-2002; 2002US-00125926.
 PF
 XX 05-JUN-2000; 2000US-0209832P.
 PR
 XX 01-DEC-2000; 2000WO-US032678.
 PR
 XX 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-755106/71.
 DR P-PSDB; ADA97462.
 XX
 PT Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
 PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
 PT generating antisense RNA and DNA, and in gene therapy.
 XX
 XX Claim 2; Fig 221; 666pp; English.
 PS
 CC The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

```
Query Match      1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTCATTCACAGATTCCTTCAGTTGCGTTTCTTT 1881
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 116
ADB27218/c
ID ADB27218 standard; cDNA; 1129 BP.
AC ADB27218;
XX
DT 20-NOV-2003 (first entry)
XX
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; Proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; hemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003022239-A1.
XX
PD 30-JAN-2003.
XX
PF 12-APR-2002; 2002US-00121049.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 21-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 31-MAR-1998; 98US-0079728P.
PR 09-APR-1998; 98US-0080165P.
PR 14-APR-1998; 98US-0081229P.
PR 15-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 15-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-0088858P.
PR 17-JUN-1998; 98US-0089332P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 26-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-0091982P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
```


Db 1129 TTTTTCCTTTTTTTTTTTTACGCTGGCACAGCGCTGGTTTATT 1083

RESULT 117
ADB22151/c
ID ADB22151 standard; cDNA; 1129 BP.
XX AC ADB22151;
XX DT
XX XX
XX 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
XX KW tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
OS XX
PN US2003087344-A1.
XX PD
XX 08-MAY-2003.
PF 16-APR-2002; 2002US-00123905.
XX 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059580P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063732P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0068362P.
PR 24-NOV-1997; 97US-0068453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.

```
PR 09-FEB-1998; 98US-0074082P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 22-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98US-0089012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98US-00914552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094551P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 12-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98US-0097988P.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0098536P.
PR 09-SEP-1998; 98US-0098598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 09-FEB-1998; 98US-0099816P.
PR 10-SEP-1998; 98US-0099824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98US-0100303.
PR 14-SEP-1998; 98US-0100304.
PR 15-SEP-1998; 98US-0100304P.
PR 15-SEP-1998; 98US-0100304P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98US-0100634P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98US-0100858P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101474P.
PR 24-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 27-OCT-1998; 98US-0103315P.
PR 27-OCT-1998; 98US-0103328P.
PR 27-OCT-1998; 98US-0103328P.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98US-0106030P.
PR 30-OCT-1998; 98US-01062292.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98US-0109304P.
PR 01-DEC-1998; 98US-01094855.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 98US-0113621P.
PR 12-JAN-1999; 98US-0115549P.
PR 12-JAN-1999; 98US-0115557P.
PR 12-JAN-1999; 98US-0115560P.
PR 12-JAN-1999; 98US-0115562P.
PR 12-JAN-1999; 98US-0115564P.
PR 12-JAN-1999; 98US-0115630P.
PR 12-JAN-1999; 98US-0115705P.
PR 12-JAN-1999; 98US-0115733P.
PR 20-JAN-1999; 98US-0116533P.
PR 01-FEB-1999; 98US-0118210P.
PR 01-FEB-1999; 98US-0118210P.

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.8%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCTTTCAGTTTGGGTTTGGTTT 1881
Db 1129 TTTTTTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 118
ADA66842/c
ID ADA66842 standard; cdNA; 1129 Bp.
XX
```

AC ADA66842;
 XX 20-NOV-2003 (first entry)
 DT Human PRO polynucleotide #111.
 XX
 XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 FN US2003068793-A1.
 XX
 XX 10-APR-2003.
 PD
 XX 15-APR-2002; 2002US-00123108.
 XX
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022931.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 99WO-US000106.
 PR 08-MAR-1999; 99WO-US005028.
 PR 10-MAR-1999; 99WO-US005190.
 PR 20-APR-1999; 99WO-US008615.
 PR 14-MAY-1999; 99WO-US010733.
 PR 02-JUN-1999; 99WO-US012252.
 PR 01-SEP-1999; 99WO-US020111.
 PR 08-SEP-1999; 99WO-US020594.
 PR 13-SEP-1999; 99WO-US020944.
 PR 15-SEP-1999; 99WO-US021090.
 PR 15-SEP-1999; 99WO-US021547.
 PR 05-OCT-1999; 99WO-US023089.
 PR 29-NOV-1999; 99WO-US028214.
 PR 30-NOV-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028409.
 PR 01-DEC-1999; 99WO-US028301.
 PR 01-DEC-1999; 99WO-US028634.
 PR 02-DEC-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028564.
 PR 16-DEC-1999; 99WO-US028565.
 PR 16-DEC-1999; 99WO-US030095.
 PR 20-DEC-1999; 99WO-US030911.
 PR 20-DEC-1999; 99WO-US030999.
 PR 22-DEC-1999; 99WO-US030720.
 PR 30-DEC-1999; 99WO-US031243.
 PR 30-DEC-1999; 99WO-US031274.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000277.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004341.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 22-FEB-2000; 2000WO-US004414.

PR 24-FEB-2000; 2000WO-US004914.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 01-MAR-2000; 2000WO-US005601.
 PR 02-MAR-2000; 2000WO-US005746.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 10-MAR-2000; 2000WO-US006319.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 20-MAR-2000; 2000WO-US007377.
 PR 21-MAR-2000; 2000WO-US007532.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 28-JUL-2000; 2000WO-US020710.
 PR 11-AUG-2000; 2000WO-US020331.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 20-DEC-2000; 2000US-00747259.
 PR 20-DEC-2000; 2000WO-US034956.
 PR 28-FEB-2001; 2001US-00796498.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 09-MAR-2001; 2001US-00802706.
 PR 14-MAR-2001; 2001US-00808699.
 PR 22-MAR-2001; 2001US-00816744.
 PR 05-APR-2001; 2001US-00828366.
 PR 10-MAY-2001; 2001US-00854208.
 PR 18-MAY-2001; 2001US-00854280.
 PR 18-MAY-2001; 2001US-00860216.
 PR 25-MAY-2001; 2001US-00866028.
 PR 25-MAY-2001; 2001US-00866034.
 PR 25-MAY-2001; 2001WO-US017092.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 05-JUN-2001; 2001US-00874503.
 PR 14-JUN-2001; 2001US-00882636.
 PR 19-JUN-2001; 2001US-00886342.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 21-JUN-2001; 2001US-00887879.
 PR 22-JUN-2001; 2001WO-US020116.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 08-JUL-2001; 2001WO-US021735.
 PR 18-JUL-2001; 2001US-00908827.
 PR 06-AUG-2001; 2001US-00924419.
 PR 09-AUG-2001; 2001US-00927796.
 PR 16-AUG-2001; 2001US-00931836.
 PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-695925/66.

XX P-PSDB; ADA66843.

XX Novel secreted and transmembrane PRO polypeptides useful for stimulating
 XX release of tumor necrosis factor-alpha from human blood and detecting the
 XX presence of a tumor in a mammal.

XX Claim 2; Fig 22i; 660pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
 XX transmembrane polypeptides) and the polynucleotides encoding them. The
 XX invention also relates to an antibody which specifically binds to a PRO
 XX polypeptide, a method for stimulating the release of tumour necrosis
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 XX proliferation or differentiation of chondrocyte cells and a method for

PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
XX	(GETH) GENENTECH INC.
PA	
XX	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
XX	WPI; 2003-755066/71.
DR	
DR	P-PSDB; ADB22704.
XX	
PT	New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT	in gene therapy, as diagnostic markers for the presence of a disease
PT	condition, or as therapeutic targets for treating tumors, diabetes,
PT	obesity or arthritis.
PT	

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor- α (TNF- α) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful

reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumors, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at scsdata.uspto.gov/sequence.html.

RESULT 119

CC proliferation or of gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating

AC ADB22703;

20-NOV-2003 (first entry)

polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which

sequence represents a human ppo polynucleotide of the invention. Note:

The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html

CC FROM USPIO at seqdata.uspio.gov/sequence.html.
XX

Sequence 1129 BP: 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
84

Query Match	1.18;	Score 21.4;	DB 1;	Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

```
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
```

1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881
QY

D**b** 1129 TTTTNTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTTATT 1083

PERMIT 120

ADB23476/c
ID ADB23476 standard: CDNA: 1128 BP

XX
XC
XDB23476.
XX

AC
ADB23476;
XX

DT 20-NOV-2003 (first entry)

20 NOV 2003 (1118Z GULF)
XX

DE Human PRO polynucleotide SEQ ID NO 221.

The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. NO. 45; Indels 0; Gaps 0;
Matches 31; Conservative 0; Mismatches 16;

1835 TTCTTAATTTTTTCATTCCAGATTTCCCTTCAGTTCGTTGGTTGGTTT 1881
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGCGTGGGTITTTAAT 1083

RESULT 121
ADA92198/c
ID ADA92198 standard; cDNA; 1129 BP.
XX AC ADA92198;
XX DT 20-NOV-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; Gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX OS Homo sapiens.
XX PN US2003082712-A1.
XX PD 01-MAY-2003.
XX PF 16-MAY-2002; 2002US-00147512.
XX PR 15-MAY-1998; 98US-0085697P.
PR 08-MAR-1999; 99WO-US005028.
PR 25-AUG-1999; 99US-00380138.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX PG (GETH) GENENTECH INC.
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tomas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI: 2003-786915/74.
DR P-PADB; ADA92199.
XX PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX PS Claim 2; Fig 221; 637pp; English.
XX CC The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PMBC cells, for inhibiting the binding of
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; FFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

Homo sapiens.

US2003077712-A1.

24-APR-2003.

22-APR-2002; 2002US-00127835.

20-OCT-1998; 98US-01049887P.
01-SEP-1999; 99WO-US020111.
18-OCT-1999; 99US-00403297.
18-FEB-2000; 2000WO-US004342.
01-DEC-2000; 2000WO-US032676.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart IA, Tumas D, Watanabe CK, Wood WL, Zhang Z;

WPI; 2003-755067/71.
P-PSDB; ADB23477.

New isolated, secreted and transmembrane PRO nucleic acid, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note:

XX 01-MAY-2003.
PD 30-MAY-2002; 2002US-00158782.
XX 97WO-US005230.
PF 98WO-US012456.
XX 98WO-US014552.
XX 98WO-US017888.
XX 98WO-US018824.
XX 98WO-US019093.
XX 98WO-US019094.
XX 98WO-US019177.
XX 98WO-US019330.
XX 98WO-US019437.
XX 98WO-US021141.
XX 98WO-US022991.
XX 98WO-US022992.
XX 98WO-US024855.
XX 98WO-US025108.
XX 98WO-US025106.
XX 98WO-US025028.
XX 98WO-US025190.
XX 98WO-US025615.
XX 98WO-US010733.
XX 98WO-US012252.
XX 98WO-US020111.
XX 98WO-US020594.
XX 98WO-US020944.
XX 98WO-US021547.
XX 98WO-US021547.
XX 98WO-US023089.
XX 98WO-US028214.
XX 98WO-US028313.
XX 98WO-US028409.
XX 98WO-US028301.
XX 98WO-US028634.
XX 98WO-US028551.
XX 98WO-US028564.
XX 98WO-US028565.
XX 98WO-US030095.
XX 98WO-US030911.
XX 98WO-US030999.
XX 98WO-US030720.
XX 98WO-US031243.
XX 98WO-US031274.
XX 2000WO-US000219.
XX 2000WO-US000277.
XX 2000WO-US000376.
XX 2000WO-US003565.
XX 2000WO-US004341.
XX 2000WO-US004342.
XX 2000WO-US004414.
XX 2000WO-US004414.
XX 2000WO-US005004.
XX 2000WO-US005601.
XX 2000WO-US005746.
XX 2000WO-US005841.
XX 2000WO-US006319.
XX 2000WO-US006884.
XX 2000WO-US007377.
XX 2000WO-US007532.
XX 2000WO-US008439.
XX 2000WO-US013705.
XX 2000WO-US014042.
XX 2000WO-US014941.
XX 2000WO-US015264.
XX 2000WO-US020710.
XX 2000WO-US022031.
XX 2000WO-US023522.
XX 2000WO-US023328.
XX 2000WO-US030952.
XX 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006566.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00806889.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866028.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017892.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882536.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
08-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-785921/74.
P-PSDB; ADB38514.
New secreted and transmembrane PRO polypeptides and nucleic acids, useful
in gene therapy, detecting the presence of tumor in a mammal, or
modulating the uptake of glucose or free fatty acid by skeletal muscle
cells or adipocyte cells.
Claim 2; Fig 221; 660pp; English.
The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PMBC cells, for inhibiting the binding of
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
 RESULT 124
 ADB37961/C
 ID ADB37961 standard; cDNA; 1129 BP.
 XX
 AC ADB37961;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 FN US2003087347-A1.
 XX
 PD 08-MAY-2003.
 XX
 PF 19-APR-2002; 2002US-00125921.
 XX
 PR 17-AUG-1998; 98US-0096791P.
 PR 02-JUN-1999; 99WO-US012252.
 PR 25-AUG-1999; 99US-00380137.
 PR 30-MAR-2000; 2000WO-US008439.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tunas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 DR WPI; 2003-786938/74.
 DR P-PSDB; ADB37962.
 XX
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
 PT and for manufacturing a medicament for diagnosing or treating tumor.
 PT
 PS Claim 2; Fig 221; 637pp; English.
 XX
 CC The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of or proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC and gene mapping. A polynucleotide (II) encoding (I) is useful in chromosome
 CC interaction. A polynucleotide (II) encoding (I) is useful in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
 RESULT 125
 ADB6433/C
 ID ADB6433 standard; cDNA; 1129 BP.
 XX
 AC ADB6433;
 XX
 DT 04-DEC-2003 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 OS Homo sapiens.
 XX
 FN US2003082689-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 22-APR-2002; 2002US-00127831.
 XX
 PR 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.
 PR 17-SEP-1998; 98WO-US019437.
 PR 07-OCT-1998; 98WO-US021141.
 PR 29-OCT-1998; 98WO-US022991.
 PR 29-OCT-1998; 98WO-US022992.
 PR 20-NOV-1998; 98WO-US024855.
 PR 01-DEC-1998; 98WO-US025108.
 PR 05-JAN-1999; 98WO-US000106.


```
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US0112252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 10-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 24-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00803706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00818744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00865028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00308827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-786905/74.
XX P-PSDB; ADB66434.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g. tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PMBC cells, for inhibiting the binding of
XX alpha-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (i) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (ii) encoding (i) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(i)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (i) and (ii) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred.No.45;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX
XX QY 1835 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTTCGGTTTCTTT 1881
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX DB 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083
XX ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
XX RESULT 126
XX ADB89513/C
XX ID ADB89513 standard; cDNA; 1129 BP.
XX
XX AC ADB89513;
XX
XX DT 04-DEC-2003 (first entry)
XX
```


KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.

PN US2003082764-A1.
XX
PD 01-MAY-2003.
XX
PF 03-MAY-2002; 2002US-00137868.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017898.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 16-SEP-1998; 98WO-US019177.
PR 17-SEP-1998; 98WO-US019330.
PR 07-OCT-1998; 98WO-US019437.
PR 29-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US020111.
PR 01-SEP-1999; 99WO-US020594.
PR 08-SEP-1999; 99WO-US020944.
PR 13-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 22-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021056.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786919/74.
DR P-PSDB; ADE39347.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 2; Fig 221; 659pp; English.

XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage,
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from BMC cells, for inhibiting the binding of
a-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
and gene mapping. In generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.

XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTTGCGTTTGGTTT 1881
||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 1129 TTTTTTTTTTTTTTTTTCAGTCGACACAGGCTGGGTTTTATT 1083

RESULT 129
ADB46969/c
ID : ADB46969 standard; cDNA; 1129 BP.
XX AC ADB46969;
DT 04-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PR04327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; gene; ss;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW Glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX Homo sapiens.
QS US2003082687-A1.
XN 01-MAY-2003.
PD 19-APR-2002; 2002US-00125930.
PF 05-JUN-2000; 2000US-0209832P.
PR 18-DEC-2000; 2000MC-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen NE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-786904/74.
DR P-PSDB; ADB46970.
DR
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX Claim 2; Fig 221; 627pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for

```

simulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PMC cells, for inhibiting the binding of
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
croses. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

Qy 1835 TCTCTAAATTTTTTCATTTCCAGATTCCTTCAGTTTCGGTTTGTGTTT 1881
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTITTTTTTTTTTTTTTTCAGCTGGCACAGCGCTGGTTTATT 1083

RESULT 130
ADB86576/c
ID ADB86576 standard; cDNA; 1129 BP.
XX
XX ADB86576;
XX
XX 04-DEC-2003 (first entry)
XX
XX Human PRO polynucleotide #111.
XX
XX Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.
XX
XX Homo sapiens.
XX
XX US2003082697-A1.
XX
XX 01-MAY-2003.
XX
XX 22-APR-2002; 2002US-00127849.
XX
XX 20-OCT-1998; 98US-0104987P.
XX
XX 01-SEP-1999; 99WO-US020111.
XX
XX 18-OCT-1999; 99US-00403237.
XX
XX 18-FEB-2000; 2000WO-US004342.
XX
XX 01-DEC-2000; 2000WO-US032678.
XX
XX 19-DEC-2001; 2001US-00028072.
XX
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

```


XX ADB34890;
AC XX
DT 04-DEC-2003 (first entry)
XX XX
DE Human PRO polynucleotide SEQ ID NO 221.
XX XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX XX
OS Homo sapiens.
XX XX
PN US200307718-A1.
XX XX
PD 24-APR-2003.
XX XX
PF 24-APR-2002; 2002US-00131823.
XX XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US019824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 28-OCT-1998; 98WO-US022991.
PR 28-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006894.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00829366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-755073/71.
P-PSDB; ADB34891.

New isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis

KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
XX Homo sapiens.
OS

XX US2003082692-A1.
XX 01-MAY-2003.
XX

XX 22-APR-2002; 2002US-00127842.
XX

XX 03-MAR-2000; 2000US-0187202P.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX

XX (GETH) GENENTECH INC.
XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

XX WPI; 2003-786906/74.
XX P-PSDB; ADB46390.
XX

XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g., tumor or for tissue typing.
XX

XX Claim 2; Fig 221; 637pp; English.
XX

XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage for
XX stimulating the proliferation of inner ear uricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Watch 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTCCTTCAGTTGGGTTTGT 1881
DB 1129 TTTTITTTTTTTTTTTTCAGTGGCACACAGGCTGGTGT 1083

RESULT 138

ADCS0262/c

ID ADCS0262 standard; cDNA; 1129 BP.

XX ADCS0262;

XX 18-DEC-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
XX rectum; kidney; cervix; liver; microvascular endothelial cell;
XX glucose uptake modulator; FFA uptake modulator; cell proliferation;
XX cell differentiation; skeletal muscle cell; adipocyte cell;
XX pericyte cell; inner ear uricular supporting cell; T-lymphocyte cell;
XX endothelial cell tube formation; bone disorder; cartilage disorder;
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
XX immune system cell infiltration; chromosome mapping; gene mapping;
XX gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.

XX US2003092106-A1.

XX 15-MAY-2003.

XX 24-APR-2002; 2002US-00131822.

XX 19-AUG-1998; 98US-0097141P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99US-00380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

XX WPI; 2003-801171/75.

XX P-PSDB; ADCS0263.

XX New secreted and transmembrane nucleic acid useful for treating
XX inflammation, organ failure, atherosclerosis, cardiac injury,
XX infertility, birth defects, premature aging, acquired immunodeficiency
XX syndrome or cancer.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
XX transmembrane polypeptides) and the polynucleotides encoding them. The
XX invention also relates to an antibody which specifically binds to a PRO
XX polypeptide, a method for stimulating the release of tumour necrosis
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX proliferation or differentiation of chondrocyte cells and a method for
XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX polynucleotides are useful in molecular biology, including uses as
XX hybridisation probes, in chromosome and gene mapping, in generating
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also
XX be used in preparing PRO polypeptides by recombinant techniques and in
XX generating either transgenic animals or knock-out animals which are
XX useful in the development and screening of therapeutically useful
XX reagents. The PRO polypeptides or antibodies are used in preparing a
XX medicament for treating a condition responsive to the polypeptides or
XX antibodies, such as tumours, for stimulating and inhibiting proliferation
XX of human microvascular endothelial cells, for modulating the uptake of

OS	Homo sapiens.	
XX	US2003092107-A1.	
XX		
XX	15-MAY-2003.	
XX		
XX	24-APR-2002; 2002US-00131828.	
XX		
XX	07-OCT-1998; 98US-0103311P.	
PR	01-SEP-1999; 99WO-US020111.	
PR	18-OCT-1999; 99US-00403297.	
PR	18-FEB-2000; 2000WO-US004342.	
PR	10-NOV-2000; 2000WO-US030873.	
PR	01-DEC-2000; 2000WO-US032678.	
PR	19-DEC-2001; 2001US-00028072.	
XX		
XX	(GETH) GENENTECH INC.	
PA		
XX	Baker KP, Bersini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,	
XX	Garritsen MB, Goddard A, Godowski PJ, Gurney AL, Sherwood S,	
PI	Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;	
PI		
XX		

XX	Human; secreted and transmembrane protein; PRO; secreted polypeptide;
XX	transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW	chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW	rectum; kidney; cervix; liver; microvascular endothelial cell;
KW	glucose uptake modulator; rPA uptake modulator; cell proliferation;
KW	cell differentiation; skeletal muscle cell; adipocyte cell;
KW	pericyte cell; inner ear; utricular supporting cell; T-lymphocyte cell;
KW	endothelial cell tube formation; bone disorder; cartilage disorder;
KW	osteoclast; osteoclast; osteoclast; osteoclast; osteoclast; osteoclast;

KW	rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW	immune system cell infiltration; chromosome mapping; gene mapping;
KW	gene therapy; chromosome identification; chromosome marker; gene; ss.
XX	
XX	Homo sapiens.
OS	
PN	US2003092105-A1.
XX	
PD	15-MAY-2003.
XX	
XX	24-APR-2002; 2002US-00131821.
PF	
XX	09-DEC-1999; 99US-0170262P.
PR	01-DEC-2000; 2000WO-US032678.
PR	19-DEC-2001; 2001US-00028072.
XX	
PA	(GETH) GENENTECH INC.
XX	
PI	Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX	
WPI	2003-801170/75.
DR	P-PSDB; ADCS9789.
DR	
XX	
PT	New secreted and transmembrane nucleic acids and polypeptides, designed as
PT	PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT	cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT	cancer.
XX	
XX	Claim 2; Fig 221; 637pp; English.
XX	
CC	The invention relates to isolated human PRO polypeptides (secreted and
CC	transmembrane polypeptides) and the polynucleotides encoding them. The
CC	invention also relates to an antibody which specifically binds to a PRO
CC	polypeptide, a method for stimulating the release of tumour necrosis
CC	factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC	proliferation or differentiation of chondrocyte cells and a method for
CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC	polynucleotides are useful in molecular biology, including uses as
CC	hybridisation probes, in chromosome and gene mapping, in generating
CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC	be used in preparing PRO polypeptides by recombinant techniques and in
CC	generating either transgenic animals or knock-out animals which are
CC	useful in the development and screening of therapeutically useful
CC	reagents. The PRO polypeptides or antibodies are used in preparing a
CC	medicament for treating a condition responsive to the polypeptides or
CC	antibodies, such as tumours, for stimulating and inhibiting proliferation
CC	of human microvascular endothelial cells, for modulating the uptake of
CC	glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC	cells, for stimulating differentiation of adipocyte cells, for
CC	stimulating proliferation of or gene expression in pericyte cells, for
CC	stimulating the proliferation of inner ear utricular supporting cells or
CC	T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC	treating various bone and/or cartilage disorders such as sports injuries
CC	and arthritis. PRO polypeptides which stimulate the release of
CC	proteoglycans from cartilage are useful for treating sports-related joint
CC	problems, articular cartilage defects, osteoarthritis and rheumatoid
CC	arthritis. PRO polypeptides are also useful for treating various
CC	mammalian haemoglobin-associated disorders such as various thalassaemias
CC	and conditions which may benefit from enhanced local immune system cell
CC	infiltration. This sequence represents a human PRO polynucleotide of the
CC	invention. Note: The sequence data for this patent is also available in
CC	electronic format from USPTO at seqdata.uspto.gov/sequence.html .
XX	
XX	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX	
Query Watch	1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity	66.0%; Pred. No. 45;
Matches	31; Conservative 0; Mismatches 16; Indels 0; Gaps 0
QY	1835 TTCTTAATTTTTCATTTCCAGATTTCTCTCAGTTTCGGTTTGTGTT 1881

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881

Db 1129 TTTTTCCTTTTTCAGCTGGCACACAGGCTGGGTTTTATT 1083

RESULT 141

ADC52795/c

ID ADC52795 standard; cDNA; 1129 BP.

XX AC ADC52795;

XX DT 18-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221

XX KW human; PRO; membrane bound protein; membrane bound receptor;

KW cell proliferation; cell migration; cell differentiation;

KW mitogenic factor; survival factor; cytotoxic factor;

KW differentiation factor; neuropeptide; hormone; cell receptor;

KW receptor-ligand interaction; cytostatic; chondrocyte; tumour;

XX OS Homo sapiens.

XX FN US2003087365-A1.

XX PD 08-MAY-2003.

XX PF 23-APR-2002; 2002US-00128689.

XX PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.

PR 14-JUL-1998; 98WO-US014552.

PR 28-AUG-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 10-MAR-1999; 2000WO-US006319.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020111.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023069.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 02-DEC-1999; 99WO-US028565.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.

PR 30-DEC-1999; 99WO-US031243.

PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.

PR 06-JAN-2000; 2000WO-US000377.

PR 06-JAN-2000; 2000WO-US000376.

11-FEB-2000; 2000WO-US003565.
18-FEB-2000; 2000WO-US004341.
18-FEB-2000; 2000WO-US004342.
22-FEB-2000; 2000WO-US004414.
24-FEB-2000; 2000WO-US004914.
24-FEB-2000; 2000WO-US005004.
01-MAR-2000; 2000WO-US005601.
02-MAR-2000; 2000WO-US005746.
02-MAR-2000; 2000WO-US005941.
15-MAR-2000; 2000WO-US006884.
20-MAR-2000; 2000WO-US007377.
31-MAR-2000; 2000WO-US007532.
30-MAR-2000; 2000WO-US008439.
17-MAY-2000; 2000WO-US013705.
22-MAY-2000; 2000WO-US014042.
30-MAY-2000; 2000WO-US014941.
02-JUN-2000; 2000WO-US015264.
28-JUL-2000; 2000WO-US020710.
11-AUG-2000; 2000WO-US022031.
23-AUG-2000; 2000WO-US023522.
24-AUG-2000; 2000WO-US023328.
08-NOV-2000; 2000WO-US030952.
10-NOV-2000; 2000WO-US030873.
01-DEC-2000; 2000WO-US032678.
20-DEC-2000; 2000US-00747259.
20-DEC-2000; 2000WO-US034956.
28-FEB-2001; 2001US-00796498.
28-FEB-2001; 2001WO-US006520.
01-MAR-2001; 2001WO-US006866.
09-MAR-2001; 2001US-00802706.
14-MAR-2001; 2001US-00808689.
22-MAR-2001; 2001US-00816744.
05-APR-2001; 2001US-00828366.
10-MAY-2001; 2001US-00854208.
10-MAY-2001; 2001US-00854280.
18-MAY-2001; 2001US-00860216.
25-MAY-2001; 2001US-00866034.
25-MAY-2001; 2001WO-US017092.
01-JUN-2001; 2001US-00872035.
01-JUN-2001; 2001WO-US017800.
05-JUN-2001; 2001US-00874503.
14-JUN-2001; 2001US-00882636.
19-JUN-2001; 2001US-00886342.
20-JUN-2001; 2001WO-US019692.
21-JUN-2001; 2001US-00887879.
22-JUN-2001; 2001WO-US020116.
29-JUN-2001; 2001WO-US021066.
09-JUL-2001; 2001WO-US021735.
18-JUL-2001; 2001US-00908827.
06-AUG-2001; 2001US-00924419.
09-AUG-2001; 2001US-00927796.
16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801150/75.
P-PSDB; ADC52796.
New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
Claim 2; SEQ ID NO 221; 637pp; English.
This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,
migration or differentiation) is typically governed by information
received from other cells and the immediate environment. The information
is often transmitted by secreted polypeptides (for example mitogenic
factors, survival factors, cytotoxic factors, differentiation factors,
neuropeptides or hormones) which are received and interpreted by diverse
cell receptors or membrane bound proteins. These membrane bound proteins
and receptors may be of use as pharmaceutical and diagnostic agents, such
as in the blocking of receptor-ligand interactions. The current invention
provides the amino acid sequences of novel human membrane bound receptors
and proteins, along with the cDNA sequences encoding them. The novel
proteins of the invention may have cytostatic activities through the
stimulation of chondrocytes. The nucleic acids of the invention may be
useful for the manufacture of a medicament for diagnosing or treating a
tumour in a mammal. In addition, they may be useful for measuring or
detecting the expression of a tumour associated gene. The present
sequence is a cDNA sequence which encodes a human PRO protein of the
invention.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TCTTAATTTTTCATTCACAGATTCTTCAGTTGGGTTTCTTT 1881
Db 1129 TTTTTCATTTTTCATTCACAGATTCTTCAGTTGGGTTTCTTT 1083
RESULT 142
ADC57149/C
ID ADC57149 standard; cDNA; 1129 BP.
XX
AC ADC57149;
DT 18-DEC-2003 (first entry)
XX Novel human secreted and transmembrane protein cDNA Seq ID221.
XX human; PRO; membrane bound protein; membrane bound receptor;
cell proliferation; cell migration; cell differentiation;
mitogenic factor; survival factor; cytotoxic factor;
differentiation factor; neuropeptide; hormone; cell receptor;
receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
OS Homo sapiens.
XX
XX US2003087366-A1.
PD 08-MAY-2003.
XX 23-APR-2002; 2002US-00128694.
XX 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
XX (GETH) GENENTECH INC.
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-801151/75.
DR P-PSDB; ADC57150.
DR
XX New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor.
PT
PS Claim 2; SEQ ID NO 221; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
and transmembrane proteins. Extracellular proteins play important roles
in the formation, differentiation and maintenance of multicellular
organisms. The fate of many individual cells (for example proliferation,

CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is a cDNA sequence which encodes a human PRO protein of the
CC invention.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTTCTAAATTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881
1129 TTTTITTTTTTTTTTTTTCAGTGCACACAGGCTGGGTTTATT 1083

RESULT 143
ADC60340/c
ID ADC60340 standard; cDNA; 1129 BP.
XX AC ADC60340;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;
KW immune system cell infiltration; chromosome mapping; gene mapping; ss.
XX gene therapy; chromosome identification; chromosome marker; gene; ss.
XX OS Homo sapiens.

XX US2003087367-A1.
XX PD 08-MAY-2003.
XX XX 24-APR-2002; 2002US-00131825.
XX 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028501.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-0080689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.


```
XX PD 08-MAY-2003.
XX OS
XX PN 22-APR-2002; 2002US-00127834.
XX PR 17-SEP-1998; 98US-0100710P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-801144/75.
XX DR P-PSDB; ADCS8925.
XX PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX PT and for manufacturing a medicament for diagnosing or treating tumor.
XX PS Claim 2; SEQ ID NO 221; 637pp; English.
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX CC and transmembrane proteins. Extracellular proteins play important roles
XX CC in the formation, differentiation and maintenance of multicellular
XX CC organisms. The fate of many individual cells (for example proliferation,
XX CC migration or differentiation) is typically governed by information
XX CC received from other cells and the immediate environment. The information
XX CC is often transmitted by secreted polypeptides (for example mitogenic
XX CC factors, survival factors, cytotoxic factors, differentiation factors,
XX CC neurotrophic factors or hormones) which are received and interpreted by diverse
XX CC cell receptors or membrane bound proteins. These membrane bound proteins
XX CC and receptors may be of use as pharmaceutical and diagnostic agents, such
XX CC as in the blocking of receptor-ligand interactions. The current invention
XX CC provides the amino acid sequences of novel human membrane bound receptors
XX CC and proteins, along with the cDNA sequences encoding them. The novel
XX CC proteins of the invention may have cytostatic activities through the
XX CC stimulation of chondrocytes. The nucleic acids of the invention may be
XX CC useful for the manufacture of a medicament for diagnosing or treating a
XX CC tumour in a mammal. In addition, they may be useful for measuring or
XX CC detecting the expression of a tumour associated gene. The present
XX CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX CC invention.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
RESULT 149
ADC55802/c
ID ADC55802 standard; cDNA; 1129 BP.
XX AC ADC55802;
XX DT 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.
XX KW human; PRO; membrane bound protein; membrane bound receptor;
XX KW cell proliferation; cell migration; cell differentiation;
XX KW mitogenic factor; survival factor; cytotoxic factor;
XX KW differentiation factor; neurotrophic; hormone; cell receptor;
```

```
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX OS Homo sapiens.
XX PN US2003087360-A1.
XX PD 08-MAY-2003.
XX PF 22-APR-2002; 2002US-00127836.
XX PR 17-NOV-1998; 98US-0108802P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 18-OCT-1999; 99US-00403297.
XX PR 02-FEB-2000; 2000WO-US004342.
XX PR 02-JUN-2000; 2000WO-US015264.
XX PR 23-AUG-2000; 2000WO-US023522.
XX PR 01-DEC-2000; 2000WO-US032678.
XX PR 19-DEC-2001; 2001US-00028072.
XX PA (GETH ) GENENTECH INC.
XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX DR WPI; 2003-801145/75.
XX DR P-PSDB; ADC55803.
XX PT New PRO nucleic acid, useful for manufacturing a medicament for
XX PT diagnosing or treating tumor.
XX PS Claim 2; SEQ ID NO 221; 637pp; English.
XX CC This invention relates to novel nucleic acids encoding human PRO secreted
XX CC and transmembrane proteins. Extracellular proteins play important roles
XX CC in the formation, differentiation and maintenance of multicellular
XX CC organisms. The fate of many individual cells (for example proliferation,
XX CC migration or differentiation) is typically governed by information
XX CC received from other cells and the immediate environment. The information
XX CC is often transmitted by secreted polypeptides (for example mitogenic
XX CC factors, survival factors, cytotoxic factors, differentiation factors,
XX CC neurotrophic factors or hormones) which are received and interpreted by diverse
XX CC cell receptors or membrane bound proteins. These membrane bound proteins
XX CC and receptors may be of use as pharmaceutical and diagnostic agents, such
XX CC as in the blocking of receptor-ligand interactions. The current invention
XX CC provides the amino acid sequences of novel human membrane bound receptors
XX CC and proteins, along with the cDNA sequences encoding them. The novel
XX CC proteins of the invention may have cytostatic activities through the
XX CC stimulation of chondrocytes. The nucleic acids of the invention may be
XX CC useful for the manufacture of a medicament for diagnosing or treating a
XX CC tumour in a mammal. In addition, they may be useful for measuring or
XX CC detecting the expression of a tumour associated gene. The present
XX CC sequence is a cDNA sequence which encodes a human PRO protein of the
XX CC invention.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881
Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
RESULT 150
ADC558372/c
ID ADC558372 standard; cDNA; 1129 BP.
XX AC ADC558372;
XX DT 18-DEC-2003 (first entry)
```


10664775-3.rng

Mon Aug 9 17:47:19 2004

CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells and for treating
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polynucleotide of the invention. Note:
CC The sequence data for this patent is also available in electronic format
CC from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1881
DB 1129 TTTTTCATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1083

RESULT 156
ID ADD04450/c
XX ID ADD04450 standard; cDNA; 1129 BP.
XX ADD04450;
XX 01-JAN-2004 (first entry)
XX Novel human secreted and transmembrane protein PRO4327 cDNA.
XX Human; secreted and transmembrane protein; PRO: secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker; gene; ss.
XX Homo sapiens.
OS
XX US2003087354-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127827.
PF

XX 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-00012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX (GENTH) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801139/75.
DR P-PSDB; ADD04451.
XX New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX Claim 2; Fig 221; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polynucleotide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1881
DB 1129 TTTTTCATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1083
RESULT 157
ID ADC80406/c
XX ID ADC80406 standard; cDNA; 1129 BP.
XX ADC80406;
AC

XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTCATTCCAGATTTCCTTCAGTTCGGTGTTTTTT 1881
DB 1129 TTTTITTTTTTTTTTTTTCAGTCGCACACAGCGCTTTTATT 1083

RESULT 161
ADD09323/c
ID ADD09323 standard; cDNA; 1129 BP.
AC ADD09323;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
immune system cell infiltration.

XX
OS Homo sapiens.
XX
PN US2003194775-A1.
XX
PD 16-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156848.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PP (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Gołowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart FA, Tomas D, Watanabe CK, Wood WI, Zhang Z;
XX
PP WI; 2003-852595/79.
DR P-PSDB; ADD09324.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
for detecting a tumor, stimulating the release of tumor necrosis factor
alpha from blood and stimulating the release of proteoglycans from
cartilage.

XX
PP Claim 2; Fig 221; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in

10-MAY-2002; 2002US-00142896.
05-JUN-2000; 2000US-0209832P.
01-DEC-2000; 2000WO-US032678.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI: 2003-875639/81.
P-PSDB; AD54039.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 2; SEQ ID NO 221; 637pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and
transmembrane) polypeptides (I). (I) is useful for stimulating the
release of TNF-alpha from human blood, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating the proliferation or differentiation of chondrocyte cells,
for stimulating the proliferation of or gene expression in pericyte
cells, for stimulating the release of proteoglycans from cartilage, for
stimulating the proliferation of inner ear utricular supporting cells,
for stimulating the proliferation of T-lymphocyte cells, for stimulating
the release of a cytokine from PMBC cells, for inhibiting the binding of
A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte
cells, for stimulating proliferation of endothelial cells, for detecting
the presence of tumour in a mammal. The tumour is lung, colon, breast,
prostate, rectal, cervical or liver tumour. The oligonucleotide probes
are useful for isolating genomic and cDNA nucleotide sequences or
antisense probes. (I) is also useful as therapeutic agent. PRO is useful
in assays to identify other proteins or molecules involved in binding
interaction. A polynucleotide (II) encoding (I) is useful in chromosome
and gene mapping, in generation of antisense RNA and DNA, in the
preparation of PRO polypeptide, for generating transgenic animals or
knockout animals which in turn are useful in the development and
screening of therapeutically useful reagents, in gene therapy, for
chromosome identification, as chromosome marker, and for generating
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
detecting its expression in specific cells, tissues or serum, and for
affinity purification of PRO from recombinant cell culture or natural
sources. (I) and (II) are useful for tissue typing. This sequence encodes
a novel human secreted and transmembrane PRO polypeptide.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Try Match 1.1%; Score 21.4; DB 1; Length 1129;
Local Similarity 66.0%; Pred. No. 45;
ches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0

1835 TCTTAATTTTTCATTTCCAGATTCTCTTCAGTTTCGGTGTGTTT 1881
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
1129 TTTTNTTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTTATT 1083
||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

T 170
3355/c
ADD92355 standard; cDNA; 1129 BP.
ADD92355;
29-JAN-2004 (first entry)
Human PRO polynucleotide #111.
Human; gere; ss; PRO; secreted polypeptide; transmembrane polypeptide;

generating transmembrane RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at seqdata.uspto.gov/sequence.html.

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTTGT 1881
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTNTTTTTTTTTTTTTCAGCTGCACACAGCGTGCTTTTATT 1083

RESULT 169
ADD54038/C
ID ID ADD54038 standard; cDNA; 1129 BP.
XX AC ADD54038;
XX AC
XX XX
DT 15-JAN-2004 (first entry)
DX DE
DE DE
KW Human; secreted and transmembrane protein PRO4327 cDNA.
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX KW
XX Homo sapiens.
XX XX
XX US2003203432-A1.
PN PN
PD 30-OCT-2003.

CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTGGGTTTGTGTTT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
 RESULT 173
 ADE32162/c
 ID ADE32162 standard; cDNA; 1129 BP.
 XX
 XX ADE32162;
 AC
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.
 XX
 KW Human; secreted and transmembrane protein; PRO; gene; ss;
 KW Tumour necrosis factor alpha release; TNF-alpha release;
 KW glucose uptake modulator; FFA uptake modulator;
 KW cell proliferation stimulator; cell differentiation stimulator;
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
 KW gene therapy; chromosome identification; chromosome marker.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003194765-A1.
 PN
 XX
 PD 16-OCT-2003.
 XX
 XX 09-MAY-2002; 2002US-00142889.
 XX
 PR 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 PA
 XX
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-899784/82.
 DR
 DR P-PSDB; ADE32163.
 XX
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 XX Claim 2; SEQ ID NO 221; 636pp; English.
 XX
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from FMC cells, for inhibiting the binding of
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TTCTTAATTTTTCATTTCCAGATTCTCTTCAGTTGGGTTTGTGTTT 1881
 DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083
 RESULT 174
 ADE22094/c
 ID ADE22094 standard; cDNA; 1129 BP.
 XX
 XX ADE22094;
 AC
 XX
 DT 29-JAN-2004 (first entry)
 XX
 XX cDNA encoding human PRO polypeptide #111.
 DE
 XX
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 XX Homo sapiens.
 OS
 XX
 XX US2003199056-A1.
 PN
 XX
 PD 23-OCT-2003.
 XX
 XX 15-APR-2002; 2002US-00123212.
 PF
 XX
 XX 31-MAR-1997; 97WO-US005230.
 PR 12-JUN-1998; 98WO-US012456.
 PR 14-JUL-1998; 98WO-US014552.
 PR 28-AUG-1998; 98WO-US017888.
 PR 10-SEP-1998; 98WO-US018824.
 PR 14-SEP-1998; 98WO-US019093.
 PR 14-SEP-1998; 98WO-US019094.
 PR 14-SEP-1998; 98WO-US019177.
 PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028430.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030311.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 21-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900166/82.
DR P-PSDB; ADE22095.
XX
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 221; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC the proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1835 TTCTTAATTTTTCATTCCAGATTCCTTCAGTTGGGTTGTTT 1881
DB 1129 TTTTTCATTTTTCATTTTCAGTGCACACAGGCTGGTTTATT 1083

RESULT 175
ADD79318/C
ID ADD79318 standard; cDNA; 1129 BP.
XX
AC ADD79318;
XX
DT 29-JAN-2004 (first entry)
XX
DE cDNA encoding human PRO polypeptide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203428-A1.
XX
PD 30-OCT-2003.
XX
PF 22-APR-2002; 2002US-00127852.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-875635/81.
DR P-PSDB; ADD79319.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 2; Fig 221; 637pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems, PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence encodes a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred.No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
OY 1835 TTCTTAATTTTTCATTCCAGATTCCTTCAGTTGGGTTT 1881
DB 1129 TTTTTCATTTTTCATTTTCAGTGCACACAGGCTGGTTTATT 1083

RESULT 176
ADE41854/C
ID ADE41854 standard; cDNA; 1129 BP.
XX
AC ADE41854;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194772-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152386.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
WPI; 2003-899788/82.
DR P-PSDB; ADE41855.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 2; Fig 221; 637pp; English.

KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003194767-A1.

XX 16-OCT-2003.

XX 16-MAY-2002; 2002US-00147497.

XX 26-AUG-1998; 98US-0097951P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99WO-US0380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-899786/82.

XX P-PSDB; ADE33267.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 21; 636pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and

XX transmembrane) polypeptides (I). (I) is useful for stimulating the

XX release of TNF-alpha from human blood, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating the proliferation or differentiation of chondrocyte cells,

XX for stimulating the proliferation of or gene expression in pericyte

XX cells, for stimulating the release of proteoglycans from cartilage, for

XX stimulating the proliferation of inner ear utricular supporting cells,

XX for stimulating the proliferation of T-lymphocyte cells, for stimulating

XX the release of a cytokine from PBMC cells, for inhibiting the binding of

XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

XX cells, for stimulating proliferation of endothelial cells, for detecting

XX the presence of tumour in a mammal. The tumour is lung, colon, breast,

XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes

XX are useful for isolating genomic and cDNA nucleotide sequences or

XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

XX in assays to identify other proteins or molecules involved in binding

XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome

XX and gene mapping, in generation of antisense RNA and DNA, in the

XX preparation of PRO polypeptide, for generating transgenic animals or

XX knockout animals which in turn are useful in the development and

XX screening of therapeutically useful reagents, in gene therapy, for

XX chromosome identification, as chromosome marker, and for generating

XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

XX detecting its expression in specific cells, tissues or serum, and for

XX affinity purification of PRO from recombinant cell culture or natural

XX sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

XX

XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;

XX Best Local Similarity 66.0%; Pred. No. 45;

XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TCTTAATTTTCATTCCAGATTTCTTCATGTTGGGTTTGT 1881

DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGCGTGGTTTATT 1083

RESULT 180

ADE33818/C

ID ADE33818 standard; cDNA; 1129 BP.

XX ADE33818;

AC ADE33818;

XX 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX glucose uptake modulator; FFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX cell differentiation inhibitor; cytokine release stimulator; tumour;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS US2003194791-A1.

XX 16-OCT-2003.

XX 11-APR-2002; 2002US-00121046.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 2000WO-US006319.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005501.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 31-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014541.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUN-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030352.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00742759.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001WO-US006520.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017900.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019592.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908927.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PA (GETH) GENENTECH INC.
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-899790/82.
XX P-PSDB; ADE33819.
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
XX useful for treating pericyte-associated tumors, diabetes and various bone
XX and/or cartilage disorders, e.g. arthritis.
XX Claim 2; SEQ ID NO 221; 636pp; English.
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of pericytes from cartilage, for
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PMBC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred. No. 45;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCACAGATTCTCTCAGTTGGTTGGTTTGT 1881
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
RESULT 181
ADD79870/c
ID ADD79870 standard; cDNA; 1129 BP.
XX AC ADD79870;
XX DT 29-JAN-2004 (first entry)
XX DE cDNA encoding human PRO polypeptide #111.
XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW immune system cell infiltration.
XX OS Homo sapiens.
XX PN US2003207417-A1.
XX PD 06-NOV-2003.
XX PF 07-MAY-2002; 2002US-00140805.
XX PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 98WO-US005028.
PR 10-MAR-1999; 98WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 98WO-US008615.
PR 18-MAY-1999; 98WO-US010733.
PR 02-JUN-1999; 98WO-US011252.
PR 01-SEP-1999; 98WO-US020111.
PR 08-SEP-1999; 98WO-US020594.
PR 13-SEP-1999; 98WO-US020944.
PR 15-SEP-1999; 98WO-US021090.
PR 15-SEP-1999; 98WO-US021547.
PR 03-OCT-1999; 98WO-US023089.
PR 29-NOV-1999; 98WO-US028214.
PR 30-NOV-1999; 98WO-US028313.
PR 30-NOV-1999; 98WO-US028409.
PR 01-DEC-1999; 98WO-US028301.
PR 01-DEC-1999; 98WO-US028634.
PR 02-DEC-1999; 98WO-US028551.
PR 02-DEC-1999; 98WO-US028564.
PR 02-DEC-1999; 98WO-US028565.
PR 16-DEC-1999; 98WO-US030095.
PR 20-DEC-1999; 98WO-US030911.
PR 20-DEC-1999; 98WO-US030999.
PR 22-DEC-1999; 98WO-US030720.
PR 30-DEC-1999; 98WO-US031243.
PR 30-DEC-1999; 98WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 03-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI; 2003-875867/81.
DR P-PSDB; ADD79871.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
diagnosing or treating tumor, for chromosome mapping or for tissue
typing.
XX
PS Claim 2; Fig 221; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumor necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence encodes a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
the USPTO website at seqdata.uspto.gov.
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;

10664775-3.rng

Mon Aug 9 17:47:19 2004

AC AD42971;
 XX 29-JAN-2004 (first entry)
 XX Human PRO polynucleotide #111.
 XX
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003199033-A1.
 XX
 XX 23-OCT-2003.
 XX
 XX 28-MAY-2002; 2002US-00156845.
 XX
 XX 05-JUN-2000; 2000US-0209832P.
 XX 01-DEC-2000; 2000WO-US032678.
 XX 19-DEC-2001; 2001US-00028072.
 XX
 XX (GETH) GENENTECH INC.
 XX
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX
 XX WPI; 2003-900162/82.
 XX P-PSDB; ADE42972.
 XX
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX
 XX Claim 2; Fig 221; 636pp; English.
 XX
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems,
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
 QY 1835 TCTTAAATTTTTCATTTCCAGATTCTTCAGTTGGGTTTGT 1881
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083
 RESULT 186
 ADD95760/c
 ID ADD95760 standard; cDNA; 1129 BP.
 XX
 XX ADD95760;
 XX
 XX 29-JAN-2004 (first entry)
 XX
 XX Human PRO polynucleotide #111.
 XX
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
 KW immune system cell infiltration.
 XX
 OS Homo sapiens.
 XX
 XX US2003199059-A1.
 XX
 XX 23-OCT-2003.
 XX
 XX 15-APR-2002; 2002US-00123322.
 XX
 XX 31-MAR-1997; 97WO-US005230.
 XX 12-JUN-1998; 98WO-US012456.
 XX 14-JUL-1998; 98WO-US014552.
 XX 28-AUG-1998; 98WO-US017888.
 XX 10-SEP-1998; 98WO-US018824.
 XX 14-SEP-1998; 98WO-US019093.
 XX 14-SEP-1998; 98WO-US019094.
 XX 14-SEP-1998; 98WO-US019177.
 XX 14-SEP-1998; 98WO-US019330.
 XX 16-SEP-1998; 98WO-US019437.
 XX 07-OCT-1998; 98WO-US021141.
 XX 29-OCT-1998; 98WO-US022991.
 XX 29-OCT-1998; 98WO-US022992.
 XX 20-NOV-1998; 98WO-US024855.
 XX 01-DEC-1998; 98WO-US025108.
 XX 05-JAN-1999; 99WO-US000106.
 XX 08-MAR-1999; 99WO-US005190.
 XX 10-MAR-1999; 99WO-US005190.
 XX 20-APR-1999; 2000WO-US006319.
 XX 14-MAY-1999; 99WO-US010733.
 XX 02-JUN-1999; 99WO-US012252.
 XX 01-SEP-1999; 99WO-US020111.
 XX 08-SEP-1999; 99WO-US020594.
 XX 13-SEP-1999; 99WO-US020944.
 XX 15-SEP-1999; 99WO-US021090.
 XX 15-SEP-1999; 99WO-US021547.
 XX 05-OCT-1999; 99WO-US023089.

PD 16-OCT-2003.
 XX 14-MAY-2002; 2002US-00145874.
 XX 05-JUN-2000; 2000US-0209832P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-899785/82.
 DR P-PSDB; ADE32715.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; SEQ ID NO 221; 636pp; English.
 XX The invention describes 305 nucleic acids encoding PRO (secreted and
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the
 CC release of TNF-alpha from human blood, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating the proliferation or differentiation of chondrocyte cells,
 CC for stimulating the proliferation of or gene expression in pericyte
 CC cells, for stimulating the release of proteoglycans from cartilage, for
 CC stimulating the proliferation of inner ear utricular supporting cells,
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
 CC the release of a cytokine from PMC cells, for inhibiting the binding of
 CC A-peptide to factor VITA, for inhibiting the differentiation of adipocyte
 CC cells, for stimulating proliferation of endothelial cells, for detecting
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
 CC are useful for isolating genomic and cDNA nucleotide sequences or
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
 CC in assays to identify other proteins or molecules involved in binding
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
 CC and gene mapping, in generation of antisense RNA and DNA, in the
 CC preparation of PRO polypeptide, for generating transgenic animals or
 CC knockout animals which in turn are useful in the development and
 CC screening of therapeutically useful reagents, in gene therapy, for
 CC chromosome identification, as chromosome marker, and for generating
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
 CC detecting its expression in specific cells, tissues or serum, and for
 CC affinity purification of PRO from recombinant cell culture or natural
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
 CC a novel human secreted and transmembrane PRO polypeptide.
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
 Best Local Similarity 66.0%; Pred. No. 45;
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTAAATTTTTCATTTCCAGATTCTTCAGTTTGGGTTTCTTT 1881
 |||||
 Db 1129 TTTTITTTTTTTTTTTTCAGTGGCACACAGCTGGGTTTATT 1083
 |||||

RESULT 190
 ADE42406/c
 ID ADE42406 standard; cDNA; 1129 BP.
 XX AC ADE42406;
 XX AC ADE42406;
 XX AC ADE42406;
 DT 29-JAN-2004 (first entry)
 XX Human PRO polynucleotide #111;
 DE
 XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
 KW liver; microvascular endothelial cell; glucose; FFA;
 KW skeletal muscle cell; adipocyte cell; pericyte cell;
 KW inner ear utricular supporting cell; T-lymphocyte cell;
 KW endothelial cell tube formation; bone disorder; cartilage disorder;
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
 KW immune system cell infiltration.
 XX Homo sapiens.
 OS
 XX US2003199032-A1.
 XX 23-OCT-2003.
 XX 28-MAY-2002; 2002US-00156844.
 XX 03-MAR-2000; 2000US-0187202P.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 19-DEC-2001; 2001US-00028072.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
 XX WPI; 2003-900161/82.
 DR P-PSDB; ADE42407.
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,
 PT useful for treating pericyte-associated tumors, diabetes and various bone
 PT and/or cartilage disorders, e.g. arthritis.
 XX Claim 2; Fig 221; 636pp; English.
 XX The invention relates to isolated human PRO polypeptides (secreted and
 CC transmembrane polypeptides) and the polynucleotides encoding them. The
 CC invention also relates to an antibody which specifically binds to a PRO
 CC polypeptide, a method for stimulating the release of tumour necrosis
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
 CC proliferation or differentiation of chondrocyte cells and a method for
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
 CC polynucleotides are useful in molecular biology, including uses as
 CC hybridisation probes, in chromosome and gene mapping, in generating
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
 CC be used in preparing PRO polypeptides by recombinant techniques and in
 CC generating either transgenic animals or knock-out animals which are
 CC useful in the development and screening of therapeutically useful
 CC reagents. The PRO polypeptides or antibodies are used in preparing a
 CC medicament for treating a condition responsive to the polypeptides or
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation
 CC of human microvascular endothelial cells, for modulating the uptake of
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
 CC stimulating differentiation of adipocyte cells, for stimulating
 CC proliferation of or gene expression in pericyte cells, for stimulating
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
 CC cells, for inducing endothelial cell tube formation and for treating
 CC various bone and/or cartilage disorders such as sports injuries and
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
 CC from cartilage are useful for treating sports-related joint problems, PRO
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
 CC polypeptides are also useful for treating various mammalian haemoglobin-
 CC associated disorders such as various thalassemias and conditions which
 CC may benefit from enhanced local immune system cell infiltration. This
 CC sequence represents a human PRO polynucleotide of the invention. Note:
 CC The sequence data for this patent is also available in electronic format
 CC from USPTO at seqdata.uspto.gov/sequence.html.
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
 SQ

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; Glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003100087-A1.

XX 29-MAY-2003.

XX 16-APR-2002; 2002US-00123912.

XX 31-MAR-1997; 97WO-US0005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US011252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020594.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US0003565.
PR 18-FEB-2000; 2000WO-US0004341.
PR 18-FEB-2000; 2000WO-US0004342.
PR 22-FEB-2000; 2000WO-US0004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US0005601.
PR 02-MAR-2000; 2000WO-US0005746.
PR 02-MAR-2000; 2000WO-US0005841.
PR 10-MAR-2000; 2000WO-US0006319.

PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00806689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019852.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-0089956/01.

P-PSDB; ADD76407.

XX New PRO nucleic acid, useful for recombinantly producing a PRO
PT polypeptide and for manufacturing a medicament for diagnosing or treating
PT a tumor.

XX Claim 2; Fig 221; 638pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides), and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in

immune system cell infiltration.

Homo sapiens.

US2003203440-A1.

30-OCT-2003.

29-MAY-2002; 2002US-00157798.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2004-021363/02.

F-PSDB; ADD86175.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1835 TCTTAAATTTTCATTTCAGATTTTCCTTCAGTTGGGTTTGT 1881

1129 TTTTATTTTATTTTATTTTTCAGTGGCACACAGGCTGTTTAT 1083

RESULT 199

ADE75622/C

ID ADE75622 standard; cDNA; 1129 BP.

XX

XX ADE75622;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #111.

XX

XX Human; gene: ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX liver; microvascular endothelial cell; glucose; FFA;

XX skeletal muscle cell; adipocyte cell; pericyte cell;

XX inner ear utricular supporting cell; T-lymphocyte cell;

XX endothelial cell tube formation; bone disorder; cartilage disorder;

XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

XX

OS Homo sapiens.

XX

XX US2003211571-A1.

XX

PD 13-NOV-2003.

XX

XX 20-MAY-2002; 2002US-00152405.

PF

XX

XX 03-MAR-2000; 2000US-0187202P.

XX

PR 01-DEC-2000; 2000WO-US032678.

PR

XX 19-DEC-2001; 2001US-00028072.

XX

XX (GETH) GENENTECH INC.

XX

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

XX WPI; 2004-051576/05.

DR

DR F-PSDB; ADE75623.

XX

XX New secreted and transmembrane PRO polypeptide and nucleic acid encoding

PT it, for use in gene therapy, as diagnostic markers for the presence of a

XX disease condition, or as therapeutic targets for treating tumours,

PT diabetes, or arthritis.

XX

XX Claim 2; Fig 221; 637pp; English.

PS

XX The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTTGTTT 1891
|| || || || || || || || || || || || || || || || || ||
DB 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCGTGCGTTTATT 1083

RESULT 203
ADD87218/C
ID ADD87218 standard; cDNA; 1129 BP.
XX
XX ADD87218;
XX
XX
DT 29-JAN-2004 (first entry)
DE Human PRO polynucleotide #111.

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
liver; microvascular endothelial cell; glucose; FFA;
skeletal muscle cell; adipocyte cell; pericyte cell;
inner ear utricular supporting cell; T-lymphocyte cell;
endothelial cell tube formation; bone disorder; cartilage disorder;
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
immune system cell infiltration.

OS Homo sapiens.
XX
PN US2003203439-A1.
XX
PD 30-OCT-2003.
XX
PF 17-MAY-2002; 2002US-00147499.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.

(GETH) GENENTECH INC.
XX
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W,
PI Gerritsen WE, Goddard A, Godowski PJ, Gurney AL, Sherwood S,
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WT, Zhang Z;
DR MPI; 2004-021362/02.
DR P-PSDB; ADD87219.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PRO4978, useful in molecular biology, chromosome and gene mapping, in
generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 648pp; English.

The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also

10664775-3.rng

Mon Aug 9 17:47:19 2004

PF 16-APR-1999; 99US-00294093.
 XX
 PR 21-APR-1998; 98US-0082567P.
 XX
 PA (LALG/) LALGUDI R V.
 FA (ITOL/) ITO L Y.
 PA (SHER/) SHERMAN B K.
 XX
 PI Lalgudi RV, Ito LY, Sherman BK;
 XX
 XX MPI; 2002-163647/21.
 DR
 XX Novel purified corn tassel-derived polynucleotide useful for determining
 PT altered gene expression, to recover regulatory elements and to follow
 PT inheritance of desirable characteristics through hybrid breeding
 PT programs.
 XX
 XX Claim 1; SEQ ID NO 6030; 201pp; English.
 PS
 XX The present sequence describes a purified corn tassel-derived
 CC polynucleotide sequence (cdps) comprising a nucleic acid sequence
 CC selected from those given in ABL70627 to ABL76833. The cdps sequences
 CC encode corn tassel-derived polypeptides (CDPs). The cdps sequences (I)
 CC can be used for determining altered gene expression, to recover
 CC regulatory elements and to follow inheritance of desirable
 CC characteristics through hybrid breeding programs. (I) are also useful in
 CC the evaluation, and alteration of desired characteristics associated with
 CC growth and development, disease resistance, environmental adaptability,
 CC quality and yield, and as molecular markers for studying inheritance of
 CC multigene traits in a plant breeding program. (I) can be used to produce
 CC a tassel-specific profile of gene transcription, a transcript image, to
 CC clone regulatory elements for use in transformation vectors, to express a
 CC polypeptide, to identify, isolate or extend identical or related corn
 CC tassel nucleic acid sequences from DNA libraries, in nucleic acid
 CC hybridisation or amplification technologies, as query sequences to
 CC determine homology of known sequences, as probe for use in Southern or
 CC Northern hybridisation, and to identify the presence of and/or to
 CC determine the degree of similarity between two (or more) nucleic acid
 CC sequences
 XX
 SQ Sequence 286 BP; 96 A; 73 C; 89 G; 27 T; 0 U; 1 Other;
 Query Match 1.1%; Score 21.1; DB 1; Length 286;
 Best Local Similarity 46.0%; Pred. No. 40;
 Matches 104; Conservative 0; Mismatches 119; Indels 3; Gaps 1;
 QY 1594 TTTTGGTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTCTCCCTTCCCTA 1653
 DB 261 TTTGCTTGTGGTGGCGGACTGTGCGCGTGTGCGCGTGTGCTGCTGCTGCTGCTT 202
 QY 1654 TTTCTTTGTTTGTGATAGTGTCTGTGCTTCTGCTGCTTGTGATGTTTATGCTGATATTT 1713
 DB 201 CTCACGATGCTCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTT 142
 QY 1714 AGACTTACATTTCTTTGACCAAGGATCCATTTCTTCTATCTTGTCTTCACTGCGCTGA 1773
 DB 141 GTGGTGCTCTCGGCTT---CTTGTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG 85
 QY 1774 GATTTCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 1819
 DB 84 GAGCTCTCTCTGATCTTGTGATGATGATGATGATGATGATGATGATGATGATGATGATG 39
 RESULT 210
 AAV88246/C
 ID AAV88246 standard, cDNA; 267 BP.
 XX
 AC AAV88246;
 XX
 DT 12-FEB-1999 (first entry)
 XX
 DE EST clone EA90.
 XX

XX Expressed sequence tag; secreted protein; haematopoiesis regulator;
 KW tissue growth; activin; inhibitor; tumour invasion suppressor; EST; human;
 KW chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis;
 KW receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO9845437-A2.
 XX
 PD 15-OCT-1998.
 XX
 PF 10-APR-1998; 98WO-US006956.
 XX
 PR 10-APR-1997; 97US-00837312.
 XX
 XX (GENY) GENETICS INST INC.
 PA
 XX Jacobs K, McCoy JM, Lavallie ER, Racie LA, Merberg D, Treacy M;
 PI Spaulding V, Agostino MJ;
 PI MPI; 1999-070078/06.
 DR
 XX New polynucleotides encoding human secreted proteins - derived from e.g.
 PT human blood, kidney, foetal lung, placenta, testes, brain, ovary,
 PT pituitary, retina and colon cDNA libraries.
 PT
 XX Claim 1; Page 332; 641pp; English.
 PS
 XX The present sequence represents an expressed sequence tag (EST), and is a
 CC polynucleotide of the invention. The polynucleotides of the invention are
 CC all secreted EST sequences isolated from a variety of human tissue
 CC sources. The EST sequences and proteins encoded by them are predicted to
 CC have useful biological activities which would make them suitable for
 CC treating, preventing or ameliorating medical conditions in humans and
 CC animals, although no supporting data is given. Suggested activities
 CC include nutritional activity, immune stimulating or suppressing activity,
 CC haematopoiesis regulating activity, tissue growth activity, haemostatic
 CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
 CC and thrombolytic activity, receptor/ligand activity, anti-inflammatory
 CC activity, cadherin/tumour invasion suppressor activity, tumour inhibition
 CC activity. The EST sequences are also stated to be useful for gene therapy
 XX
 SQ Sequence 267 BP; 75 A; 45 C; 90 G; 57 T; 0 U; 0 Other;
 Query Match 1.0%; Score 21; DB 1; Length 267;
 Best Local Similarity 49.5%; Pred. No. 42;
 Matches 54; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
 QY 1543 GCTTCTGTACCTTCATAGGATCTCTTCTCAAGGTTAGGAAATTTCTTTTGGTT 1602
 DB 243 GATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATGAT 184
 QY 1603 TTCTTGAAATAATTTTCCCTGCTTTTGACCTGCTTCTTCTTCTTCTTCTTCTTCTTCT 1651
 DB 183 TTCTTCAAAAGTCCACATTTGCTGCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCT 135
 RESULT 211
 ABX37095/C
 ID ABX37095 standard; cDNA; 372 BP.
 XX
 XX ABX37095;
 AC
 XX
 DT 20-FEB-2003 (first entry)
 XX
 DE Bovine EST associated with lactation/muscle/fat deposition #2260.
 XX
 KW Bovine; ss; EST; expressed sequence tag; lactation; LMFD;
 KW muscle deposition; fat deposition; genome mapping; gene identification;
 KW gene analysis; cattle breeding.
 XX
 OS Bos Taurus.
 XX

Query Match 1.0%; Score 20.8; DB 1; Length 263;
Best Local Similarity 52.3%; Pred. No. 47;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;
QY 1614 AATTTCCTGCTTTGACCTGCTCTTCCCTCTCTCTATTCCTTTGGTTTTTCGAAG 1673

AC ABA43030;
XX
XX
DT 01-FEB-2002 (first entry)
XX
DE Human breast cell single exon nucleic acid probe #1725.
XX
XX Human; microarray; single exon probe; gene expression; breast; disease;
KW cancer; ss.
XX
XX Homo sapiens.
XX
XX WO200157271-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR
XX 26-MAY-2000; 2000US-0207456P.
PR
XX 30-JUN-2000; 2000US-00608408.
PR
XX 03-AUG-2000; 2000US-00632366.
PR
XX 21-SEP-2000; 2000US-0234687P.
PR
XX 27-SEP-2000; 2000US-0236359P.
PR
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI
XX WPI; 2001-496933/54.
XX
XX New spatially-addressable set of single exon nucleic acid probes, useful
PT for measuring gene expression in sample derived from human breast,
PT comprises number of single exon nucleic acid probes.
XX
XX
PS Claim 1; SEQ ID NO 1725; 327bp + Sequence Listing; English.
XX
XX The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human breast and BT 474 cells. The method involves contacting the
CC probes with a collection of detectably labelled nucleic acids derived
CC from mRNA of human breast, and then measuring the label bound to each
CC probe of the microarray. The probes are useful for verifying the
CC expression of regions of genomic DNA predicted to encode proteins. They
CC are useful for gene discovery, and for determining predisposition and/or
CC prognosing breast disease. Gene expression analysis is useful for
CC assessing the toxicity of chemical agents on cells. The microarray of
CC this invention presents a far greater diversity of probes for measuring
CC gene expression, with far less bias than expressed sequence tag
CC microarrays. The method is suitable for rapid production of functional
CC information from genomic sequence. The present sequence is a single exon
CC nucleic acid probe of the invention. Note: The sequence data for this
CC patent did not form part of the printed specification, but was obtained
CC in electronic format directly from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;
Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTTGAGTCATTTGAGATTTATCAATGAGCA 973
DB 182 ATATATTTCCATTCAGTGTCTATTTATATATAAATTTGAGGAGAAACAAAATCAATTC 123
QY 974 GTGTTTGGGACATCTGCTGCTGGGTTTGTCCAG 87
DB 122 CTGTCGGGACATCTGCTGCTGGGTTTGTCCAG 87
RESULT 227
ABA23216/c
XX
XX ID AAK27166 standard; DNA; 474 BP.
XX
XX AAK27166;
DT 06-NOV-2001 (first entry)

ID ABA23216 standard; DNA; 474 BP.
XX
XX ABA23216;
XX
XX 23-JAN-2002 (first entry)
DT
DE Probe #1682 for gene expression analysis in human heart cell sample.
XX
XX Human; gene expression; heart; microarray; vascular system; probe;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease; ss.
XX
XX Homo sapiens.
XX
XX WO200157274-A2.
XX
XX 09-AUG-2001.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 04-FEB-2000; 2000US-0180312P.
PR
XX 26-MAY-2000; 2000US-0207456P.
PR
XX 30-JUN-2000; 2000US-00608408.
PR
XX 03-AUG-2000; 2000US-00632366.
PR
XX 21-SEP-2000; 2000US-0234687P.
PR
XX 27-SEP-2000; 2000US-0236359P.
PR
XX 04-OCT-2000; 2000GB-00024263.
XX
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
PI
XX WPI; 2001-488899/53.
XX
XX Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX
XX Claim 1; SEQ ID NO 1682; 530pp; English.
XX
XX The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart. The
CC present sequence is one such probe. The probes may be used for
CC predicting, measuring and displaying gene expression in samples derived
CC from the human heart via microarrays. By measuring gene expression, the
CC probes are useful for predicting, diagnosing, grading, staging,
CC monitoring and prognosing diseases of the human heart and vascular system
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and
CC congenital heart disease. Note: The sequence data for this patent did not
CC form part of the printed specification, but was obtained in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;
Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTTGAGTCATTTGAGATTTATCAATGAGCA 973
DB 182 ATATATTTCCATTCAGTGTCTATTTATATATAAATTTGAGGAGAAACAAAATCAATTC 123
QY 974 GTGTTTGGGACATCTGCTGCTGGGTTTGTCCAG 87
DB 122 CTGTCGGGACATCTGCTGCTGGGTTTGTCCAG 87
RESULT 228
AAK27166/c
XX
XX ID AAK27166 standard; DNA; 474 BP.
XX
XX AAK27166;
DT 06-NOV-2001 (first entry)

```
XX DE Human bone marrow expressed single exon probe SEQ ID NO: 1723.
XX XX
XX KW Human; bone marrow expressed exon; gene expression analysis; probe;
XX KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX XX
XX OS Homo sapiens.
XX PN WO200157276-A2.
XX XX
XX PD 09-AUG-2001.
XX XX
XX PF 30-JAN-2001; 2001WO-US000668.
XX XX
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX XX
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX XX
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX XX
XX DR WPI; 2001-488900/53.
XX XX
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human bone marrow.
XX XX
XX PS Example 4; SEQ ID NO 1723; 658pp + Sequence Listing; English.
XX XX
XX CC The present invention provides a number of single exon nucleic acid
XX CC probes which are derived from genomic sequences expressed in the human
XX CC bone marrow. They can be used to measure gene expression in bone marrow
XX CC samples, which may enable the improved diagnosis and treatment of cancers
XX CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX CC the probes of the invention
XX XX
XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 914 ATCTTTTCTAGAGAAATTAGATCATTCAGTCATTGATGAGTATTCATCAATGAGCA 973
DB 182 ATATATTCCTCAGTGCTATTCATTTATTAACCTTTGATGAGGAAACAAATCAATTC 123

QY 974 GTGTTTGTGGATTCCTGTTATCTTGCATCTGTGAAG 1009
DB 122 CTGCTGGGACACTGCTGCTGGGTTTGTCCAG 87

RESULT 229
AAK01714/c
ID AAK01714 standard; DNA; 474 BP.
XX AC AAK01714;
XX XX
XX DT 05-NOV-2001 (first entry)
XX XX
XX DE Human brain expressed single exon probe SEQ ID NO: 1705.
XX XX
XX KW Human; brain expressed exon; gene expression analysis; probe; microarray;
XX KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX KW ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200157275-A2.
XX XX
```

```
PD 09-AUG-2001.
XX XX
XX PF 30-JAN-2001; 2001WO-US000667.
XX XX
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX XX
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX XX
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX XX
XX DR WPI; 2001-483446/52.
XX XX
XX PT Single exon nucleic acid probes for analyzing gene expression in human
XX PT brains.
XX XX
XX PS Example 4; SEQ ID NO 1705; 650pp + Sequence Listing; English.
XX XX
XX CC The present invention provides a number of single exon nucleic acid
XX CC probes which are derived from genomic sequences expressed in the human
XX CC brain. They can be used to measure gene expression in brain cell samples,
XX CC which may enable the diagnosis and improved treatment of nervous system
XX CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX CC epilepsy and cancers. The present sequence is one of the probes of the
XX CC invention
XX XX
XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 914 ATCTTTTCTAGAGAAATTAGATCATTCAGTCATTGATGAGTATTCATCAATGAGCA 973
DB 182 ATATATTCCTCAGTGCTATTCATTTATTAACCTTTGATGAGGAAACAAATCAATTC 123

QY 974 GTGTTTGTGGATTCCTGTTATCTTGCATCTGTGAAG 1009
DB 122 CTGCTGGGACACTGCTGCTGGGTTTGTCCAG 87

RESULT 230
ABS26749/c
ID ABS26749 standard; DNA; 474 BP.
XX XX
XX AC ABS26749;
XX XX
XX DT 25-FEB-2003 (first entry)
XX XX
XX DE Human liver single exon probe, SEQ ID No 1739.
XX XX
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO200157273-A2.
XX XX
XX PD 09-AUG-2001.
XX XX
XX PF 30-JAN-2001; 2001WO-US000664.
XX XX
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
```


PR 04-OCT-2000; 2000GB-00024263.
XX (MOLE-) MOLECULAR DYNAMICS INC.
XX
XX Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX WPI; 2002-114183/15.
XX
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
XX Claim 1; SEQ ID NO 1708; 634pp; English.
XX
XX The invention relates to a spatially-addressable set of single exon
XX nucleic acid probes for measuring gene expression in a sample derived
XX from human lung comprising single exon nucleic acid probes having one of
XX 12614 nucleic acid sequences mentioned in the specification, or their
XX complements or the 12387 open reading frames derived from the 12614
XX probes. Also included are a microarray comprising the novel set of probes
XX; the novel set of probes which hybridise at high stringency to a nucleic
XX acid expressed in the human lung; measuring gene expression in a sample
XX derived from human lung, comprising (a) contacting the array with a
XX collection of detectably labeled nucleic acids derived from human lung
XX mRNA, and (b) measuring the label detectably bound to each probe of the
XX array; identifying exons in a eukaryotic genome, comprising (a)
XX algorithmically predicting at least one exon from genomic sequences of
XX the eukaryote; and (b) detecting specific hybridisation of detectably
XX labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
XX having a fragment identical to the predicted exon, the probe is included
XX in the above mentioned microarray; assigning exons to a single gene,
XX comprising (a) identifying exons from genomic sequence by the method
XX above and (b) measuring the expression of each of the exons in several
XX tissues and/or cell types using hybridisation to a single exon
XX microarrays having a probe with the exon, where a common pattern of
XX expression of the exons in the tissues and/or cell types indicates that
XX the exons should be assigned to a single gene; a peptide comprising one
XX of 12011 sequences, mentioned in the specification, or encoded by the
XX probes/open reading frames (ORF). The probes are used for gene expression
XX analysis, and for identifying exons in a gene, particularly using human
XX lung derived mRNA and for the study of lung diseases such as asthma, lung
XX cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
XX disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
XX tuberculosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
XX Jaudak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
XX histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,
XX Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
XX dyskinesia, pulmonary hypertension and hyaline membrane disease. The
XX present sequence is a single exon probe of the invention. Note: The
XX sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 914 ATCTTTTCAGAGAAATTAAGATCATTTGAGTCATTCATTCAGATTAATCATGACCA 973
DB 182 ATATATTCATTCAGTCGTCATTCATTAATTAATTCAGAGGAGAAACAAATCATCTTC 123

QY 974 GTGTTTGTGGAATCTTGTGTTATCTGTCACCTTGTGAAG 1009
DB 122 CTGTCTGGGACACTGTCTGCTGGGTTTGTGCCAG 87

RESULT 233
AAAG1697/C
ID AAA61697 standard; cDNA; 1036 BP.
XX
XX AAA61697;
XX

DT 23-OCT-2000 (first entry)
XX
XX cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.
DE
XX BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.
XX
XX Homo sapiens.
OS
XX WO200031277-A1.
PN
XX 02-JUN-2000.
PD
XX 19-NOV-1999; 99WO-JP006472.
PF
XX 20-NOV-1998; 98JP-00347813.
PR
XX (FUSO) FUSO PHARM IND LTD.
PA
XX Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
PI
XX WPI; 2000-400084/34.
DR
XX P-PSDB; AAB11702.
DR
XX Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and
PT diagnosis of diseases in which BSSP4 expression is altered.
PT
XX Claim 6; Page 71-73; ilpp; Japanese.
PS
XX The invention relates to novel serine proteases designated BSSP4
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,
CC AAA61799). The invention also relates to vectors and transformants
CC comprising BSSP4 nucleic acids; transgenic animals in which the
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.
CC The invention additionally encompasses anti-BSSP4 antibodies and methods
CC of production of such antibodies, methods of BSSP4 detection using the
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were
CC initially isolated in a human brain cDNA library using degenerate PCR
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.
CC The BSSP4 serine proteases and nucleotides encoding them are useful in
CC detecting homologues, mutants and polymorphic variants in biological
CC samples (e.g., blood, urine, brain, prostate gland and testis) as
CC diagnostic markers for diseases associated with altered BSSP4 expression
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),
CC cancer or inflammation of brain, prostate, testis or bone. Sequences
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine
CC BSSP4 (mBSSP4)
XX
SQ Sequence 1036 BP; 205 A; 310 C; 301 G; 220 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1036;
Best Local Similarity 62.7%; Pred. No. 73;
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1131 TTATTTATTCATCATTTCTTGAATGTGGTAAACATCTTTAGATTGAAG 1181
DB 1029 TTTTITTTTTTTTTTTCTGGAGATAAATAATTATTGAAATTGGAG 979

RESULT 234
AAH19463/C
ID AAH19463 standard; DNA; 1206 BP.
XX
XX AAH19463;
AC
XX 31-JUL-2001 (first entry)
DT
XX Mutant blood coagulant factor VII (FVII-31) coding sequence.
XX
XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;
XX KW

```

KW mutant; ds.
XX
XX OS Homo sapiens.
OS Synthetic.
XX
XX FH Key
XX CDS Location/Qualifiers
FT 1..1206
FT /*tag= a
FT /product= "FVII-31"
FT /partial
FT /note= "No start codon given"
XX
XX PN JP2001061479-A.
XX
XX PD 13-MAR-2001.
XX
XX PF 24-AUG-1999; 99JP-00237610.
XX
XX PR 24-AUG-1999; 99JP-00237610.
XX
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.
XX
XX WPI; 2001-310677/33.
XX P-PSDB; AAB84870.
XX
XX Mutant of blood coagulant factor VII, used for substitution therapy in
XX the treatment of hemophilia.
XX
XX PS Disclosure; Page 19-20; 29pp; Japanese.
XX
XX CC The present invention relates to mutants of blood coagulant factor VII
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present
XX sequence is the coding sequence for one such mutant FVII: VII-31. The
XX mutants can be used as an agent for the substitution therapy of
XX haemophilia inhibitor patients
XX
XX SQ Sequence 1206 BP; 244 A; 359 C; 386 G; 217 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 76;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGCTTTATCTGTCGACACTGCTTTGTTTGAATATGATTCAAATTTGG 392
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
444 TTGCTGCAATTTCTTTTCTAGAAATAGGTATTTTCCACATGATTCACACTGTGG 386

RESULT 235
AAH19464/c
ID AAH19464 standard; DNA; 1206 BP.
XX
XX AC AAH19464;
XX
XX DT 31-JUL-2001 (first entry)
XX
XX DE Mutant blood coagulant factor VII (FVII-39) coding sequence.
XX
XX KW Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;
XX mutant; ds.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX FH Key
XX CDS Location/Qualifiers
FT 1..1206
FT /*tag= a
FT /product= "FVII-39"
FT /partial
FT /note= "No start codon given"
XX
XX PN JP2001061479-A.
XX
XX PD 13-MAR-2001.

```

```

XX
XX PF 24-AUG-1999; 99JP-00237610.
XX
XX PR 24-AUG-1999; 99JP-00237610.
XX
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.
XX
XX WPI; 2001-310677/33.
XX P-PSDB; AAB84871.
XX
XX Mutant of blood coagulant factor VII, used for substitution therapy in
XX the treatment of hemophilia.
XX
XX PS Disclosure; Page 22-23; 29pp; Japanese.
XX
XX CC The present invention relates to mutants of blood coagulant factor VII
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present
XX sequence is the coding sequence for one such mutant FVII: VII-39. The
XX mutants can be used as an agent for the substitution therapy of
XX haemophilia inhibitor patients
XX
XX SQ Sequence 1206 BP; 247 A; 354 C; 387 G; 218 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 76;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGCTTTATCTGTCGACACTGCTTTGTTTGAATATGATTCAAATTTGG 392
Db ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
444 TTGCTGCAATTTCTTTTCTAGAAATAGGTATTTTCCACATGATTCACACTGTGG 386

RESULT 236
AAH19459/c
ID AAH19459 standard; DNA; 1221 BP.
XX
XX AC AAH19459;
XX
XX DT 31-JUL-2001 (first entry)
XX
XX DE Wild-type human blood coagulant factor VII (FVII) coding sequence.
XX
XX KW Human; haemostatic; blood coagulant factor VII; FVII; haemophilia; ds.
XX
XX OS Homo sapiens.
XX
XX FH Key
XX CDS Location/Qualifiers
FT 1..1221
FT /*tag= a
FT /product= "FVII"
FT /partial
FT /note= "No start codon given"
XX
XX PN JP2001061479-A.
XX
XX PD 13-MAR-2001.
XX
XX PF 24-AUG-1999; 99JP-00237610.
XX
XX PR 24-AUG-1999; 99JP-00237610.
XX
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.
XX
XX WPI; 2001-310677/33.
XX P-PSDB; AAB84866.
XX
XX Mutant of blood coagulant factor VII, used for substitution therapy in
XX the treatment of hemophilia.
XX
XX PS Example 1; Page 7-8; 29pp; Japanese.
XX
XX CC The present invention relates to mutants of blood coagulant factor VII
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present

```


CC sequence is the coding sequence for wild-type human FVII. The mutants can
CC be used as an agent for the substitution therapy of haemophilia inhibitor
CC patients
XX
SQ Sequence 1221 BP; 248 A; 362 C; 392 G; 219 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 76;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCATTTGG 392
DB 444 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 237
AAH19460/c
ID AAH19460 standard; DNA; 1221 BP.

XX AC AAH19460;

DT 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-5) coding sequence.

XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;
XX mutant; ds.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT CDS 1..1221

FT /*tag= a

FT /product= "FVII-5"

FT /partial

FT /note= "No start codon given"

XX JP2001061479-A.

PN 13-MAR-2001.

XX 24-AUG-1999; 99JP-00237610.

XX 24-AUG-1999; 99JP-00237610.

XX (KAGA) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.

XX WPI; 2001-310677/33.

DR P-PSDB; AAB84867.

XX Mutant of blood coagulant factor VII, used for substitution therapy in
XX the treatment of hemophilia.

XX Disclosure; Page 10-11; 29pp; Japanese.

XX The present invention relates to mutants of blood coagulant factor VII
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present
XX sequence is the coding sequence for one such mutant FVII: VII-5. In the
XX wild-type protein (AAB84866), there is a disulphide bond (159Cys-164Cys).
XX In VII-5, the disulphide bond is disrupted. The mutants can be used as an
XX agent for the substitution therapy of haemophilia inhibitor patients

XX Sequence 1221 BP; 248 A; 365 C; 392 G; 216 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 76;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCATTTGG 392
DB 444 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 238

AAH19461/c

ID AAH19461 standard; DNA; 1221 BP.

XX AC AAH19461;

DT 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-6) coding sequence.

XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;
XX mutant; ds.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT CDS 1..1221

FT /*tag= a

FT /product= "FVII-6"

FT /partial

FT /note= "No start codon given"

XX JP2001061479-A.

PN 13-MAR-2001.

XX 24-AUG-1999; 99JP-00237610.

XX 24-AUG-1999; 99JP-00237610.

XX (KAGA) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.

XX WPI; 2001-310677/33.

DR P-PSDB; AAB84868.

XX Mutant of blood coagulant factor VII, used for substitution therapy in
XX the treatment of hemophilia.

XX Disclosure; Page 13-14; 29pp; Japanese.

XX The present invention relates to mutants of blood coagulant factor VII
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present
XX sequence is the coding sequence for one such mutant FVII: VII-6. The
XX mutants can be used as an agent for the substitution therapy of
XX haemophilia inhibitor patients

XX Sequence 1221 BP; 248 A; 365 C; 391 G; 217 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 76;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTCATTTGG 392
DB 444 TTTCGTGGCATTTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 239

AAH19462/c

ID AAH19462 standard; DNA; 1221 BP.

XX AC AAH19462;

DT 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-30) coding sequence.

XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;
XX mutant; ds.

OS Homo sapiens.

PA (AFY-) AFFYMETRIX INC.
 XX Alshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 PI Lipshutz RJ, Patil N, Sklar P;
 XX WPI; 2000-611722/58.
 DR Nucleic acid selected from one of 106 genes comprising single nucleotide
 PT polymorphisms, allele-specific oligonucleotides to the genes are useful
 PT for phenotypic correlations, forensics, paternity testing, medicine and
 XX genetic analysis.
 PS Claim 1; Fig 5; 214pp; English.
 CC The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases. Note: The degenerate codon within the sequence represents the
 CC position of an SNP, for example the letter S represents a polymorphism
 CC where the nucleotide may be C or G
 XX Sequence 259 BP; 67 A; 61 C; 59 G; 71 T; 0 U; 1 Other;
 SQ Query Match 1.0%; Score 20.4; DB 1; Length 259;
 Best Local Similarity 58.1%; Pred. No. 61;
 Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
 QY 334 TTCAATGCTCTTATCTGCGAGACTTGCTTTGTTTGAATATGATTCATTTTGA 393
 DB 128 TTTCGTGCAATCTCTTTTCTAGATAGGATTTTCCACATGATTCACACTGGTA 69
 QY 394 GA 395
 DB 68 AA 67
 RESULT 248
 ACL21595/c
 ID ACL21595 standard; DNA; 288 BP.
 XX AC ACL21595;
 XX AC ACL21595;
 XX 27-OCT-2003 (revised)
 DT 17-OCT-2003 (first entry)
 XX DNA clone originating in barley containing SNP encoding sequence #11586.
 XX Barley; single nucleotide polymorphism; SNP; genotype-phenotype analysis;
 XX gene; ss.
 XX Hordeum vulgare; var. (cul.Akashinriki).
 XX WO2003057877-A1.
 XX 17-JUL-2003.
 XX 16-DEC-2002; 2002WO-IB005403.
 XX 20-DEC-2001; 2001JP-00387059.
 XX 20-DEC-2001; 2001JP-00387131.
 XX 20-DEC-2001; 2001JP-00403299.
 XX 20-DEC-2001; 2001JP-00403300.
 XX 27-SEP-2002; 2002JP-00327515.
 XX (UYN-) UNIV JAPAN OKAYAMA.
 XX Sato K, Takeda K, Kohara Y;
 PI WPI; 2001-662795/76.
 XX Novel isolated nucleic acid molecule associated with cancerous state of
 PT prostate cells and correlating with presence of prostate cancer, useful

DR WPI; 2003-587127/55.
 XX Single nucleotide polymorphism sites in barley varieties and DNA
 PT sequences containing them for analysis and identification of barley
 PT varieties and production of barley transformants with desired
 PT characteristics.
 XX Disclosure; SEQ ID XX; 284pp; Japanese.
 PS The present invention relates to oligonucleotide clones originating in
 XX barley (Hordeum vulgare) which contain single nucleotide polymorphisms
 CC (SNP). The oligonucleotides may be used for analysis of SNPs among barley
 CC varieties, identification of particular varieties and genotype-phenotype
 CC analysis, isolation of specific genes and creation of new varieties by
 CC transformation of barley varieties with them and production of new barley
 CC varieties with desired properties. The present sequence represents an
 CC oligonucleotide clone DNA sequence featured in the specification. The
 CC sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published-pct-sequences. (Updated on 27-OCT-2003 to
 CC standardise OS field)
 XX Sequence 288 BP; 82 A; 75 C; 69 G; 52 T; 0 U; 10 Other;
 SQ Query Match 1.0%; Score 20.4; DB 1; Length 288;
 Best Local Similarity 49.0%; Pred. No. 63;
 Matches 51; Conservative 0; Mismatches 53; Indels 0; Gaps 0;
 QY 1472 CTTTAGTGATTGATTATGACTGTGGGAGTTCTTTTCGGTCCCAATCTATTG 1531
 DB 112 CTTGAGNCCATAATATTTTGACGTACGTACGCGCGATGCTGATCTCTTT 53
 QY 1532 GGTGTTGTATGCTTCTTGTACCTGTAGGCAATCTTTCTCA 1575
 DB 52 CGGCTCTGTCGGTCAATGCGGTATGATGATCTGTTCTTTTAA 9
 RESULT 249
 ABV08821
 ID ABV08821 standard; cDNA; 397 BP.
 XX AC ABV08821;
 XX DT 13-SEP-2002 (first entry)
 XX DE Human prostate expression marker cDNA 8812.
 XX Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker;
 KW pharmacogenomic marker; gene; ss.
 XX OS Homo sapiens.
 XX PN WO200160860-A2.
 XX 23-AUG-2001.
 XX 20-FEB-2001; 2001WO-US005171.
 XX 17-FEB-2000; 2000US-0183119P.
 XX 16-MAR-2000; 2000US-0189862P.
 XX 25-MAY-2000; 2000US-0207454P.
 XX 09-JUN-2000; 2000US-0211314P.
 XX 18-JUL-2000; 2000US-0219007P.
 XX 13-DEC-2000; 2000US-0255281P.
 XX (WILL-) MILLENNIUM PREDICTIVE MEDICINE INC.
 XX Schlegel R, Endege WO, Monahan JE;
 PI WPI; 2001-662795/76.
 XX Novel isolated nucleic acid molecule associated with cancerous state of
 PT prostate cells and correlating with presence of prostate cancer, useful

PT for detecting presence of prostate cancer, stage of prostate cancer.
 XX
 PS Claim 1; Page 1389; 11750pp; English.
 XX
 CC The invention relates to an isolated nucleic acid molecule (I) comprising
 CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the
 CC specification or its complement. (I) is useful for: (a) assessing whether
 CC a patient is afflicted with prostate cancer; (b) monitoring the
 CC progression of prostate cancer in a patient; (c) assessing the efficacy
 CC of a test compound to inhibit prostate cancer in a patient; (d) assessing
 CC the efficacy of a therapy for inhibiting prostate cancer in a patient;
 CC (e) selecting a composition for inhibiting prostate cancer in a patient;
 CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)
 CC determining whether prostate cancer has metastasized in a patient; (h)
 CC assessing the aggressiveness or indolence of prostate cancer in a patient
 CC ; (I) is also useful as a pharmacodynamic or pharmacogenomic marker
 XX
 SQ Sequence 397 BP; 85 A; 89 C; 82 G; 141 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.4; DB 1; Length 397;
 Best Local Similarity 52.3%; Pred. No. 67;
 Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
 QY 1097 TGTTCTCTCCCTTTTGATTTTGGCTGGAATTATTATTATTCATATTTCTTGAA 1156
 Db 34 TCTTCTTTGCACACACGCTCAATGTGGCTGTCTTATTTCTCAAAAACCCATTAGCT 93
 QY 1157 TGTTGGTAACATCTTTAGATTGAAGT 1182
 Db 94 CTGTGGTAGCGTTTAAATAGGAATT 119

RESULT 250
 AAA61659
 ID AAA61659 standard; cDNA; 717 BP.

AC AAA61659;
 XX
 DT 23-OCT-2000 (first entry)
 XX
 DE cDNA encoding mouse serine protease BSSP2 (mBSSP2), SEQ ID NO:1.
 XX
 KW BSSP2; serine protease; mouse; mBSSP2; human; hBSSP2; brain;
 KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;
 KW epilepsy; cancer; inflammation; inflammatory disorder; infertility;
 KW prostatic hypertrophy; ss.
 XX
 OS Mus sp.
 XX
 PN W0200031272-A1.
 XX
 PD 02-JUN-2000.
 XX
 PF 19-NOV-1999; 99WO-JP006475.
 XX
 PR 20-NOV-1998; 98JP-00347785.
 XX
 PA (FUSO) FUSO PHARM IND LTD.
 XX
 FI Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;
 XX
 DR WPI; 2000-400082/34.
 DR P-PSDB; AAB11695.

PT Serine protease BSSP2, useful in detecting homologs, mutants and
 PT polymorphic variants as markers for diagnosis of e.g. Alzheimer's
 PT disease, cancer, inflammation and prostate hypertrophy, using blood,
 PT urine or other tissues.

PS Claim 2; Page 55-57; 92pp; Japanese.

XX The invention relates to novel serine proteases designated BSSP2
 CC (AAB11695-B11699), and to nucleic acids encoding them (AAA61659-A61663).

CC The invention also relates to vectors and transformants comprising BSSP2
 CC nucleic acids; transgenic animals in which the expression level of BSSP2
 CC can be varied; and an mBSSP2 knockout mouse. The invention additionally
 CC encompasses anti-BSSP2 antibodies and methods of production of such
 CC antibodies, methods of BSSP2 detection using the antibodies, and the use
 CC of BSSP2 proteins or fragments as diagnostic markers for certain medical
 CC conditions. Nucleotides encoding BSSP2 were initially isolated in a mouse
 CC brain cDNA library using degenerate PCR primers (AAA61673-AAA61674)
 CC based on conserved regions of serine proteases. The BSSP2 serine
 CC proteases and nucleotides encoding them are useful in detecting
 CC homologues, mutants and polymorphic variants in biological samples (e.g.,
 CC blood, urine, brain, prostate gland and testis) as diagnostic markers for
 CC conditions such as Alzheimer's disease, epilepsy, cancer, inflammation,
 CC infertility and prostatic hypertrophy. Sequences AAA61659-A61662
 CC represent cDNAs encoding murine BSSP2 variants (mBSSP2), and sequence
 CC AAA61663 represents cDNA encoding human BSSP2 (hBSSP2)

XX Sequence 717 BP; 138 A; 204 C; 221 G; 154 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.4; DB 1; Length 717;
 Best Local Similarity 52.3%; Pred. No. 77;
 Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;
 QY 26 TATTTTCTTGAAGCTCTGCTGGCAATACTTCTGGGGCTGCTTCTCCCTGTCTGA 85
 Db 107 TAGTGACTGCTGCCCACTGCATGTACGTTTACGCTGTCCCGCTATCCAGCTGGCGG 166
 QY 86 TTCCTAGGGTGAGGGTTACCACTGCT 111
 Db 167 TTCATGCAGGGCTGGTCAAGCATGGT 192

Search completed: August 9, 2004, 17:01:34
 Job time : 790 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:49:06 ; Search time 10 seconds
(without alignments)
3.696 Million cell updates/sec

Title: us-10-664-775-3
Perfect score: 2000000000
Sequence: 1 agcttccagagacttca.....tcaaggacatttatgaatt 2003

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues

Total number of hits satisfying chosen parameters: 40

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rniidb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	1.0	1440	1	US-07-882-202A-3
C 2	20.6	1.0	1440	1	US-08-021-615A-3
C 3	20.6	1.0	1440	1	US-08-321-777-3
C 4	20.6	1.0	1440	1	US-09-009-217-13
C 5	20.6	1.0	1440	1	US-09-009-656-13
C 6	20.6	1.0	1440	1	PCT-US93-04493-3
C 7	16.6	0.8	1440	1	US-07-882-202A-3
C 8	16.6	0.8	1440	1	US-08-021-615A-3
C 9	16.6	0.8	1440	1	US-08-321-777-3
C 10	16.6	0.8	1440	1	US-09-009-217-13
C 11	16.6	0.8	1440	1	US-09-009-656-13
C 12	16.6	0.8	1440	1	PCT-US93-04493-3
C 13	12.8	0.6	141	1	US-08-849-248-6
C 14	12.6	0.6	141	1	US-08-849-248-6
C 15	12	0.6	38	1	US-09-558-027-4
C 16	11.2	0.6	27	1	US-08-293-778-17
C 17	11	0.5	27	1	US-08-293-778-16
C 18	11	0.5	38	1	US-09-558-027-4
C 19	10.6	0.5	42	1	US-08-955-636-8
C 20	10.6	0.5	45	1	US-08-756-506-13
C 21	10.4	0.5	45	1	US-08-756-506-13
C 22	10	0.5	35	1	US-07-998-972A-7
C 23	10	0.5	35	1	US-08-463-953-7
C 24	10	0.5	35	1	US-08-462-261-7
C 25	10	0.5	35	1	PCT-US92-11357-7
C 26	9.8	0.5	27	1	US-08-293-778-16
C 27	9.4	0.5	27	1	US-08-293-778-17
C 28	9.4	0.5	35	1	US-07-998-972A-7
C 29	9.4	0.5	35	1	US-08-463-953-7
C 30	9.4	0.5	35	1	US-08-462-261-7
C 31	9.4	0.5	35	1	PCT-US92-11357-7
C 32	9.4	0.5	36	1	US-08-955-636-9
C 33	9.4	0.5	36	1	US-08-955-636-10

C 34	9.2	0.5	26	1	US-08-293-778-22	Sequence 22, Appl
C 35	9.2	0.5	27	1	US-08-293-778-20	Sequence 20, Appl
C 36	8.8	0.4	42	1	US-08-955-636-8	Sequence 8, Appl
C 37	8.6	0.4	27	1	US-08-293-778-20	Sequence 20, Appl
C 38	8.4	0.4	36	1	US-08-955-636-9	Sequence 9, Appl
C 39	8.4	0.4	36	1	US-08-955-636-10	Sequence 10, Appl
C 40	7.4	0.4	26	1	US-08-293-778-22	Sequence 22, Appl

ALIGNMENTS

RESULT 1
US-07-882-202A-3/c
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note="Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-07-882-202A-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

OY 334 TTCAATTGCTTTATCTGTCGAGACTTCTTCTTTTGAATATGATTCATTGG 392

Db 659 TTTCCTGCATTTCTTTTCTAGATAGGATTTTCCACATGGAATTCACACTGG 601

10664775-3.rni

Mon Aug 9 17:47:19 2004

RESULT 2
US-08-021-615A-3/C
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021.615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGCCTTTGTTTGAATATGTTCAATTGG 392
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGGATATTTCCACATGATATTCACCTGG 601

RESULT 3
US-08-321-777-3/C
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321.777
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-321-777-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGCCTTTGTTTGAATATGTTCAATTGG 392
DB 659 TTGCTGGCAATTCCTTTTCTAGATAGGATATTTCCACATGATATTCACCTGG 601

RESULT 4
US-09-009-217-13/C
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas

```

; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGCGAGACTTGTCTTTTGAATATGATATTCATTTGG 392
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGTATTTCCACATGATATTCACGTGG 601

RESULT 5
US-09-009-656-13/c
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:

; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGCGAGACTTGTCTTTTGAATATGATATTCATTTGG 392
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGTATTTCCACATGATATTCACGTGG 601

RESULT 6
PCT-US93-04493-3/c
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
```

10664775-3.rn1

Mon Aug 9 17:47:19 2004

```

;
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85; 24; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24;

QY 334 TTCAATGCTTTTATCTGTCGACACTGCTTTGTTTGAATATGTAATTCATTTTGG 392
Db 659 TTGCTGCAATCTTTTCTAGAAAGGTAATTTTCCACATGGATATTCACACTGTTG 601

RESULT 7
US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882,202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMERF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION:
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /citation= ([1])
US-07-882-202A-3

Query Match 0.8%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTTGCATAGTCTCTCGCTTCCTCGATG 1693
Db 58 TCCCTGCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021,615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882,202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMERF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION:
; OTHER INFORMATION: /note= "Coding portion of human factor VII cDNA"
; OTHER INFORMATION: /citation= ([1])
US-08-021-615A-3

Query Match 0.8%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTTGCATAGTCTCTCGCTTCCTCGATG 1693
Db 58 TCCCTGCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
```

QY 1655 TCCTTTGGTTTTCATAGTGTCTCGCTTCCTGGATG 1693
|||||
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 9

US-08-321-777-3
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4

; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321,777
; FILING DATE:

; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRP B34290C
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500

; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:

; NAME/KEY: CDS
; LOCATION: 35..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
US-08-321-777-3

Query Match 0.8%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTGTCTCGCTTCCTGGATG 1693
|||||
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 10

US-09-009-217-13
; Sequence 13, Application US/09009217

; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997

; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577

; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-009-217-13

Query Match 0.8%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTGTCTCGCTTCCTGGATG 1693
|||||
Db 58 TCCTCTGCCTTCTGCTTGGGCTTCAGGGCTGCTGGCTG 96
|||||

RESULT 11

US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning

; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433

```

; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13
;
; Query Match 0.8%; Score 16.6; DB 1; Length 1440;
; Best Local Similarity 64.1%; Pred. No. 12;
; Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;
; QY 1655 TCCTTGGTTTTCGATAGTCTCTGGCTTCCTGGATG 1693
; DB 58 TCCTCTGCCTTCTCTGGCTTCAGGCTGCCTGGCTG 96
;
; RESULT 12
; PCT-US93-04493-3
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
;
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:537
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-656-13
;
; Query Match 0.8%; Score 16.6; DB 1; Length 1440;
; Best Local Similarity 64.1%; Pred. No. 12;
; Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;
; QY 1655 TCCTTGGTTTTCGATAGTCTCTGGCTTCCTGGATG 1693
; DB 58 TCCTCTGCCTTCTCTGGCTTCAGGCTGCCTGGCTG 96
;
; RESULT 13
; US-08-849-248-6/c
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OWRB B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /citation= {[1]}
; PCT-US93-04493-3
;
; Query Match 0.8%; Score 16.6; DB 1; Length 1440;
; Best Local Similarity 64.1%; Pred. No. 12;
; Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;
; QY 1655 TCCTTGGTTTTCGATAGTCTCTGGCTTCCTGGATG 1693
; DB 58 TCCTCTGCCTTCTCTGGCTTCAGGCTGCCTGGCTG 96
;
; RESULT 13
; US-08-849-248-6/c
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: IBM PC compatible
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
;

```

```
;
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6
;
Query Match          0.6%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 61;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
QY 41 TCTGCTGGCAATCTCTCTGGGCT 64
   |||||
Db 25 TCAGCTGGTCATCTCTGGGCT 2
   |||||

RESULT 14
US-08-849-248-6
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Hushyn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6
;
Query Match          0.6%; Score 12.6; DB 1; Length 141;
Best Local Similarity 55.8%; Pred. No. 70;
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
;
QY 1288 TTCTAGTGCAGTACTGCTGGCTGACATCTGTAGTCTTGA 1330
   |||||
Db 97 TGGCAGAGGGTACTCTGCTGGCAGAGGGGTGCTGCA 139
   |||||

RESULT 15
US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
;
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4
;
Query Match          0.6%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
;
QY 787 AGGGCCATTTCTTAGAATA 806
   |||||
Db 31 AGCCCATTTCCCTAGACTA 12
   |||||

RESULT 16
US-08-293-778-17/C
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DX 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agriis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17
;
Query Match          0.6%; Score 11.2; DB 1; Length 27;
```

Best Local Similarity 81.2%; Pred. No. 47;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GCTTCCTGGATGTTT 1697
Db 23 GCGTCCTGGAAGATT 8

RESULT 17
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaissen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 57;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1981 TCTTCAAGGAC 1991
Db 11 TCTTCAAGGAC 21

RESULT 18
US-09-558-027-4
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match 0.5%; Score 11; DB 1; Length 38;
Best Local Similarity 57.1%; Pred. No. 83;
Matches 20; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 527 GACCTAACTGTGGAGAGATGGGTATTGAAGTA 561
Db 4 GAATTCATAGTCTAGGAAATGGGCTCGCAGGA 38

RESULT 19
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGCCAGGCTAGGGGCAC 156
Db 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 20
US-08-756-506-13/c
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.

;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
;; TITLE OF INVENTION: ANIMALS
;; NUMBER OF SEQUENCES: 25
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: ZymoGenetics, Inc.
;; STREET: 1201 Eastlake Avenue East
;; CITY: Seattle
;; STATE: WA
;; COUNTRY: USA
;; ZIP: 98102
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/756,506
;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A.
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6678
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13
;;
Query Match 0.5%; Score 10.6; DB 1; Length 45;
Best Local Similarity 57.8%; Pred. No. 1.3e+02;
Matches 19; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
;;
QY 135 TTCTGGCCAGGCTAGGCGACCTACCGCATTC 167
Db 35 TGCTGCAAGCGGCAGCGGCCAATCTCTTCC 3
;;
RESULT 21
US-08-756-506-13
; Sequence 13, Application US/08/756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garnek, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC
; TITLE OF INVENTION: ANIMALS
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: ZymoGenetics, Inc.
; STREET: 1201 Eastlake Avenue East
; CITY: Seattle
; STATE: WA
; COUNTRY: USA
; ZIP: 98102
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/756,506

;; FILING DATE:
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Sawislak, Deborah A.
;; REGISTRATION NUMBER: 37,438
;; REFERENCE/DOCKET NUMBER: 95-28
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 206-442-6678
;; TELEFAX: 206-442-6678
;; INFORMATION FOR SEQ ID NO: 13:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 45 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; IMMEDIATE SOURCE:
;; CLONE: ZC6337
;; US-08-756-506-13
;;
Query Match 0.5%; Score 10.4; DB 1; Length 45;
Best Local Similarity 60.7%; Pred. No. 1.6e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
;;
QY 536 GTTGAGAGAAATGGGTATTGAAGTAGC 563
Db 10 GTTGGCGGCTTGGCGCGTTCAGCACC 37
;;
RESULT 22
US-07-998-972A-7/c
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

```
; Sequence 7, Application US/08462261.
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-462-261-7

Query Match 0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1296 GCAGTAGTCTGGCCTGAC 1313
DB 21 GGAGTTGGCTCGCCGGAC 4

RESULT 25
PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

Query Match 0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1296 GCAGTAGTCTGGCCTGAC 1313
DB 21 GGAGTTGGCTCGCCGGAC 4

RESULT 24
US-08-462-261-7/c
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/463,953
; FILING DATE:
; CLASSIFICATION: 514
; APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-463-953-7

Query Match 0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1296 GCAGTAGTCTGGCCTGAC 1313
DB 21 GGAGTTGGCTCGCCGGAC 4

RESULT 24
US-08-463-953-7
```

ZIP: 94105
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US92/11357
FILING DATE: 19921230
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/860,701
FILING DATE: 31-MAR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/816,281
FILING DATE: 31-DEC-1991
ATTORNEY/AGENT INFORMATION:
NAME: Parmelee, Steven W
REGISTRATION NUMBER: 31,990
REFERENCE/DOCKET NUMBER: 13952-12-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 206-467-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 7:
SEQUENCE CHARACTERISTICS:
LENGTH: 35 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
IMMEDIATE SOURCE:
CLONE: ZC1324
PCT-US92-11357-7

Query Match 0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1296 GCAGTAGTCTGGCTGAC 1313
DB 21 GCAGTTGGCTCGCGGAC 4

RESULT 26
US-08-293-778-16/c
Sequence 16, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/898,248
FILING DATE: 12-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Agis, Cheryl H.
REGISTRATION NUMBER: 34,086
REFERENCE/DOCKET NUMBER: 3129.224-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-867-0298
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 27 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
US-08-293-778-16

Query Match 0.5%; Score 9.8; DB 1; Length 27;
Best Local Similarity 66.7%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 447 GTCTGTAATATCTTAGGTC 467
DB 21 GTCTTGAGATCTCCGGGC 1

RESULT 27
US-08-293-778-17
Sequence 17, Application US/08293778
Patent No. 5580560
GENERAL INFORMATION:
APPLICANT: Nicolaisen, Else M.
APPLICANT: Bjorn, Soren E.
APPLICANT: Wiberg, Finn C.
APPLICANT: Woodbury, Richard
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
NUMBER OF SEQUENCES: 26
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.
STREET: 405 Lexington Avenue, 62nd Floor
CITY: New York
STATE: New York
COUNTRY: United States of America
ZIP: 10174-6201
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/293,778
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/104,509
FILING DATE:
APPLICATION NUMBER: DK 3235/87
FILING DATE: 25-JUN-1987
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/434,149
FILING DATE: 13-NOV-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/DK88/00103
FILING DATE: 24-JUN-1988

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-293-778-17

Query Match 0.5%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1981 TCTTCAAGGAC 1991
DB 11 TCTTCCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US/07/998,972A
; FILING DATE: 31-MAR-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-463-953-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGATG 1693
DB 21 CTTCTGGAGG 31

RESULT 30
US-08-462-261-7
```

```

; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-07-998-972A-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGATG 1693
DB 21 CTTCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: US/08/463,953
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-463-953-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGATG 1693
DB 21 CTTCTGGAGG 31

RESULT 30
US-08-462-261-7
```

; Sequence 7, Application US/08462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-462-261-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGGATG 1693
|||
Db 21 CTTCTGGGAGG 31

RESULT 31
PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA

; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGGATG 1693
|||
Db 21 CTTCTGGGAGG 31

RESULT 32
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

Query Match 0.5%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 153 GCACTACCGCATTCCTCT 171
|||
Db 13 GCCGTGCCGAGCTCCTCT 31

RESULT 33

US-08-955-636-10/c
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955.636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match 0.5%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 153 GCACCTACCGCATTCCTCT 171
Db 24 GCGGTGGCGAGCTCCCT 6

RESULT 34
US-08-293-778-22/c
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELEPHONE: 212-867-0298
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match 0.5%; Score 9.2; DB 1; Length 26;
Best Local Similarity 78.6%; Pred. No. 2.5e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1814 GTCTGTGAGTTCC 1827
Db 25 GTCTCCGACCTTC 12

RESULT 35
US-08-293-778-20
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match
Best Local Similarity 0.5%; Score 9.2; DB 1; Length 27;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 134 CTCTGGGCGCAGG 147
Db 2 CTCTGGACCTGGG 15

RESULT 36
US-08-955-636-8/c
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match
Best Local Similarity 0.4%; Score 8.8; DB 1; Length 42;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTGAAGCCTCTGTGGCAATACCTCTGGGCTG 65
Db 42 TTCTGGAGGAGCTCCGTCCAGCAGCCTTGAGCGG 7

RESULT 37
US-08-293-778-20/c
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agriis, Cheryl H.
; REGISTRATION NUMBER: 34,066
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match
Best Local Similarity 0.4%; Score 8.6; DB 1; Length 27;
Matches 14; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 403 AGGTCGTGTGACAGAAGGTACAG 425
Db 27 AGGGCCGTGGCGCCAGGTCCAG 5

RESULT 38
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match
Best Local Similarity 0.4%; Score 8.4; DB 1; Length 36;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 52 TACTTCTGGGCTGCTGC 69
Db 35 TCCTAGAGGAGCTGCGGC 18

RESULT 39
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
```

```
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match          0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred. No. 4.4e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 52 TACTTCGGGCTGCTGC 69
DB 2 TCCTAGAGGAGTGGGC 19

RESULT 40
US-08-293-778-22
; Sequence 22; Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298

; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match          0.4%; Score 7.4; DB 1; Length 26;
Best Local Similarity 64.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 943 AGTCATTGATGTTGAGA 959
DB 6 AGTCACGGAGGTCGGA 22

Search completed: August 9, 2004, 16:49:17
Job time: 11 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:49:40 ; Search time 26 Seconds
(without alignments)

3.874 Million cell updates/sec

Title: us-10-664-775-3

Perfect score: 2003

Sequence: 1 agctttccagagacttca.....tcaaggacatttatgaatt 2003

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpbdb.*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	20.6	1.0	1332	1	US-10-411-037-7 Sequence 7, Appl
C 2	20.6	1.0	1332	1	US-10-411-026-7 Sequence 7, Appl
C 3	20.6	1.0	1332	1	US-10-410-962-7 Sequence 7, Appl
C 4	20.6	1.0	1332	1	US-10-411-049-7 Sequence 7, Appl
C 5	20.6	1.0	1332	1	US-10-410-930-7 Sequence 7, Appl
C 6	20.6	1.0	1332	1	US-10-410-997-7 Sequence 7, Appl
C 7	20.6	1.0	1332	1	US-10-411-012-7 Sequence 7, Appl
C 8	20.6	1.0	1332	1	US-10-287-994-7 Sequence 7, Appl
C 9	20.6	1.0	1332	1	US-10-410-913-7 Sequence 13, Appl
C 10	20.6	1.0	1440	1	US-10-375-741-13 Sequence 12, Appl
C 11	20.6	1.0	2040	1	US-10-617-619-12 Sequence 9, Appl
C 12	20.6	1.0	2106	1	US-10-617-619-9 Sequence 35, Appl
C 13	17.8	0.9	1361	1	US-10-382-248-35 Sequence 8429, Ap
C 14	17	0.8	483	1	US-09-918-995-8429 Sequence 7, Appl
C 15	17	0.8	1332	1	US-10-411-037-7 Sequence 7, Appl
C 16	17	0.8	1332	1	US-10-411-026-7 Sequence 7, Appl
C 17	17	0.8	1332	1	US-10-410-962-7 Sequence 7, Appl
C 18	17	0.8	1332	1	US-10-411-049-7 Sequence 7, Appl
C 19	17	0.8	1332	1	US-10-410-930-7 Sequence 7, Appl
C 20	17	0.8	1332	1	US-10-410-997-7 Sequence 7, Appl
C 21	17	0.8	1332	1	US-10-411-012-7 Sequence 7, Appl
C 22	17	0.8	1332	1	US-10-287-994-7 Sequence 7, Appl
C 23	17	0.8	1332	1	US-10-410-913-7 Sequence 12, Appl
C 24	17	0.8	2040	1	US-10-617-619-12 Sequence 9, Appl
C 25	16.6	0.8	1338	1	US-09-782-587B-2 Sequence 4, Appl
C 26	16.6	0.8	1357	1	US-09-782-587B-4 Sequence 35, Appl
C 27	16.6	0.8	1361	1	US-10-382-248-35 Sequence 13, Appl
C 28	16.6	0.8	1440	1	US-10-375-741-13 Sequence 9, Appl
C 29	16.6	0.8	2106	1	US-10-617-619-9 Sequence 8429, Ap
C 30	16.4	0.8	483	1	US-09-918-995-8429 Sequence 9623, Ap
C 31	14.8	0.7	555	1	US-10-029-386-9623 Sequence 23323, A
C 32	14.6	0.7	222	1	US-10-029-386-9623 Sequence 9623, Ap
C 33	14.6	0.7	555	1	US-10-029-386-9623 Sequence 9623, Ap

C 34	14.2	0.7	60	1	US-10-272-665-22 Sequence 22, Appl
C 35	14.2	0.7	60	1	US-10-273-321-22 Sequence 22, Appl
C 36	14.2	0.7	60	1	US-10-272-756-22 Sequence 22, Appl
C 37	14.2	0.7	60	1	US-10-273-228-22 Sequence 22, Appl
C 38	14.2	0.7	100	1	US-10-272-665-107 Sequence 107, App
C 39	14.2	0.7	100	1	US-10-273-321-107 Sequence 107, App
C 40	14.2	0.7	100	1	US-10-272-756-107 Sequence 107, App
C 41	14.2	0.7	100	1	US-10-273-228-107 Sequence 107, App
C 42	14.2	0.7	100	1	US-10-272-665-106 Sequence 106, App
C 43	14.2	0.7	100	1	US-10-273-321-106 Sequence 106, App
C 44	14.2	0.7	100	1	US-10-272-756-106 Sequence 106, App
C 45	14.2	0.7	100	1	US-10-273-228-106 Sequence 2, Appl
C 46	14.2	0.7	1338	1	US-09-782-587B-2 Sequence 2, Appl
C 47	14.2	0.7	1357	1	US-09-782-587B-4 Sequence 23323, A
C 48	12	0.6	222	1	US-10-029-386-23323 Sequence 8, Appl
C 49	11.8	0.6	54	1	US-10-349-858-8 Sequence 6, Appl
C 50	11.6	0.6	32	1	US-10-281-727-6 Sequence 7, Appl
C 51	11.6	0.6	32	1	US-10-281-727-7 Sequence 7, Appl
C 52	11.4	0.6	38	1	US-10-398-422A-20 Sequence 20, Appl
C 53	11.4	0.6	38	1	US-09-969-357-2 Sequence 2, Appl
C 54	11.4	0.6	38	1	US-10-254-394-2 Sequence 2, Appl
C 55	11.2	0.6	33	1	US-09-951-121A-14 Sequence 14, Appl
C 56	11.2	0.6	33	1	US-09-951-121A-15 Sequence 15, Appl
C 57	11.2	0.6	33	1	US-10-295-682-14 Sequence 14, Appl
C 58	11.2	0.6	33	1	US-10-295-682-15 Sequence 15, Appl
C 59	10.6	0.5	36	1	US-09-951-121A-8 Sequence 8, Appl
C 60	10.6	0.5	36	1	US-09-951-121A-9 Sequence 9, Appl
C 61	10.6	0.5	36	1	US-10-255-032-8 Sequence 8, Appl
C 62	10.6	0.5	36	1	US-10-255-032-9 Sequence 9, Appl
C 63	10.6	0.5	36	1	US-10-295-682-8 Sequence 8, Appl
C 64	10.6	0.5	36	1	US-10-295-682-9 Sequence 9, Appl
C 65	10.6	0.5	42	1	US-09-803-810-8 Sequence 8, Appl
C 66	10.6	0.5	42	1	US-10-298-330-8 Sequence 8, Appl
C 67	10.6	0.5	60	1	US-10-272-665-23 Sequence 23, Appl
C 68	10.6	0.5	60	1	US-10-273-321-23 Sequence 23, Appl
C 69	10.6	0.5	60	1	US-10-272-756-23 Sequence 23, Appl
C 70	10.6	0.5	60	1	US-10-273-228-23 Sequence 23, Appl
C 71	10.4	0.5	36	1	US-10-281-727-2 Sequence 2, Appl
C 72	10.4	0.5	36	1	US-10-281-727-3 Sequence 3, Appl
C 73	10.2	0.5	38	1	US-10-398-422A-20 Sequence 20, Appl
C 74	10.2	0.5	38	1	US-09-969-357-2 Sequence 2, Appl
C 75	10.2	0.5	38	1	US-10-254-394-2 Sequence 2, Appl
C 76	10.2	0.5	35	1	US-10-109-498-5 Sequence 5, Appl
C 77	10	0.5	35	1	US-10-109-498-6 Sequence 6, Appl
C 78	10	0.5	60	1	US-10-272-665-22 Sequence 22, Appl
C 79	10	0.5	60	1	US-10-273-321-22 Sequence 22, Appl
C 80	10	0.5	60	1	US-10-272-756-22 Sequence 22, Appl
C 81	10	0.5	60	1	US-10-273-228-22 Sequence 22, Appl
C 82	10	0.5	100	1	US-10-272-665-107 Sequence 107, App
C 83	10	0.5	100	1	US-10-273-321-107 Sequence 107, App
C 84	10	0.5	100	1	US-10-272-756-107 Sequence 107, App
C 85	10	0.5	100	1	US-10-273-228-107 Sequence 107, App
C 86	10	0.5	100	1	US-10-272-665-106 Sequence 106, App
C 87	10	0.5	100	1	US-10-273-321-106 Sequence 106, App
C 88	10	0.5	100	1	US-10-272-756-106 Sequence 106, App
C 89	10	0.5	100	1	US-10-273-228-106 Sequence 106, App
C 90	9.8	0.5	36	1	US-09-951-121A-8 Sequence 8, Appl
C 91	9.8	0.5	36	1	US-09-951-121A-9 Sequence 9, Appl
C 92	9.8	0.5	36	1	US-10-255-032-8 Sequence 8, Appl
C 93	9.8	0.5	36	1	US-10-255-032-9 Sequence 9, Appl
C 94	9.8	0.5	36	1	US-10-295-682-8 Sequence 8, Appl
C 95	9.8	0.5	36	1	US-10-295-682-9 Sequence 9, Appl
C 96	9.8	0.5	54	1	US-10-349-858-8 Sequence 8, Appl
C 97	9.8	0.5	60	1	US-10-272-665-23 Sequence 23, Appl
C 98	9.8	0.5	60	1	US-10-273-321-23 Sequence 23, Appl
C 99	9.8	0.5	60	1	US-10-272-756-23 Sequence 23, Appl
C 100	9.8	0.5	60	1	US-10-273-228-23 Sequence 23, Appl
C 101	9.4	0.5	35	1	US-10-109-498-5 Sequence 5, Appl
C 102	9.4	0.5	35	1	US-10-109-498-6 Sequence 6, Appl
C 103	9.2	0.5	31	1	US-10-017-122-4 Sequence 4, Appl
C 104	9.2	0.5	34	1	US-09-951-121A-2 Sequence 2, Appl
C 105	9.2	0.5	34	1	US-09-951-121A-3 Sequence 3, Appl
C 106	9.2	0.5	34	1	US-10-295-682-2 Sequence 2, Appl

Sequence 3, Appli
Sequence 2, Appli
Sequence 3, Appli
Sequence 14, Appli
Sequence 15, Appli
Sequence 14, Appli
Sequence 15, Appli
Sequence 8, Appli
Sequence 6, Appli
Sequence 7, Appli
Sequence 4, Appli
Sequence 2, Appli
Sequence 3, Appli
Sequence 3, Appli

c 107 9.2 0.5 34 1 US-10-295-682-3
108 9.2 0.5 36 1 US-10-281-727-2
c 109 9.2 0.5 36 1 US-10-281-727-3
110 9 0.4 33 1 US-09-951-121A-14
c 111 9 0.4 33 1 US-09-951-121A-15
112 9 0.4 33 1 US-10-295-682-14
c 113 9 0.4 33 1 US-10-295-682-15
c 114 8.8 0.4 42 1 US-09-803-810-8
c 115 8.8 0.4 42 1 US-10-298-330-8
116 8.4 0.4 32 1 US-10-281-727-6
c 117 8.4 0.4 32 1 US-10-281-727-7
c 118 8.2 0.4 34 1 US-10-017-122-4
c 119 7.8 0.4 34 1 US-09-951-121A-2
120 7.8 0.4 34 1 US-09-951-121A-3
c 121 7.8 0.4 34 1 US-10-295-682-2
122 7.8 0.4 34 1 US-10-295-682-3

ALIGNMENTS

RESULT 1
US-10-411-037-7/c
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bows, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411.037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

US-10-411-026-7

GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411.026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens

Query Match 1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGTAATTCATTTGG 392
DB 558 TTTCGTGCAATTCCTTTTCTAGATAGGATATTTTCCACATGGATATTCACACTGG 500

RESULT 3
US-10-410-962-7/c
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bows, Caryn
; TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410.962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527


```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGTCGAGACTGCTTTCTTTGAAATATGATTCATTTTGG 392
DB 558 TTGCTGCAATTCCTTTTCTAGAAATAGGATTTTCCACATGGATATCAACTGTGG 500

RESULT 7
US-10-411-012-7/c
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match          1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGTCGAGACTGCTTTCTTTGAAATATGATTCATTTTGG 392
DB 558 TTGCTGCAATTCCTTTTCTAGAAATAGGATTTTCCACATGGATATCAACTGTGG 500

RESULT 8
US-10-287-994-7/c
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
```



```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)...(1301)
US-10-382-248-35

Query Match          0.9%; Score 17.8; DB 1; Length 1361;
Best Local Similarity 58.5%; Pred. No. 18;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 334 TTCATTCTCTTATCTGTGAGACTGCTTTCTTTTGAATATGATTCAA 386
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 527 TTGCTGCATTCTCTTTTCTAGAAATGATTTTCCACATGATATTCAA 475

RESULT 14
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match          0.8%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 17;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 122 TCCTCTGCCTCTCTGCTTGGCTTCAGGCTGCCCTGGCTGCTTCGT 170

RESULT 15
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
```

```
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match          0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 23 TCCTCTGCCTCTCTGCTTGGCTTCAGGCTGCCCTGGCTGCTTCGT 71

RESULT 16
US-10-411-026-7
; Sequence 7, Application US/10411026
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match          0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 23 TCCTCTGCCTCTCTGCTTGGCTTCAGGCTGCCCTGGCTGCTTCGT 71

RESULT 17
US-10-410-962-7
```

```
; Sequence 7, Application US/10410962
; Publication No. US2004007836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-962-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCCTGGCTTCTGCTGGGCTTCAGGGCTCCCTGGCTGCAGTCTTCGT 71

RESULT 18
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
```

```
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCCTGGCTTCTGCTGGGCTTCAGGGCTCCCTGGCTGCAGTCTTCGT 71

RESULT 19
US-10-410-930-7
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-930-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCCTGGCTTCTGCTGGGCTTCAGGGCTCCCTGGCTGCAGTCTTCGT 71

RESULT 20
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: FSH
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match 0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCCCTGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 21
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US2004013240A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
```

```
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match 0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCCCTGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 22
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match 0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCCCTGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 23
US-10-410-913-7
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
```



```

US-10-375-741-13
Query Match      0.8%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 30;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1693
      |||||
Db 58 TCCTTGGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 96
      |||||

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaisen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      0.8%; Score 16.6; DB 1; Length 2106;
Best Local Similarity 64.1%; Pred. No. 23;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATG 1693
      |||||
Db 23 TCCTTGGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 61
      |||||

RESULT 30
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FILE OF INVENTION: FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match      0.8%; Score 16.4; DB 1; Length 483;
Best Local Similarity 55.2%; Pred. No. 27;

```

	Matches	32: Conservative	0: Mismatches	26: Indels	0: Gaps
Qy	580	AGTCAATATGTGATTTTAGCTGAGCTGCTTGTGTTTATGAACCTTGGGTGACATTG	637		
Db	415	AGNACTGGAGCTGTCTCTTGAGGAGGCCCCCACTTCTGGCATGTGACTGAGGCACACTG	358		

RESULT 31
 US-10-029-386-9623
 ; Sequence 9623, Application US/10029386
 ; Publication No. US20030194704A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Penn, Sharon G.
 ; APPLICANT: Rank, David R.
 ; APPLICANT: Hanzel, David K.
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
 ; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
 ; FILE REFERENCE: AEOMICA-X-2
 ; CURRENT APPLICATION NUMBER: US/10/029,386
 ; CURRENT FILING DATE: 2001-12-20
 ; NUMBER OF SEQ ID NOS: 34288
 ; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1
 ; SEQ ID NO 9623
 ; LENGTH: 555
 ; TYPE: DNA
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; OTHER INFORMATION: MAP TO CHR13.3
 ; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
 ; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
 ; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
 ; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
 ; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
 ; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
 ; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
 ; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
 ; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
 US-10-029-386-9623

	Query Match	0.7%	Score 14.8;	DB 1;	Length 555;
	Best Local Similarity	56.0%	Pred. No. 70;		
	Matches	28;	Conservative	0;	Mismatches 22; Indels 0; Gaps 0;
QY	148	TAGGGCAGCATCGGCAATTCCTCTCTCTCCAAACACTTCTATTTCTTGA	197		
DB	12	TGGGGAGTCTCCACACTTCGTTACTGCTGCAGGCAGTCTCGGTCAATCA	61		

```

RESULT 32
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEONICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CH13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2

```

```

; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT_HIT: G114783796, EVALUATE 1.00e-122
; OTHER INFORMATION: EST_HUMAN_HIT: A45314727.1, EVALUATE 3.00e-26
; OTHER INFORMATION: SWISSPROT_HIT: P08709, EVALUATE 3.00e-37
US-10-029-386-23323

```

```

Query March      0.7%; Score 14.6; DB 1; Length 222;
Best Local Similarity 54.7%; Pred. No. 60;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 1799 CTGTCAGTGGCGCTGTCTCTGAGGTTCTCTGTGGTTCCTTAATTTTTTCATT 1851
Db 152 CTGCCCCAAGCGAGTTCCTCTGAGAGACGCTGCGCTTCGTGGCGTCTCTATT 100

```

```

RESULT 33
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC A
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN SWISSPROT HIT: P08709, EVALUE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

```

	Query Match	0.7%	Score 14.6;	DB 1;	Length 555;
	Best Local Similarity	54.7%;	Pred. No. 75;		
	Matches	29;	Conservative	0;	Mismatches 24; Indels 0; Gaps 0;
Qy	1799	CTGTGAGTGAGGCTTCTCTCAGGTTCTCTGTGGTCTTTAAATTTTTCATT			1851
Db	188	CTGCCGGAACGGACGTTCTCTGAGAGGACGCTGGCTTCGTGGCTTCATT			136

```

RESULT 34
US/10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,659
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176

```

```

; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22

Query Match          0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCCTCTATTCCTT 1659
DB 58 TGTGGCCTCCACTGTCCCTTCGAGGATCCTT 24

RESULT 35
US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

Query Match          0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCCTCTATTCCTT 1659
DB 58 TGTGGCCTCCACTGTCCCTTCGAGGATCCTT 24

RESULT 36
US-10-272-756-22/c
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C

```

```

; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

Query Match          0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCCTCTATTCCTT 1659
DB 58 TGTGGCCTCCACTGTCCCTTCGAGGATCCTT 24

RESULT 37
US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

Query Match          0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCCTCTATTCCTT 1659
DB 58 TGTGGCCTCCACTGTCCCTTCGAGGATCCTT 24

RESULT 38
US-10-272-665-107/c

```


Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4
|||||

RESULT 42

US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4
|||||

RESULT 43

US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;

Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4
|||||

RESULT 44

US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4
|||||

RESULT 45

US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 0; Gaps 0;

Qy 1625 TTGTGACTGCTTCTCCCTTCTCTATTCCTT 1659
Db 38 TGTGGGCTCCACTGTCCCTTCTCAGGAGTCCTT 4

RESULT 46
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: PEDERSEN, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match 0.7%; Score 14.2; DB 1; Length 1338;
Best Local Similarity 70.4%; Pred. No. 38;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 42 CTGCTGGCAATATCTTCTGGGGCTGCTG 68
Db 22 CTCTGTGCTGCTCTCTGGGGCTGCAG 48

RESULT 47
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match 0.7%; Score 14.2; DB 1; Length 1357;
Best Local Similarity 70.4%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 42 CTGCTGGCAATATCTTCTGGGGCTGCTG 68
Db 35 CTCCTGTGCTGCTCTCTGGGGCTGCAG 61

RESULT 48
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: g14783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match 0.6%; Score 12; DB 1; Length 222;
Best Local Similarity 58.3%; Pred. No. 2.1e+02;
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 657 AAGATTGCAATGTCTTCTGTCGATTTTCCTTG 692
Db 112 ACGAAGCCAGCGTCTCTCAGAGACGTCGTTG 147

RESULT 49
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16

```
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.6%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.8%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1819 TGAGGTTCTCGTGGGTTCTTAA 1841
    ||||| ||||| ||||| |||||
Db 29 TGGGCTTCTCTCGTGGGTTACGAA 7

RESULT 50
US-10-281-727-6/C
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.6%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1893 TTCCACTTTCAGGTCCTG 1910
    ||||| ||||| ||||| |||||
Db 26 TCCACCTTCGCTCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 21 TAATATATTTCCTGAAGCCTCTCTGCGC 49
    ||||| ||||| ||||| |||||
Db 10 TAAAACGCTTTCCTGGAGAGCTCGCGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
US-10-398-422A-20

Query Match          0.6%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1893 TTCCACTTTCAGGTCCTG 1910
    ||||| ||||| ||||| |||||
Db 7 TCCACCTTCGCTCTG 24

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DR01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 21 TAATATATTTCCTGAAGCCTCTCTGCGC 49
    ||||| ||||| ||||| |||||
Db 10 TAAAACGCTTTCCTGGAGAGCTCGCGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
US-10-398-422A-20
```


; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/236,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match 0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 21 TAATATATTTCTTGAAGCCTCTGCTGGC 49
Db 10 TAAACGCTTCTCTGGAGGAGCTGCGGCC 38

RESULT 54
US-10-254-394-2
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; FILE REFERENCE: 6480 500-US
; CURRENT APPLICATION NUMBER: US/10/254,394
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: PCT/DK01/00632
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PCT/DK01/00634
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PA 2002 00460
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: 60/374,855
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match 0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 21 TAATATATTTCTTGAAGCCTCTGCTGGC 49
Db 10 TAAACGCTTCTCTGGAGGAGCTGCGGCC 38

RESULT 55
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A

; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match 0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1295 TGCAGTAGTCTGGCCTGACATCTG 1318
Db 31 TGCAGGAGTCTTGGCGCATCCG 8

RESULT 56
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match 0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY 1295 TGCAGTAGTCTGGCCTGACATCTG 1318
Db 3 TGCAGGAGTCTTGGCGCATCCG 26

RESULT 57
US-10-295-692-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants

```

; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1295 TGCAGTACTGCGCTGACATCTG 1318
Db 31 TGCAGGAGTCTTCCGCCATCCG 8

RESULT 58
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1295 TGCAGTACTGCGCTGACATCTG 1318
Db 3 TGCAGGAGTCTTCCGCCATCCG 26

RESULT 59
US-09-951-121A-8/c
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13

```

```

; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCTCTGAA 1912
Db 33 CACGTTGAGGACCTGGA 17

RESULT 60
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCTCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 61
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1c No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGTCTCTGAA 1912
Db 33 CACGTTGAGGACCTGGA 17

RESULT 62
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGTCTCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 63
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGTCTCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 63
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 3.7e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGCCAGGCTAGGGGCAC 156
Db 2 CACTCCCGCTCCAGGCTGCTGGAC 26

RESULT 66
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Nelstuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 3.7e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGGCGAGGTAGGGGCAC 156
Db 2 CACTCCCGCTCAGGCTCTGGGAC 26

RESULT 67
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 4.4e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCTTTATCTTGCACTTGTGAAGTGTGTGTG 1019
Db 42 TGACGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2

RESULT 68
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 4.4e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCTTTATCTTGCACTTGTGAAGTGTGTGTG 1019
Db 42 TGACGATGCCGTCAGGTACCACGTCGCCCGTAGTGGTG 2
```

```
RESULT 70
US-10-273-228-23/c
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23
Query Match 0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 4.4e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;
QY 979 TGTGGATTCCTGTACTTCACCTTGTGAGTGTGTGTG 1019
DB 42 TGACAGTCCCGTACGTACACGTGCCCGGTAGTGGTG 2
RESULT 71
US-10-281-727-2/c
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2
Query Match 0.5%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1805 GTGAGGCTTCTCTGTGAGGTTCTCTGTG 1832
DB 35 GGGAGTCTCCACGTGCGTTCCTGTG 8
```

```
RESULT 72
US-10-281-727-3
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3
Query Match 0.5%; Score 10.4; DB 1; Length 36;
Best Local Similarity 60.7%; Pred. No. 3.9e+02;
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;
QY 1805 GTGAGGCTTCTCTGTGAGGTTCTCTGTG 1832
DB 2 GGGAGTCTCCACGTGCGTTCCTGTG 29
RESULT 73
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20
Query Match 0.5%; Score 10.2; DB 1; Length 38;
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGCTGCAATACTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 74
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGCTGCAATACTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 75
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: PCT/DK01/00632
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PCT/DK01/00634
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PA 2002 00460
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: 60/374,855
; PRIOR FILING DATE: 2002-10-04
; NUMBER OF SEQ ID NOS: 2
```

```
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGCTGCAATACTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 76
US-10-109-498-5/c
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match      0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 573 GTGTGTGAGCTCAATATGTGATTTAGCTGTAGC 605
    |||||
Db 34 GTCAGTGAGGACCCAGCGACAGTGCAGCGGAGC 1

RESULT 77
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
```



```
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 22
/ LENGTH: 60
/ TYPE: DNA
/ ORGANISM: Homo Sapien
/ FEATURE:
/ OTHER INFORMATION: Probe
US-10-273-228-22
```

```
Query Match 0.5%; Score 10; DB 1; Length 60;
Best Local Similarity 72.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGCCAC 156
||| ||| ||| ||| ||| |||
Db 40 GGGACAGTGGAGGCCAC 57
```

RESULT 82

```
US-10-272-665-107
/ Sequence 107, Application US/10272665
/ Publication No. US20030180748A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033E
/ CURRENT APPLICATION NUMBER: US/10/272,665
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-272-665-107
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGCCAC 156
||| ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 83

```
US-10-273-321-107
/ Sequence 107, Application US/10273321
/ Publication No. US20030180749A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033B
/ CURRENT APPLICATION NUMBER: US/10/273,321
```

```
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-273-321-107
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGCCAC 156
||| ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 84

```
US-10-272-756-107
/ Sequence 107, Application US/10272756
/ Publication No. US20030190644A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033C
/ CURRENT APPLICATION NUMBER: US/10/272,756
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-272-756-107
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGCCAC 156
||| ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 85

```
US-10-273-228-107
/ Sequence 107, Application US/10273228
/ Publication No. US20030207297A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```



```
; GENERAL INFORMATION:
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 86

```
US-10-272-665-106
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 87

```
US-10-273-321-106
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 88

```
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106
```

```
Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

RESULT 89

US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POLYPEPTIDES
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match 0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 139 GGCACAGGTAGGGCCAC 156
DB 20 GGCACAGGTAGGGCCAC 37

RESULT 90
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match 0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
DB 2 CCACGGCCCTGTGCTCCAGGTCCTCAAC 30

RESULT 91
US-09-951-121A-9/c

; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match 0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
DB 35 CCACGGCCCTGTGCTCCAGGTCCTCAAC 7

RESULT 92
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match 0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
DB 2 CCACGGCCCTGTGCTCCAGGTCCTCAAC 30

RESULT 93
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24

```
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
Db 35 CCACGGCCCTGTGCTCCAGGTCCTCAAC 7

RESULT 94
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
Db 2 CCACGGCCCTGTGCTCCAGGTCCTCAAC 30

RESULT 95
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
```

```
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.5%; Score 9.8; DB 1; Length 36;
Best Local Similarity 58.6%; Pred. No. 5.9e+02;
Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTGCTCTCTCTCCCTTTCTCTAAC 132
Db 35 CCACGGCCCTGTGCTCCAGGTCCTCAAC 7

RESULT 96
US-10-349-858-8
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY W.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DARREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT (
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.5%; Score 9.8; DB 1; Length 54;
Best Local Similarity 84.6%; Pred. No. 6.4e+02;
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 11 AGAGACTTCTATAA 23
Db 1 AGAGTCCTTCGTAA 13

RESULT 97
US-10-272-665-23
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
```

; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583
|||||
Db 4 CCCACTACCGGGCAGGTGT 24

RESULT 98

US-10-273-321-23
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583
|||||
Db 4 CCCACTACCGGGCAGGTGT 24

RESULT 99

US-10-272-756-23
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583
|||||
Db 4 CCCACTACCGGGCAGGTGT 24

RESULT 100

US-10-273-228-23
; Sequence 23, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:

; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;
Best Local Similarity 66.7%; Pred. No. 6.4e+02;
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583
|||||
Db 4 CCCACTACCGGGCAGGTGT 24

RESULT 101

US-10-109-498-5
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:

; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20

```

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match          0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 7.4e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1493 TGCACGTGGGAGTTCT 1511
Db 9 TGCACGTGCCGTGTCCT 27

RESULT 102
US-10-109-498-6/c
; Sequence 6, Application US/10109498
; Publication No. US2003004908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; CURRENT FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-6

Query Match          0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 68.4%; Pred. No. 7.4e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1493 TGCACGTGGGAGTTCT 1511
Db 27 TGCACGTGCCGTGTCCT 9

RESULT 103
US-10-017-122-4
; Sequence 4, Application US/10017122
; Publication No. US2003008724A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-017-122-4

Query Match          0.5%; Score 9.2; DB 1; Length 31;
Best Local Similarity 56.7%; Pred. No. 8e+02;

QY 1006 GAAGTGTGTGTGTGTGTGTG 1027
Db 32 GAATTGTGGGGCGCGGTGTG 11

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match          0.5%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1514 TCCGGTCCCAATCTATTTGGTGTGTGTG 1543
Db 2 TCTGTGGTGCCATGAGGGGTACTCTCTG 31

RESULT 104
US-09-951-121A-2
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match          0.5%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTG 1027
Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 105
US-09-951-121A-3/c
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match          0.5%; Score 9.2; DB 1; Length 34;
Best Local Similarity 63.6%; Pred. No. 8.2e+02;
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTG 1027
Db 32 GAATTGTGGGGCGCGGTGTG 11
```

RESULT 106

US-10-295-682-2

; Sequence 2, Application US/10295682

; Publication No. US20030100740A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants

; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/10/295,682

; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361

; PRIOR FILING DATE: 2000-09-13

; PRIOR APPLICATION NUMBER: 60/236,455

; PRIOR FILING DATE: 2000-09-29

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 34

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-295-682-2

Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 34;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTGTG 1027

-Db 3 GAATTGTGGGGCGCGGTGTG 24

RESULT 107

US-10-295-682-3/c

; Sequence 3, Application US/10295682

; Publication No. US20030100740A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants

; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/10/295,682

; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361

; PRIOR FILING DATE: 2000-09-13

; PRIOR APPLICATION NUMBER: 60/236,455

; PRIOR FILING DATE: 2000-09-29

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 34

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-295-682-3

Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 34;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTGTG 1027

-Db 32 GAATTGTGGGGCGCGGTGTG 11

RESULT 108

US-10-281-727-2

; Sequence 2, Application US/10281727

; Publication No. US20030130191A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII

; TITLE OF INVENTION: Polypeptides

; FILE REFERENCE: 6410.200-US

; CURRENT APPLICATION NUMBER: US/10/281,727

; CURRENT FILING DATE: 2002-10-28

; PRIOR APPLICATION NUMBER: PA 2001 01627

; PRIOR FILING DATE: 2001-11-02

; PRIOR APPLICATION NUMBER: 60/335,383

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 36

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-2

Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 36;

Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 862 TGGATGCAGCAGTA 875

-Db 2 TGCCTGCAGCAGGA 15

RESULT 109

US-10-281-727-3/c

; Sequence 3, Application US/10281727

; Publication No. US20030130191A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII

; TITLE OF INVENTION: Polypeptides

; FILE REFERENCE: 6410.200-US

; CURRENT APPLICATION NUMBER: US/10/281,727

; CURRENT FILING DATE: 2002-10-28

; PRIOR APPLICATION NUMBER: PA 2001 01627

; PRIOR FILING DATE: 2001-11-02

; PRIOR APPLICATION NUMBER: 60/335,383

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 36

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-3

Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 36;

Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 862 TGGATGCAGCAGTA 875

-Db 35 TGCCTGCAGCAGGA 22

RESULT 110

US-09-951-121A-14

; Sequence 14, Application US/0951121A

; Publication No. US20030104978A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

```

: APPLICANT: Olesen, Ole Hvilsted
: TITLE OF INVENTION: Human Coagulation Factor VII Variants
: FILE REFERENCE: 6224.200-US
: CURRENT APPLICATION NUMBER: US/10/295.682
: CURRENT FILING DATE: 2002-11-15
:

```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 9.8e+02;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 65
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCG 7

RESULT 115
US-10-298-330-8/c
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; TYPE: DNA
; LENGTH: 42
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 9.8e+02;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 65
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCG 7

RESULT 116
US-10-281-727-6
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; TYPE: DNA
; LENGTH: 32
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION:
US-10-281-727-6

Query Match      0.4%; Score 8.4; DB 1; Length 32;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 866 TGCAGCAGTA 875
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 29 TGCAGCAGGA 20

RESULT 117
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; TYPE: DNA
; LENGTH: 32
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.4%; Score 8.4; DB 1; Length 32;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 866 TGCAGCAGTA 875
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 29 TGCAGCAGGA 20

RESULT 118
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; CURRENT FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; TYPE: DNA
; LENGTH: 31
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-017-122-4

Query Match      0.4%; Score 8.2; DB 1; Length 31;
Best Local Similarity 61.9%; Pred. No. 1.3e+03;
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1278 CAGAAAGTTTCTAAGTCCA 1298
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
```



```
Db 31 CAGAGACTACCCCTCATGGCA 11

RESULT 119
US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTTGGTGCATA 650
Db 31 TTTGGGCACA 21

RESULT 120
US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTTGGTGCATA 650
Db 31 TTTGGGCACA 21

RESULT 121
US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTTGGTGCATA 650
Db 31 TTTGGGCACA 21

RESULT 122
US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTTGGTGCATA 650
Db 4 TTTGGGCACA 14

Search completed: August 9, 2004, 16:50:07
Job time : 27 secs
```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:50:27 ; Search time 3 seconds
(without alignments)
3.679 Million cell updates/sec

Title: US-10-664-775-3
Perfect score: 2003
Sequence: 1 aggttcacagagacttca.....tcaaggacctttatgaatt 2003

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 4 segs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 250 summaries

Database : rstdb:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20.6	1.0	1201	1	AL531727
C 2	19.8	1.0	645	1	AL116939
C 3	18	0.9	1201	1	AL531727
4	17	0.8	300	1	AU099140
C 5	16.3	0.8	609	1	AI099321
6	14.4	0.7	609	1	AI099321
C 7	13.6	0.7	300	1	AU099140
8	13.6	0.7	645	1	AL116939

ALIGNMENTS

RESULT 1
AL531727/c
LOCUS
DEFINITION AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone
CSODM003YI01 5-PRIME, mRNA sequence.
ACCESSION AL531727
VERSION AL531727.2 GI:31069559
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 1201)
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.
Full-length cDNA libraries and normalization
Unpublished (2001)
JOURNAL On Feb 13, 2001 this sequence version replaced gi:12795220.
COMMENT Contact: Genoscope
Genoscope - Centre National de Sequencage
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 7252.f For more information about this cluster, see

http://www.genoscope.cns.fr/
cgi-bin/Cluster.cgi?seq=CSODM003AE01QI&cluster=7252.f. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODM003AE01QI.

FEATURES

source

1..1201
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="CSODM003YI01"
/tissue_type="FETAL LIVER"
/dev_stage="fetal"
/clone_lib="Homo sapiens FETAL LIVER"
/note="Organ: liver; Vector: pCMVSPORT_6; 1st strand cDNA was primed with a NotI-oligo (GT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

Query Match 1.0%; Score 20.6; DB 1; Length 1201;
Best Local Similarity 59.3%; Pred. No. 0.32; Mismatches 24; Indels 0; Gaps 0;
Matches 35; Conservative 0;

QY 334 TTCAATTGCTTTTATCTGCGAGACTTGGCTTTTGTGTTTGAATATGTTCAATTGCG 392
DB 648 TTTCGTGCAATTCCTTTTCTAGATAGGATATTTCCACATGATATTCACCTGTGG 590

RESULT 2

AL116939/c

LOCUS

DEFINITION

KEYWORDS

SOURCE

ORGANISM

REFERENCE

AUTHORS

AL116939 645 bp mRNA linear EST 02-SEP-1998
ue29g08.y1 Sugano mouse liver mlia Mus musculus cDNA clone
IMAGE:1481822 5', similar to gb:MI3232 COAGULATION FACTOR VII
PRECURSOR (HUMAN);, mRNA sequence.

AL116939 GI:3517263
EST.
Mus musculus (house mouse)
Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 645)
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.
The WashU-HMI Mouse EST Project
Unpublished (1996)
Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu

TITLE

JOURNAL

COMMENT

Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@watson.wustl.edu
This clone is available royalty-free through LNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930178

Seq primer: custom primer used
High quality sequence stop: 483.

FEATURES

source

1..645
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1481822"

TITLE The WashU-HHMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
Washington University School of MedicineP
WashU-HHMI Mouse EST Project
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. .609
Location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTTCGTCTTAAAGCTCG and 3' end
primer CGACCTGCAGTCGAGACA."

Query Match 0.8%; Score 16.3; DB 1; Length 609;
Best Local Similarity 63.5%; Pred. No. 4.3;
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

QY 60 GGCGTGTGCTTCTCCCTGCTGATCTCAGGTGAGGTTAC-CATGCTCTCTTC 118
|||||
Db 209 GGCGCTTGAAGATCTCCGGGCTCTCTCAAGGAGCACTGTTCTCTCATTCCTCTCTC 150
|||||

QY 119 TCC 121
|||
Db 149 TCC 147
|||

RESULT 6
AI099321 609 bp mRNA linear EST 20-AUG-1998
LOCUS us37003.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1482509.5, similar to gb:W13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN); mRNA sequence.

ACCESSION AI099321
VERSION AI099321
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 609)
Marra,M., Haller,T., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)

TITLE The WashU-HHMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
Washington University School of MedicineP
WashU-HHMI Mouse EST Project
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. .609
Location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTTCGTCTTAAAGCTCG and 3' end
primer CGACCTGCAGTCGAGACA."

Query Match 0.8%; Score 16.3; DB 1; Length 609;
Best Local Similarity 63.5%; Pred. No. 4.3;
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

QY 60 GGCGTGTGCTTCTCCCTGCTGATCTCAGGTGAGGTTAC-CATGCTCTCTTC 118
|||||
Db 209 GGCGCTTGAAGATCTCCGGGCTCTCTCAAGGAGCACTGTTCTCTCATTCCTCTCTC 150
|||||

QY 119 TCC 121
|||
Db 149 TCC 147
|||

RESULT 6
AI099321 609 bp mRNA linear EST 20-AUG-1998
LOCUS us37003.y1 Sugano mouse liver mlia Mus musculus cDNA clone
DEFINITION IMAGE:1482509.5, similar to gb:W13232 COAGULATION FACTOR VII
PRECURSOR (HUMAN); mRNA sequence.

ACCESSION AI099321
VERSION AI099321
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 609)
Marra,M., Haller,T., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
The WashU-HHMI Mouse EST Project
Unpublished (1996)

TITLE The WashU-HHMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
Washington University School of MedicineP
WashU-HHMI Mouse EST Project
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.edu
This clone is available royalty-free through LNL ; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGI:930865
Seq primer: custom primer used
High quality sequence stop: 289.

FEATURES
source
1. .609
Location/Qualifiers
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="taxon:10090"
/clone="IMAGE:1482509"
/sex="female"
/dev_stage="adult"
/lab_host="DH10B"
/clone_lib="Sugano mouse liver mlia"
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [TGTGGCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTTCGTCTTAAAGCTCG and 3' end
primer CGACCTGCAGTCGAGACA."

Query Match 0.7%; Score 14.4; DB 1; Length 609;
Best Local Similarity 65.6%; Pred. No. 7.3;
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 413 CAAGAAGGTACAGCTTTTGTGTTTGGTGAAA 444
|||||
Db 360 CAAGAATGAACAGTGTGATCTGTGCMAATGAAA 391
|||||

RESULT 7
AU099140/c 300 bp mRNA linear EST 05-APR-2001
LOCUS AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
DEFINITION HEP20983 similar to Human factor VII serine protease precursor mRNA
clone lambda-HVII2463, mRNA sequence.

ACCESSION AU099140
VERSION AU099140
KEYWORDS EST.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1 (bases 1 to 300)
Hata,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S.,
Okubo,K., Suyama,A. and Sugano,S.
In silico mapping of the 5'-ends of human mRNAs using full-length
enriched and 5'-end enriched cDNA libraries constructed by
oligo-capping method
Unpublished (2001)
Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: ysuzuki@ms.u-tokyo.ac.jp
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and

